WEST Search History

Hide Items | Restore | Clear | Cancel

DATE: Thursday, December 02, 2004

Hide?	Set Name	Query	Hit Count
	DB=PGPB,USPT,USOC,EPAB,JPAB,DWPI; PLUR=YES; OP=ADJ		
☐	L8	L7 AND L1	94
☐	L7	L4 AND L6	203
☐	L6	Krebs solution	1286
☐	L5	L2 AND L4	28
☐	L4	(cortex OR cerebellum)	23875
☐	L3	L1 AND L2	71
☐	L2	435/378,379.CCLS.	241
☐	L1	(grid OR mesh OR sieve)	990831

END OF SEARCH HISTORY

h e b b cg b chh e b h f c e c ch

Hit List

Clear | Generate Collection | Print | Fwd Refs | Bkwd Refs | Generate OACS

Search Results - Record(s) 1 through 71 of 71 returned.

☐ 1. Document ID: US 20040175690 A1

Using default format because multiple data bases are involved.

L3: Entry 1 of 71 File: PGPB Sep 9, 2004

PGPUB-DOCUMENT-NUMBER: 20040175690
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20040175690 A1

TITLE: Tissue harvesting device and method

PUBLICATION-DATE: September 9, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Mishra, Ajit	San Antonio	TX	US	
Seegert, Charles	San Antonio	TX	US	
Ohira, Makoto	Newton	MA	US	

US-CL-CURRENT: 435/1.1; 435/379

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWIC | Draw. Des

☐ 2. Document ID: US 20040023387 A1

L3: Entry 2 of 71 File: PGPB Feb 5, 2004

PGPUB-DOCUMENT-NUMBER: 20040023387
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20040023387 A1

TITLE: Method of making demineralized bone particles

PUBLICATION-DATE: February 5, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Morris, John	Beachwood	NJ	US	
Shimp, Lawrence A.	Morganville	NJ	US	
Petersen, Kenneth C.	Brick	NJ	US	
Manrique, Albert	Manalapan	NJ	US	
Kaes, David	Toms River	NJ	US	
Scarborough, Nelson	Andover	MA	US	
Dowd, Michael	Eastampton	NJ	US	

US-CL-CURRENT: 435/379

ABSTRACT:

Demineralized bone particles are obtained by demineralizing whole bone and thereafter subdividing the demineralized bone to provide the demineralized bone particles.

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWIC | Draw Des

---

☐ 3. Document ID: US 20030215935 A1

L3: Entry 3 of 71 File: PGPB Nov 20, 2003

PGPUB-DOCUMENT-NUMBER: 20030215935
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20030215935 A1

TITLE: Apparatus and method for isolating living cells from an encapsulated organ tissue sample

PUBLICATION-DATE: November 20, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Coon, David James	Chapel Hill	NC	US	

US-CL-CURRENT: 435/284.1; 435/268, 435/308.1, 435/378

ABSTRACT:

An apparatus and method are disclosed for isolating living cells from an encapsulated organ or encapsulated organ tissue sample within a sealed environment. The apparatus and method utilize a sealed perfusion tank, a sealed perfusion box to create a sealed environment for the perfusion tank, and a filter cartridge containing one or more filters for separating the cells from the digested tissue sample.

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWIC | Draw Des

---

☐ 4. Document ID: US 20030187515 A1

L3: Entry 4 of 71 File: PGPB Oct 2, 2003

PGPUB-DOCUMENT-NUMBER: 20030187515
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20030187515 A1

TITLE: Collagen biofabric and methods of preparing and using the collagen biofabric

PUBLICATION-DATE: October 2, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Hariri, Robert J.	Florham Park	NJ	US	

Kaplunovsky, Aleksandr M.	Rockaway	NJ	US
Murphy, Patricia A.	Wayne	NJ	US

US-CL-CURRENT: 623/23.72; 424/583, 435/378, 435/399, 623/1.41, 623/915

ABSTRACT:

A method of preparing a placental-derived amniotic membrane biofabric is provided. The biofabric is a dry decellularized amniotic membrane that is capable of being stored at room temperature, and subsequent to rehydration can be used for a variety of medical and/or research purposes. A laminate of said biofabric is also provided that can be shaped into complex shapes and repopulated with cells to generate both acellular and cellularized engineered tissues and organoids.

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWIC | Draw. Des

---

☐ 5. Document ID: US 20030129751 A1

L3: Entry 5 of 71 File: PGPB Jul 10, 2003

PGPUB-DOCUMENT-NUMBER: 20030129751
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20030129751 A1

TITLE: Tissue-engineered organs

PUBLICATION-DATE: July 10, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Grikscheit, Tracy C.	Boston	MA	US	
Ogilvie, Jennifer	Boston	MA	US	
Vacanti, Joseph P.	Boston	MA	US	

US-CL-CURRENT: 435/378; 435/396, 623/23.71, 623/915

ABSTRACT:

The present invention relates to a method for producing a tissue-engineered organ or organ portion or specific section thereof comprising the steps of loading organoid units into a biocompatible polymer scaffold and implanting the polymer scaffold into a subject. Organs produced by this method are also encompassed by the invention. Organoid units can be derived from tissues including, but not limited to, spleen, lung, liver, kidney, pancreas, endocrine tissue, heart, esophagus, colon, stomach, gall bladder and uterus. The resulting engineered tissue can comprise spleen, lung, liver, kidney, pancreas, endocrine, cardiac muscle, esophagus, colon, stomach, gall bladder or uterus. The invention further relates to a tissue-engineered organ or organ portion or specific section thereof comprising compact tissue grown in a biocompatible polymer scaffold, wherein the tissue is derived from spleen, lung, liver, kidney, pancreas, endocrine, heart, esophagus, colon, stomach, gall bladder or uterus.

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWIC | Draw. Des

☐ 6. Document ID: US 20020127719 A1

L3: Entry 6 of 71 File: PGPB Sep 12, 2002

PGPUB-DOCUMENT-NUMBER: 20020127719
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20020127719 A1

TITLE: Xenograft heart valves

PUBLICATION-DATE: September 12, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Stone, Kevin R.	Mill Valley	CA	US	

US-CL-CURRENT: 435/378; 424/423, 435/380

ABSTRACT:

The invention provides an article of manufacture comprising a substantially non-immunogenic heart valve xenograft for implantation into humans. The invention further provides methods for preparing a heart valve xenograft by removing at least a portion of a soft tissue from a non-human animal to provide a xenograft; washing the xenograft in saline and alcohol; subjecting the xenograft to cellular disruption treatment; treating the xenograft with crosslinking agents, and digesting the xenograft with a proteoglycan-depleting factor and/or glycosidase. The invention also provides an article of manufacture produced by the above-identified method of the invention. The invention further provides a heart valve xenograft for implantation into a human including a portion of a heart valve from a non-human animal, wherein the portion has extracellular components and substantially only dead cells. The extracellular components have reduced proteoglycan molecules. Each of the xenografts of the invention are substantially non-immunogenic and have substantially the same mechanical properties as a corresponding native heart valve.

☐ 7. Document ID: US 20020028192 A1

L3: Entry 7 of 71 File: PGPB Mar 7, 2002

PGPUB-DOCUMENT-NUMBER: 20020028192
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20020028192 A1

TITLE: Non-contracting tissue equivalent

PUBLICATION-DATE: March 7, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Dimitrijevich, S. Dan	Bedford	TX	US	
Gracy, Robert W.	Fort Worth	TX	US	

US-CL-CURRENT: 424/93.7; 435/371, 435/378

ABSTRACT:

The present invention provides a non-contracting tissue equivalent comprising at least one cellular component and at least one non-cellular component. The tissue equivalent closely resembles normal tissue in being substantially non-contracting. In addition, the non-contracting tissue equivalent is translucent, allowing direct visual observation of the different layers of cells in the tissue equivalent. The non-contracting tissue equivalent is useful for a variety of complete tissue replacements including skin and cornea. The non-contracting tissue equivalent is useful for in vitro testing, evaluation and screening of potential pharmaceuticals or consumer products, production of biocompatible clinical products for tissue replacement and augmentation, and research studies on fundamental aspects of tissue structure and function. The capability for direct visual observation of layers of cells permits manual or automated assessment of important biological parameters of the tissue, including cell viability, proliferation, motility, and differentiation.

☐ 8. Document ID: US 6783983 B1

L3: Entry 8 of 71 File: USPT Aug 31, 2004

US-PAT-NO: 6783983
DOCUMENT-IDENTIFIER: US 6783983 B1

TITLE: Methods for cultivating cells and propagating viruses

DATE-ISSUED: August 31, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Condon; Russell G. G.	New Brunswick	NJ		
Connelly; Nancy V.	Union	NJ		
Frei; Andreas	Freehold	NJ		
Glowacki; Edward	Pt. Pleasant	NJ		
Yabannavar; Vijay	Lafayette	CA		
Batandolo; Serge	Edison	NJ		

US-CL-CURRENT: 435/403; 435/289.1, 435/325, 435/378, 435/395

ABSTRACT:

This invention relates to methods for the cultivating cells, and in particular to methods for propagating viruses.

14 Claims, 2 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 2

☐ 9. Document ID: US 6767738 B1

L3: Entry 9 of 71 File: USPT Jul 27, 2004

US-PAT-NO: 6767738
DOCUMENT-IDENTIFIER: US 6767738 B1

TITLE: Method of isolating adult mammalian CNS-derived progenitor stem cells using density gradient centrifugation

DATE-ISSUED: July 27, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Gage; Fred H.	La Jolla	CA		
Palmer; Theo	San Carlos	CA		
Safar; Francis G.	Irvine	CA		
Takahashi; Jun	Kyoto			JP
Takahashi; Masayo	Kyoto			JP

US-CL-CURRENT: 435/325; 435/366, 435/368, 435/378

ABSTRACT:

The present invention is directed to methods of repairing damaged or diseased, specialized or differentiated tissue in mature animals, particularly neuronal tissue such as retinas. In particular, the invention relates to transplantation of adult, hippocampus-derived progenitor cells into a selected neural tissue site of a recipient. These cells can functionally integrate into mature and immature neural tissue. The invention encompasses, in one aspect, repopulating a retina of a dystrophic animal with neurons, by injecting clonally derived, adult central nervous system derived stem cells (ACSC) derived from a healthy donor animal into an eye of the dystrophic recipient. Herein disclosed is the first successful and stable integration of clonally derived ACSC into same-species but different strain recipients (e. g., Fischer rat-derived adult hippocampal derived progenitor cells (AHPCs) into dystrophic RCS rats). Surprisingly, AHPCs were also found to integrate successfully into a xenogeneic recipient (e.g., rat AHPCs into the retina of dystropic rd-I mice).

13 Claims, 0 Drawing figures
Exemplary Claim Number: 1

☐ 10. Document ID: US 6753181 B2

L3: Entry 10 of 71 File: USPT Jun 22, 2004

US-PAT-NO: 6753181
DOCUMENT-IDENTIFIER: US 6753181 B2

TITLE: Methods and compositions for organ decellularization

DATE-ISSUED: June 22, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Atala; Anthony	Weston	MA		

US-CL-CURRENT: 435/376; 435/1.1, 435/379, 435/395

ABSTRACT:

The invention is directed to methods for producing a decellularized organ or part of an organ. A decellularized organ is produced using an isolated organ mechanically agitated to remove cellular membranes surrounding the isolated organ without destroying the interstitial structure of the organ. After the cellular membrane is removed, the isolated organ is exposed to a solubilizing fluid that extracts cellular material without dissolving the interstitial structure of the organ. A washing fluid is used to remove the solubilized components, leaving behind a decellularized organ.

26 Claims, 0 Drawing figures
Exemplary Claim Number: 1

☐ 11. Document ID: US 6664106 B1

L3: Entry 11 of 71 File: USPT Dec 16, 2003

US-PAT-NO: 6664106
DOCUMENT-IDENTIFIER: US 6664106 B1
**** See image for Certificate of Correction ****

TITLE: Production of primmorphs from disassociated cells of sponges and corals

DATE-ISSUED: December 16, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Muller; Werner E. G.	65203 Wiesbaden			DE

US-CL-CURRENT: 435/325; 435/378, 435/379, 435/383

ABSTRACT:

This invention relates to the establishment of a novel method of culturing sponge cells, coral cells and cells from other invertebrates in vitro. The cells cultured in vitro, which can be cultured as units similar to aggregates, are referred to as primmorphs. The method makes the following methods possible for the first time, using cells/aggregates/primmorphs from sponges, corals and other invertebrates:

Methods (i) of preparing substances which modulate proliferation and DNA synthesis, (ii) of identifying/detecting environmentally harmful substances, (iii) of culturing bacteria and other micro-organisms, (iv) of preparing asexual reproductive bodies that can be used in aquaculture for growing corresponding organisms, (v) of preparing cell libraries, (vi) of optimising the nutritional requirements of the cells/aggregates/primmorphs, and (vii) of identifying substances which modulate telomerase activity in cells/aggregates/primmorphs.

1 Claims, 0 Drawing figures
Exemplary Claim Number: 1

☐ 12. Document ID: US 6534095 B1

L3: Entry 12 of 71 File: USPT Mar 18, 2003

US-PAT-NO: 6534095
DOCUMENT-IDENTIFIER: US 6534095 B1

TITLE: Pulsatile acidification wave demineralization process for producing osteoinductive bone; and osteoinductive bone produced thereby

DATE-ISSUED: March 18, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Moore-Smith; Debra	Chesapeake	VA		
O'Leary; Robert K.	Deltaville	VA		
Wilson; Anne	Virginia Beach	VA		

US-CL-CURRENT: 424/549; 435/284.1, 435/286.5, 435/288.1, 435/378

ABSTRACT:

The invention is directed to a process for producing demineralized osteoinductive bone, and demineralized osteoinductive bone produced thereby. The process achieves demineralization of bone by subjecting bone, including for example ground bone, bone cubes, chips, strips, or essentially intact bone, to a rapid high volume, pulsatile acidification wave process. The process includes subjecting bone to two or more rapid pulse/drain cycles where one or more demineralizing acids are rapidly pulsed into a vessel containing bone, and after a desired period of time, is rapidly drained from the vessel, the vessel containing the bone is then rapidly refilled with the one or more demineralizing acids (pulsed). The process allows bone to be rapidly demineralized to a precise ans specific desired residual calcium level, without sacrificing osteoinductivity.

39 Claims, 3 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 2

Full | Title | Citation | Front | Review | Classification | Date | Reference | Claims | KWIC | Draw. Des

☐ 13. Document ID: US 6489164 B1

L3: Entry 13 of 71 File: USPT Dec 3, 2002

US-PAT-NO: 6489164
DOCUMENT-IDENTIFIER: US 6489164 B1

TITLE: Isolation of cells from organ tissue using sonication

DATE-ISSUED: December 3, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Gray; Brad	Huntington Beach	CA		
Baird; Monty Kahn	Garden Grove	CA		
Lamberti; Francis	Irvine	CA		

US-CL-CURRENT: 435/378; 435/325, 435/379, 435/380, 435/381

ABSTRACT:

A method for isolating specific viable cell types from surrounding organ tissue is provided. The method entails the use of sonication in conjunction with tissue dissociating agents to free the cells of interest. A specific application of the method is the isolation of the insulin producing tissue of the pancreas, the islets of Langerhans. The method results in a high yield of islets that maintain a high level of viability.

3 Claims, 0 Drawing figures
Exemplary Claim Number: 1

☐ 14. Document ID: US 6455309 B2

L3: Entry 14 of 71 File: USPT Sep 24, 2002

US-PAT-NO: 6455309
DOCUMENT-IDENTIFIER: US 6455309 B2

TITLE: Proteoglycan-reduced soft tissue xenografts

DATE-ISSUED: September 24, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Stone; Kevin R.	Mill Valley	CA		

US-CL-CURRENT: 435/378; 623/23.72, 623/915

ABSTRACT:

The invention provides an article of manufacture comprising a substantially non-immunogenic soft tissue xenograft for implantation into humans. The invention further provides methods for preparing a soft tissue xenograft by removing at least a portion of a soft tissue from a non-human animal to provide a xenograft; washing the xenograft in saline and alcohol; subjecting the xenograft to cellular disruption treatment; and digesting the xenograft with a proteoglycan-depleting factor and/or glycosidase and optionally following with a capping treatment. The invention also provides an article of manufacture produced by the above-identified method of the invention. The invention further provides a soft tissue xenograft for implantation into a human including a portion of a soft tissue from a non-human animal, wherein the portion has extracellular components and substantially only dead cells. The extracellular components have reduced proteoglycan molecules. Each of the xenografts of the invention are substantially non-immunogenic and have substantially the same mechanical properties as a corresponding native soft tissue.

25 Claims, 12 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 6

Full | Title | Citation | Front | Review | Classification | Date | Reference | | | Claims | KWMC | Draw. Des

☐ 15. Document ID: US 6383805 B1

L3: Entry 15 of 71 File: USPT May 7, 2002

US-PAT-NO: 6383805
DOCUMENT-IDENTIFIER: US 6383805 B1

TITLE: Epithelial cell cultures for in vitro testing

DATE-ISSUED: May 7, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Latimer; Jean J.	Pittsburgh	PA		

US-CL-CURRENT: 435/325; 435/371, 435/378, 435/379, 435/380, 435/383, 435/392, 435/404, 435/408

ABSTRACT:

A method and a medium for culturing epithelial cells of both normal and malignant origin is provided. The method entails physically disaggregating tissue samples, placing the resulting fragments onto a surface comprised of basement membrane matrix components, and culturing the tissue in a medium containing preselected fetal and newborn calf sera and rat sera. Both primary explant cell cultures and cell lines, which are long-lived and particularly suitable for further study, are produced. The cultured primary explant cells undergo differentiation to form complex structures resembling those seen in vivo.

28 Claims, 1 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 1

Full | Title | Citation | Front | Review | Classification | Date | Reference | | | Claims | KWMC | Draw. Des

☐ 16. Document ID: US 6376244 B1

L3: Entry 16 of 71 File: USPT Apr 23, 2002

US-PAT-NO: 6376244
DOCUMENT-IDENTIFIER: US 6376244 B1

TITLE: Methods and compositions for organ decellularization

DATE-ISSUED: April 23, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Atala; Anthony	Weston	MA		

US-CL-CURRENT: 435/376; 435/1.1, 435/379, 435/395, 530/356

ABSTRACT:

The invention is directed to methods for producing a decellularized organ or part of an organ. A decellularized organ is produced using an isolated organ mechanically agitated to remove cellular membranes surrounding the isolated organ without destroying the interstitial structure of the organ. After the cellular membrane is removed, the isolated organ is exposed to a solubilizing fluid that extracts cellular material without dissolving the interstitial structure of the organ. A washing fluid is used to remove the solubilized components, leaving behind a decellularized organ.

8 Claims, 0 Drawing figures
Exemplary Claim Number: 1

☐ 17. Document ID: US 6326201 B1

L3: Entry 17 of 71 File: USPT Dec 4, 2001

US-PAT-NO: 6326201
DOCUMENT-IDENTIFIER: US 6326201 B1
**** See image for Certificate of Correction ****

TITLE: Pancreatic progenitor cells, methods and uses related thereto

DATE-ISSUED: December 4, 2001

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Fung; Brenda	Belmont	MA		
Pang; Kevin	Belmont	MA		
Kagan; David	Brighton	MA		

US-CL-CURRENT: 435/377; 435/325, 435/371, 435/378

ABSTRACT:

The present invention relates to a substantially pure population of viable pancreatic progenitor cells, and methods for isolating such cells. The present invention further concerns certain therapeutic uses for such progenitor cells, and their progeny.

39 Claims, 59 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 44

☐ 18. Document ID: US 6294383 B1

L3: Entry 18 of 71 File: USPT Sep 25, 2001

US-PAT-NO: 6294383
DOCUMENT-IDENTIFIER: US 6294383 B1

TITLE: Porcine neural cells and their use in treatment of neurological deficits due to neurodegenerative diseases

DATE-ISSUED: September 25, 2001

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Isacson; Ole	Cambridge	MA		
Dinsmore; Jonathan	Brookline	MA		

US-CL-CURRENT: 435/379; 435/325

ABSTRACT:

Porcine neural cells and methods for using the cells to treat neurological deficits due to neurodegeneration are described. The porcine neural cells are preferably embryonic mesencephalic, embryonic striatal cells, or embryonic cortical cells. The porcine neural cells can be modified to be suitable for transplantation into a xenogeneic subject, such as a human. For example, the porcine neural cells can be modified such that an antigen (e.g., an MHC class I antigen) on the cell surface which is capable of stimulating an immune response against the cell in a xenogeneic subject is altered (e.g., by contact with an anti-MHC class I antibody, or a fragment or derivative thereof) to inhibit rejection of the cell when introduced into the subject. In one embodiment, the porcine neural cells are obtained from a pig which is essentially free from organisms or substances which are capable of transmitting infection or disease to the recipient subject. The porcine neural cells of the present invention can be used to treat neurological deficits due to neurodegeneration in the brain of a xenogeneic subject (e.g., a human with epilepsy, head trauma, stroke, amyotrophic lateral sclerosis, Parkinson's disease, Alzheimer's disease, or Huntington's disease) by introducing the cells into the brain of the subject.

8 Claims, 49 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 21

☐ 19. Document ID: US 6242252 B1

L3: Entry 19 of 71 File: USPT Jun 5, 2001

US-PAT-NO: 6242252
DOCUMENT-IDENTIFIER: US 6242252 B1

TITLE: Hepatic progenitors and method of isolating same

DATE-ISSUED: June 5, 2001

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Reid; Lola M.	Chapel Hill	NC		
Sigal; Samuel H.	Riverdale	NY		
Brill; Shlomo	Ramat-Gan			IL
Holst; Patricia A.	Ossining	NY		

US-CL-CURRENT: 435/325; 435/378, 435/379, 435/380, 435/381

ABSTRACT:

This invention relates to methods of isolating hepatic progenitors utilizing panning techniques and fluorescence activated cell sorting. This invention further relates to isolated hepatic progenitors and to a method of treating liver dysfunction as well as to methods of forming artificial livers.

32 Claims, 11 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 11

☐ 20. Document ID: US 6235527 B1

L3: Entry 20 of 71 File: USPT May 22, 2001

US-PAT-NO: 6235527
DOCUMENT-IDENTIFIER: US 6235527 B1

TITLE: Lineage restricted glial precursors from the central nervous system

DATE-ISSUED: May 22, 2001

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Rao; Mahendra S.	Salt Lake City	UT		
Noble; Mark	Sandy	UT		
Mayer-Proschel; Margot	Sandy	UT		

US-CL-CURRENT: 435/325; 435/368, 435/378, 435/395, 435/402

ABSTRACT:

A glial precursor cell population from mammalian central nervous system has been isolated. These A2B5.sup.+ E-NCAM.sup.- glial-restricted precursor (GRP) cells are capable of differentiating into oligodendrocytes, A2B5.sup.+ process-bearing astrocytes, and A2B5.sup.- fibroblast-like astrocytes, but not into neurons. GRP cells can be maintained by regeneration in culture. GRP cells differ from oligodendrocyte-type-2 astrocyte (O-2A) progenitor cells in growth factor requirements, morphology, and progeny. Methods of use of GRP cells are also disclosed.

5 Claims, 0 Drawing figures
Exemplary Claim Number: 1

☐ 21. Document ID: US 6197061 B1

L3: Entry 21 of 71 File: USPT Mar 6, 2001

US-PAT-NO: 6197061
DOCUMENT-IDENTIFIER: US 6197061 B1

TITLE: In vitro production of transplantable cartilage tissue cohesive cartilage produced thereby, and method for the surgical repair of cartilage damage

DATE-ISSUED: March 6, 2001

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Masuda; Koichi	Glenview	IL	60025	
Thonar; Eugene J-M. A.	Lockport	IL	60441	
Hejna; Michael	Riverside	IL	60546	

US-CL-CURRENT: 623/11.11; 435/366, 435/378, 435/401, 623/915

ABSTRACT:

The present invention is directed to a transplantable cartilage matrix and a method for its in vitro production.

23 Claims, 5 Drawing figures
Exemplary Claim Number: 15
Number of Drawing Sheets: 2

Full | Title | Citation | Front | Review | Classification | Date | Reference | Claims | KWIC | Draw Desc

☐ 22. Document ID: US 6168944 B1

L3: Entry 22 of 71 File: USPT Jan 2, 2001

US-PAT-NO: 6168944
DOCUMENT-IDENTIFIER: US 6168944 B1

TITLE: Methods for cultivating cells and propagating viruses

DATE-ISSUED: January 2, 2001

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Condon; Russell G. G.	New Brunswick	NJ		
Connelly; Nancy V.	Union	NJ		
Frei; Andreas	Freehold	NJ		
Glowacki; Edward	Pt. Pleasant	NJ		
Yabannavar; Vijay	Lafayette	CA		
Batandolo; Serge	Edison	NJ		

US-CL-CURRENT: 435/239; 435/291.3, 435/306.1, 435/325, 435/366, 435/378, 435/380, 435/403, 435/41

ABSTRACT:

This invention relates to methods for the cultivating cells, and in particular to methods for propagating recombinant viruses for gene therapy.

22 Claims, 2 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 2

Full | Title | Citation | Front | Review | Classification | Date | Reference | Claims | KWIC | Draw. Des.

☐ 23. Document ID: US 6146891 A

L3: Entry 23 of 71 File: USPT Nov 14, 2000

US-PAT-NO: 6146891
DOCUMENT-IDENTIFIER: US 6146891 A

TITLE: Methods for cultivating cells and propagating viruses

DATE-ISSUED: November 14, 2000

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Condon; Russell G.G.	New Brunswick	NJ		
Connelly; Nancy V.	Union	NJ		
Frei; Andreas	Freehold	NJ		
Glowacki; Edward	Pt. Pleasant	NJ		
Yabannavar; Vijay	Lafayette	CA		
Batandolo; Serge	Edison	NJ		

US-CL-CURRENT: 435/378; 435/235.1, 435/239, 435/289.1, 435/325, 435/380, 435/395, 435/403, 435/41

ABSTRACT:

This invention relates to methods for the cultivating cells, and in particular to methods for propagating viruses.

24 Claims, 2 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 2

Full | Title | Citation | Front | Review | Classification | Date | Reference | Claims | KWIC | Draw. Des.

☐ 24. Document ID: US 6099832 A

L3: Entry 24 of 71 File: USPT Aug 8, 2000

US-PAT-NO: 6099832

DOCUMENT-IDENTIFIER: US 6099832 A

TITLE: Transplants for myocardial scars

DATE-ISSUED: August 8, 2000

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Mickle; Donald A. G.	Toronto			CA
Li; Ren-Ke	Scarborough			CA
Weisel; Richard D.	Toronto			CA

US-CL-CURRENT: 424/93.21; 435/325, 435/378, 435/455

ABSTRACT:

A method is provided for forming a graft in heart tissue which comprises the transplantation of cells chosen from cardiomyocytes, fibroblasts, smooth muscle cells, endothelial cells and skeletal myoblasts. The grafts are especially useful in treating scar tissue on the heart.

23 Claims, 26 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 16

☐ 25. Document ID: US 6080579 A

L3: Entry 25 of 71 File: USPT Jun 27, 2000

US-PAT-NO: 6080579
DOCUMENT-IDENTIFIER: US 6080579 A

TITLE: Method for producing human intervertebral disc cells

DATE-ISSUED: June 27, 2000

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Hanley, Jr.; Edward Nathaniel	Charlotte	NC		
Gruber; Helen Elizabeth	Charlotte	NC		

US-CL-CURRENT: 435/366; 435/378, 435/379, 435/382, 435/395, 435/399

ABSTRACT:

There is provided a method for growing human intervertebral cells. Disc tissue is surgically removed from a normal disc of a patient, the cells expanded by feeding with a cell stimulant such as a growth factor, or a cytokine or a bioactive agent to form monolayer primary cell cultures on a plastic mesh such as a nylon mesh. In the case of a growth factor, fetal bovine serum is preferred as it improves cell proliferation and production of appropriate extracellular matrix components. In another aspect of this invention, the monolayer primary cell cultures are seeded in alginate or agarose and fed again with the cell stimulant until three-dimensional

cell cultures are formed. The cells are recovered from the alginate or agarose or from monolayer cultures. Re-implantation is carried out using bioresorbable carriers or cell suspensions.

11 Claims, 8 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 5

☐ 26. Document ID: US 6017760 A

L3: Entry 26 of 71 File: USPT Jan 25, 2000

US-PAT-NO: 6017760
DOCUMENT-IDENTIFIER: US 6017760 A

TITLE: Isolation and culture of porcine hepatocytes

DATE-ISSUED: January 25, 2000

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Jauregui; Hugo O.	Providence	RI		
Naik; Sharda	Cranston	RI		
Santangini; Henry	Cranston	RI		
Trenkler; Donna M.	Greene	RI		

US-CL-CURRENT: 435/378; 435/1.1, 435/174, 435/29, 435/325, 435/379, 435/384, 435/389, 435/394, 435/395, 435/399, 435/400 , 435/401, 435/402, 623/17.11

ABSTRACT:

A perfusion device such as a liver assist device containing a housing defining a perfusion inlet and a perfusion outlet, a porous membrane structure mounted within said housing to define a perfusion compartment and an adjacent hepatocyte compartment, and porcine hepatocytes isolated from a porcine liver by retrograde perfusion.

26 Claims, 22 Drawing figures
Exemplary Claim Number: 5
Number of Drawing Sheets: 16

☐ 27. Document ID: US 6015713 A

L3: Entry 27 of 71 File: USPT Jan 18, 2000

US-PAT-NO: 6015713
DOCUMENT-IDENTIFIER: US 6015713 A

TITLE: Transgenic fish and a method of harvesting islet cells therefrom

DATE-ISSUED: January 18, 2000

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Wright, Jr.; James R.	Halifax			CA
Pohajdak; Bill	Dartmouth			CA

US-CL-CURRENT: 435/378; 435/325, 800/20, 800/21

ABSTRACT:

This invention relates to transgenic fish containing a humanized insulin gene which has been altered to secrete human insulin and its use in the treatment of diabetes. In the transgenic fish of the present invention, the fish insulin gene has been modified to code for human insulin gene while leaving the regulatory sequences of fish insulin gene intact. Islet transplantation may provide the meticulous glycemia control required in the treatment of diabetes. The islet tissue of the present invention offers an inexpensive and a nearly unlimited supply of human insulin-producing tissue and therefore, may be useful in the treatment of diabetes. In this regard, an improved method of mass isolation of islet tissue is provided by the present invention. The present invention also provides the use of the humanized insulin gene to promote growth in fish.

2 Claims, 5 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 4

☐ 28. Document ID: US 6008047 A

L3: Entry 28 of 71 File: USPT Dec 28, 1999

US-PAT-NO: 6008047
DOCUMENT-IDENTIFIER: US 6008047 A

TITLE: Cell culturing method and medium

DATE-ISSUED: December 28, 1999

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Curcio; Francesco	Pagnacco			IT
Coon; Hayden G.	East Sebago	ME		
Ambesi-Impiombato; F. Saverio	Udine			IT

US-CL-CURRENT: 435/370; 424/93.7, 435/1.1, 435/378, 435/383, 435/391, 435/392, 435/397

ABSTRACT:

The present invention provides a method for producing an expanded non-transformed cell culture of human liver cells comprising the steps of: (1) preparing partially purified, minced human liver tissue, (2) concentrating the resulting cells and tissue pieces, (3) resuspending the concentrated tissue cells and pieces in a growth medium, (4) culturing the resuspended cells in the growth medium for a time and under

conditions to effect sustained cell division, and (5) passaging the cultured human liver cells periodically to expand the culture. The growth medium comprises a combination of a basal medium and ingredients to provide a medium in which the cultured human liver cells are selectively proliferated without being transformed, providing an expanded culture of proliferated, functionally differentiated human liver cells that is substantially free of fibroblast, macrophage and capillary endothelial cells. Also provided is the improvement of harvesting cells of the expanded culture at a selected PDL preferably>5, providing a high density cell suspension of such proliferated human liver cells, and incubating such high density cell suspension in a calm-down medium to induce a mitotically quiescent state and, using a culture procedure which encourages aggregation, making the cells adhere tightly to form a three-dimensional cell organization typical of the organ of origin, thereby forming organoids.

16 Claims, 18 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 11

☐ 29. Document ID: US 5962324 A

L3: Entry 29 of 71 File: USPT Oct 5, 1999

US-PAT-NO: 5962324
DOCUMENT-IDENTIFIER: US 5962324 A

TITLE: Three dimensional optic tissue culture and process

DATE-ISSUED: October 5, 1999

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
O'Connor; Kim C.	New Orleans	LA		
Spaulding; Glenn F.	Houston	TX		
Goodwin; Thomas J.	Friendswood	TX		
Aten; Laurie A.	Dickinson	TX		
Francis; Karen M.	Aiken	SC		
Caldwell; Delmar R.	Folsom	LA		
Prewett; Tacey L.	Friendswood	TX		
Fitzgerald; Wendy S.	Webster	TX		

US-CL-CURRENT: 435/394; 435/325, 435/378, 435/379

ABSTRACT:

A process for artificially producing three-dimensional optic tissue has been developed. The optic cells are cultured in a bioreactor at low shear conditions. The tissue forms as normal, functional tissue grows with tissue organization and extracellular matrix formation.

22 Claims, 5 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 3

☐ 30. Document ID: US 5945101 A

L3: Entry 30 of 71 File: USPT Aug 31, 1999

US-PAT-NO: 5945101
DOCUMENT-IDENTIFIER: US 5945101 A

TITLE: Skin model system

DATE-ISSUED: August 31, 1999

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Berg; Richard A.	Lambertville	NJ	08530-3302	
Geesin; Jeffrey	Newtown	PA	18940	

US-CL-CURRENT: 424/93.7; 424/574, 435/378, 435/395, 435/402, 623/15.12

ABSTRACT:

This invention relates to a skin model system that can be used as an in vitro test system or which can be used for therapeutic purposes. The skin model system comprises a three-dimensional, cross-linked matrix of insoluble collagen containing fibroblast cells therein, and stratified layers of differentiated epidermal cells supported thereon.

29 Claims, 11 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 6

Full | Title | Citation | Front | Review | Classification | Date | Reference | Claims | KWMC | Draw. Desc

☐ 31. Document ID: US 5919703 A

L3: Entry 31 of 71 File: USPT Jul 6, 1999

US-PAT-NO: 5919703
DOCUMENT-IDENTIFIER: US 5919703 A

TITLE: Preparation and storage of pancreatic islets

DATE-ISSUED: July 6, 1999

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Mullen; Yoko	Sherman Oaks	CA		
Kenmochi; Takashi	Hanamigawaku			JP

US-CL-CURRENT: 435/381; 435/1.1, 435/325, 435/378, 435/394

ABSTRACT:

A method, a solution and a chamber for the preparation and storage of pancreatic islets. The method includes contacting a pancreas with a warm collagenase solution, digesting the pancreas in the warm collagenase solution to form warm digest, adding cold preservative solution to the warm digest, agitating the warm digest/cold preservative solution at a temperature between about 0.degree. and 15.degree. C., to thereby further digest the partially digested pancreas included in the warm digest, to form cold digest and collecting liquid from the cold digest to form isolated islets. The cold preservative solution and a pancreatic islet preservative solution of the present invention include D-mannitol, K-lactobionate and a buffer.

10 Claims, 1 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 1

☐ 32. Document ID: US 5919702 A

L3: Entry 32 of 71 File: USPT Jul 6, 1999

US-PAT-NO: 5919702
DOCUMENT-IDENTIFIER: US 5919702 A

TITLE: Production of cartilage tissue using cells isolated from Wharton's jelly

DATE-ISSUED: July 6, 1999

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Purchio; Anthony F.	La Jolla	CA		
Naughton; Brian A.	El Cajon	CA		
San Roman; Julia	San Diego	CA		

US-CL-CURRENT: 435/378; 424/93.1, 435/325, 435/366, 435/377

ABSTRACT:

The invention relates to the isolation and use of pre-chondrocytes from the umbilical cord, specifically from Wharton's jelly, that give rise to chondrocytes which produce cartilage. The isolated pre-chondrocytes, or the chondrocytes to which they give rise, can be mitotically expanded in culture and used in the production of new cartilage tissue for therapeutic use. "Banks" of pre-chondrocytes or chondrocytes can be stored frozen, and thawed and used to produce new cartilage tissue as needed.

6 Claims, 15 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 11

☐ 33. Document ID: US 5900374 A

L3: Entry 33 of 71 File: USPT May 4, 1999

US-PAT-NO: 5900374
DOCUMENT-IDENTIFIER: US 5900374 A

TITLE: Cell culture harvesting device

DATE-ISSUED: May 4, 1999

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Otto-Nagels; Hans	Bovenden			DE

US-CL-CURRENT: 435/379; 15/220.2, 435/261, 435/299.2, 435/304.1, 435/308.1

ABSTRACT:

The invention concerns a cell culture harvesting device consisting of a scraper head with a blade and a guide strip, the scraper head and the guide strip being connected with one another only by magnetic attraction. The magnetic attraction is achieved by the fact that one of the ends of the scraper head and the guide strip which are turned toward one another have a magnet and the other has either a magnet or a material which can be magnetized by the magnet of the respective counterpart. In this way, the scraper head and the guide strip can be moved synchronously and in parallel at a distance from one another. This has the advantage that the scraper head can be placed into the cell culture vessel before a cell culture is started and can be sterilized together with it thereby eliminating the risk of contamination due to a cell culture harvesting device later being placed into the cell culture vessel. Furthermore, the scraper head can have a net-like collection container arranged on it which collects the cells lifted off the growth surface of the cell culture vessel in a manner that avoids damage to the cells.

15 Claims, 5 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 2

☐ 34. Document ID: US 5888816 A

L3: Entry 34 of 71 File: USPT Mar 30, 1999

US-PAT-NO: 5888816
DOCUMENT-IDENTIFIER: US 5888816 A

TITLE: Cell cultures of and cell culturing method for nontransformed pancreatic, thyroid, and parathyroid cells

DATE-ISSUED: March 30, 1999

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Coon; Hayden G.	Gaithersburg	MD		
Ambesi-Impiombato; Francesco Saverio	Tricesimo			IT
Curcio; Francesco	Pagnacco			IT

US-CL-CURRENT: 435/366; 435/325, 435/378, 435/382, 435/383, 435/391, 435/392, 435/404, 435/408

ABSTRACT:

The present invention provides a method for producing an expanded, enriched, non-transformed human cell culture of human pancreatic, thyroid or parathyroid endocrine cells and other types of cells which comprises (1) preparing partially purified, minced tissue that includes a desired type of cells; (2) concentrating the desired cells; (3) resuspending the concentrated cells in a growth medium which selects in favor of the desired cells and in which those cells are proliferated without being transformed and differentiated functions are retained through periodic passaging; (4) culturing the resuspended cells in the growth medium to effect sustained cell division; and (5) passaging the cultured cells periodically to expand the culture. The present invention further provides clonal strains of cells derived from the above-mentioned cell culture and procedures to form matrix-embedded aggregated and non-aggregated cells for providing pseudotissues and products such as matrix-embedded pancreatic islets (pseudoislets). Growth medium and conditioned medium is provided for the culturing of the cells and clonal strains, the growth medium comprising a suitable basal medium supplemented with effective concentrations of hypothalamus and pituitary extracts, serum and other ingredients, which growth medium selects in favor of desired human cells and against passenger cells including fibroblast, macrophage, and capillary endothelial cells such that the desired cells are selectively proliferated without being transformed and an expanded cell culture is provided of functionally differentiated, expanded, non-transformed human cells that is substantially free of such passenger cells.

34 Claims, 18 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 11

☐ 35. Document ID: US 5885829 A

L3: Entry 35 of 71 File: USPT Mar 23, 1999

US-PAT-NO: 5885829
DOCUMENT-IDENTIFIER: US 5885829 A
**** See image for Certificate of Correction ****

TITLE: Engineering oral tissues

DATE-ISSUED: March 23, 1999

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Mooney; David J.	Ann Arbor	MI		
Rutherford; Robert B.	Ann Arbor	MI		

US-CL-CURRENT: 435/325; 424/422, 424/435, 424/49, 435/374, 435/378, 435/69.1

ABSTRACT:

Disclosed are methods for regenerating dental and oral tissues from viable cells using ex vivo culture on a structural matrix. The regenerated oral tissues and tissue-matrix preparations thus provided have both clinical applications in dentistry and oral medicine and are also useful in in vitro toxicity and biocompatibility testing.

109 Claims, 17 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 11

Full | Title | Citation | Front | Review | Classification | Date | Reference | Claims | KWIC | Draw Des

☐ 36. Document ID: US 5879939 A

L3: Entry 36 of 71 File: USPT Mar 9, 1999

US-PAT-NO: 5879939
DOCUMENT-IDENTIFIER: US 5879939 A

TITLE: Isolation of cells from organ tissue using sonication

DATE-ISSUED: March 9, 1999

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Gray; Brad	Huntington Beach	CA		
Baird; Monty Kahn	Garden Grove	CA		
Lamberti; Francis	Irvine	CA		

US-CL-CURRENT: 435/379; 435/325, 435/378, 435/380, 435/381

ABSTRACT:

A method for isolating specific viable cell types from surrounding organ tissue is provided. The method entails the use of sonication in conjunction with tissue dissociating agents to free the cells of interest. A specific application of the method is the isolation of the insulin producing tissue of the pancreas, the islets of Langerhans. The method results in a high yield of islets that maintain a high level of viability.

33 Claims, 0 Drawing figures
Exemplary Claim Number: 1

Full | Title | Citation | Front | Review | Classification | Date | Reference | Claims | KWIC | Draw Des

☐ 37. Document ID: US 5866417 A

L3: Entry 37 of 71 File: USPT Feb 2, 1999

US-PAT-NO: 5866417
DOCUMENT-IDENTIFIER: US 5866417 A

TITLE: Method of tissue transfer

DATE-ISSUED: February 2, 1999

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Matyas; John R.	Calgary, Alberta			CA

Rattner; Jerome B. Calgary Alberta CA

US-CL-CURRENT: 435/378; 435/174

ABSTRACT:

The Tissue Transfer method consists of transferring intact, organized cells from the surfaces of biological tissues or organs to a transfer substrate. A surface of the tissue or organ is selected, in most cases, a freshly cut surface. At least one layer of intact cells is transferred by adhesion of the cells to a transfer substrate, which is a membrane, film, plate or liquid layer bound to a solid structure. The substrate is brought into contact with the selected surface and removed. A layer of cells is removed by the adhesion of the cells to the substrate and the cells retain the organization of the organ or tissue.

3 Claims, 18 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 6

☐ 38. Document ID: US 5866414 A

L3: Entry 38 of 71 File: USPT Feb 2, 1999

US-PAT-NO: 5866414
DOCUMENT-IDENTIFIER: US 5866414 A

TITLE: Submucosa gel as a growth substrate for cells

DATE-ISSUED: February 2, 1999

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Badylak; Stephen F.	West Lafayette	IN	47906	
Voytik; Sherry	Lafayette, Indiana	IN	47905	
Boder; George	Martinsville	IN	46151	

US-CL-CURRENT: 435/325; 424/551, 435/366, 435/378, 435/408, 623/915

ABSTRACT:

A cell culture growth substrate comprising submucosal tissue of a warm-blooded ... vertebrate and a method for culturing eukaryotic cells are described. Submucosal tissue used in accordance with the present invention supports the proliferation and differentiation of eukaryotic cells when said cells are contacted with submucosal tissue under conditions conducive to cell proliferation.

5 Claims, 0 Drawing figures
Exemplary Claim Number: 1

☐ 39. Document ID: US 5856186 A

L3: Entry 39 of 71 File: USPT Jan 5, 1999

US-PAT-NO: 5856186
DOCUMENT-IDENTIFIER: US 5856186 A

TITLE: Method for producing a highly enriched population of osteoclast cells

DATE-ISSUED: January 5, 1999

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Rodan; Sevgi B.	Bryn Mawr	PA		
Wesolowski; Gregg	Lansdale	PA		
Rodan; Gideon A.	Bryn Mawr	PA		

US-CL-CURRENT: 435/372; 435/325, 435/366, 435/373, 435/378, 435/383

ABSTRACT:

Methods of obtaining enriched populations of osteoclast precursor cells which can be released from tissue culture dishes and used for biochemical studies are described. Osteoblastic cells and bone marrow cells are co-cultured. Next a .alpha..sub.v .beta..sub.3 receptor ligand, such as echistatin is used for cell detachment. The result is an 75-95% pure enriched population of tartrate resistant acid phosphatase (TRAP.sup.+) cells, in high yields (2-3.times.10.sup.6 cells per experiment) can be obtained. These cells are mostly mononucleated and based on their characteristics are considered to be pre-fusion osteoclasts (pOC cells). The precursor osteoclasts can be reseeded onto osteoblasts to obtain an enriched population of mature, multinucleated osteoclast cells.

6 Claims, 0 Drawing figures
Exemplary Claim Number: 1

☐ 40. Document ID: US 5851833 A

L3: Entry 40 of 71 File: USPT Dec 22, 1998

US-PAT-NO: 5851833
DOCUMENT-IDENTIFIER: US 5851833 A

TITLE: Neomorphogenesis of urological structures in vivo from cell culture

DATE-ISSUED: December 22, 1998

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Atala; Anthony	Newton	MA		

US-CL-CURRENT: 435/378; 424/422, 424/423, 424/426, 424/486, 435/1.1, 435/380, 435/395, 435/402

ABSTRACT:

Methods and artificial matrices for the growth and implantation of urological structures and surfaces are disclosed in which urothelial cells are grown in culture on biodegradable, biocompatible, fibrous matrices formed of polymers, such as polyglycolic acid, polylactic acid, or other polymers which degrade over time. The cells can be cultured in vitro until an adequate cell volume and density has developed for the cells to survive and proliferate in vivo. Alternatively, when adequate cell numbers for implantation are available, the cells can be attached to the matrix and implanted directly, without proliferation in vitro. The implants approximate the desired urological structure to be replaced or repaired, such as the kidney, urether, bladder, urethra, and the like. Implantation is followed by remodeling through cell growth and proliferation in vivo. In another aspect of the invention, techniques are disclosed for selectively extracting or harvesting urothelial cells either from excised urological tissue in vitro or from intact urological tissue in vivo by treating the tissue with a digestive enzyme, such as collagenase.

8 Claims, 0 Drawing figures
Exemplary Claim Number: 1

☐ 41. Document ID: US 5851756 A

L3: Entry 41 of 71 File: USPT Dec 22, 1998

US-PAT-NO: 5851756
DOCUMENT-IDENTIFIER: US 5851756 A
**** See image for Certificate of Correction ****

TITLE: Method for in vitro proliferation of dendritic cell precursors and their use to produce immunogens

DATE-ISSUED: December 22, 1998

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Steinman; Ralph M.	Westport	CT		
Inaba; Kayo	Kyoto			JP
Schuler; Gerold	Innsbruck			AT

US-CL-CURRENT: 435/2; 435/325, 435/355, 435/372, 435/378, 435/384, 435/395, 530/351

ABSTRACT:

A method for producing proliferating cultures of dendritic cell precursors is provided. Also provided is a method for producing mature dendritic cells in culture from the proliferating dendritic cell precursors. The cultures of mature dendritic cells provide an effective means of producing novel T cell dependent antigens comprised of dendritic cell modified antigens or dendritic cells pulsed with antigen, including particulates, which antigen is processed and expressed on the antigen-activated dendritic cell. The novel antigens of the invention may be used as immunogens for vaccines or for the treatment of disease. These antigens may also be used to treat autoimmune diseases such as juvenile diabetes and multiple sclerosis.

38 Claims, 53 Drawing figures

Exemplary Claim Number: 1
Number of Drawing Sheets: 20

Full | Title | Citation | Front | Review | Classification | Date | Reference | Claims | KWMC | Draw Des

☐ 42. Document ID: US 5849584 A

L3: Entry 42 of 71 File: USPT Dec 15, 1998

US-PAT-NO: 5849584
DOCUMENT-IDENTIFIER: US 5849584 A

TITLE: Cell cultures of and cells culturing method for nontransformed parotid cells

DATE-ISSUED: December 15, 1998

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Coon; Hayden G.	Gaithersburg	MD		
Ambesi-Impiombato; Francesco Saverio	Tricesimo			IT
Curcio; Francesco	Pagnacco			IT

US-CL-CURRENT: 435/366; 435/325, 435/378, 435/382, 435/383, 435/391

ABSTRACT:

The present invention provides a method for producing an expanded non-transformed cell culture comprising the steps of: (1) preparing partially purified, minced tissue; (2) concentrating the resulting cells and tissue pieces; (3) resuspending the concentrated tissue cells and pieces in a culture medium capable of supporting sustained cell division that is contained in a culture vessel; (4) incubating the cells; and (5) passaging the cells periodically. The present invention further provides clonal strains of cells derived from the above-mentioned cell culture, medium and conditioned medium designed for the culturing of parotid cells and other glandular cells such as pancreatic, thyroid, and parathyroid, and cells, and the use of cultured pancreatic cells to form pancreatic pseudotissues composed of matrix-embedded aggregated (pseudoislets) or individual cells, to treat blood sugar disorders in mammals, and to test for cytotoxicity and autoimmune activities with reference to pancreatic endocrine cells. The nontransformed cells are cultured in a growth medium comprising a suitable basal medium supplemented with effective concentrations of hypothalamus and pituitary extracts, and serum.

17 Claims, 18 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 11

Full | Title | Citation | Front | Review | Classification | Date | Reference | Claims | KWMC | Draw Des

☐ 43. Document ID: US 5830708 A

L3: Entry 43 of 71 File: USPT Nov 3, 1998

US-PAT-NO: 5830708
DOCUMENT-IDENTIFIER: US 5830708 A

TITLE: Methods for production of a naturally secreted extracellular matrix

DATE-ISSUED: November 3, 1998

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Naughton; Gail K.	La Jolla	CA		

US-CL-CURRENT: 435/70.1; 435/366, 435/368, 435/371, 435/372, 435/373, 435/378, 435/395, 514/8

ABSTRACT:

The present invention is directed to methods for producing naturally secreted human extracellular matrix material and compositions containing the extracellular matrix material. The method includes culturing extracellular matrix-secreting human stromal cells on a biocompatible three-dimensional framework in vitro. After secretion of the extracellular matrix onto the framework, the stromal cells are killed and the cells and cellular contents are removed from the framework. The extracellular matrix material deposited on the framework is collected and further processed to obtain a physiologically acceptable compositions. The compositions of the present invention are useful for the repair of soft tissue and skin defects, including wrinkles and scars.

10 Claims, 1 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 1

☐ 44. Document ID: US 5744347 A

L3: Entry 44 of 71 File: USPT Apr 28, 1998

US-PAT-NO: 5744347
DOCUMENT-IDENTIFIER: US 5744347 A

TITLE: Yolk sac stem cells and their uses

DATE-ISSUED: April 28, 1998

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Wagner; Thomas E.	Albany	OH		
Antczak; Michael R.	Albany	OH		

US-CL-CURRENT: 435/354; 435/355, 435/378, 435/401, 435/7.21

ABSTRACT:

The present invention is directed to mammalian yolk sac stem cells. In particular, it relates to the characterization, culturing, long-term expansion and uses of yolk sac stem cells for in vivo reconstitution and therapy. Yolk sac stem cells isolated from the early embryonic yolk sac prior to blood island formation exhibit a homogeneous morphology and a primitive cell surface phenotype without the expression of mature leukocyte markers and major histocompatibility complex-encoded antigens. The cells

can be cultured and expanded long-term with minimal differentiation, and without alteration of their pluripotency. However, such cells can be induced to express various blood cell markers upon stimulation with specific cytokines. In addition, the cells also express certain endothelial cell markers and growth characteristics. Such yolk sac cells may be particularly effective in the reconstitution of a lymphohematopoietic system, as they are capable of forming both endothelial cells and blood cells. Therefore, yolk sac stem cells may have a wide range of applications including but not limited to the reconstitution of a destroyed or deficient human hematopoietic system, and the construction of large and small animal models for the production of human blood cells, human antibodies, and testing of human diseases, immune function, vaccines, drugs and immunotherapy.

36 Claims, 50 Drawing figures
Exemplary Claim Number: 1,19
Number of Drawing Sheets: 26

☐ 45. Document ID: US 5646035 A

L3: Entry 45 of 71 File: USPT Jul 8, 1997

US-PAT-NO: 5646035
DOCUMENT-IDENTIFIER: US 5646035 A

TITLE: Method for preparing an expanded culture and clonal strains of pancreatic, thyroid or parathyroid cells

DATE-ISSUED: July 8, 1997

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Coon; Hayden G.	Gaithersburg	MD		
Ambesi-Impiombato; Francesco Saverio	Tricesimo			IT
Curcio; Francesco	Pagnacco			IT

US-CL-CURRENT: 435/378; 435/383, 435/397

ABSTRACT:

The present invention provides a method for producing an expanded non-transformed cell culture comprising the steps of: (1) preparing partially purified, minced tissue; (2) concentrating the resulting cells and tissue pieces; (3) resuspending the concentrated tissue cells and pieces in a culture medium capable of supporting sustained cell division that is contained in a culture vessel; (4) incubating the cells; and (5) passaging the cells periodically. The present invention further provides clonal strains of cells derived from the above-mentioned cell culture, medium and conditioned medium designed for the culturing of such cells, including pancreatic, thyroid, parathyroid, and parotid cells, and the use of cultured pancreatic cells to form pancreatic pseudotissues composed of matrix-embedded aggregated (pseudoislets) or individual cells, to treat blood sugar disorders in mammals, and to test for cytotoxicity and autoimmune activities with reference to pancreatic endocrine cells.

16 Claims, 18 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 11

☐ 46. Document ID: US 5639654 A

L3: Entry 46 of 71 File: USPT Jun 17, 1997

US-PAT-NO: 5639654
DOCUMENT-IDENTIFIER: US 5639654 A

TITLE: Process for creating a skin substitute and the resulting skin substitute

DATE-ISSUED: June 17, 1997

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Bernard; Bruno	Antibes			FR
Lenoir; Maris-Cecile	Valbonne			FR
Shroot; Braham	Antibes			FR
Darmon; Yves-Michel	Antibes			FR
Asselineau; Daniel	Valbonne			FR

US-CL-CURRENT: 435/325; 424/574, 424/78.06, 435/1.1, 435/347, 435/378, 435/395, 435/70.1, 602/42, 602/43, 602/44, 602/45 , 602/46, 606/132

ABSTRACT:

The invention concerns a process for obtaining a skin substitute and the skin substitute itself. According to this process, a dermis substitute is prepared by mixing contractile cells, a nutritive medium, and collagen, in order to form a contracting gel; this dermis substitute is used as a substrate for an epidermis substitute obtained by culturing, using keratinocytes from an animal or human skin sample. According to the invention, the substrate is implanted with at least one section of a hair follicle retaining at least partially its cellular sheath, this section being implanted perpendicularly to the free surface of the substrate.

21 Claims, 5 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 2

Full | Title | Citation | Front | Review | Classification | Date | Reference | Claims | KWIC | Draw. Desc

☐ 47. Document ID: US 5635387 A

L3: Entry 47 of 71 File: USPT Jun 3, 1997

US-PAT-NO: 5635387
DOCUMENT-IDENTIFIER: US 5635387 A

TITLE: Methods and device for culturing human hematopoietic cells and their precursors

DATE-ISSUED: June 3, 1997

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Fei; Rui G.	Seattle	WA		
Heimfeld; Shelly	Woodinville	WA		
Minshall; Billy W.	Mill Creek	WA		
Berenson; Ronald J.	Mercer Island	WA		

US-CL-CURRENT: 435/378; 424/529, 435/384, 435/403

ABSTRACT:

Methods for increasing the number of human hematopoietic precursor cells in vitro are provided. The methods generally comprise (a) separating human hematopoietic precursor cells from mature hematopoietic cells present in a blood product; (b) inoculating the separated precursor cells into a culture vessel containing a culture medium comprising a nutritive medium and a source of growth factors at a density of between 1.times.10.sup.3 cells/ml and 4.times.10.sup.6 cells/ml; and (c) culturing the cells under conditions and for a time sufficient to increase the number of precursor cells relative to the number of such cells present in the blood product. The culture medium may also include a suitable amount of microcarrier beads. Suitable blood products include bone marrow, umbilical cord blood, and peripheral blood. A device for carrying out such methods is also provided.

28 Claims, 6 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 5

☐ 48. Document ID: US 5635386 A

L3: Entry 48 of 71 File: USPT Jun 3, 1997

US-PAT-NO: 5635386
DOCUMENT-IDENTIFIER: US 5635386 A

TITLE: Methods for regulating the specific lineages of cells produced in a human hematopoietic cell culture

DATE-ISSUED: June 3, 1997

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Palsson; Bernhard O.	Ann Arbor	MI		
Armstrong; R. Douglas	Ann Arbor	MI		
Clarke; Michael F.	Ann Arbor	MI		
Emerson; Stephen G.	Ann Arbor	MI		

US-CL-CURRENT: 435/372; 435/373, 435/375, 435/378, 435/395

ABSTRACT:

Methods, including culture media conditions, which provide for in vitro human stem cell division and/or the optimization of human hematopoietic progenitor cell cultures and/or increasing the metabolism or GM-CSF secretion or IL-6 secretion of human

stromal cells and/or a method for assaying the effect of a substance or condition on a human hematopoietic cell population, and/or depleting the malignant cell or T-cell and B-cell content of a human hematopoietic cell population are disclosed. The methods rely on culturing human stem cells and/or human hematopoietic progenitor cells and/or human stromal cells in a liquid culture medium which is replaced, preferably perfused, either continuously or periodically, at a rate of 1 ml of medium per ml of culture per about 24 to about 48 hour period, and removing metabolic products and replenishing depleted nutrients while maintaining the culture under physiologically acceptable conditions. Optionally, growth factors are added to the culture medium. The disclosed culture conditions afford improved methods for bone marrow transplantation.

57 Claims, 0 Drawing figures
Exemplary Claim Number: 1

☐ 49. Document ID: US 5599705 A

L3: Entry 49 of 71 File: USPT Feb 4, 1997

US-PAT-NO: 5599705
DOCUMENT-IDENTIFIER: US 5599705 A

TITLE: In vitro method for producing differentiated universally compatible mature human blood cells

DATE-ISSUED: February 4, 1997

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Cameron; Robert B.	Agoura Hill	CA	91303-3510	

US-CL-CURRENT: 435/378; 435/384, 435/385, 435/386

ABSTRACT:

In vitro production of clinically useful quantities of mature, differentiated human blood cells by a method in which human pluripotent hematopoietic stem cells, preferably from a universal donor, are incubated in a bioreactor in a growth medium also containing specific recombinant human growth and maturation promoting polypeptide factors in combinations that expand stem cell cultures and promote the maturation and differention of stem cells into erythroid, thrombocytic or granulocytic human blood cells, and harvesting the mature cells. The growth and maturation promoting polypeptides employed include SCGF, Interleukins 1,3,4,5,6, and 11, GM-CSF, M-CSF, G-CSF and EPO. Stem cells may be modified so as to remove histocompatibility and/or blood group antigens, or may be genetically altered by transfection with appropriate DNA-containing vectors, prior to addition to the bioreactor. Erythrocytes prepared in large quantities by this method are a good source of iron, as iron-saturated hemoglobin, for use in iron replacement therapy.

14 Claims, 1 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 1

☐ 50. Document ID: US 5576207 A

L3: Entry 50 of 71 File: USPT Nov 19, 1996

US-PAT-NO: 5576207
DOCUMENT-IDENTIFIER: US 5576207 A

TITLE: Method of expanding hepatic precursor cells

DATE-ISSUED: November 19, 1996

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Reid; Lola M.	Chapel Hill	NC		
Agelli; Maria	Summit	NJ		
Ochs; Andreas	Bronx	NY		

US-CL-CURRENT: 435/378; 435/370, 435/400, 435/401, 435/402

ABSTRACT:

A composition which comprises an animal cell population, and which contains immature animal cells. The immature animal cells are characterized by expression of alpha-fetoprotein or lack of essential expression of alpha-fetoprotein and albumin, and at least a portion of said immature animal cells or at least a portion of the progeny of said immature cells is capable of differentiating into cells which express albumin. The cell population is cultured under conditions which result in expansion of the cells. Expansion of the cells may be achieved by culturing the cells in the presence of an extracellular matrix and liver stromal cells; and preferably in the presence of growth factors. Such cells may be used for liver transplantation, artificial livers, and for toxicology and pharmacology studies. Such cells may also be genetically engineered to express proteins or polypeptides of interest.

13 Claims, 0 Drawing figures
Exemplary Claim Number: 1

☐ 51. Document ID: US 5559022 A

L3: Entry 51 of 71 File: USPT Sep 24, 1996

US-PAT-NO: 5559022
DOCUMENT-IDENTIFIER: US 5559022 A

TITLE: Liver reserve cells

DATE-ISSUED: September 24, 1996

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Naughton; Brian A.	El Cajon	CA		
Sibanda; Benson	Oceanside	CA		

US-CL-CURRENT: 435/370; 424/93.1, 435/379

ABSTRACT:

The present invention relates to liver reserve or progenitor cells. In particular, it relates to the isolation, characterization, culturing, and uses of liver reserve cells. Liver reserve cells isolated by density gradient centrifugation can be distinguished from other liver parenchymal cells by their morphology, staining characteristics, high proliferative activity and ability to differentiate in vitro. In long-term cultures described herein, these cells expand in numbers and differentiate into morphologically mature liver parenchymal cells, capable of mediating liver-specific functions. Therefore, isolated liver reserve cells may have a wide range of applications, including, but not limited to, their uses as vehicles of exogenous genes in gene therapy, and/or to replace and reconstitute a destroyed, infected, or genetically deficient mammalian liver by transplantation.

11 Claims, 19 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 18

☐ 52. Document ID: US 5503981 A

L3: Entry 52 of 71 File: USPT Apr 2, 1996

US-PAT-NO: 5503981
DOCUMENT-IDENTIFIER: US 5503981 A

TITLE: Isolation of fetal cells from maternal blood to enable prenatal diagnosis

DATE-ISSUED: April 2, 1996

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Mueller; Utz W.	Torens Park			AU
Hawes; Catherine S.	Fullarton			AU

US-CL-CURRENT: 435/7.21; 435/378, 435/7.92, 435/70.21, 435/968, 436/526, 436/548, 530/388.2

ABSTRACT:

This invention relates to a method for the isolation of trophoblast (placental) cells from the blood of a pregnant mammal so as to provide the essential starting material, namely cells derived from the fetus, to enable genetic and/or biochemical information about the fetus to be obtained. In particular, this invention relates to the use of monoclonal antibodies specific for membrane protein markers on mammalian trophoblasts to isolate trophoblast cells from maternal blood. These cells may then be used to obtain fetal genetic and/or biochemical information early in pregnancy. The present invention is particularly relevant for detecting human fetal abnormalities.

12 Claims, 1 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 1

☐ 53. Document ID: US 5447861 A

L3: Entry 53 of 71 File: USPT Sep 5, 1995

US-PAT-NO: 5447861
DOCUMENT-IDENTIFIER: US 5447861 A

TITLE: Continuous mammalian cell lines having monocyte/macrophage characteristics and their establishment in vitro

DATE-ISSUED: September 5, 1995

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Collins; Geary W.	Wilmington	DE		
Largen; Michael T.	Newark	DE		

US-CL-CURRENT: 435/378; 435/387, 435/389, 435/392

ABSTRACT:

Continuous mammalian cell lines having characteristics of immature monocytes and/or macrophages which have been established from normal mammalian cells, continuous human cell lines having characteristics of immature monocytes and/or macrophages which are substantially free of malignant cells, and a method for establishing such cell lines through long-term culturing of normal mammalian cells with periodic, partial medium changes during culturing are provided.

4 Claims, 0 Drawing figures
Exemplary Claim Number: 1

Full | Title | Citation | Front | Review | Classification | Date | Reference | Claims | KWIC | Draw. Desc

☐ 54. Document ID: US 5378624 A

L3: Entry 54 of 71 File: USPT Jan 3, 1995

US-PAT-NO: 5378624
DOCUMENT-IDENTIFIER: US 5378624 A
**** See image for Certificate of Correction ****

TITLE: Methods for removing ligands from a particle surface

DATE-ISSUED: January 3, 1995

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Berenson; Ronald J.	Mercer Island	WA		
Peterson; Dale R.	Bothell	WA		

US-CL-CURRENT: 435/239; 435/243, 435/254.1, 435/261, 435/325, 435/378, 436/541,

436/824, 436/828

ABSTRACT:

A method is provided for removing a second ligand from a particle surface without substantially affecting the particle surface, comprising the step of exposing the particle to a first ligand immobilized onto a support, wherein the particle is exposed under conditions and for a residence time sufficient to allow the second ligand to desorb from the particle surface, and wherein the first ligand has an affinity for the second ligand that is at least two orders of magnitude greater than the affinity of the second ligand for the particle surface, such that the second ligand is removed from the particle surface without substantially affecting the particle surface.

8 Claims, 0 Drawing figures
Exemplary Claim Number: 1

☐ 55. Document ID: US 5328843 A

L3: Entry 55 of 71 File: USPT Jul 12, 1994

US-PAT-NO: 5328843
DOCUMENT-IDENTIFIER: US 5328843 A

TITLE: Method for allocating cells and cell allocation device

DATE-ISSUED: July 12, 1994

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Fukuda; Jun	Shibuya-ku, Tokyo			JP
Kawaguchi; Hideo	Saitama			JP
Ushiroda; Takejiro	Saitama			JP
Shimizu; Norio	Sayama			JP
Sato; Kazuo	Tokyo			JP

US-CL-CURRENT: 435/378; 422/947, 435/283.1, 435/309.1, 435/396, 435/402

ABSTRACT:

Apertures in a definite shape having a definite width and length are provided on one surface of a plate material having a definite thickness. One end of the apertures is connected with the other surface of the plate material and at the same time, is opened. Another end of the apertures is connected with the plate material on one surface and is also opened toward the other surface of a culture substrate. The plate material is closely contacted to one surface of the culture substrate for allocating nerve cells and observing growth of the neurites. Then, the cell suspension is supplied to the apertures. The cells in the suspension are allocated on the culture substrate in response to the apertures by centrifugation or spontaneous sedimentation. The plate material is then withdrawn.

48 Claims, 32 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 15

☐ 56. Document ID: US 5308763 A

L3: Entry 56 of 71 File: USPT May 3, 1994

US-PAT-NO: 5308763
DOCUMENT-IDENTIFIER: US 5308763 A

TITLE: Method of making primary culture of olfactory neurons

DATE-ISSUED: May 3, 1994

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Ronnett; Gabriele V.	Baltimore	MD		
Hester; Lynda	Towson	MD		
Snyder; Solomon H.	Baltimore	MD		

US-CL-CURRENT: 435/379

ABSTRACT:

A method of producing primary cultures of olfactory neurons which are purified from sustentacular cells and basal cells. The neuronal cells demonstrate responsiveness to physiologic levels of odorants and express Olfactory Marker Protein (OMP). The steps required to obtain the primary cultures are:

1. providing olfactory epithelium of an animal;

2. dissociation of neuronal cells using enzymatic digestion;

3. filtering using a mesh filter having a pore size between 10 and 25 microns to separate cell aggregates;

4. removal of the cell aggregates; and

5. plating the dissociated neuronal cells in a nutrient medium containing D-valine, Nerve Growth Factor (NGF), and other significant ingredients to obtain a culture of olfactory neurons. In addition to OMP the neurons are capable of expressing vimentin, neuron-specific enolase but not expressing glial fibrillary acidic proteins, S-100 protein, keratin, or neurofilament protein.

10 Claims, 63 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 9

Full | Title | Citation | Front | Review | Classification | Date | Reference | Claims | KWMC | Draw. Des

☐ 57. Document ID: US 5215927 A

L3: Entry 57 of 71 File: USPT Jun 1, 1993

US-PAT-NO: 5215927
DOCUMENT-IDENTIFIER: US 5215927 A
**** See image for Certificate of Correction ****

TITLE: Method for immunoselection of cells using avidin and biotin

DATE-ISSUED: June 1, 1993

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Berenson; Ronald J.	Bellevue	WA		
Bensinger; William I.	Seattle	WA		

US-CL-CURRENT: 436/541; 424/93.71, 435/177, 435/379, 435/7.21, 435/7.24, 436/501, 436/538, 530/388.7, 530/388.73

ABSTRACT:

The selectivity of immunoselection systems employing insolubilized avidin and biotinylated specific antibody is amplified, and nonspecific recovery is improved, by employing an indirect sandwich technique using a biotin-conjugated antispecies immunoglobulin that is directed to one or more nonbiotinylated specific antibodies in conjunction with insolubilized avidin. Specific cell populations can be removed and recovered from bone marrow, providing excellent recovery of bone marrow and preservation of hematopoietic stem cells for transplantation. Mixed populations of T cells or of tumor cells can be conveniently and simultaneously removed with minimal manipulation of the marrow cells. An improved positive immunoselection method provides viable and functional recovered cells, e.g., hematopoietic stem cells or activated killer cells, that can be clinically employed.

5 Claims, 9 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 9

☐ 58. Document ID: US 5035708 A

L3: Entry 58 of 71 File: USPT Jul 30, 1991

US-PAT-NO: 5035708
DOCUMENT-IDENTIFIER: US 5035708 A

TITLE: Endothelial cell procurement and deposition kit

DATE-ISSUED: July 30, 1991

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Alchas; Paul G.	Wayne	NJ		
Augello; Frank A.	Cedar Knolls	NJ		
Brooks; Christopher J.	Glen Cove	NY		
Cutshall; Tony A.	Boonton	NJ		
DiPisa, Jr.; Joseph A.	Wyckoff	NJ		
Williams; Stuart K.	Wilmington	DE		

Gabel; Jonathan B.	Clifton	NJ
Mulhauser; Paul J.	New York	NY
Prais; Wes	Hewitt	NJ
Jarrell; Bruce E.	Philadelphia	PA
Rose; Deborah G.	Warrington	PA

US-CL-CURRENT: 623/1.45; 435/1.1, 435/379, 600/36, 604/319, 604/35, 604/48, 604/902

ABSTRACT:

The invention is an endothelial cell procurement and deposition kit for collecting fat from a patient, processing said fat to produce an endothelial cell deposition product, and depositing said product on the surface of a graft, all under sterile conditions established and maintained within the components of said kit comprised of: fat collection means for collecting subcutaneous fat from a patient; digestion means connectable to said fat collection means to maintain sterility during reception of said fat and for retaining said fat under sterile conditions during rinsing and digestion to produce a digested product; endothelial cell isolation means connectable to said digestion means for maintaining sterile conditions during reception of said digested product and for separating and isolating microvessel endothelial cells from said digested product to produce an endothelial cell product; cell deposition means connectable to said isolation means for maintaining sterile conditions during reception of said endothelial cell product and for depositing said cells on the surface of a graft to be implanted in a patient and facilitating implantation of said endothelial graft into a patient.

18 Claims, 17 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 12

☐ 59. Document ID: US 4937187 A

L3: Entry 59 of 71 File: USPT Jun 26, 1990

US-PAT-NO: 4937187
DOCUMENT-IDENTIFIER: US 4937187 A

TITLE: Methods for separating malignant cells from clinical specimens

DATE-ISSUED: June 26, 1990

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Rotman; M. Boris	Jamestown	RI		

US-CL-CURRENT: 435/30; 435/261, 435/267, 435/268, 435/34, 435/379, 435/381, 435/803, 436/63, 436/800, 436/813

ABSTRACT:

Fragments of a biopsy sample on the order of about 50 to 5000 cells are preferred for establishing viable tumor cell cultures for purposes such as establishing cell lines, chemotherapeutic assays and the like. Such fragments retain the three-dimensional cellular structure or organization of the original tumor and, therefore, can be

cultured more readily. To obtain such fragments suitable for culturing, the biopsy sample can be enzymatically digested in a proteolytic or nucleolytic enzyme, such as collagenase, or by mechanical dissociation, or both where necessary. The fragments can then be suspended in an aqueous medium so that non-aggregated cells (e.g., red blood cells, lymphocytes, macrophages) and cellular debris will form a supernatant while the remaining fragments containing aggregated tumor cells are deposited in a sediment layer. Preferably, the medium is an isotonic tissue culture medium and decantation is conducted at least twice; first in a serum-containing medium and then, secondly, in a serum-free medium. Fragments containing living tumor cells can be selected by fluorochromasia, that is, by contacting the sedimented layer with a fluorogenic substrate such that viable tumor cells take up and hydrolyse the substrate, and then exhibit fluorescence. Cytotoxicity assay protocols employing tumor cell aggregates prepared by the present techniques are also disclosed.

19 Claims, 0 Drawing figures
Exemplary Claim Number: 1

☐ 60. Document ID: US 4929542 A

L3: Entry 60 of 71 File: USPT May 29, 1990

US-PAT-NO: 4929542
DOCUMENT-IDENTIFIER: US 4929542 A

TITLE: In vitro screening test for mutagenicity and genotoxicity during spermatogenesis

DATE-ISSUED: May 29, 1990

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Risley; Michael S.	City Island	NY		

US-CL-CURRENT: 435/2; 435/243, 435/244, 435/29, 435/379, 435/4, 435/406, 435/809

ABSTRACT:

An in vitro screening test for identifying mutagenic and genotoxic agents during spermatogenesis, comprising: (1) Culturing Xenopus testis explants in vitro in the presence of one or more suspected mutagenic and/or genotoxic agent(s); (2) Removing said one or more suspected agent(s) and continue culturing said Xenopus testis explants such that spermatogonia in said Xenopus testis explants undergo spermatogenesis; (3) Isolating sperm and/or one or more types of spermatogenic cells at various times during step (2); and (4) Determining the mutagenic and/or genotoxic affect of said agent(s). A novel medium suitable for culturing Xenopus testis explants. A novel method for culturing Xenopus testis explants in vitro such that cells at all stages of the spermatogenic cycle are produced comprising culturing Xenopus tests fragments in the novel medium under an atmosphere of air and at a temperature in a range of from about 20.degree. C. to about 24.degree. C.

12 Claims, 8 Drawing figures
Exemplary Claim Number: 1,9
Number of Drawing Sheets: 4

☐ 61. Document ID: US 4814434 A

L3: Entry 61 of 71 File: USPT Mar 21, 1989

US-PAT-NO: 4814434
DOCUMENT-IDENTIFIER: US 4814434 A

TITLE: Inducer of T-suppressor cells

DATE-ISSUED: March 21, 1989

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Goldfarb; Marcia F.	Portland	ME		

US-CL-CURRENT: 530/380; 424/580, 435/373, 435/378, 514/2, 530/395, 530/399, 530/413, 530/414, 530/415, 530/837

ABSTRACT:

A biologically active composition extracted from thymus tissue, capable of inducing immature bone marrow cells to differentiate into competent suppressor T-cells.

8 Claims, 0 Drawing figures
Exemplary Claim Number: 1

Full | Title | Citation | Front | Review | Classification | Date | Reference | Claims | KWMC | Draw Desc

☐ 62. Document ID: US 4721096 A

L3: Entry 62 of 71 File: USPT Jan 26, 1988

US-PAT-NO: 4721096
DOCUMENT-IDENTIFIER: US 4721096 A

TITLE: Process for replicating bone marrow in vitro and using the same

DATE-ISSUED: January 26, 1988

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Naughton; Brian A.	Yorktown Heights	NY		
Naughton; Gail K.	Yorktown Heights	NY		

US-CL-CURRENT: 128/898; 435/374, 435/379

ABSTRACT:

According to the present invention there is provided a process for treating a person whose bone marrow has been destroyed or lost its functional ability. The process includes the steps of obtaining bone marrow from a donor, cryopreserving the marrow,

replicating the bone marrow cells in vitro, and then infusing the replicated bone marrow cells into a person whose bone marrow has been destroyed or functionally compromised by disease or the treatment of disease. The person receiving the replicated bone marrow infusion may be the donor or another person. There is also disclosed a process for replicating bone marrow in vitro.

12 Claims, 0 Drawing figures
Exemplary Claim Number: 1

Full | Title | Citation | Front | Review | Classification | Date | Reference | Claims | KWIC | Draw. Des

---

☐ 63. Document ID: US 4670394 A

L3: Entry 63 of 71 File: USPT Jun 2, 1987

US-PAT-NO: 4670394
DOCUMENT-IDENTIFIER: US 4670394 A

TITLE: Isolation and culture of adrenal medullary endothelial cells producing blood clotting factor VIII:C

DATE-ISSUED: June 2, 1987

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Pollard; Harvey B.	Potomac	MD		
Ornberg; Richard	Bethesda	MD		
Banerjee; Dipak	Rockville	MD		
Youdim; Moussa	Rockville	MD		
Lelkes; Peter	Rockville	MD		
Heldman; Eli	Rockville	MD		

US-CL-CURRENT: 435/70.3; 435/325, 435/378, 435/392, 435/948, 530/383

ABSTRACT:

The present invention discloses a new line of endothelial cell of adrenal medullary origin capable of producing blood clotting Factor VIII:C. A method of isolating and culturing said cell line has also been disclosed. Factor VIII:C is useful in treating hemophilia.

10 Claims, 6 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 5

Full | Title | Citation | Front | Review | Classification | Date | Reference | Claims | KWIC | Draw. Des

---

☐ 64. Document ID: US 4350768 A

L3: Entry 64 of 71 File: USPT Sep 21, 1982

US-PAT-NO: 4350768
DOCUMENT-IDENTIFIER: US 4350768 A

TITLE: Method for preparing single cell suspension

DATE-ISSUED: September 21, 1982

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Tihon; Claude	Manlius	NY		
Curry; M. E.	Syracuse	NY		

US-CL-CURRENT: 435/379; 210/460, 241/169.2, 241/30, 435/803

ABSTRACT:

A method and apparatus for preparing a liquid suspension of single, independent tissue cells for, e.g., subsequent cell proliferation as by in vitro culturing, is disclosed. The method involves introducing the combination of subdivided tissue and liquid medium into a chamber defined in part by a foraminous wall portion, and contracting the chamber to force the tissue through the foraminous wall, thereby further subdividing the tissue. An apparatus embodiment includes the combination of confining means for confining a liquid suspension of tissue; a screen; means supporting the screen; and pump means for passing the liquid suspension of tissue from the confining means back and forth through the screen.

20 Claims, 8 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 4

☐ 65. Document ID: US 4326026 A

L3: Entry 65 of 71 File: USPT Apr 20, 1982

US-PAT-NO: 4326026
DOCUMENT-IDENTIFIER: US 4326026 A

TITLE: Method for fractionating cells

DATE-ISSUED: April 20, 1982

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Sarkar; Siddhartha	Solana Beach	CA		

US-CL-CURRENT: 435/2; 424/561, 435/378

ABSTRACT:

Enriched quantities of male and female sperm are obtained in physically separate fractions utilizing the hydrodynamic behavior of sperm in laminar flow. A flowcell fractionator is provided for performing the method, and includes a specially constructed pipette, valve and infusion pump combination.

9 Claims, 5 Drawing figures
Exemplary Claim Number: 1,9
Number of Drawing Sheets: 2

☐ 66. Document ID: US 4299819 A

L3: Entry 66 of 71 File: USPT Nov 10, 1981

US-PAT-NO: 4299819
DOCUMENT-IDENTIFIER: US 4299819 A
** See image for Certificate of Correction **

TITLE: Process for treating burn victims

DATE-ISSUED: November 10, 1981

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Eisinger; Magdalena G.	Demarest	NJ		

US-CL-CURRENT: 424/574; 435/1.1, 435/379, 435/392, 435/395, 623/915

ABSTRACT:

Burn victims are treated with human epidermis cells grown in tissue culture by separating the epidermis in human skin from the dermis, dissociating the epidermis into epidermal cells, and growing the epidermal cells in a tissue culture medium having a pH of from about 5.6 to 5.8.

13 Claims, 0 Drawing figures
Exemplary Claim Number: 1

Full | Title | Citation | Front | Review | Classification | Date | Reference | Claims | KWIC | Draw Desc

☐ 67. Document ID: US 4254226 A

L3: Entry 67 of 71 File: USPT Mar 3, 1981

US-PAT-NO: 4254226
DOCUMENT-IDENTIFIER: US 4254226 A

TITLE: Process for growing human epidermal cells in tissue culture

DATE-ISSUED: March 3, 1981

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Eisinger; Magdalena G.	Demarest	NJ		
Hefton; John M.	New York	NY		

US-CL-CURRENT: 435/379; 424/574, 435/235.1, 435/392

ABSTRACT:

Human epidermal cells are grown in tissue culture by separating the epidermis in human skin from the dermis, dissociating the epidermis into epidermal cells, and growing the epidermal cells in a tissue culture medium having a pH of from about 5.6 to about 5.8.

12 Claims, 0 Drawing figures
Exemplary Claim Number: 1

☐ 68. Document ID: US 3906929 A

L3: Entry 68 of 71 File: USPT Sep 23, 1975

US-PAT-NO: 3906929
DOCUMENT-IDENTIFIER: US 3906929 A
**** See image for Certificate of Correction ****

TITLE: Processes for reproduction of cellular bodies

DATE-ISSUED: September 23, 1975

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Augspurger; Lynn Lawrence	Birmingham	MI	48009	

US-CL-CURRENT: 600/34; 424/172.1, 424/184.1, 424/811, 435/2, 435/325, 435/378, 600/35

ABSTRACT:

Disclosed are processes for reproduction of cellular bodies of herbivorous and omnivorous mammals. The techniques include obtaining ova, preparation of recipients and transplant techniques. Methods of sex selection of spermatozoa are shown as well as several techniques for clonal production of like embryos.

26 Claims, 0 Drawing figures
Exemplary Claim Number: 1

☐ 69. Document ID: US 3854470 A

L3: Entry 69 of 71 File: USPT Dec 17, 1974

US-PAT-NO: 3854470
DOCUMENT-IDENTIFIER: US 3854470 A

TITLE: REPRODUCTION PROCESSES FOR CELLULAR BODIES

DATE-ISSUED: December 17, 1974

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Augspurger; Lynn Lawrence	Birmingham	MI	48009	

US-CL-CURRENT: 600/34; 424/561, 435/1.3, 435/2, 435/325, 435/374, 435/378

ABSTRACT:

Disclosed a process for making greater use of female gametes in herbivorous mannals. The techniques include methods of obtaining ova from donor, preparation of recipients, detection of oestrus, and transplant techniques. Also disclosed are methods of making greater desired use of ova of these mammals. Among those are techniques by sex determination, for freezing and thawing eggs, for tissue culture of eggs and for clonal production of like embroyos utilized for transplantation to achieve a greater number of clonal differentiated cellular bodies having like genetic characteristics.

100 Claims, 0 Drawing figures

Full | Title | Citation | Front | Review | Classification | Date | Reference | Claims | KWIC | Draw. Des.

☐ 70. Document ID: US 3702605 A

L3: Entry 70 of 71 File: USPT Nov 14, 1972

US-PAT-NO: 3702605
DOCUMENT-IDENTIFIER: US 3702605 A

TITLE: CELL DISPERSAL METHOD FOR MONKEY KIDNEY TISSUE

DATE-ISSUED: November 14, 1972

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Daly; William F.	Hillsdale	NJ		
Vallancourt; Ronald J.	Park Ridge	NJ		

US-CL-CURRENT: 128/898; 435/379, 435/381

ABSTRACT:

A method for increasing the cell yield from mammalian kidney tissue by perfusion of the decapsulated kidney in situ with a proteolytic enzyme under pressure and a means for dispersal of the cells by mechanical agitation.

11 Claims, 0 Drawing figures

Full | Title | Citation | Front | Review | Classification | Date | Reference | Claims | KWIC | Draw. Des.

☐ 71. Document ID: US 3843324 A

L3: Entry 71 of 71 File: USOC Oct 22, 1974

US-PAT-NO: 3843324
DOCUMENT-IDENTIFIER: US 3843324 A

TITLE: METHOD OF CELL FRACTIONATION AND APPARATUS THEREFOR

DATE-ISSUED: October 22, 1974

US-CL-CURRENT: 435/2; 422/101, 435/261, 435/308.1, 435/317.1, 435/379, 436/529, 436/531

DOCUMENT TEXT:

Oct. 22, 1974 G. M. EDELMAN ET AL 3@843,324 METIIOD OF CBLL f'RACTIONATION AN[). AP PARATUS THEREFOR Fi.led Sept. 13, 1972 -2 Sheets-Shect, 1. -/o 12 F I G O 2 1 /0 ('2 0 - - . O 0 - - o 0 r 1 6 F l@Ge 3 24 -T II I FIG-4 60 6,4 61 6 6 56 40 5211 54 15

Oct. 22, 1974 G. M. EDELMAN ET AL 3t843p324 METHOD OF CELL FRACTIONATION AND APP ARATUS THEAEFOR Filed Sept. 13, 1972 2 Sheets-Sheet 2 tn L A J L4j -N - ,j Lii -_j LU u Lu LL LU LJ Lu L-L y y LL L4LJ 0 0 0 0 LI ():j

United States Patent Office 39843@324 3,843,324 METHOD OF CELL FRACTIONATION iiND APPARATUS THEREFOR Gerald M. Edelman, John L. Wang, Urs S. Rutishauser, and Clarke F. Milleffe, New York, N.Y., assignors to Research Corporation, New York, N.Y. Filed Sept. 13, 1972, Ser. No. 288,815 Int. Cl. GOIN 33116 U.S. Cl. 23-2 23 (Iaims 30 B ABSTRACT OF THE DISCLOSURE Fibers, suitably in filament form, are tensioned on a frame or woven in the form of a substantially rigid mesh and materials containing immunoreactive groups are bonded thereto. The combination is lyophilized to provide a stable device which is used to selectively remove cells having predetermined immunoreactive factors attache@ thereto which have molecular complementarity with the aforementioned materials containing immunoreactive groups, from fluids containing said cells. DESCRIPTION OF THE PRIOR ART The detection of predetermined cells and suitably theil selective removal from body fluids containing them for purposes of diagnosis or experimentation has been a problem receiving a great deal of attention. It is well known in the immunologic art that cells bear upon their surface certain materiais designated as antibodies which react specifically with certain other materials designated as antigens. This propensity has been much tised in diagnostic tests wherein a solid carrier is coated with the antigen material, the body fluid suspected of containing certain types of cells havidg antibodies to said antigen is added thereto and, if the suspected antibodies are present upon the cells agglutination results which may be optically observed. The antigen may also be on the cell in which case the antibody is coated onto the carrier. Such a method however does inot provide a means of isolating the detected cells or carrying out any experimentation upon them. It has been known to bond proteins to suitable surfaces such as inylon in order to provide a biolo.-ically reactive surface which does not pass into solution and which is readily removable from the body fluid after the reaction has taken place. An example of this is the bonding of tireas to nylon (Sunderan and H I ornby, Febs Letters, 10, 325 (1970)). In another variation of this technique an antigen may be coated upon polyacrylamides and, after the cells undergo immunologic bonding with the anti.-en a competing antigen is introduced which will replace the antigen on the polyacrylamide thus releasing the adsorbed cells. The great disadvantage of this particular method of cell fractionation is that it basically alters the chemical surface characteristics of the cells since many if not all of the antibody sites are bonded to previously free soluble antigens, that is to say, the competing introduced antigen. It would be higbly desirable to provide a method of substantially clean separation of the cells from the antigen so that the seParated cells are substantially if not totally of the same chemical surface characteristic as they had in their parent fluid from which they were -,ibstracted. It would also be desirable to provide a means for selectively adsorbing cells in such a manner that operations can be carried out upon single cells. It would further be desirable to provide a substantially stable "library" of substrates having predetermined immunoreactive groups suitably, proteins adsorbed thereon in order to facilitate the rapid and selective analysis of body fluids for detection of various disorders for example, the presence of dormant serum hepatitis cells and the Patented Oct. 22, 1974 2 cells of sickle cell anemia, which althou,-h both detectable by currently available means when present in high concentrations present problems of detection in certain phases of these diseases when they are present in extremely low

concentrations. 5 SUMMARY OF THE INVENTION The invention described herein was made in the course of work under a grant or award from the Department 10 of Health, Education and Welfare. There is provided a novel method of fractionating cells from body fluids containing the same storable device for carying out the method. Monofilament fibers, comprising potentially immuno- 15 reactive groups, are attacbed to a holding frame under tension. In an alternate embodiment of the invention the filaments are woven into a substantially rigid mesh. The fibers, either in the tensioned form or in the mesh form are treated with a material containing predetermined im- 20 munoreactive groups and a coupling agent whereby the material, suitably a protein, is coupled to the surface of the fibers. Heretofore, it has been known that proteins may be preserved in the dry state by the process known as lyophilization, whereby the wet protein is frozen and the 25 aqueous content removed by sublimation. The lyophilization of certain proteins bonded to the surface of certain polymers or tubes has been reported (Levin et al., Biochem., 3, 1905 (1964); Barber et al., Carbohyd. Res., 30 8, 491, (1968); Barber et al., ibid., 14, 287 (1970). In order to carry out the process of the present invention the fibers must be under tension in a holder or in a mesh wherein a holding effect similar to tension is achieved. Attempts to carry out lyophilization upon the coated fibers 35 under tension or the coated meshes destroyed the antigenic activity of the bonded proteins. It is necessary to totally immerse the fibers under the surface of water, and freeze the water in such a way that the fibers are entirely coated with ice. Thereafter sublimation of the ice under reduced 40 pressure yields a coating of lyopbilized protein wbich is in no way denatured and which upon the readdition of water yields the anti,-enically active substance. The thus produced coated fibers either under tension or in mesh form have a substantially indefinite shelf life. 45 In order to remove cells bearing predetermined immunoreactive factors from fluids containing the same, the fibers either under tension or in mesh form having prede- termined immunoreactive groups adsorbed thereon which have molecular complementarity with the immunoreactive 50 factors on the cells which it is desired to isolate and form bonds with said factors are immersed in the fluids containidg said cells. The fibers are then agitated in the solution. In the modification where fibers under tension are employed, the fibers may not. be permitted to pass 55 through the surface layers of the medium since the surface tension will strip the cells therefrom. Therefore any changes of medium must be carried out by serial dilution. In the case of the mesh, the interstices of the mesh 60 retain sufficient fluid therebetween to counteract the stripping action of the surface layer and therefore the mesh may be transferred from, say, the fluid containing the. cells to be abstracted, into a washing medium and thence into a release medium. 65 Where it is desired to release the cells abstracted, the fibers, under tension, are lightly stroked by mechanical means. The vibration caused thereby is sufficient to break the antigen-antibody coupling bond and propel the cells into the release medium prepared for them. It should be @o noted that this mechanical method of release will remove a minute portion of the cell membrane. By appropriate adjustment of the density of antigen coating on the fibers

328431324 3 this damage can, if desired, be minimized to the extent that the cell, being a living organism, will itself repair the dam- age, or alternatively may be maximized in order to pro- vide access to the interior portion of the cell where chemical experimentation therewith may be carried out. 5 Where the fl-bers are in t.he mesh form cells are - released by directing a fine but strong jet of water thru the mesh. It should be noted that while coating and lyophilization may be carried out on fibers or filaments in their - mechani- cally unoriented form, the product obtained thereby is of 10 substantially small utility. The lyophilized layer - although stable in the biol(>gical sense is extremely sensitive to mechanical handling. Thus, for example, coated fibers cannot readily be wound onto a reel and then unwound or woven into a mesh or tensioned into a carrier. Such 15 mechanical handling would, without complex precautions, denature substantially all of the coating. Therefore, it is necessary to place the fibers into the mechanical form, that is to say, under tension or in a substantially rigid web, in which it is desired to use them prior to the coupling and 20 lyophilization process. The invention described h6rein was made in the course of work under a grant or award from the Department of Health, Education and Welfare. 25 BRIEF DESCRIPTION OF THE DRAWINGS FIG. I is a plan view of fibers in a tensioning frame. FIG. 2 is a side elevational view of the fibers and frame of FIG. I view from 7,-2. @FIG. 3 is a plan view of a

portion of the @mesh embodi- 30 ment of the present invention. FIG. 4,is a side elevational view of a handling device for manipulation of the mesh of FIG. 3. FIG. 5 is a diagrammatic representation of the com- petitive removal means of the prior art together with t@e 35 mechanical cleavage means of the present invention. DESCRIPT'ION OF THE PREFERRED ,EMBODIMENTS 40 The basic device of the present invention comprises a plurality of mechanically oriented fibers. In one embodi- ment of this invention as illustrated in FIG. I there is provided a frame 12 having a plurality of small holes 16 in the principal plane of said frame. The fibers 14 - utilized are threaded across said frame suitably but not essentially 45 in substantially mutually parallel orientation. The degree of tension applied to the fibers is not critical, it should merely be sufficient to permit the fibers, when wet to re- main in substantially their original orientation. While the 0 dimensions of the fibers are not critical, it has been found 0 useful to utiue fibers lying in the range of I micric)n to 250 microns suitably 50 to 150 microns, preferably about 125 microns in diameter. The mutually supportive effect obtained by threading the fibers through a frame may be obtained, with addi- 55 tional advantages as discussed above, by weaving the fibers into a flexible mesh, wbich nevertheless has sufficient rigidity to be self-supportive when held at one point of its edge. It has been found satisfactory to utilize meshes 60 comprising a first set of mutually parallel fibers in com- bination with a second of mutually parallel fibers woven perpendicularly to said :ftrst set of fibers. However, this orientation is utilized merely because meshes of this nature are inexpensive and readily obtained. It would be equally 65 satisfactory to utilize meshes containing more than 2 sets of mutually parahel fibers and similarly said sets of fibers could be oriented at angles other than perpendicular to each other. The fibers used in the mesh may be of diameter between 70 1 and 250 microns suitably between 50 and 150 microns and be separated by a distance of between 10 microns to about 1500 microns, suitably from 100 to about 500 microns. Any fibers may be utilized for the purposes of the present invention. There may be used natural polymers, 75 4 for example, polymers having a carbohydrate back-bone such as cotton or silk, or semi- synthetic fibers such as rayon; there may also be utilized fibers baving amino acid back- bones such as casein, and semi-synthetic polymers such as Vicara and Ardil. There may also be utilized synthetic polymers. While hydrocarbon polymers and halocarbon polymers such as polyethylene, polypropylene, and polyvinyl chloride may be activated either at their surfaces by the use of strong activating agents such as concentrated sulfuric acid or by incorporating therewith a copolymer having active sites, it is generally preferred to utilize fibers having potentially active groups such as polyamides, for example, Nylon, Nylon 60 or Nomex; polyesters such as Dacron or Terylene or polyacrylics such as Orlon, Dralon or Acrilan. It is generally preferred to utilize synthetic polymers rather than natural polymers, since it is easier to control the specificity of reaction with the immunoreactive centers in the former than in the latter. Furthermore, among the synthetic polymers it is - enerally preferred to use fibers Gf the nylon family since not only do they contain readily activatable amide centers, but such amide centers may be readily coupled to proteins using comparatively mild coupling agents which do not denature proteins and which are generally used in the protein art to couple proteins to each other. In contrast to the nylon fibers of FIG. 1 the mesh of FIG. 3 may be transferred from a vessel containing one medium to a vessel containing another without dainage to the adsorbed cells. Circumstances could be foreseen wherein it is desirable to carry out the reactions in a somewhat more controlled environment. Such a controlled environment is illustrated by the carrier of FIG. 4. This carrier comprises a frame 52 having predetermined cross-section. The actual dimensions of the cross-section are not critical. However from a point of view of construction, rectangular, square, ormost suitably circular cross-sections are to be preferred. Said frame 52 further comprises a shelf 54 around the inner circumference thereof located aproximately halfway between the top and bottom of the frame 52. There is further provided a retaining means 60 comprising a frame 61 having a cross-section similar to that of frame 52 but having outer dimensions slightly less than the appropriate inner di- mensions of frame 52 but greater than the appropriate inner dimensions of shelf 54. The frame 61 is, if desired, further provided with means for retaining itself within frame 52. In the preferred embodiment thereof, there is provided a groove 58 in the outer circumference of frame 61 and an 0-ring 56 in said groove whereby the outer diameter of 0-ring 56 when located in groove 58 is slightly greater than the internal dimensions of frame 52, but may, by slight compression be compressed to conform to

said dimensions. If desired, frame 52 may be further provided with a bottom plate 51 and frame 61 may be provided with a top plate 63 suitably having an opening 62 providcd therein and a stoppering means 64 for@removably ,sealing opening 62. Mesh 40 when utilized in the device of FIG. 5 is placed upon shelf 54 and held thereon by retainidg means 60. Proteins possess amino and carboxyl groups which are available active centers for coupling with the fibers. It is generally preferred to utilize fibers having amino and/or carboxyl groups such as polyamides, polyesters or acrylics. Where there are utilized fibers having carbohydrate backbones the hydroxyl groups thereon must be activated for coupling with proteins. The coupling procedures utilized are substantially the same whether the filaments are strung onto a retaining frame or utilized in the form of a mesh. In the following discussions it will be assumed that the fibers referred to are in one or the other of these physical orientations. The surface contaminants of the fibers are removed suitably by solvent extraction. It has been found useful to

3,843,324 6 extract the fibers at ambient temperatures for from about 10 to about 30 minutes first with petroleum ether and then with carbon tetrachloride. Where fibers having amino groups thereon, such as, polyamides or polyacrylics are utilized they are sensitized by partial acid hydrolysis suit- 5 ably with an acid such as hydrochloric acid for example, 3N hydrochloric acid at ambient temperature for from about 15 to about 60 minutes. The fibers are then washed with water for from about 1 to about 2 hours and are then ready for coupling. A large variety of coupling 10 agents may be employed. Among the coupling agents for amino groups may be mentioned 1-cyclohexyl-3-(2- morpholinoethyl)-carbodiimide metho- p-toluenesulfonate, I-ethyl-3-(3-dimethylaminopropyl) - carbodiimide hydro- chloride, glutaraldehyde, difluorodinitrobenzene, dimethyl- 15 adipimidate, phenol-2,4-disulfonylchloride, hexamethyl- enediisocyanate, tosyl chloride/sodium ethoxide, cyanogen bromide p,p-difluoro-m,m-dimitrodiphenylsulfone, Wood- ward's Reagent K; among the coupling agents for carb- oxyl groups may be mentioned, 1-cycl ohexyl-3-(2-morpho- 20 linoethyl)-carbodiimide metho-p-toluenesulfonate, 1-ethyl- 3-(3 - dimethylaminopropyl)carbodiimide - hydrocbloride, Woodward's Reagent K; among the coupling agents for phenolic groups may be mentioned, diazo reagents such as bisdiazobenzidine, p,p'-difluoro-m,m'-dinitrodiphenyl sul- 25 fone, 1,5,-difluoro-2,4-dinitrobenzene, 1-cyclohexyl-3-(2- morpholinoethyl)-carbodiimide metho- p-toluenesulfonate, I-ethyl-3 - (3 - dimethylaminopropyl) carbodiimide hydro- chloride; among the cotipling agents for sulfhydryl groups may be mentioned, N,N'-(1,3-phen ylene)bismoleimide, 30 N,N'-ethylene-bis- (iodoacetamide). As stated heretofore, it is especially preferred to utilize mono-filament nylon or mesh woven from monofilament nylon. It has been found especially suitable to utilize as a coupling agent for nylon fibers reagent comtnonly 35 known "carbodiimide" (1-cyclohexyl-3 - (2 - morpholino- ethyl)-carbodiimide metho-p-toluenesulfonate, Aldrich Chemical, Milwaukee, Wis.). In this procedure the fibers are placed in a freshly prepared solution of the antigenic protein and carbodiimide suitably in slightly acid saline. 40 It has been found practical to utilize protein concentra- tions in the range of 0.1 mg./ml. to 10 mg./ml. and "carbodiimide" at a "carbodiimide" to protein ratio of about 5:1 (w./w.). It is generally preferred to utilize a saline reaction solution of from about 0.1 to about 0.5, 45 suitably about 0.15 molar to a pH of between about 5.5 and about 6.5. The reaction mixture is agitated at ambient temperatures for from about 15 to about 16 minutes and the fibers washed in phosphate buffered saline. They are stored in this medium until the lyophilization step dis- .50 cussed hereinbelow. It should be noted that carbodiimide is a nonbonding reagent, that is to say, when carbodiimide is used the protein is directly bonded to the fiber. However most of the other coupling agents listed hereinabove are participat- 55 ing bonding agents, that is to say, at least a portion thereof forms bond with the fiber and another portion thereof forms a bond with the protein. The simplest and most readily used of these reagents is cyanogen bromide. Where cyanogen bromide is utilized the sensitized fibers 6 0 a re immersed in water and the pH adjusted to from about 1 0 to about 1 1, suitable to about 10.5 with dilute alkali, s uitably O.IN sodium hydroxide, and, approximately 1% (w./w.) solution of cyanogen bromide is added to this al kaline medium with agitation. The reaction is permitted 6 5 to proceed for from about 5 to about 10 minutes, the fibers r emoved, washed with water, and transferred to a very sli ghtly acid potassium phosphate buffer. Protein, at a con- c entration of between about I to about 2 milligrams/ml. in slightly acid saline is added and the reaction

mixture 7 0 g ently agitated suitably overnight, at about 51 C. The fi bers are then removed, and washed with saline before u se or storage. It should be recognized that the degree of coupling, that is to say, the number of protein molecules per unit length 7 5 of fiber may be finely controlled as a result of variation of a number of factors. Among the more important of these factors are initial protein-concentration, the coupling reagent to protein ratio, time of reaction, pH and temperature. Thus increasing the ratio of coupling reagent to protein increases the extent of derivatization. This effect is also achieved by increasing the time of reaction or increasing the pH. However, with re,gard to the latter two factors, it should be noted that carbodiimide@ undergoes gradual hydrolysis, therefore if the reaction time is increased, it is desirable to add fresh carbodiimide after 2 to 3 hours of reaction. The permissible pH reaction range lies between 4.5 and 8, however, the true availability of this range will depend upon the stability of the particular protein utilized. As stated heretofore, the manner of carrying out the lyophilization procedure is critical -to the preservation of immunoreactivity and native structure in the coupled protein. As stated heretofore after the coupling step the coated fibers are thoroughly washed in phosphate buffered saline. It is necessary to then remove all i,norganic salts and this is done by thorough agitation in at least 2 washes of glass distilled water. The fibers' either in the frame or in mesh form, are then transferred into a lyophilization jar containing sufficient water to totally immerse the @fibers. The jar is then swirled in a cooling bath, suitably a DryIce/ethanol bath so that a film of ice is formed in the jar covering the fibers. The jar is then connected to a vacuum pump and the water removed by stiblimation in the usual manner. The thus derivatized, dry, protein coated fibers may then be stored and can be conserved to have a substantially indefinite shelf life provided that they are kept dry, at ambient temperatures or below, and the surface thereof is not handled in any way. The unlyophilized derivatized fibers may, of course, be utilized when formed without lyophilization. In the embodiment of the present invention wherein nylon Maments, per se, are utilized, the fibers in their frames are placed under the surface of a medium containing the cells to be fractionated, which bear immunoreactive factors having molecular complementarity with the immunoreactive groups on the fibers. For example, where spleen cells are to be fractionated, it is desirable to ijtilize a saline solution such as Hank's balanced salt solution without sodium bicarbonate (Grand Island Biological Company). The cells are added to the saline and the fibers placed below the surface of the medium. The vessel containing both the medium and the fibers is placed on a horizontal shaker and the fibers are lined perpendicular to the direction of shaking, care being taken however to insure that the fibers at all times remain covered by the medium. It has been found suitable to utilize a shaker having a 3.3 centimeter stroke at about 78 oscillations per minute. After binding is complete the entire assembly is immersed in phosphate buffered saline and, if desired, the fibers removed therefrom, still under the surface of the saline, in a petri dish. Where it is desired to remove the cells from the fibers, the fibers are plucked under the surface of the medium and the cells thus ejected from con. tact with the fiber. In an alternate modification of the method, utilizing a container as illustrated in FIG. 5, the medium containing the cells is inserted into the upper sector 60 through opening 62, the air removed from the entire device and the sealing means 64 closed. The device is then placed upon a horizontal shaker oscillating a:t approximately 200 rp.m. for I hour at reduced temperatures, suitably around 4' C. The cell- suspension is permitted to tri.ckle through mesh 40 under gravity and the entire device inverted every approximately 15 minutes during shaking to facilitate pick-up of the cells by the mesh. Since the mesh retains fluid in its interstices, the surface tension problem of the single filaments is not encountered. After the adsorption is complete, the mesh is removed from the device, washed by gentle agitation in, for example, phosphate buffered sa-

3,843,324 7 line, and placed in a dish into which it is desired to eject the adsorbed cells into a medium in said dish. The cells are washed off the mesh by jetting a fine rapidly flowing stream of water through the mesh whereby the cells are sheared from the fibers. 5 It should be noted however that in order to study the cells adsorbed in this procedure, it is not necessary to eject them into a neutral medium. For example, if the pur- pose of the study is the assay of cells of a particular type in a particular fluid, this may be carried out by viewing 10 the filament or the mesh through a suitable magnifying de- vice and counting the cells adsorbed along a given

length ,of fiber. This procedure permits the cells to be counted in situ. It may be demonstrated that the method is substantially 15 specific for a given antigen-antibody response. Certain synthetic antigens were prepared such as DNP-bovine serum albumin (known as DNP8-BSA), toluene sulfonyl- BSA (also known as tOSY120-BSA), BSA itself, and soni- cated stroma were injected into the mice and after a certain 20 interval the spleens of the mice removed and the spleen cells studied by the procedures of the present invention. Table I below shows the binding of the spleen cells to fi- bers coated with these specific antigens. TABLEI 25 Binding Of MOI]SO SpleeD cells to antigen-derivatized fibers Number of cells bound2 in=u- ur@imnu- 30 Fiber antigen I ---------- nized 3 nized DNP-BSA: Exp. 1 ---------- 802 285 Exp. 2 ---------- 1,004 301 Exp. 3 ---------- 654 283 Tosyl-BSA: Exp. 1 ---------- 353 143 35 Exp. 2 ---------- 297 130 BSA: Exp. 1 ---------- 173 65 Exp. 2 ---------- 112 58 Stroma: Exp. I ---------- 160 75 Exp. 2 ---------- 145 70 40 1 The DNP-BSA ane Tosyl-BSA fibers were coated with 1011 and 2X1011 antigen molecules per cm., respectively. ' ENpressed as number of cells bound to both edges of a 2.5--cm. fiber segment. 3 Secondary responses to DNP3s-BGG [bovine gamma globulin fraction II), Armour Pharmaceutical], Tosy]3o-BSA, BSA, and sheep 45 rythrocytes, respectively. Cells from three mice Nyere polled. e In a further experiment, the soluble antigen was added to the spleen cell suspension prior to the immersion therein of the antigen coated fibers. Table II shows that the specific antigen in soluble form caused substantial inhibi- 50 tion while foreign antigens were ineffective for this purpose. TABLEII Specific inhibition of spleen cell binding to derivatized fibers 55 Inhibitor Fiber antigen Immunogen DNP Tosyl Stroma Anti 1, DNP-BSA ------- DNP-BGG..... b 91 I ---------- 93 DNP-BSA ------- None ---------- 73 2---------- 72 Tosyl-BSA ------- Tosyl-BSA ------ 3 87 ---------- 90 60 Do ---------- None ---------- 6 59 ---------- 63 Stroma ---------- SIroma ---------- <5 <5 70 80 Do ---------- None ---------- <5 <5 50 45 AU values are espressed as percent inhibition. b DNPG-BSA and TOSYI2G-BSA present at 200,.g./ml.; sonicated stroma and rabbit anti-mouse immunoglobulin at a concentratioii of 1 nig./ml. 65 In a further embodiment of the invention thymocytes may be selectively isolated from erythrocytes. The method may be adopted either for the isolation of erythrocytes or the isolation of thymocytes. In this embodiment fibers under tension, suitably nylon 70 fibers in the form of fibers tensioned on a retaining frame or in the form of fibers woven into a mesh are derivatized with Concanavalin A at concentrations of between about 7 X 1011 and about 1 X 1011 molecules of Concanavalin A 75 per centimeter of fiber. 8 At the higher level of concentration, both thymocytes and erythrocytes are absorbed, however, treatment with a hypotonic soluilon of an inhibitory sugar containing the a-methyl-D-mannosyl, a - D - mannopyranosyl, u@ and pglucopyranosyl or p-D-fractofuranosyl moieties or polysaccharides containing these groups at their non-reducing termini. Suitably, ix-methylmannoside causes the s,-Iective release of erythrocytes. Both the osmolarity and the concentration of the inhibitory sugar. If the latter is too high or too low the viability of the cells will be destroyed. If the inhibitory concentration is too low the erythrocytes are not released. It is generally preferred to utilize an osmolarity of between about 100 and about 300mOsM suitably about 150mOsM containing inhibitory concentration of between about 0.01 to about 0.07M, preferably between about 0.04 and 0.05M of the inhibiting sugar. Among the suitable inhibitors may be mentioned: D-glucose, 1,5-anhydro-D-glucitol, 2-deoxy - 1,5 - anhydro-D@arabino - h@-xitol 2-deoxy-D-glucose, 2-0 -Metbyl-D-glucose, N-acetyl- D-glucosamine M-a-D-glucopyranoside, Methylp-D-glucopyranoside. D-manniose, methyl-a-D-mannopyranoside, D-fructose, L-sorbose, methyl-a-L-sorbopyrannoside, maltose, isomaltose, niguose, kojibiose, ct,m-trehalose, sucrose, furanose, 3-0-u,-D-glucopy ranosyl-D-ara- binose, maltotriose, isomaltotriose, panose, melezitose. Unfortunately however, at the higher level of concentration the thymocytes are so tightly bound that upon mechanical release thereof in the manner discussed hereinabove by plucking the fibers in a medium compatible with the viability of the cells a substantial proporation of the thymocytes may be so mechanically damaged as to be no longer substantially viable. Thus, if it is desired to isolato the thymocytes rather than the erythrocytes there should be utilized fibers coated wtih a Coneanavalin concentration of less than 2 x 1011 suitably I x 1011 to 1.5 x 1011 molecule Concanavalin A per centimeter of fiber. At the lower end of this

concentration range erythrocytes are not absorbed, therefore in the separation procedure it is not essential to utilize the intermediate erythrocyte release step using the inhibitory su.-ar. It will be understood however by those skilled in the art that by lowering the concentration of Concanavalin A the number of erythrocytes isolated will- correspondingly be reduced. Therefore, it may be desirable to effect a compromise whereby the level of Concanavalin A concentration is raised to a point at which some erythrocytes are adsorbed, but the adsorption of the thymocytes is not so strong that excessive mechanical damage at the release step. Where a small amount of adsorption of erythrocytes does occur, they can be chemically released by the use of inhibitory sugars as discussed hereinabove. It is generally preferred to utilize nylon fibers either in the frame tensioned form or in the mesh form of the order of 150 microns in diameter. These are coupled with Concanavalin A preferably using carbodiimide as the coupling agent by the general methods of coupling discussed hereinabove. Utilizing these procedures it has been found that utilizing an initial concentration of I milligram/ml. of Coneanavalin A there is obtained a coating of 2 x 1011 Concanavalin A molecules per centimeter of fiber. Whereas under identical reaction conditions where 5 milligrams/ml. of Concanavalin A are utilized there is obtained a coating of 7 x 1011 molecules of Concanavalin A per centimeter of fiber. The extent of the coupling of Concanavalin A to the fiber can be determined using radiolabeled Concanavalin A and nieasuring the radioactivity of the fibers by methods well known in the art. EXAMPLE I Transparent nylon mono-fi!aments (size 50 sewing nylon, Dyno Merchandise Corporation, Elmhurst, N.Y.) are strung onto polyethylene collars cut from hollow-S6 stoppers (Mallinckrodt, New York, N.Y.). These fit snugly into 35 x 10 mm. petri dishes (NUNC, Vanguard International, Inc., Red Bank, N.J.) and hold the fibers under

3,843)324 9 tens ion. -Surface contaminants are removed by ten-minute extr action of the fibers by immersion first in petroleum ethe r for 15 minutes with agitation, the petroleum ether is discarded and the fibers are then washed for a further 15 minutes with carbon tetrachloride, which is then also 5 disc arded. The fibers are then immersed in 3N hydro- chlo ric acid for 30 minutes at ambient temperature fol- low ed by washing in one liter distilled water for I hour. A solution of DNP-bovine serum albumin (0.5 mg./ml.) and "carbodiimide" 2.5 mg./ml. solutions are prepaxed in 10 0.15 M aqueous sodium chloride, pH 6.0. The reaction mixt ure is agitated at ambient temperature for 30 min- utes , the fibers on the polyethylene collars are then was hed in phosphate buffered saline, pH 7.4 (8.0 g. so- diu m chloride, 0.20 g. potassium chloride, 0.20 9. POtas- 15 siu m dihydrogenphosphate, and 0.15 g. of disodium hy- dro genphosphate per liter). After washing the fibers are tran sferred to fresh containers containing the same me- diu m until the lyophilization step described hereinbelow. EX AMPLE,H 20 The nylon threads are tensioned and cleaned in accord- anc e with the procedure of Example I. The clean threads are immersed in 100 ml. water, and the pH adjusted to pH 10.5 by the addition of O.IN sodium hydroxide. A 2.5 solu tion of 200 mg. cyanogen bromide in 160 ml. of water is slowly added to the water in which the nylon threads are immersed and the pH held at pH 10 to pH 10.5, with agit ation, for between 8 and 10 minutes. The threads are was hed with cold water, and transferred to a vessel con- 30 taini ng 100 ml of O.IM potassium phosphate buffer (pH 6.5), and 50 ml. of a saline solution of DNP-bovine seru m albumin (1.0 mg./ml., 0.5M sodium chloride). The mixt ure is stirred for 8 hours at 4' C., and the fibers was hed in 0.15M saline before the lyophilization step. 35 EX AMPL,E-I]EE In accordance with the procedure of Examples I-and 11 but where in place of nylon threads tensioned on a frame ther e is utilized a nylon mesh namely 308 gage, square- 40 wea ve, Nitex (Tobler, Ernst and Traber, New York, N.Y .). The mesh is derivatized in the same manner as the individual threads. EX AMPLE IV 45 Lyo philization Procedure The derivatized fibers, either in tensioned form on the fra me, or in mesh form, as produced in Examples I thro ugh III, are thoroughly washed with phosphate buf- fere d saline, and twice with glass distilled water. The fibers 50 are then transferred to a lyophilization jar (Virtis Co., Gar diner, N.Y.) containing sufficient water to totally im- mer se the fibers. The jar is then swirled in a Dry Ice/ etha nol bath to freeze the water in such a manner as to pro vide total covering for the fibers. The jar is then con- 55 nect ed to a vacuum pump and sublimated to dryness. EX AMPLE V In accordance with the procedures of Examples I thro ugh IV but utilizing in place of DNP-bovine serum 60 albu min, tosyl bovine serum albumin, bovine serum al- bum in, sonicated stroma, there are similarly obtained lyop hilized

coatings of said proteins upon the nylon fibers or meshes. -In accordance with the foregoing procedures where 65 ther e are used in place of nylon, Nylon 6T, Nomex, Da- cro n, Terylene, Orlon, Dralon or Acrylan, there are simi- larly obtained fibers bearing the lyophilized proteins there- upo n. EX AMPLE VI 70 Tra nsparent nylon mono-filament (size 50 sewing nylon, Dyn o Merchandise Corporation, Elmhurst, N.Y.) are strung onto polye ene collars cut from hollow-S6 stop- pers (Mallinckrodt, New York, N.Y.). These fit snugly 75 10 into 35 x 10 mm. petri dishes (NUNC, Vanguard International, Inc., Red Bank, N.J.) and hold the fibers under tension. Surface contaminants are removed by ten-minute extraction of the fibers by immersion first in petroleum @ther for 15 minutes with agitation, the petroleum ether is discarded and the fibers are then washed for a further 15 minutes with carbon tetrachloride, which then also discarded. The fibers are then immersed in 3N hydrochloric acid for 30 minutes at ambient temperature, followed by washing in one liter distilled water for I hour. A solution of Concanavalin A (1.0 mg./ml.)i and "carbodiimide" 5.0 mg./ml. solutions are prepared in 0.15M aqueous sodium chloride, pH 7.4 (8.0 g. sodium chloride, 0.20 g. potassium chloride, 0.20 g. potassium dihydrogenphosphate, and 0.15 g. of disodium hydrogenphosphate per liter). After washing the fibers are transferred to fresh containers containing the same medium until the lyophilization step described hereinbelow, or direct use. The extent of coupling is determined by utilizing Concanavalin A labeled with 63Ni by the method of Inbar and Sachs (Nature, 215, 1491 (1967) and measured by the method of Wang et al. (Proe. Nat. Acad. Sci., U.S.A., 68, 1130 (1971). This analysis shows the concentration to be 2X 1011 molecules of Cancanavalin A per cm. of fiber. In accordance with the above procedure but utilizing 5 mg./ml. of Concanavalin A and 25 mg./ml. of "carbodiimide" there is obtained a coating on the fiber of 7 X 1 Oll molecules on Concanavalin A per cm. of fiber. EXAMPLE VII In accordance with the procedure of Example VI but where in place of nylon threads tensioned in a frame there is utilized a nylon mesh 33amely 308 gage, squareweave, Nitex (Tobler, Ernst and Traber, New York, N.Y.). The mesh is derivatized in the same manner as the individual threads. EXAMPLE VIII A cell suspension of 5xlG7 erythrocytes and 5XJ07 thymocytes per ml. of phosphate buffered saline is prepared. The fibers coated with 7XIO" Concanavalin A molecules per centimeter are incubated for 60 minutes at ambient temperature. The reaction solution is diluted with phosphate buffered saline to 10 times its volume, and 9 volumes are removed leaving the fibers below the surface of the medium. This dilution is repeated twice and 9 volumes of a hypotonic solution (15OmOsM) containing 0.05M a- methyl- mannoside and 0.05M sodium chloride are added thereto and the fibers u@nder tension agitated for a few minutes. Substantially instantaneous release of the erythrocytes is observed. The volume is again reduced to Ylo taking care to retain the fibers under the surface of the medium, and 9 volumes of heat inactivated fetal calf serum diluted 1:10 with phosphate buffered saline is added thereto. This medium is again reduced to '/lo of its volume and 9 volumes of the remaining same medium are added thereto. Inspection of the medium should show that absence of free floating cells. Where free floating cells are observed the volume reduction and dilution steps are repeated until no free cells are observed. The thymocytes adsorbed upon the surface of the fibers are released into the medium by plucking the fibers. EXAMPLE IX Nylon Maments under tension in a frame having a concentration of I X1011 molecules of Concanavalin A per centimeter are prepared by the method of Example VI utilizing 0.5 milligrams per ml. of Concanavalin A and 2.5 milligrams per ml. of carbodiimide. The thus produced fibers are subjected to the reaction conditions set forth in Example VIII. When the coated fibers are agitated in the a-methyl mannoside/saline the release of erythrocytes is not noted. After mechanical removal by plucking of the cells and incubation thereof in the medium containing fetal calf serum for I hour at 37' C. are found to be thymocytes which are 80 to 90% viable. Incubation ia

31843)324 phosphate buffered saline alone or substitution of 8% bovine serum albumin for the fetal calf serum leads to reduced cell viability. EXAMPLE X A derivatized nylon mesh is prepared in accordance with Example VII and placed in the enclosed version of the device shown in FIG. 4. The- dimensions of the device are 35 millimeters external diameter and 8 millimeter depth. The air is removed from the device and 8 nil. of a cell suspension consisting of 1.25X 107 erythrocytes and 1.25 X 107 thymocytes per ml. is added through opening 62 which is then sealed and the device place on horizontal shaker 200 r.p.m. for 1 hours at 4' C. The chamber is inverted every 15 minutes so that the cells filter through t e mesh under unit

gravity. The mesh 40 is then removed from the chamber washed in a solution containing 0.05M (x-methyl mannoside in 0.05M sodium chloride and then placed in a petri dish containing heat inactivated fetal calf serum diluted I to 10 with phosphate buffered saline. The adsorbed thymocytes are released into said medium by jetting a fine stream of water substantially perpendicularly through the fibers of the mesh. It should be noted that where the mesh is utilized rather the tensioned fibers in a frame provided that a film of medium remains in the interstices of the mesh, the mesh may be passed through surface layers of medium provided this is done fairly gently. EXAMPLE XI Transparent nylon monofilaments (size 50 nylon, Dyno Merchandise Corporation, Elmhurst, N.Y.) are strung onto polyethylene collars and held under tension. Surface contaminants are removed by ten-rninute extraction of the fibers by immersion first in petroleum ether for 15 minutes with agitation, the petroleum ether is discarded and the fibers are then washed for a further 15 minutes with carbon tetrachloride, which is then also discarded. The fibers are then immersed in 3N liydrochloric acid for 30 minutes at ambient temperature, followed by washing in one liter distilled water for I hour. A solution of rabbit antiserum against chicken liver (0.1 ml.) and "carbodiimide" (0.01 Ml., loo mg./ml. solutions in 0.15M aqueous sodium chloride, pH 6.0) are added to the fibers and agitated at ambient 'Lemperature for 30 minutes, the fibers on the polyethylene collars are then washed in phosphate buffered saline (PBS), pH 7.4 (8.0 -,. sodium chloride, 0.20 g. potassium chloride, 0.20 g. potassium- dihydi-ogen phosphate, and 0.15 g. of disodium hydrogen phosphate per liter). The PBS solution is diluted to ca. 10 times its original volume, 9 volumes removed and a fresh 9 volumes of PBS added and 9 volumes removed. One volume of chicken liver cells in PBS is added and the mixture agitated. The solution is then diluted as above until no free floating cells are observed; plucking the fibers releases the chicken liver cells into the PBS. In place of rabbit antiserum a.-ainst chicken liver, there may be used rabbit antiserum against chicken skin and against cliicken neural retina cells. Fibers thus coated are utilized to isolate chicken skin cells and chicken neural retina cells respectively. We claim: 1. A device for selectively separating cells having predetermined immunoreactive factors attached thereto from a fluid containing said cells comprising: (a) a frame, (b) fibers under tension attached to said frame, (c) and having chemically bonded to said fibers lyophil,ized material containing immunoreactive groups having molecular complementarity with said predetermined immunoreactive factors capable of forming bonds with said predetermined immunoreactive factors attached to said cells. 12 2. A device of Claim I wherein the immunoreactive groups are anti.-ens and the immunoreactive factors are antibodies. 3. A device according to Claim I wherein the immiinoreactive groups are antibodies and the immunore- active factors are antigens. 4. A device of Claim I wherein the fibers are selected from the grotip consistin- of fibers having a carbohydrate back-bone, an aminoacid- back-bone, polyamides, 10 polyesters, and polyacrylics. S. A device according to Claim I wherein proteinaceous material is directly bonded to the fiber. 6. A device accordinng to Claim I wherein proteinaccous material is connected to the fiber through a 15 coupling group. 7. A device of Claim 4 wherein the fibers are selected from synthetic fibers of the group consisting of polyamides, polyesters, and polyacrylics. 8. A device of Claim 4 wherein the fibers are mono- 20 filament jiylon fibers. 9. A method of preparing a device of Claim I which comprises the steps of: (1) treating nylon fibers under tension with a predetermined material having immunoreactive groups at- 25 tached thereto and a coupling agent, (11) washing the device with distilled water to remove unreacted sdid material and coupling agent; (III) immersing the device entirely-under the surface of distilled water and freezing the water, 30 (IV) removin.- the frozen water by sublimation under reduced pressure. 10. A method of Claim 9 wherein step (1) comprises: (a) reacting a protein with the fibers in the presence of a coupling agent. 11. A method accordin- to Claim 10 wherein step 35 (1) comprises the sequential steps of: (a) reacting the fibers with a coupling agent, and (b) reacting the thus activated fibers with a protein. 12. A device for selectively separating cells having pre- '10 determined immunoreactive factors attached thereto from a fluid containin- said cells comprising: (a) a substantially rigid fiber mesh having at least 2 sets of mutually parallel filaments constituting said mesh,and (b) having chemically bonded to said fibers lyophilized 45 material containing immunoreactive groups having molecular complementarity with said predetermined immunoreactive factors capable of forming bonds with said predetermined immunoreactive factors attached to said cells. 50 1.3. A device of Claim 12 wherein the immunoreactive

groups are antigens and the immunoreactive, factors are antibodies. 14. A device according to Claim 13 wherein the immurioreactive groups are antibodies and the immunore- 55 active factors are antigens. 15. A device of Claim 12 wherein the fibers of said mesh are between I and 250 microns in diameter and the distance between the mutua]Iy parallel filaments is between 10 microns and 1500 microns. 60 16. A device according to Claim 12 wherein the diameter of the fibers is between 50 and 150 microns and the distance between parallel filaments is between 100 and 500 microns. 17. A device according to Claim 15 wherein the fibers 65 are selected from synthetic fibers of the group consisting of polyamides, polyesters, and polyacrylies. 18. A device according to Claim 17 wherein the fibers are nylon monofilaments. 19. A method of preparing a device of Claim 12 which 70 comprises the steps of: (a) treating nylon fibers me-h with a predetermined material having immunoreactive groups attached thereto and a coupling a,-Cnt, (b) washing the device witii distilled water to remove 75 unreactetd said niatcrial and cotipling agent,

13 (c) immersing the device entirely under the surface of distilled water and freezing the water, (d) removing the frozen water by sublimation under reduced pressure. 20. A method of selectin.- cells having predeterinined- immunoreactive factors attached thereto from a fluid contaiiiii3g said cells which comprises the sequential steps of: (a) immersing below the surface of the fluid, fibers under tension having bonded thereto material containing immunoreactive groups having molecular complementarity with said predetermined immunoreactive factors capable o,f forming a bond with said immunoreactive factors attached to said cells, (b) agitating said fibers below the surface of said fluid, . 1 (c) removing the unbonded material from the c@nvironment of the fibers by dilution with a medium compatible with the visability of the cells, (d) removing said added medium and addirig further quantities of the niedium until all non-adsorbed cells in the original fluid have been remon,ed while maintaining th,- fibers below the surface of the med;lum. 21. A process accordina to Claim 20 additionally com- prising the step of: (a) removing the cells attached to the fibers by plucking said fibers under the surface of said medium whereby said adsorbed cells are released into said medium. 22. A method of selecting cells having a predetermined immunoreactive factors attached thereto from fluids containing said cells which comprises the sequential steps of: (a) immersing a fiber mesh having bonded to the fibers thereof materials containing immunoreactive grotips having molectilar complementarity with said predetermined immunoreactive factors, capable of forming a bond with said immunoreactive factors attached tg said cells, in said fluid containipg said cells, 3)843,324 14 (b) immersing said mesh in a medium compatible with a visbility of said cells. 23. A method according to Claim 22 additionally com- prising the step of: (a) directing a fine j.-t of water through said mesh sub- stantially perpendicular to the plane thereof, whereby the cells are dislodged from the fibers. References Cited 10 UNITED STATES PATENTS 3,655,838 4/1972 Price ---------- 424-12 UX 31658,982 4/1972 Reiss ---------- 424-12 3,692,486 9/1972 Glenn ---------- 23-230 B 3,720,760 3/1973 Bennich -------- 23-230 BX 15 3,721,528 3/1973 Mead ---------- 23-230 B 3,736,100 5/1973 Rains ---------- 23-230 BX 3 188,181 6/1965 Peterson ---------- 424-12 X 3:389,966 6/1968 Saravis ---------- 23-230 B 3,551-,555 12/1970 Hermanus ---------- 424-12 20 3,562,384 2/1971 Arquilla ---------- 424-12 3,607,783 9/1971 Tata ---------- 23-230 B X 3,619,371 11/1971 Crook ---------- 424-12 3,639,558 2/1972 Csizmas ---------- 424-12 3,645,687 2/1972 Nerenber,a ---------- 424-12 X 25 3,645,852 2/1972 Axen ---------- 424-12 X 3,646,346 2/1972 Catt ---------- 424-12 X 3,652,761 3/1972 Weetall ---------- 424-12 OTHER REFERENCES 30 G. M. Edelman, U. Rtitishauser and C. F. Millette, Proc. Nat. Acad. Sci., 68 (9), 2153-57, (September 1971). MORRIS 0. WOLK, Primary Examiner 35 S. MARANTZ, Assistant Examiner U.S. Cl. X.R. 23-259; 117-119.2, 138.8 N; 195-66 R; 424-12

Display Format: - Change Format

Previous Page Next Page Go to Doc#

Hit List

Clear | Generate Collection | Print | Fwd Refs | Bkwd Refs | Generate OACS

Search Results - Record(s) 1 through 28 of 28 returned.

☐ 1. Document ID: US 20030129751 A1

Using default format because multiple data bases are involved.

L5: Entry 1 of 28 File: PGPB Jul 10, 2003

PGPUB-DOCUMENT-NUMBER: 20030129751
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20030129751 A1

TITLE: Tissue-engineered organs

PUBLICATION-DATE: July 10, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Grikscheit, Tracy C.	Boston	MA	US	
Ogilvie, Jennifer	Boston	MA	US	
Vacanti, Joseph P.	Boston	MA	US	

US-CL-CURRENT: 435/378; 435/396, 623/23.71, 623/915

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWIC | Draw. Desc

☐ 2. Document ID: US 20020183857 A1

L5: Entry 2 of 28 File: PGPB Dec 5, 2002

PGPUB-DOCUMENT-NUMBER: 20020183857
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20020183857 A1

TITLE: Vascular tissue composition

PUBLICATION-DATE: December 5, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Yang, Jun	Dove Canyon	CA	US	

US-CL-CURRENT: 623/23.72; 435/378, 623/13.17, 623/14.12, 623/916

ABSTRACT:

A tissue composition includes the subendothelial layer, the elastica interna, and at least a portion of the tunica media of a blood vessel harvested from a mammal, with the endothelial cells removed from the blood vessel. The tissue composition can also

include a portion of the tunica adventitia of a blood vessel harvested from a mammal. The tissue composition can be formed into a graft, a patch, a connective tissue for surgical repair, an orthopedic graft, and a substrate for cell growth, among other applications. The tissue composition can also be fluidized, or made into powdered form.

☐ 3. Document ID: US 6787355 B1

L5: Entry 3 of 28 File: USPT Sep 7, 2004

US-PAT-NO: 6787355
DOCUMENT-IDENTIFIER: US 6787355 B1

TITLE: Multipotent neural stem cells from peripheral tissues and uses thereof

DATE-ISSUED: September 7, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Miller; Freda D.	Montreal			CA
Gloster; Andrew	Saskatoon			CA
Toma; Jean	Montreal			CA

US-CL-CURRENT: 435/377; 435/325, 435/375, 435/378, 435/383

ABSTRACT:

This invention relates to multipotent neural stem cells, purified from the peripheral nervous system of mammals, capable of differentiating into neural and non-neural cell types. These stem cells provide an accessible source for autologous transplantation into CNS, PNS, and other damaged tissues.

8 Claims, 0 Drawing figures
Exemplary Claim Number: 1

☐ 4. Document ID: US 6767738 B1

L5: Entry 4 of 28 File: USPT Jul 27, 2004

US-PAT-NO: 6767738
DOCUMENT-IDENTIFIER: US 6767738 B1

TITLE: Method of isolating adult mammalian CNS-derived progenitor stem cells using density gradient centrifugation

DATE-ISSUED: July 27, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY

Gage; Fred H.	La Jolla	CA	
Palmer; Theo	San Carlos	CA	
Safar; Francis G.	Irvine	CA	
Takahashi; Jun	Kyoto		JP
Takahashi; Masayo	Kyoto		JP

US-CL-CURRENT: 435/325; 435/366, 435/368, 435/378

ABSTRACT:

The present invention is directed to methods of repairing damaged or diseased, specialized or differentiated tissue in mature animals, particularly neuronal tissue such as retinas. In particular, the invention relates to transplantation of adult, hippocampus-derived progenitor cells into a selected neural tissue site of a recipient. These cells can functionally integrate into mature and immature neural tissue. The invention encompasses, in one aspect, repopulating a retina of a dystrophic animal with neurons, by injecting clonally derived, adult central nervous system derived stem cells (ACSC) derived from a healthy donor animal into an eye of the dystrophic recipient. Herein disclosed is the first successful and stable integration of clonally derived ACSC into same-species but different strain recipients (e. g., Fischer rat-derived adult hippocampal derived progenitor cells (AHPCs) into dystrophic RCS rats). Surprisingly, AHPCs were also found to integrate successfully into a xenogeneic recipient (e.g., rat AHPCs into the retina of dystropic rd-I mice).

13 Claims, 0 Drawing figures
Exemplary Claim Number: 1

☐ 5. Document ID: US 6506576 B2

L5: Entry 5 of 28 File: USPT Jan 14, 2003

US-PAT-NO: 6506576
DOCUMENT-IDENTIFIER: US 6506576 B2
**** See image for Certificate of Correction ****

TITLE: Serum-and steroid-free culture media for cerebellar granule neurons

DATE-ISSUED: January 14, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Belcher; Scott M.	Little Rock	AR	72205	

US-CL-CURRENT: 435/29; 435/379, 435/402, 435/406, 435/407

ABSTRACT:

The invention is a system for maintenance and high-throughput analysis of cerebellar granule neurons in tissue culture plates under chemically defined conditions. The invention includes serum-free granule culture medium, which is composed of high glucose Dulbecco's Modified Eagle Media (DMEM), NaHCO3, sodium pyruvate, and HEPES, which is subsequently adjusted to pH 7.2. The HEPES buffered DMEM is then supplemented with L-glutamine, KCl, bovine albumin, insulin, transferrin, selenium,

penicillin, and streptomycin. Unlike proprietary neuronal culture media, this invention does not include any serum, steroid hormones, phenol red, or added anti-oxidants. The serum-free granule culture medium is then placed in conventional poly-lysine coated tissue culture plates in order to conduct subsequent assays. The invention also includes the ability to package the complete neuronal culture system into a "kit" for isolation, maintenance, treatment, and analysis of cerebellar neurons. A kit would include all the necessary culture medium preparations, tissue culture plates with an appropriate cellular attachment matrix, reagents, disposables and protocols. The kit could be used to evaluate neuronal viability, growth, the role of steroid hormones on neuronal function, drug or toxicant-induced changes in gene expression, or other bioassays. In addition, the invention will be useful in the field of pharmocogenomics because of the ability to analyze small sample sizes.

56 Claims, 15 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 15

☐ 6. Document ID: US 6485969 B1

L5: Entry 6 of 28 File: USPT Nov 26, 2002

US-PAT-NO: 6485969
DOCUMENT-IDENTIFIER: US 6485969 B1

TITLE: Biomaterial derived from follicle basement membranes

DATE-ISSUED: November 26, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Asem; Elikplimi K.	West Lafayette	IN		
Turek; John J.	West Lafayette	IN		
Robinson; J. Paul	West Lafayette	IN		

US-CL-CURRENT: 435/325; 435/1.1, 435/373, 435/378, 435/401

ABSTRACT:

A composition comprising follicle basement membrane is described. The composition can be utilized as a cell culture substrate for proliferating cells in vitro.

11 Claims, 58 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 21

☐ 7. Document ID: US 6416999 B1

L5: Entry 7 of 28 File: USPT Jul 9, 2002

US-PAT-NO: 6416999

DOCUMENT-IDENTIFIER: US 6416999 B1

TITLE: Human Mullerian duct-derived epithelial cells and methods of isolation and uses thereof

DATE-ISSUED: July 9, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Li; Rong-hao	LaJolla	CA		
Mather; Jennie Powell	Millbrae	CA		

US-CL-CURRENT: 435/366; 435/325, 435/363, 435/378, 435/383, 435/405

ABSTRACT:

This invention discloses a substantially pure population of human Mullerian duct-derived epithelial cells and methods of isolating and culturing the Mullerian duct-derived epithelial cells. By carefully manipulating the microenvironment in which the Mullerian duct-derived epithelial cells are grown, multiple passages are attainable wherein the Muillerian duct-derived epithelial cells are capable of becoming uterine, cervical, vaginal, and oviductal cells. In addition, several uses of human Mullerian duct-derived epithelial cells and cells differentiating therefrom are disclosed herein.

10 Claims, 4 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 4

☐ 8. Document ID: US 6368854 B2

L5: Entry 8 of 28 File: USPT Apr 9, 2002

US-PAT-NO: 6368854
DOCUMENT-IDENTIFIER: US 6368854 B2

TITLE: Hypoxia mediated neurogenesis

DATE-ISSUED: April 9, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Weiss; Samuel	Calgary			CA
Sorokan; S. Todd	Victoria			CA

US-CL-CURRENT: 435/325; 424/85.1, 435/367, 435/375, 435/378, 514/2

ABSTRACT:

Methods are described for the production of neurons or neuronal progenitor cells. Multipotent neural stem cells are proliferated in the presence of growth factors and erythropoietin which induces the generation of neuronal progenitor cells. The erythropoietin may be exogenously applied to the multipotent neural stem cells, or

alternatively, the cells can be subjected to hypoxic insult which induces the cells to express erythropoietin.

3 Claims, 0 Drawing figures
Exemplary Claim Number: 1

Full | Title | Citation | Front | Review | Classification | Date | Reference | Claims | KWIC | Draw. Des

---

☐ 9. Document ID: US 6294383 B1

L5: Entry 9 of 28 File: USPT Sep 25, 2001

US-PAT-NO: 6294383
DOCUMENT-IDENTIFIER: US 6294383 B1

TITLE: Porcine neural cells and their use in treatment of neurological deficits due to neurodegenerative diseases

DATE-ISSUED: September 25, 2001

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Isacson; Ole	Cambridge	MA		
Dinsmore; Jonathan	Brookline	MA		

US-CL-CURRENT: 435/379; 435/325

ABSTRACT:

Porcine neural cells and methods for using the cells to treat neurological deficits due to neurodegeneration are described. The porcine neural cells are preferably embryonic mesencephalic, embryonic striatal cells, or embryonic cortical cells. The porcine neural cells can be modified to be suitable for transplantation into a xenogeneic subject, such as a human. For example, the porcine neural cells can be modified such that an antigen (e.g., an MHC class I antigen) on the cell surface which is capable of stimulating an immune response against the cell in a xenogeneic subject is altered (e.g., by contact with an anti-MHC class I antibody, or a fragment or derivative thereof) to inhibit rejection of the cell when introduced into the subject. In one embodiment, the porcine neural cells are obtained from a pig which is essentially free from organisms or substances which are capable of transmitting infection or disease to the recipient subject. The porcine neural cells of the present invention can be used to treat neurological deficits due to neurodegeneration in the brain of a xenogeneic subject (e.g., a human with epilepsy, head trauma, stroke, amyotrophic lateral sclerosis, Parkinson's disease, Alzheimer's disease, or Huntington's disease) by introducing the cells into the brain of the subject.

8 Claims, 49 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 21

Full | Title | Citation | Front | Review | Classification | Date | Reference | Claims | KWIC | Draw. Des

---

☐ 10. Document ID: US 6235527 B1

L5: Entry 10 of 28 File: USPT May 22, 2001

US-PAT-NO: 6235527
DOCUMENT-IDENTIFIER: US 6235527 B1

TITLE: Lineage restricted glial precursors from the central nervous system

DATE-ISSUED: May 22, 2001

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Rao; Mahendra S.	Salt Lake City	UT		
Noble; Mark	Sandy	UT		
Mayer-Proschel; Margot	Sandy	UT		

US-CL-CURRENT: 435/325; 435/368, 435/378, 435/395, 435/402

ABSTRACT:

A glial precursor cell population from mammalian central nervous system has been isolated. These A2B5.sup.+ E-NCAM.sup.- glial-restricted precursor (GRP) cells are capable of differentiating into oligodendrocytes, A2B5.sup.+ process-bearing astrocytes, and A2B5.sup.- fibroblast-like astrocytes, but not into neurons. GRP cells can be maintained by regeneration in culture. GRP cells differ from oligodendrocyte-type-2 astrocyte (O-2A) progenitor cells in growth factor requirements, morphology, and progeny. Methods of use of GRP cells are also disclosed.

5 Claims, 0 Drawing figures
Exemplary Claim Number: 1

☐ 11. Document ID: US 6165783 A

L5: Entry 11 of 28 File: USPT Dec 26, 2000

US-PAT-NO: 6165783
DOCUMENT-IDENTIFIER: US 6165783 A

TITLE: Erythropoietin-mediated neurogenesis

DATE-ISSUED: December 26, 2000

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Weiss; Samuel	Calgary			CA
Sorokan; S. Todd	Victoria			CA

US-CL-CURRENT: 435/325; 424/85.1, 435/367, 435/375, 435/378, 514/2

ABSTRACT:

Methods are described for the production of neurons or neuronal progenitor cells.

Multipotent neural stem cells are proliferated in the presence of growth factors and erythropoietin which induces the generation of neuronal progenitor cells. The erythropoietin may be exogenously applied to the multipotent neural stem cells, or alternatively, the cells can be subjected to hypoxic insult which induces the cells to express erythropoietin.

12 Claims, 0 Drawing figures
Exemplary Claim Number: 1

☐ 12. Document ID: US 6008047 A

L5: Entry 12 of 28 File: USPT Dec 28, 1999

US-PAT-NO: 6008047
DOCUMENT-IDENTIFIER: US 6008047 A

TITLE: Cell culturing method and medium

DATE-ISSUED: December 28, 1999

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Curcio; Francesco	Pagnacco			IT
Coon; Hayden G.	East Sebago	ME		
Ambesi-Impiombato; F. Saverio	Udine			IT

US-CL-CURRENT: 435/370; 424/93.7, 435/1.1, 435/378, 435/383, 435/391, 435/392, 435/397

ABSTRACT:

The present invention provides a method for producing an expanded non-transformed cell culture of human liver cells comprising the steps of: (1) preparing partially purified, minced human liver tissue, (2) concentrating the resulting cells and tissue pieces, (3) resuspending the concentrated tissue cells and pieces in a growth medium, (4) culturing the resuspended cells in the growth medium for a time and under conditions to effect sustained cell division, and (5) passaging the cultured human liver cells periodically to expand the culture. The growth medium comprises a combination of a basal medium and ingredients to provide a medium in which the cultured human liver cells are selectively proliferated without being transformed, providing an expanded culture of proliferated, functionally differentiated human liver cells that is substantially free of fibroblast, macrophage and capillary endothelial cells. Also provided is the improvement of harvesting cells of the expanded culture at a selected PDL preferably>5, providing a high density cell suspension of such proliferated human liver cells, and incubating such high density cell suspension in a calm-down medium to induce a mitotically quiescent state and, using a culture procedure which encourages aggregation, making the cells adhere tightly to form a three-dimensional cell organization typical of the organ of origin, thereby forming organoids.

16 Claims, 18 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 11

☐ 13. Document ID: US 5955343 A

L5: Entry 13 of 28 File: USPT Sep 21, 1999

US-PAT-NO: 5955343
DOCUMENT-IDENTIFIER: US 5955343 A

TITLE: Stable macroscopic membranes formed by self-assembly of amphiphilic peptides and uses therefor

DATE-ISSUED: September 21, 1999

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Holmes; Todd	Somerville	MA		
Zhang; Shuguang	Cambridge	MA		
Rich; Alexander	Cambridge	MA		
DiPersio; C. Michael	Norton	MA		
Lockshin; Curtis	Lexington	MA		

US-CL-CURRENT: 435/325; 435/378, 435/395, 435/401

ABSTRACT:

Described herein is the self-assembly of amphiphilic peptides, i.e., peptides with alternating hydrophobic and hydrophilic residues, into macroscopic membranes. The membrane-forming peptides are greater than 12 amino acids in length, and preferably at least 16 amino acids, are complementary and are structurally compatible. Specifically, two peptides, (AEAEAKAK).sub.2 (ARARADAD).sub.2, were shown to self-assemble into macroscopic membranes. Conditions under which the peptides self-assemble into macroscopic membranes and methods for producing the membranes are also described. The macroscopic membranes have several interesting properties: they are stable in aqueous solution, serum, and ethanol, are highly resistant to heat, alkaline and acidic pH, chemical denaturants, and proteolytic digestion, and are non-cytotoxic. The membranes are potentially useful in biomaterial applications such as slow-diffusion drug delivery systems, artificial skin, and separation matrices, and as experimental models for Alzheimer's disease and scrapie infection. The sequence of the peptide, EAK16, was derived from a putative Z-DNA binding protein from yeast, called zuotin. The cloning and characterization of the ZUO1 gene are also described.

4 Claims, 25 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 14

Full | Title | Citation | Front | Review | Classification | Date | Reference | Claims | KWIC | Draw Desc

☐ 14. Document ID: US 5888816 A

L5: Entry 14 of 28 File: USPT Mar 30, 1999

US-PAT-NO: 5888816
DOCUMENT-IDENTIFIER: US 5888816 A

TITLE: Cell cultures of and cell culturing method for nontransformed pancreatic, thyroid, and parathyroid cells

DATE-ISSUED: March 30, 1999

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Coon; Hayden G.	Gaithersburg	MD		
Ambesi-Impiombato; Francesco Saverio	Tricesimo			IT
Curcio; Francesco	Pagnacco			IT

US-CL-CURRENT: 435/366; 435/325, 435/378, 435/382, 435/383, 435/391, 435/392, 435/404, 435/408

ABSTRACT:

The present invention provides a method for producing an expanded, enriched, non-transformed human cell culture of human pancreatic, thyroid or parathyroid endocrine cells and other types of cells which comprises (1) preparing partially purified, minced tissue that includes a desired type of cells; (2) concentrating the desired cells; (3) resuspending the concentrated cells in a growth medium which selects in favor of the desired cells and in which those cells are proliferated without being transformed and differentiated functions are retained through periodic passaging; (4) culturing the resuspended cells in the growth medium to effect sustained cell division; and (5) passaging the cultured cells periodically to expand the culture. The present invention further provides clonal strains of cells derived from the above-mentioned cell culture and procedures to form matrix-embedded aggregated and non-aggregated cells for providing pseudotissues and products such as matrix-embedded pancreatic islets (pseudoislets). Growth medium and conditioned medium is provided for the culturing of the cells and clonal strains, the growth medium comprising a suitable basal medium supplemented with effective concentrations of hypothalamus and pituitary extracts, serum and other ingredients, which growth medium selects in favor of desired human cells and against passenger cells including fibroblast, macrophage, and capillary endothelial cells such that the desired cells are selectively proliferated without being transformed and an expanded cell culture is provided of functionally differentiated, expanded, non-transformed human cells that is substantially free of such passenger cells.

34 Claims, 18 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 11

☐ 15. Document ID: US 5866417 A

L5: Entry 15 of 28 File: USPT Feb 2, 1999

US-PAT-NO: 5866417
DOCUMENT-IDENTIFIER: US 5866417 A

TITLE: Method of tissue transfer

DATE-ISSUED: February 2, 1999

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Matyas; John R.	Calgary, Alberta			CA
Rattner; Jerome B.	Calgary Alberta			CA

US-CL-CURRENT: 435/378; 435/174

ABSTRACT:

The Tissue Transfer method consists of transferring intact, organized cells from the surfaces of biological tissues or organs to a transfer substrate. A surface of the tissue or organ is selected, in most cases, a freshly cut surface. At least one layer of intact cells is transferred by adhesion of the cells to a transfer substrate, which is a membrane, film, plate or liquid layer bound to a solid structure. The substrate is brought into contact with the selected surface and removed. A layer of cells is removed by the adhesion of the cells to the substrate and the cells retain the organization of the organ or tissue.

3 Claims, 18 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 6

☐ 16. Document ID: US 5851756 A

L5: Entry 16 of 28 File: USPT Dec 22, 1998

US-PAT-NO: 5851756
DOCUMENT-IDENTIFIER: US 5851756 A
**** See image for Certificate of Correction ****

TITLE: Method for in vitro proliferation of dendritic cell precursors and their use to produce immunogens

DATE-ISSUED: December 22, 1998

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Steinman; Ralph M.	Westport	CT		
Inaba; Kayo	Kyoto			JP
Schuler; Gerold	Innsbruck			AT

US-CL-CURRENT: 435/2; 435/325, 435/355, 435/372, 435/378, 435/384, 435/395, 530/351

ABSTRACT:

A method for producing proliferating cultures of dendritic cell precursors is provided. Also provided is a method for producing mature dendritic cells in culture from the proliferating dendritic cell precursors. The cultures of mature dendritic cells provide an effective means of producing novel T cell dependent antigens comprised of dendritic cell modified antigens or dendritic cells pulsed with antigen, including particulates, which antigen is processed and expressed on the antigen-activated dendritic cell. The novel antigens of the invention may be used as immunogens for vaccines or for the treatment of disease. These antigens may also be used to treat autoimmune diseases such as juvenile diabetes and multiple sclerosis.

38 Claims, 53 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 20

Full | Title | Citation | Front | Review | Classification | Date | Reference | Claims | KWIC | Draw. Desc

☐ 17. Document ID: US 5849584 A

L5: Entry 17 of 28 File: USPT Dec 15, 1998

US-PAT-NO: 5849584
DOCUMENT-IDENTIFIER: US 5849584 A

TITLE: Cell cultures of and cells culturing method for nontransformed parotid cells

DATE-ISSUED: December 15, 1998

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Coon; Hayden G.	Gaithersburg	MD		
Ambesi-Impiombato; Francesco Saverio	Tricesimo			IT
Curcio; Francesco	Pagnacco			IT

US-CL-CURRENT: 435/366; 435/325, 435/378, 435/382, 435/383, 435/391

ABSTRACT:

The present invention provides a method for producing an expanded non-transformed cell culture comprising the steps of: (1) preparing partially purified, minced tissue; (2) concentrating the resulting cells and tissue pieces; (3) resuspending the concentrated tissue cells and pieces in a culture medium capable of supporting sustained cell division that is contained in a culture vessel; (4) incubating the cells; and (5) passaging the cells periodically. The present invention further provides clonal strains of cells derived from the above-mentioned cell culture, medium and conditioned medium designed for the culturing of parotid cells and other glandular cells such as pancreatic, thyroid, and parathyroid, and cells, and the use of cultured pancreatic cells to form pancreatic pseudotissues composed of matrix-embedded aggregated (pseudoislets) or individual cells, to treat blood sugar disorders in mammals, and to test for cytotoxicity and autoimmune activities with reference to pancreatic endocrine cells. The nontransformed cells are cultured in a growth medium comprising a suitable basal medium supplemented with effective concentrations of hypothalamus and pituitary extracts, and serum.

17 Claims, 18 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 11

Full | Title | Citation | Front | Review | Classification | Date | Reference | Claims | KWIC | Draw. Desc

☐ 18. Document ID: US 5646035 A

L5: Entry 18 of 28 File: USPT Jul 8, 1997

US-PAT-NO: 5646035

DOCUMENT-IDENTIFIER: US 5646035 A

TITLE: Method for preparing an expanded culture and clonal strains of pancreatic, thyroid or parathyroid cells

DATE-ISSUED: July 8, 1997

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Coon; Hayden G.	Gaithersburg	MD		
Ambesi-Impiombato; Francesco Saverio	Tricesimo			IT
Curcio; Francesco	Pagnacco			IT

US-CL-CURRENT: 435/378; 435/383, 435/397

ABSTRACT:

The present invention provides a method for producing an expanded non-transformed cell culture comprising the steps of: (1) preparing partially purified, minced tissue; (2) concentrating the resulting cells and tissue pieces; (3) resuspending the concentrated tissue cells and pieces in a culture medium capable of supporting sustained cell division that is contained in a culture vessel; (4) incubating the cells; and (5) passaging the cells periodically. The present invention further provides clonal strains of cells derived from the above-mentioned cell culture, medium and conditioned medium designed for the culturing of such cells, including pancreatic, thyroid, parathyroid, and parotid cells, and the use of cultured pancreatic cells to form pancreatic pseudotissues composed of matrix-embedded aggregated (pseudoislets) or individual cells, to treat blood sugar disorders in mammals, and to test for cytotoxicity and autoimmune activities with reference to pancreatic endocrine cells.

16 Claims, 18 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 11

☐ 19. Document ID: US 5643782 A

L5: Entry 19 of 28 File: USPT Jul 1, 1997

US-PAT-NO: 5643782
DOCUMENT-IDENTIFIER: US 5643782 A

TITLE: Immortalized epithelial cell lines

DATE-ISSUED: July 1, 1997

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Andley; Usha P.	Ballwin	MO		
Fleming; Timothy P.	Ballwin	MO		

US-CL-CURRENT: 435/371; 435/346, 435/378, 435/948

ABSTRACT:

An immortalized epithelial lens cell line obtained from human lens epithelial cells infected with hybride adenovirus/SV40 (Ad12-SV40), and methods for making and using the cell line are disclosed.

8 Claims, 8 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 6

Full | Title | Citation | Front | Review | Classification | Date | Reference | Claims | KWIC | Draw. Desc

☐ 20. Document ID: US 5612211 A

L5: Entry 20 of 28 File: USPT Mar 18, 1997

US-PAT-NO: 5612211
DOCUMENT-IDENTIFIER: US 5612211 A

TITLE: Stimulation, production and culturing of hematopoietic progenitor cells by fibroblast growth factors

DATE-ISSUED: March 18, 1997

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Wilson; Elaine L.	New York	NY		
Gabrilove; Janice	New York	NY		

US-CL-CURRENT: 435/378; 424/577, 435/325, 435/377, 435/384, 514/12, 514/2, 530/324, 530/351, 530/399

ABSTRACT:

Fibroblast growth factors are used in vivo, in situ and in vitro to stimulate stem cells, hemopoiesis, the immune system, transplant donor cells, culture and/or engraftment, wherein the use of fibroblast growth factors is disclosed for the stimulation of stem cells or hemopoietic cells, supporting cells and their progeny, in vitro, in situ and in vivo, as well as corresponding engrafting sites in vivo.

6 Claims, 27 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 16

Full | Title | Citation | Front | Review | Classification | Date | Reference | Claims | KWIC | Draw. Desc

☐ 21. Document ID: US 5583033 A

L5: Entry 21 of 28 File: USPT Dec 10, 1996

US-PAT-NO: 5583033
DOCUMENT-IDENTIFIER: US 5583033 A

TITLE: T lymphocyte precursor

DATE-ISSUED: December 10, 1996

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Terstappen; Leon W. M. M.	Palo Alto	CA		
Picker; Louis J.	Dallas	TX		

US-CL-CURRENT: 435/7.21; 435/378, 435/7.24

ABSTRACT:

A population of T lymphocyte precursor cells is disclosed. In bone marrow, the earliest identifiable T lymphocyte precursor is CD34.sup.+, CD7.sup.+ and Leu 8.sup.+++. Methods of isolation and methods of therapeutic use of such cells also are disclosed.

17 Claims, 37 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 20

☐ 22. Document ID: US 5503981 A

L5: Entry 22 of 28 File: USPT Apr 2, 1996

US-PAT-NO: 5503981
DOCUMENT-IDENTIFIER: US 5503981 A

TITLE: Isolation of fetal cells from maternal blood to enable prenatal diagnosis

DATE-ISSUED: April 2, 1996

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Mueller; Utz W.	Torens Park			AU
Hawes; Catherine S.	Fullarton			AU

US-CL-CURRENT: 435/7.21; 435/378, 435/7.92, 435/70.21, 435/968, 436/526, 436/548, 530/388.2

ABSTRACT:

This invention relates to a method for the isolation of trophoblast (placental) cells from the blood of a pregnant mammal so as to provide the essential starting material, namely cells derived from the fetus, to enable genetic and/or biochemical information about the fetus to be obtained. In particular, this invention relates to the use of monoclonal antibodies specific for membrane protein markers on mammalian trophoblasts to isolate trophoblast cells from maternal blood. These cells may then be used to obtain fetal genetic and/or biochemical information early in pregnancy. The present invention is particularly relevant for detecting human fetal abnormalities.

12 Claims, 1 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 1

☐ 23. Document ID: US 5411883 A

L5: Entry 23 of 28 File: USPT May 2, 1995

US-PAT-NO: 5411883
DOCUMENT-IDENTIFIER: US 5411883 A
**** See image for Certificate of Correction ****

TITLE: Proliferated neuron progenitor cell product and process

DATE-ISSUED: May 2, 1995

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Boss; Barbara D.	Alameda	CA		
Spector; Dennis H.	Oakland	CA		

US-CL-CURRENT: 435/29; 435/325, 435/368, 435/378

ABSTRACT:

This invention is based on the development of procedures for isolation and proliferation of neuron progenitor cells and is directed to growth, storage, production and implantation of proliferated neuron progenitor cells. The isolation and culture methods are designed to proliferate mammalian ventral mesencephalon neuron progenitor cells in vitro to produce a culture which differentiates to produce dopamine-producing cells. The products of this invention include a culture containing neuron progenitor cells, preferably, grown as aggregates in suspension cultures. The process of this invention for preparing neuron progenitor cells comprises obtaining ventral mesencephalon tissue from a donor at the appropriate stage of embryonic development; dissociation of the tissue to obtain single cells and small cell clusters for culture; culturing the neuron progenitor cells in an initial culture medium which selects for a novel cell culture containing neuron progenitor cells and growing the cells for a period of time in a second medium, during which the neuron progenitor cells proliferate.

16 Claims, 0 Drawing figures
Exemplary Claim Number: 1

Full | Title | Citation | Front | Review | Classification | Date | Reference | Claims | KWIC | Draw. Desc

☐ 24. Document ID: US 5328843 A

L5: Entry 24 of 28 File: USPT Jul 12, 1994

US-PAT-NO: 5328843
DOCUMENT-IDENTIFIER: US 5328843 A

TITLE: Method for allocating cells and cell allocation device

DATE-ISSUED: July 12, 1994

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Fukuda; Jun	Shibuya-ku, Tokyo			JP
Kawaguchi; Hideo	Saitama			JP
Ushiroda; Takejiro	Saitama			JP
Shimizu; Norio	Sayama			JP
Sato; Kazuo	Tokyo			JP

US-CL-CURRENT: 435/378; 422/947, 435/283.1, 435/309.1, 435/396, 435/402

ABSTRACT:

Apertures in a definite shape having a definite width and length are provided on one surface of a plate material having a definite thickness. One end of the apertures is connected with the other surface of the plate material and at the same time, is opened. Another end of the apertures is connected with the plate material on one surface and is also opened toward the other surface of a culture substrate. The plate material is closely contacted to one surface of the culture substrate for allocating nerve cells and observing growth of the neurites. Then, the cell suspension is supplied to the apertures. The cells in the suspension are allocated on the culture substrate in response to the apertures by centrifugation or spontaneous sedimentation. The plate material is then withdrawn.

48 Claims, 32 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 15

☐ 25. Document ID: US 5277907 A

L5: Entry 25 of 28 File: USPT Jan 11, 1994

US-PAT-NO: 5277907
DOCUMENT-IDENTIFIER: US 5277907 A

TITLE: Regulation of the immune system

DATE-ISSUED: January 11, 1994

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Loria; Roger M.	Richmond	VA		

US-CL-CURRENT: 424/93.71; 435/372, 435/378, 435/383, 435/404

ABSTRACT:

The addition of 5-androstene 3.beta.,17.beta.diol and/or 5-androstene 3.beta.,7.beta.,17.beta. triol to growth media increases proliferation of lymphocytes in culture. By methods of the invention it is possible to increase production of autogenous lymphocytes for administration to the patient.

8 Claims, 0 Drawing figures
Exemplary Claim Number: 1

☐ 26. Document ID: US 5087570 A

L5: Entry 26 of 28 File: USPT Feb 11, 1992

US-PAT-NO: 5087570
DOCUMENT-IDENTIFIER: US 5087570 A

TITLE: Homogeneous mammalian hematopoietic stem cell composition

DATE-ISSUED: February 11, 1992

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Weissman; Irving L.	Stanford	CA	94305	
Spangrude; Gerald J.				
	VIC 3050			AU
Muller-Sieburg; Christa	San Diego	CA	92117	
Heimfeld; Shelly	Menlo Park	CA	94025	

US-CL-CURRENT: 424/93.7; 424/577, 435/2, 435/355, 435/379, 436/808, 530/388.7, 530/388.75

ABSTRACT:

Highly concentrated hematopoietic stem cell compositions are provided which are substantially free of differentiated or dedicated hematopoietic cells. The cells are obtained by subtraction of cells having particular markers and selection of cells having particular markers. The resulting composition may be used to provide for individual or groups of hematopoietic lineages, to reconstitute stem cells of the host, and to identify an assay for a wide variety of hematopoietic growth factors.

7 Claims, 0 Drawing figures
Exemplary Claim Number: 1,3

Full | Title | Citation | Front | Review | Classification | Date | Reference | Claims | KWMC | Draw. Desc

☐ 27. Document ID: US 4670394 A

L5: Entry 27 of 28 File: USPT Jun 2, 1987

US-PAT-NO: 4670394
DOCUMENT-IDENTIFIER: US 4670394 A

TITLE: Isolation and culture of adrenal medullary endothelial cells producing blood clotting factor VIII:C

DATE-ISSUED: June 2, 1987

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Pollard; Harvey B.	Potomac	MD		
Ornberg; Richard	Bethesda	MD		
Banerjee; Dipak	Rockville	MD		
Youdim; Moussa	Rockville	MD		
Lelkes; Peter	Rockville	MD		
Heldman; Eli	Rockville	MD		

US-CL-CURRENT: 435/70.3; 435/325, 435/378, 435/392, 435/948, 530/383

ABSTRACT:

The present invention discloses a new line of endothelial cell of adrenal medullary origin capable of producing blood clotting Factor VIII:C. A method of isolating and culturing said cell line has also been disclosed. Factor VIII:C is useful in treating hemophilia.

10 Claims, 6 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 5

Full | Title | Citation | Front | Review | Classification | Date | Reference | Claims | KWMC | Draw Des

☐ 28. Document ID: US 4423151 A

L5: Entry 28 of 28 File: USPT Dec 27, 1983

US-PAT-NO: 4423151
DOCUMENT-IDENTIFIER: US 4423151 A

TITLE: Process for preparation of control for use in estrogen receptor tests

DATE-ISSUED: December 27, 1983

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Baranczuk; Richard J.	Overland Park	KS		

US-CL-CURRENT: 436/8; 424/559, 424/582, 435/379, 436/817, 530/350

ABSTRACT:

A process is disclosed for producing steroid hormone receptor samples to be utilized as controls during assays of various human tissue for steroid hormones, especially estrogen. The process comprises collecting tissue known to include such receptors, adding a buffer solution to the tissue, homogenizing the tissue and buffer solution, centrifuging the homogenized mixture, and thereafter collecting the supernatant. The supernatant which contains the desired receptors is subdivided into suitable control sample size and preferably lyophilized to a flake.

12 Claims, 0 Drawing figures
Exemplary Claim Number: 6

Clear | Generate Collection | Print | Fwd Refs | Bkwd Refs | Generate OACS

Terms	Documents
L2 AND L4	28

Display Format: - Change Format

Previous Page Next Page Go to Doc#

Hit List

Clear | Generate Collection | Print | Fwd Refs | Bkwd Refs | Generate OACS

Search Results - Record(s) 1 through 94 of 94 returned.

☐ 1. Document ID: US 20040241154 A1

Using default format because multiple data bases are involved.

L8: Entry 1 of 94 File: PGPB Dec 2, 2004

PGPUB-DOCUMENT-NUMBER: 20040241154
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20040241154 A1

TITLE: Secretin for the treatment of asthma

PUBLICATION-DATE: December 2, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Davis, Richard Jon	Hertfordshire		GB	
Clark, Kenneth	Hertfordshire		GB	

US-CL-CURRENT: 424/94.2

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWIC | Draw Desc

☐ 2. Document ID: US 20040198693 A1

L8: Entry 2 of 94 File: PGPB Oct 7, 2004

PGPUB-DOCUMENT-NUMBER: 20040198693
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20040198693 A1

TITLE: Compounds for the treatment of ischemia

PUBLICATION-DATE: October 7, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
DeNinno, Michael P.	Gales Ferry	CT	US	
Masamune, Hiroko	Noank	CT	US	
Scott, Robert W.	Mystic	CT	US	

US-CL-CURRENT: 514/46; 514/263.23, 514/263.4, 514/303, 536/27.3, 544/277, 546/119

ABSTRACT:

A.sub.3 agonists, methods of using such A.sub.3 agonists and pharmaceutical compositions containing such A.sub.3 agonists. The A.sub.3 agonists are useful for

the reduction of tissue damage resulting from tissue ischemia or hypoxia.

☐ 3. Document ID: US 20040171798 A1

L8: Entry 3 of 94 File: PGPB Sep 2, 2004

PGPUB-DOCUMENT-NUMBER: 20040171798
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20040171798 A1

TITLE: Nicotinamide acids, amides, and their mimetics active as inhibitors of PDE4 isozymes

PUBLICATION-DATE: September 2, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Magee, Thomas V.	Mystic	CT	US	
Marfat, Anthony	Mystic	CT	US	
Chambers, Robert J.	Mystic	CT	US	

US-CL-CURRENT: 530/331; 546/315

ABSTRACT:

Compounds useful as inhibitors of PDE4 in the treatment of diseases regulated by the activation and degranulation of eosinophils, especially asthma, chronic bronchitis, and chronic obstructuive pulmonary disease, of the formula: 1

wherein j is 0 or 1, k is 0 or 1, m is 0, 1, or 2; n is 1 or 2; A is selected from the partial Formulas: 2

where q is 1, 2, or 3, W.sup.3, --O--; --N(R.sup.9)--; --OC(.dbd.O)--; R.sup.7 is selected from --H; --(C.sub.1-C.sub.6)alkyl, --(C.sub.2-C.sub.6)alkenyl, or --(C.sub.2-C.sub.6)alkynyl substituted by 0 to 3 substituents R.sup.10; --(CH.sub.2).sub.u--(C.sub.3-C.sub.7)cycloa- lkyl where u is 0, 1 or 2, substituted by 0 to 3 R.sup.10; and phenyl or benzyl substituted by 0 to 3 R.sup.14; R.sup.8 is tetrazol-5-yl; 1,2,4-triazol-3-yl; 1,2,4-triazol-3-on-5-yl; 1,2,3-triazol-5-yl; imidazol-2-yl; imidazol-4-yl; imidazolidin-2-on-4-yl; 1,3,4-oxadiazolyl; 1,3,4-oxadiazol-2-on-5-yl; 1,2,4-oxadiazol-3-yl; 1,2,4-oxadiazol-5-on-3-y- l; 1,2,4-oxadiazol-5-yl; 1,2,4-oxadiazol-3-on-5-yl; 1,2,5-thiadiazolyl; 1,3,4-thiadiazolyl; morpholinyl; parathiazinyl; oxazolyl; isoxazolyl; thiazolyl; isothiazolyl; pyrrolyl; pyrazolyl; succinimidyl; glutarimidyl; pyrrolidonyl; 2-piperidonyl; 2-pyridonyl; 4-pyridonyl; pyridazin-3-onyl; pyridyl; pyrimidinyl; pyrazinyl; pyridazinyl; indolyl; indolinyl; isoindolinyl; benzo[b]furanyl; 2,3-dihydrobenzofuranyl; 1,3-dihydroisobenzofuranyl; 2H-1-benzopyranyl; 2-H-chromenyl; chromanyl; benzothienyl; 1H-indazolyl; benzimidazolyl; benzoxazolyl; benzisoxazolyl; benzothiazolyl; benzotriazolyl; benzotriazinyl; phthalazinyl; 1,8-naphthyridinyl; quinolinyl; isoquinolinyl; quinazolinyl; quinoxalinyl; pyrazolo[3,4-d]pyrimidinyl; pyrimido[4,5-d]pyrimidinyl; imidazo[1,2-a]pyridinyl; pyridopyridinyl; pteridinyl; or 1H-purinyl; or A is selected from phosphorous and sulfur acid groups; W is ; --O--; --S(.dbd.O).sub.t--, where t is 0, 1, or 2; or --N(R.sup.3)--; Y is .dbd.C(R.sup.1.sub.a)--, or --[N(O).sub.k] where k is 0 or 1; R.sup.4, R.sup.5 and R.sup.6 are (1) --H; provided that R.sup.5 and R.sup.6 are not both --H at the same time, --F; --Cl; --(C.sub.2-C.sub.4)alkynyl; --R.sup.16; --OR.sup.16; --S

(.dbd.O).sub.pR.sup.16; --C(.dbd.O)R.sup.16, --C(.dbd.O)OR.sup.16; --OC(.dbd.O)R.sup.16; --CN; --NO.sub.2; --C(.dbd.O)NR.sup.16R.sup.17; --OC(.dbd.O)NR.sup.16R.sup.17; --NR.sup.12.sub.aC(.dbd.O)NR.sup.16R.sup.17; --NR.sup.12.sub.aC(.dbd.NR.s- up.12)NR.sup.16R.sup.17; --NR.sup.12.sub.aC(.dbd.NCN)NR.sup.15R.sup.16; --NR.sup.12.sub.aC(.dbd.N--NO.sub.2)NR.sup.15R.sup.16; --C(.dbd.NR.sup.12.sub.a)NR.sup.15R.sup.16; --CH.sub.2C(.dbd.NR.sup.12.su- b.a)NR.sup.16R.sup.17; --OC(.dbd.NR.sup.12.sub.a)NR.sup.16R.sup.17; --OC(.dbd.N--NO.sub.2)NR.sup.16R.sup.17; --NR.sup.16R.sup.17; --CH.sub.2NR.sup.16R.sup.17; --NR.sup.12.sub.aC(.dbd.O)R.sup.16; --NR.sup.12.sub.aC(.dbd.O)OR.sup.16; .dbd.NOR.sup.16; --NR.sup.12.sub.aS(.dbd.O).sub.pR.sup.17--S(.dbd.O).sub.pNR.sup.16R.sup.1- 7; and --CH.sub.2C(.dbd.NR.sup.12.sub.a)NR.sup.16R.sup.17; (2) --(C.sub.1-C.sub.4)alkyl including dimethyl and --(C.sub.1-C.sub.4)alkoxy substituted with 0 to 3 substituents --F or --Cl; or 0 or 1 substituent (C.sub.1-C.sub.2)alkoxycarbonyl-, (C.sub.1-C.sub.2)alkylcarbonyl-, or (C.sub.1-C.sub.2)alkylcarbonyloxy-; or (3) an aryl or heterocyclic moiety; or (4) R.sup.5 and R.sup.6 are taken together to form a moiety of partial Formulas (1.3.1) through (1.3.15): 34

or a pharmaceutically acceptable salt thereof.

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWIC | Draw. Des

---

☐ 4. Document ID: US 20040162316 A1

L8: Entry 4 of 94 File: PGPB Aug 19, 2004

PGPUB-DOCUMENT-NUMBER: 20040162316
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20040162316 A1

TITLE: Combination treatment for alcoholism and alcohol dependence

PUBLICATION-DATE: August 19, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Howard, Harry R. JR.	Bristol	CT	US	

US-CL-CURRENT: 514/317; 514/649

ABSTRACT:

The present invention relates to a method of treating alcoholism or alcohol dependence in a mammal, including a human, by administering to the mammal a monoamine reuptake inhibitor in combination with an opioid antagonist. It also relates to pharmaceutical compositions containing a pharmaceutically acceptable carrier, a monoamine reuptake inhibitor and an opioid antagonist.

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWIC | Draw. Des

---

☐ 5. Document ID: US 20040157929 A1

L8: Entry 5 of 94 File: PGPB Aug 12, 2004

PGPUB-DOCUMENT-NUMBER: 20040157929

PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20040157929 A1

TITLE: Method for increasing serotonin levels in a person by administration of a composition incorporating(-)hydroxycitric acid, and related compositions thereof

PUBLICATION-DATE: August 12, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Ohia, Sunny E.	Omaha	NE	US	
Preuss, Harry G.	Fairfax Station	VA	US	
Bagchi, Debasis	Concord	CA	US	

US-CL-CURRENT: 514/574

ABSTRACT:

A method for increasing serotonin levels in a person includes identifying a person having a deficient serotonin level and administering to the person a composition incorporating hydroxycitric acid, preferably in the form of an extract of Garcinia cambogia, in an amount sufficient to increase the person's serotonin levels. The method also can incorporate administering chromium, preferably in the form of oxygen-coordinated, niacin-bound chromium, and gymnemic acid, preferably in the form of an extract of Gymnema sylvestre, to synergistically work to further increase serotonin levels in the person.

☐ 6. Document ID: US 20040105859 A1

L8: Entry 6 of 94 File: PGPB Jun 3, 2004

PGPUB-DOCUMENT-NUMBER: 20040105859
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20040105859 A1

TITLE: Methods for inhibiting pain

PUBLICATION-DATE: June 3, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Woolf, Clifford J	Newton	MA	US	
Samad, Tarek A	Charlestown	MA	US	
Ji, Ru-Rong	Medford	MA	US	

US-CL-CURRENT: 424/145.1

ABSTRACT:

The invention provides methods for the treatment or prevention of pain. The invention also provides screening methods for determining whether a compound inhibits IL-1.beta. activity in the central nervous system of a mammal.

☐ 7. Document ID: US 20040077671 A1

L8: Entry 7 of 94 File: PGPB Apr 22, 2004

PGPUB-DOCUMENT-NUMBER: 20040077671
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20040077671 A1

TITLE: Sorbitol dehydrogenase inhibitors

PUBLICATION-DATE: April 22, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Chu-Moyer, Margaret Y.	Old Lyme	CT	US	
Murry, Jerry A.	Mystic	CT	US	
Mylari, Banavara L.	Waterford	CT	US	
Zembrowski, William J.	Oakdale	CT	US	

US-CL-CURRENT: 514/275; 544/230, 544/331

ABSTRACT:

This invention is directed to sorbitol dehydrogenase inhibitory compounds of the formula I, 1

wherein R.sup.1, R.sup.2 and R.sup.3 are as defined in the specification. This invention is also directed to pharmaceutical compositions containing those compounds and methods of treating or preventing diabetic complications, particularly diabetic neuropathy, diabetic nephropathy, diabetic microangiopathy, diabetic macroangiopathy and diabetic cardiomyopathy by administering such compounds to a mammal suffering from diabetes and therefore at risk for developing such complications. This invention is also directed to pharmaceutical compositions comprising a combination of a compound of formula I of this invention with an aldose reductase inhibitor and to methods of treating or preventing diabetic complications therewith. This invention is also directed to pharmaceutical compositions comprising a combination of a compound of formula I of this invention with an NHE-1 inhibitor and to methods of treating cardiomyopathy and other heart-related problems therewith. This invention is also directed to certain intermediates used in the synthesis of the compounds of formula I and to processes for preparing those intermediates.

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWIC | Draw. Des

☐ 8. Document ID: US 20040048856 A1

L8: Entry 8 of 94 File: PGPB Mar 11, 2004

PGPUB-DOCUMENT-NUMBER: 20040048856
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20040048856 A1

TITLE: Monoamine reuptake inhibitors for treatment of CNS disorders

PUBLICATION-DATE: March 11, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Howard, Harry R. JR.	Bristol	CT	US	
Schmidt, Christopher J.	Old Lyme	CT	US	
Seeger, Thomas F.	Mystic	CT	US	
Elliott, Mark L.	Canterbury	CT	US	

US-CL-CURRENT: 514/227.5; 514/231.2, 514/252.12, 514/317, 514/650, 544/170, 544/399, 544/59, 546/236, 564/365

ABSTRACT:

The present invention relates to compounds that are useful exhibit activity as serotonin, norepinephrine and dopamine reuptake inhibitors, and their pharmaceutically acceptable salts, and their use in the treatment of central nervous system and other disorders.

☐ 9. Document ID: US 20030187219 A1

L8: Entry 9 of 94 File: PGPB Oct 2, 2003

PGPUB-DOCUMENT-NUMBER: 20030187219
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20030187219 A1

TITLE: Regulation of human alpha 1A adrenergic receptor-line G protein-coupled receptor

PUBLICATION-DATE: October 2, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Ramakrishnan, Shyam	Brighton	MA	US	

US-CL-CURRENT: 530/350; 435/320.1, 435/325, 435/69.1, 536/23.5

ABSTRACT:

Reagents which regulate human .alpha..sub.1aadrenergic receptor-like GPCR and reagents which bind to human .alpha..sub.1a adrenergic receptor-like GPCR gene products can play a role in preventing, ameliorating, or correcting dysfunctions or diseases including, but not limited to, infections such as bacterial, fungal, protozoan, and viral infections, particularly those caused by HIV viruses, pain, obesity cancers, anorexia, bulimia, asthma, Parkinson's diseases, acute heart failure, hypotension, hypertension, urinary retention, osteoporosis, angina pectoris, myocardial infarction, ulcers, asthma, allergies, multiple sclerosis, benign prostatic hypertrophy, and psychotic and neurological disorders, including anxiety, schizophrenia, manic depression, delirium, dementia, several mental retardation, and dyskinesias, such as Huntington's disease and Tourett's syndrome.

☐ 10. Document ID: US 20030171349 A1

L8: Entry 10 of 94 File: PGPB Sep 11, 2003

PGPUB-DOCUMENT-NUMBER: 20030171349
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20030171349 A1

TITLE: Novel muscarinic receptor agonists

PUBLICATION-DATE: September 11, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Villalobos, Anabella	Niantic	CT	US	
Yohannes, Daniel	Groton	CT	US	
Nowakowski, Jolanta	Old Saybrook	CT	US	
Liston, Dane R.	Noank	CT	US	

US-CL-CURRENT: 514/210.01; 514/217.12, 514/227.5, 514/237.8, 514/331, 514/365, 514/408, 540/609, 544/167, 544/59, 546/229, 548/205, 548/566, 548/950

ABSTRACT:

This invention relates to a novel class of partial or full muscarinic receptor agonists intermediates for their preparation, and pharmaceutical compositions and methods of use for the treatment or prevention of diseases the treatment or prevention of which is mediated by muscarinic receptor agonism.

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWIC | Draw. Desc

☐ 11. Document ID: US 20030171302 A1

L8: Entry 11 of 94 File: PGPB Sep 11, 2003

PGPUB-DOCUMENT-NUMBER: 20030171302
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20030171302 A1

TITLE: Opioid derivative

PUBLICATION-DATE: September 11, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Okada, Yoshio	Akashi-shi	NC	JP	
Tsuda, Yuko	Akashi-shi	NC	JP	
Yokoi, Toshio	Akashi-shi		JP	
Bryant, Sharon D.	Chapel Hill		US	

Lazarus, Lawrence H. Durham US

US-CL-CURRENT: 514/19; 564/157

ABSTRACT:

1. A peptide derivative represented by the following formula (1) or a salt thereof; 1

, wherein R.sup.1 is hydrogen atom or methyl group, R.sup.2 is hydrogen atom or hydroxy group and n is an integer of 1-8, provided that R.sup.1 is hydrogen atom when R.sup.2 is hydrogen atom, which has specific and high binding affinity with the .mu.-opioid receptor.

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWIC | Draw. Des

---

☐ 12. Document ID: US 20030153559 A1

L8: Entry 12 of 94 File: PGPB Aug 14, 2003

PGPUB-DOCUMENT-NUMBER: 20030153559
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20030153559 A1

TITLE: Propenecarboxylic acid amidoxime derivatives, a process for the preparation thereof , and pharmaceutical compositions containing the same

PUBLICATION-DATE: August 14, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Literati Nagy, Peter	Budapest		HU	
Sumegi, Balazs	Pecs		HU	
Takacs, Kalman	Budapest		HU	

US-CL-CURRENT: 514/227.5; 514/237.8, 514/252.12, 514/331, 514/365, 514/374, 514/400, 514/406, 514/408, 514/633, 544/167 , 544/398, 544/59, 546/229, 548/203, 548/215, 548/221, 548/336.1, 548/370.1, 548/566, 564/229

ABSTRACT:

The invention refers to novel propenecarboxylic acid amidoxime derivatives furthermore N-oxides and/or geometrical isomers and/or optical isomers and/or pharmaceutically suitable acid addition salts and/or quaternary derivatives thereof. The novel compounds are suitable for the treatment of a state connected with oxygen deficit and/or energy deficit, or a disease based on PARP inhibition, especially an autoimmune or neurodegenerative disease, and/or a viral disease, and/or a disease caused by a toxic effect.

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWIC | Draw. Des

---

☐ 13. Document ID: US 20030149043 A1

L8: Entry 13 of 94 File: PGPB Aug 7, 2003

PGPUB-DOCUMENT-NUMBER: 20030149043
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20030149043 A1

TITLE: N-[(substituted five-membered di-or triaza diunsaturated ring)carbonyl] guanidine derivatives for the treatment of ischemia

PUBLICATION-DATE: August 7, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Hamanaka, Ernest S.	Gales Ferry	CT	US	
Guzman-Perez, Angel	Stonington	CT	US	
Mularski, Christian J.	Chester	CT	US	
Ruggeri, Roger B.	Waterford	CT	US	
Wester, Ronald T.	Ledyard	CT	US	

US-CL-CURRENT: 514/248; 514/249, 514/266.23, 514/307, 514/314, 514/406, 544/167, 544/235, 544/237, 544/284, 544/355, 546/146, 548/365.1, 548/374.1

ABSTRACT:

NHE-1 inhibitors, methods of using such NHE-1 inhibitors and pharmaceutical compositions containing such NHE-1 inhibitors. The NHE-1 inhibitors are useful for the reduction of tissue damage resulting from tissue ischemia.

☐ 14. Document ID: US 20030130322 A1

L8: Entry 14 of 94 File: PGPB Jul 10, 2003

PGPUB-DOCUMENT-NUMBER: 20030130322
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20030130322 A1

TITLE: Combination treatment for alcoholism and alcohol dependence

PUBLICATION-DATE: July 10, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Howard, Harry R. JR.	Bristol	CT	US	

US-CL-CURRENT: 514/357; 514/408, 514/438, 514/534, 514/649, 546/334, 548/561, 549/74, 558/418, 564/336

ABSTRACT:

The present invention relates to a method of treating alcoholism or alcohol dependence in a mammal, including a human, by administering to the mammal a monoamine reuptake inhibitor in combination with an opioid antagonist. It also relates to pharmaceutical compositions containing a pharmaceutically acceptable carrier, a

monoamine reuptake inhibitor and an opioid antagonist.

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWIC | Draw. Des.

☐ 15. Document ID: US 20030119913 A1

L8: Entry 15 of 94 File: PGPB Jun 26, 2003

PGPUB-DOCUMENT-NUMBER: 20030119913
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20030119913 A1

TITLE: Method for increasing serotonin levels in a person by administration of a composition incorporating (-)-hydroxycitric acid, and related compositions thereof

PUBLICATION-DATE: June 26, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Ohia, Sunny E.	Omaha	NE	US	
Preuss, Harry G.	Fairfax Station	VA	US	
Bagchi, Debasis	Concord	CA	US	

US-CL-CURRENT: 514/574

ABSTRACT:

A method for increasing serotonin levels in a person includes identifying a person having a deficient serotonin level and administering to the person a composition incorporating hydroxycitric acid, preferably in the form of an extract of Garcinia cambogia, in an amount sufficient to increase the person's serotonin levels. The method also can incorporate administering chromium, preferably in the form of oxygen-coordinated, niacin-bound chromium, and gymnemic acid, preferably in the form of an extract of Gymnema sylvestre, to synergistically work to further increase serotonin levels in the person.

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWIC | Draw. Des.

☐ 16. Document ID: US 20030118545 A1

L8: Entry 16 of 94 File: PGPB Jun 26, 2003

PGPUB-DOCUMENT-NUMBER: 20030118545
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20030118545 A1

TITLE: Methods and compositions for treating mammalian nerve tissue injuries

PUBLICATION-DATE: June 26, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Shi, Riyi	West Lafayette	IN	US	

Borgens, Richard B.	Delphi	IN	US
Lee, Raphael C.	Chicago	IL	US

US-CL-CURRENT: 424/78.37

ABSTRACT:

To achieve, an in vivo repair of injured mammalian nerve tissue, an effective amount of a biomembrane fusion agent is administered to the injured nerve tissue. The application of the biomembrane fusion agent may be preformed by directly contacting the agent with the nerve tissue at the site of the injury. Alternatively, the biomembrane fusion agent is delivered to the site of the injury through the blood supply after administration of the biomembrane fusion agent to the patient. The administration is preferably by parenteral administration including including intravascular, intramuscular, subcutaneous, or intraperitoneal injection of an effective quantity of the biomembrane fusion agent so that an effective amount is delivered to the site of the nerve tissue injury.

☐ 17. Document ID: US 20030096407 A1

L8: Entry 17 of 94 File: PGPB May 22, 2003

PGPUB-DOCUMENT-NUMBER: 20030096407
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20030096407 A1

TITLE: Creation of tissue engineered female reproductive organs

PUBLICATION-DATE: May 22, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Atala, Anthony	Weston	MA	US	
Yoo, James J.	Brookline	MA	US	

US-CL-CURRENT: 435/366; 424/93.7

ABSTRACT:

The invention is directed to compositions and methods for reconstructing artificial female reproductive organs. The constructs and methods of the invention can be used for ameliorating congenital malformations and disorders of female reproductive tract using tissue engineered female reproductive organs, such as the uterus, vagina, cervix, and fallopian tubes. These tissue engineered female reproductive organs can be generated by perfusing cultured cell populations derived from cells of the female reproductive tissues, such as uterine, vaginal, cervical, fallopian tube epithelial cells as well as smooth muscle cells.

☐ 18. Document ID: US 20030096406 A1

L8: Entry 18 of 94 File: PGPB May 22, 2003

PGPUB-DOCUMENT-NUMBER: 20030096406
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20030096406 A1

TITLE: Tissue engineered uterus

PUBLICATION-DATE: May 22, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Atala, Anthony	Weston	MA	US	
Yoo, James J.	Brookline	MA	US	

US-CL-CURRENT: 435/366; 424/93.7

ABSTRACT:

The invention is directed to compositions and methods for reconstructing artificial female reproductive organs. The constructs and methods of the invention can be used for ameliorating congenital malformations and disorders of female reproductive tract using tissue engineered female reproductive organs, such as the uterus, vagina, cervix, and fallopian tubes. These tissue engineered female reproductive organs can be generated by perfusing cultured cell populations derived from cells of the female reproductive tissues, such as uterine, vaginal, cervical, fallopian tube epithelial cells as well as smooth muscle cells.

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWIC | Draw Desc

☐ 19. Document ID: US 20030065179 A1

L8: Entry 19 of 94 File: PGPB Apr 3, 2003

PGPUB-DOCUMENT-NUMBER: 20030065179
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20030065179 A1

TITLE: Sorbitol dehydrogenase inhibitors

PUBLICATION-DATE: April 3, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Chu-Moyer, Margaret Y.	Old Lyme	CT	US	
Murry, Jerry A	Mystic	CT	US	
Mylari, Banavara L	Waterford	CT	US	
Zembrowski, William J	Oakdale	CT	US	

US-CL-CURRENT: 544/295; 540/575, 544/279, 544/324

ABSTRACT:

This invention is directed to sorbitol dehydrogenase inhibitory compounds of the

formula I, 1

wherein R.sup.1, R.sup.2 and R.sup.3 are as defined in the specification. This invention is also directed to pharmaceutical compositions containing those compounds and methods of treating or preventing diabetic complications, particularly diabetic neuropathy, diabetic nephropathy, diabetic microangiopathy, diabetic macroangiopathy and diabetic cardiomyopathy by administering such compounds to a mammal suffering from diabetes and therefore at risk for developing such complications. This invention is also directed to pharmaceutical compositions comprising a combination of a compound of formula I of this invention with an aldose reductase inhibitor and to methods of treating or preventing diabetic complications therewith. This invention is also directed to pharmaceutical compositions comprising a combination of a compound of formula I of this invention with an NHE-1 inhibitor and to methods of treating cardiomyopathy and other heart-related problems therewith. This invention is also directed to certain intermediates used in the synthesis of the compounds of formula I and to processes for preparing those intermediates.

☐ 20. Document ID: US 20030056239 A1

L8: Entry 20 of 94 File: PGPB Mar 20, 2003

PGPUB-DOCUMENT-NUMBER: 20030056239
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20030056239 A1

TITLE: NMP35 apoptosis inhibitor gene disruptions, compositions and methods related thereto

PUBLICATION-DATE: March 20, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Reeder, Thadd C.	San Carlos	CA	US	
Phillips, Russell	Menlo Park	CA	US	

US-CL-CURRENT: 800/18; 435/354, 800/21

ABSTRACT:

The present invention relates to transgenic animals, as well as compositions and methods relating to the characterization of gene function. Specifically, the present invention provides transgenic mice comprising mutations in a NMP35 gene. Such transgenic mice are useful as models for disease and for identifying agents that modulate gene expression and gene function, and as potential treatments for various disease states and disease conditions.

☐ 21. Document ID: US 20030055038 A1

L8: Entry 21 of 94 File: PGPB Mar 20, 2003

PGPUB-DOCUMENT-NUMBER: 20030055038
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20030055038 A1

TITLE: Novel biaryl ether derivatives useful as monoamine reuptake inhibitors

PUBLICATION-DATE: March 20, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Howard, Harry R.	Bristol	CT	US	
Adam, Mavis D.	East Lyme	CT	US	

US-CL-CURRENT: 514/212.01; 514/227.5, 514/231.2, 514/252.12, 514/317, 514/365, 514/374, 514/385, 514/408, 514/649

ABSTRACT:

The present invention relates to compounds of formula I, 1

and to their pharmaceutically acceptable salts. Compounds of formula I exhibit activity as serotonin, norepinephrine, and dopamine reuptake inhibitors and can be used in the treatment of central nervous system and other disorders.

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWIC | Draw. Des

☐ 22. Document ID: US 20030055021 A1

L8: Entry 22 of 94 File: PGPB Mar 20, 2003

PGPUB-DOCUMENT-NUMBER: 20030055021
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20030055021 A1

TITLE: Compounds for the treatment of ischemia

PUBLICATION-DATE: March 20, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
DeNinno, Michael P.	Gales Ferry	CT	US	
Masamune, Hiroko	Noank	CT	US	

US-CL-CURRENT: 514/45; 514/263.23, 514/263.38, 514/263.4, 514/303, 514/43, 514/46, 536/27.13, 536/27.21, 536/27.3, 544/276, 544/277, 546/118

ABSTRACT:

A.sub.3 agonists having Formula I are described herein as well as methods of using such A.sub.3 agonists and pharmaceutical compositions containing such A.sub.3 agonists. 1

The A.sub.3 agonists are useful for the reduction of tissue damage resulting from tissue ischemia or hypoxia.

☐ 23. Document ID: US 20020155098 A1

L8: Entry 23 of 94 File: PGPB Oct 24, 2002

PGPUB-DOCUMENT-NUMBER: 20020155098
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20020155098 A1

TITLE: Methods for treating the inflammatory component of a brain disorder

PUBLICATION-DATE: October 24, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Bolton, Anthony E.	Tideswell		GB	
Mandel, Arkady	North York		CA	

US-CL-CURRENT: 424/93.7

ABSTRACT:

Disclosed are methods for treating and preventing neurological disorders which have a significant inflammatory component. The methods of the present invention involve extracting blood from a patient, subjecting the blood ex vivo to at least one stressor selected from the group consisting of an oxidative environment, thermal stress and UV light, and then re-administering the blood to the patient, thereby reducing inflammation.

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWIC | Draw. Desc

☐ 24. Document ID: US 20020143003 A1

L8: Entry 24 of 94 File: PGPB Oct 3, 2002

PGPUB-DOCUMENT-NUMBER: 20020143003
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20020143003 A1

TITLE: Monoamine reuptake inhibitors for treatment of CNS disorders

PUBLICATION-DATE: October 3, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Howard, Harry R. JR.	Bristol	CT	US	
Schmidt, Christopher J.	Old Lyme	CT	US	
Seeger, Thomas F.	Mystic	CT	US	
Elliott, Mark L.	Canterbury	CT	US	

US-CL-CURRENT: 514/210.01; 514/183, 514/212.01, 514/317, 514/408, 514/649, 540/484,

546/232, 548/570, 548/950, 564/336

ABSTRACT:

The present invention relates to compounds of the formula 1

wherein R.sup.1 through R.sup.4, X, Y, m and n are defined as in the specification. Such compounds are useful exhibit activity as serotonin, norepinephrine and dopamine reuptake inhibitors, and their pharmaceutically acceptable salts, and their use in the treatment of central nervous system and other disorders.

☐ 25. Document ID: US 20020115617 A1

L8: Entry 25 of 94 File: PGPB Aug 22, 2002

PGPUB-DOCUMENT-NUMBER: 20020115617
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20020115617 A1

TITLE: Methods for the prevention and / or the treatment of glutamate cytotoxicity

PUBLICATION-DATE: August 22, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Israel, Maurice	Bure-Sur-Yvette		FR	
Molgo, Jordi	Antony		FR	
Bloy, Christian	Lyon		FR	
Mattei, Cesar	Herts		GB	

US-CL-CURRENT: 514/25; 514/590, 514/614, 514/640

ABSTRACT:

The present invention relates to the use of beta-naphthoquinone derivatives, and salts thereof, for the prevention and/or the treatment of glutamate cytotoxicity. It further relates to the use of beta-naphthoquinone derivatives, and salts thereof, for preventing and/or treating glutamate induced neurological disorders. Additionally, it concerns the use of beta-naphthoguinone derivatives, and salts thereof, for making drugs exerting an inhibitory effect on the release of glutamate.

☐ 26. Document ID: US 20020111495 A1

L8: Entry 26 of 94 File: PGPB Aug 15, 2002

PGPUB-DOCUMENT-NUMBER: 20020111495
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20020111495 A1

TITLE: Nicotinamide acids, amides, and their mimetics active as inhibitors of PDE4 isozymes

PUBLICATION-DATE: August 15, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Magee, Thomas Victor	Mystic	CT	US	
Marfat, Anthony	Mystic	CT	US	
Chambers, Robert James	Mystic	CT	US	

US-CL-CURRENT: 546/291; 546/298, 546/315

ABSTRACT:

Compounds useful as inhibitors of PDE4 in the treatment of diseases regulated by the activation and degranulation of eosinophils, especially asthma, chronic bronchitis, and chronic obstructuive pulmonary disease, of the formula: 1

wherein j is 0 or 1, k is 0 or 1, m is 0, 1, or 2; n is 1 or 2; A is selected from the partial Formulas: 2

where q is 1, 2, or 3, W.sup.3 is --O--; --N(R.sup.9)--; or --OC(.dbd.O)--; R.sup.7 is selected from --H; --(C.sub.1-C.sub.6) alkyl, --(C.sub.2-C.sub.6) alkenyl, or --(C.sub.2-C.sub.6) alkynyl substituted by 0 to 3 substituents R.sup.10; --(CH.sub.2).sub.u--(C.sub.3-C.sub.7) cycloalkyl where u is 0, 1 or 2, substituted by 0 to 3 R.sup.10; and phenyl or benzyl substituted by 0 to 3 R.sup.14; R.sup.8 is tetrazol-5-yl; 1,2,4-triazol-3-yl; 1,2,4-triazol-3-on-5-yl; 1,2,3-triazol-5-yl; imidazol-2-yl; imidazol-4-yl; imidazolidin-2-on-4-yl; 1,3,4-oxadiazolyl; 1,3,4-oxadiazol-2-on-5-yl; 1,2,4-oxadiazol-3-yl; 1,2,4-oxadiazol-5-on-3-yl; 1,2,4-oxadiazol-5-yl; 1,2,4-oxadiazol-3-on-5-y- l; 1,2,5-thiadiazolyl; 1,3,4-thiadiazolyl; morpholinyl; parathiazinyl; oxazolyl; isoxazolyl; thiazolyl; isothiazolyl; pyrrolyl; pyrazolyl; succinimidyl; glutarimidyl; pyrrolidonyl; 2-piperidonyl; 2-pyridonyl; 4-pyridonyl; pyridazin-3-onyl; pyridyl; pyrimidinyl; pyrazinyl; pyridazinyl; indolyl; indolinyl; isoindolinyl; benzo[b]furanyl; 2,3-dihydrobenzofuranyl; 1,3-dihydroisobenzofuranyl; 2H-1-benzopyranyl; 2-H-chromenyl; chromanyl; benzothienyl; 1H-indazolyl; benzimidazolyl; benzoxazolyl; benzisoxazolyl; benzothiazolyl; benzotriazolyl; benzotriazinyl; phthalazinyl; 1,8-naphthyridinyl; quinolinyl; isoquinolinyl; quinazolinyl; quinoxalinyl; pyrazolo[3,4-d]pyrimidinyl; pyrimido[4,5-d]pyrimidinyl; imidazo[1,2-a]pyridinyl; pyridopyridinyl; pteridinyl; or 1H-purinyl; or A is selected from phosphorous and sulfur acid groups; W is --O--; --S(.dbd.O).sub.t--, where t is 0, 1, or 2; or --N(R.sup.3)--; Y is .dbd.C(R.sup.1.sub.a)--, or --[N(O).sub.k] where k is 0 or 1; R.sup.4, R.sup.5 and R.sup.6 are (1) --H; provided that R.sup.5 and R.sup.6 are not both --H at the same time, --F; --Cl; --(C.sub.2-C.sub.4) alkynyl; --R.sup.16; --OR.sup.16; --S(.dbd.O).sub.pR.sup.16; --C(.dbd.O)R.sup.16, --C(.dbd.O)OR.sup.16, --C(.dbd.O)OR.sup.16; --OC(.dbd.O)R.sup.16; --CN; --NO.sub.2; --C(.dbd.O)NR.sup.16R.sup.17; --OC(.dbd.O)NR.sup.16R.sup.17; --NR.sup.12.sub.aC(.dbd.O)NR.sup.16R.sup.17; --NR.sup.12.sub.aC(.dbd.NR.s- up.12)NR.sup.16R.sup.17; --NR.sup.12.sub.aC(.dbd.NCN)NR.sup.16R.sup.16; --NR.sup.12.sub.aC(.dbd.N--NO.sub.2)NR.sup.15R.sup.16; --C(.dbd.NR.sup.12.sub.a)NR.sup.15R.sup.16; --CH.sub.2C(.dbd.NR.sup.12.su- b.a)NR.sup.16R.sup.17; --OC(.dbd.NR.sup.12.sub.a)NR.sup.16R.sup.17; --OC(.dbd.N--NO.sub.2)NR.sup.16R.sup.17; --NR.sup.16R.sup.17; --CH.sub.2NR.sup.16R.sup.17; --NR.sup.12.sub.aC(.dbd.O)R.sup.16; --NR.sup.12.sub.aC(.dbd.O)OR.sup.16; .dbd.NOR.sup.16; --NR.sup.12.sub.aS(.dbd.O).sub.pR.sup.17 --S(.dbd.O).sub.pNR.sup.16R.sup.- 17; and --CH.sub.2C(.dbd.NR.sup.12.sub.a)NR.sup.16R.sup.17; (2) --(C.sub.1-C.sub.4) alkyl including dimethyl and --(C.sub.1-C.sub.4) alkoxy substituted with 0 to 3 substituents --F or --Cl; or 0 or 1 substituent (C.sub.1-C.sub.2) alkoxycarbonyl-, (C.sub.1-C.sub.2) alkylcarbonyl-, or (C.sub.1-C.sub.2) alkylcarbonyloxy-; or (3) an aryl or heterocyclic moiety; or (4)

R.sup.5 and R.sup.6 are taken together to form a moiety of partial Formulas (1.3.1) through (1.3.15): 3

or a pharmaceutically acceptable salt thereof.

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWIC | Draw Des

---

☐ 27. Document ID: US 20020103194 A1

L8: Entry 27 of 94 File: PGPB Aug 1, 2002

PGPUB-DOCUMENT-NUMBER: 20020103194
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20020103194 A1

TITLE: Novel muscarinic receptor agonists

PUBLICATION-DATE: August 1, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47
Villalobos, Anabella	Niantic	CT	US	
Yohannes, Daniel	Groton	CT	US	
Nowakowski, Jolanta	Old Saybrook	CT	US	
Liston, Dane	Noank	CT	US	

US-CL-CURRENT: 514/231.8; 514/217.03, 514/228.2, 514/231.2, 514/237.2, 514/238.5, 514/318, 514/428, 540/450, 540/609, 544/105, 544/63, 546/193, 546/231, 564/238

ABSTRACT:

This invention relates to a novel class of partial or full muscarinic receptor agonists intermediates for their preparation, and pharmaceutical compositions and methods of use for the treatment or prevention of diseases the treatment or prevention of which is mediated by muscarinic receptor agonism

Full | Title | Citation | Front | Review | Classification | Date | Reference | Sequences | Attachments | Claims | KWIC | Draw Des

---

☐ 28. Document ID: US 20020055156 A1

L8: Entry 28 of 94 File: PGPB May 9, 2002

PGPUB-DOCUMENT-NUMBER: 20020055156
PGPUB-FILING-TYPE: new
DOCUMENT-IDENTIFIER: US 20020055156 A1

TITLE: Zsig33-like peptides

PUBLICATION-DATE: May 9, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	COUNTRY	RULE-47

Jaspers, Stephen R.	Edmonds	WA	US
Sheppard, Paul O.	Granite Falls	WA	US
Deisher, Theresa A.	Seattle	WA	US
Bishop, Paul D.	Fall City	WA	US

US-CL-CURRENT: 435/183; 435/320.1, 435/325, 435/69.1, 536/23.2

ABSTRACT:

The present invention relates to peptides related to the zsig33 peptide, including agonists, antagonists, and antibodies. Methods of modulating gastric contractility, nutrient uptake, growth hormones, the secretion of digestive enzymes and hormones, and/or secretion of enzymes and/or hormones in the pancreas are also included.

☐ 29. Document ID: US 6806257 B1

L8: Entry 29 of 94 File: USPT Oct 19, 2004

US-PAT-NO: 6806257
DOCUMENT-IDENTIFIER: US 6806257 B1

TITLE: Flavones as inducible nitric oxide synthase inhibitors, cyclooxygenase-2 inhibitors and potassium channel activators

DATE-ISSUED: October 19, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Lee; Tony Jer-Fu	Springfield	IL		
Yang; Chen Ling Ling	Taipei			TW

US-CL-CURRENT: 514/23; 514/25, 514/453, 514/456, 514/465

ABSTRACT:

The present invention is directed to a method for inhibiting expression of either iNOS or COX-2, or both in mammals using flavone compounds, and pharmaceutically acceptable salts thereof. The present invention is also directed to a method of activating K.sup.+ channels in mammals; as well as methods for treating septic shock, for inhibiting expression of angiotensin converting enzyme, for treating or preventing aneurysms and for reducing inflammation and related pathological changes using these compounds. Presently preferred compounds are oroxylin A (5,7-dihydroxy-6-methoxy flavone) and wogonin (5,7-dihydroxy-8-methoxy flavone).

50 Claims, 47 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 27

☐ 30. Document ID: US 6803457 B1

L8: Entry 30 of 94 File: USPT Oct 12, 2004

US-PAT-NO: 6803457
DOCUMENT-IDENTIFIER: US 6803457 B1

TITLE: Compounds for the treatment of ischemia

DATE-ISSUED: October 12, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
DeNinno; Michael P.	Gales Ferry	CT		
Masamune; Hiroko	Noank	CT		
Scott; Robert W.	Mystic	CT		

US-CL-CURRENT: 536/27.21; 536/27.22, 536/27.23, 536/27.63

ABSTRACT:

A.sub.3 agonists, methods of using such A.sub.3 agonists and pharmaceutical compositions containing such A.sub.3 agonists. The A.sub.3 agonists are useful for the reduction of tissue damage resulting from tissue ischemia or hypoxia.

8 Claims, 0 Drawing figures
Exemplary Claim Number: 1

Full | Title | Citation | Front | Review | Classification | Date | Reference | Claims | KWMC | Draw. Des

☐ 31. Document ID: US 6677378 B2

L8: Entry 31 of 94 File: USPT Jan 13, 2004

US-PAT-NO: 6677378
DOCUMENT-IDENTIFIER: US 6677378 B2

TITLE: Monoamine reuptake inhibitors for treatment of CNS disorders

DATE-ISSUED: January 13, 2004

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Howard, Jr.; Harry R.	Bristol	CT		
Schmidt; Christopher J.	Old Lyme	CT		
Seeger; Thomas F.	Mystic	CT		
Elliott; Mark L.	Canterbury	CT		

US-CL-CURRENT: 514/649; 564/336

ABSTRACT:

The present invention relates to compounds of the formula ##STR1##

wherein R.sup.1 through R.sup.4, X, Y, m and n are defined as in the specification. Such compounds are useful exhibit activity as serotonin, norepinephrine and dopamine reuptake inhibitors, and their pharmaceutically acceptable salts, and their use in the treatment of central nervous system and other disorders.

8 Claims, 0 Drawing figures
Exemplary Claim Number: 1,8

☐ 32. Document ID: US 6660740 B1

L8: Entry 32 of 94 File: USPT Dec 9, 2003

US-PAT-NO: 6660740
DOCUMENT-IDENTIFIER: US 6660740 B1

TITLE: Sorbitol dehydrogenase inhibitors

DATE-ISSUED: December 9, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Chu-Moyer; Margaret Y.	Old Lyme	CT		
Murry; Jerry A.	Mystic	CT		
Mylari; Banavara L.	Waterford	CT		
Zembrowski; William J.	Oakdale	CT		

US-CL-CURRENT: 514/253.04; 514/183, 514/255.01, 544/295, 544/319, 544/386

ABSTRACT:

This invention is directed to sorbitol dehydrogenase inhibitory compounds of the formula I, ##STR1##

wherein R.sup.1, R.sup.2 and R.sup.3 are as defined in the specification. This invention is also directed to pharmaceutical compositions containing those compounds and methods of treating or preventing diabetic complications, particularly diabetic neuropathy, diabetic nephropathy, diabetic microangiopathy, diabetic macroangiopathy and diabetic cardiomyopathy by administering such compounds to a mammal suffering from diabetes and therefore at risk for developing such complications. This invention is also directed to pharmaceutical compositions comprising a combination of a compound of formula I of this invention with an aldose reductase inhibitor and to methods of treating or preventing diabetic complications therewith. This invention is also directed to pharmaceutical compositions comprising a combination of a compound of formula I of this invention with an NHE-1 inhibitor and to methods of treating cardiomyopathy and other heart-related problems therewith. This invention is also directed to certain intermediates used in the synthesis of the compounds of formula I and to processes for preparing those intermediates.

9 Claims, 0 Drawing figures
Exemplary Claim Number: 1

☐ 33. Document ID: US 6602875 B2

L8: Entry 33 of 94 File: USPT Aug 5, 2003

US-PAT-NO: 6602875
DOCUMENT-IDENTIFIER: US 6602875 B2

TITLE: Sorbitol dehydrogenase inhibitors

DATE-ISSUED: August 5, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Chu-Moyer; Margaret Y.	Old Lyme	CT		
Mylari; Banavara L.	Waterford	CT		
Zembrowski; William J.	Oakdale	CT		

US-CL-CURRENT: 514/253.04; 514/252.13, 514/252.16, 514/256, 514/275, 514/300, 544/242, 544/295, 544/330, 544/345, 544/358, 544/405

ABSTRACT:

This invention is directed to sorbitol dehydrogenase inhibitory compounds of the formula I, ##STR1##

wherein R.sup.1, R.sup.2 and R.sup.3 are as defined in the specification. This invention is also directed to pharmaceutical compositions containing those compounds and methods of treating or preventing diabetic complications, particularly diabetic neuropathy, diabetic nephropathy, diabetic microangiopathy, diabetic macroangiopathy and diabetic cardiomyopathy by administering such compounds to a mammal suffering from diabetes and therefore at risk for developing such complications. This invention is also directed to pharmaceutical compositions comprising a combination of a compound of formula I of this invention with an aldose reductase inhibitor and to methods of treating or preventing diabetic complications therewith. This invention is also directed to pharmaceutical compositions comprising a combination of a compound of formula I of this invention with an NHE-1 inhibitor and to methods of treating cardiomyopathy and other heart-related problems therewith. This invention is also directed to certain intermediates used in the synthesis of the compounds of formula I and to processes for preparing those intermediates.

70 Claims, 0 Drawing figures
Exemplary Claim Number: 1

☐ 34. Document ID: US 6596741 B2

L8: Entry 34 of 94 File: USPT Jul 22, 2003

US-PAT-NO: 6596741
DOCUMENT-IDENTIFIER: US 6596741 B2

TITLE: Biaryl ether derivatives useful as monoamine reuptake inhibitors

DATE-ISSUED: July 22, 2003

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Howard; Harry R.	Bristol	CT		
Adam; Mavis D.	East Lyme	CT		

US-CL-CURRENT: 514/357; 514/327, 514/383, 514/406, 514/424, 514/438, 514/471, 514/650

ABSTRACT:

The present invention relates to compounds of formula I: ##STR1##

and to their pharmaceutically acceptable salts. Compounds of formula I exhibit activity as serotonin, norepinephrine, and dopamine reuptake inhibitors and can be used in the treatment of central nervous system and other disorders.

4 Claims, 0 Drawing figures
Exemplary Claim Number: 1

☐ 35. Document ID: US 6492401 B1

L8: Entry 35 of 94 File: USPT Dec 10, 2002

US-PAT-NO: 6492401
DOCUMENT-IDENTIFIER: US 6492401 B1

TITLE: N-[(substituted five-membered di- or triaza diunsaturated ring)carbonyl] guanidine derivatives for the treatment of ischemia

DATE-ISSUED: December 10, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Hamanaka; Ernest S.	Gales Ferry	CT		
Guzman-Perez; Angel	Stonington	CT		
Ruggeri; Roger B.	Waterford	CT		
Webster; Ronald T.	Ledyard	CT		
Mularski; Christian J.	Chester	CT		

US-CL-CURRENT: 514/359; 514/406, 546/145, 546/165, 546/175, 548/255, 548/306.1, 548/362.5

ABSTRACT:

NHE-1 inhibitors, methods of using such NHE-1 inhibitors and pharmaceutical compositions containing such NHE-1 inhibitors. The NHE-1 inhibitors are useful for the reduction of tissue damage resulting from tissue ischemia.

132 Claims, 0 Drawing figures
Exemplary Claim Number: 1

☐ 36. Document ID: US 6479498 B1

L8: Entry 36 of 94 File: USPT Nov 12, 2002

US-PAT-NO: 6479498
DOCUMENT-IDENTIFIER: US 6479498 B1

TITLE: Sodium channel drugs and uses

DATE-ISSUED: November 12, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Marquess; Daniel	Half Moon Bay	CA		
Choi; Seok-Ki	Palo Alto	CA		
Beattie; David T.	Belmont	CA		
Griffin; John H.	Atherton	CA		
Armstrong; Scott	San Francisco	CA		
Church; Timothy J.	San Mateo	CA		
Jenkins; Thomas E.	La Honda	CA		
Green; David C.	Pacifica	CA		

US-CL-CURRENT: 514/256; 514/275, 544/325, 544/326, 544/327, 544/329

ABSTRACT:

The compounds of this invention comprise 2-10 ligands covalently connected, each of the ligands being capable of binding to a ligand binding site in a Na.sup.+ channel, thereby modulating the biological activities thereof.

12 Claims, 27 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 25

☐ 37. Document ID: US 6420354 B1

L8: Entry 37 of 94 File: USPT Jul 16, 2002

US-PAT-NO: 6420354
DOCUMENT-IDENTIFIER: US 6420354 B1

TITLE: Sodium channel drugs and uses

DATE-ISSUED: July 16, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Marquess; Daniel	Half Moon Bay	CA		
Choi; Seok-Ki	Palo Alto	CA		
Beattie; David T.	Belmont	CA		

Griffin; John H.	Atherton	CA
Armstrong; Scott	San Francisco	CA
Church; Timothy J.	San Mateo	CA
Jenkins; Thomas E.	La Honda	CA

US-CL-CURRENT: 514/183; 514/357, 514/438, 514/651, 540/470, 546/334, 549/75, 564/353

ABSTRACT:

The compounds of this invention comprise 2-10 ligands covalently connected, each of the ligands being capable of binding to a ligand binding site in a Na.sup.+ channel, thereby modulating the biological activities thereof.

13 Claims, 31 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 25

☐ 38. Document ID: US 6414149 B1

L8: Entry 38 of 94 File: USPT Jul 2, 2002

US-PAT-NO: 6414149
DOCUMENT-IDENTIFIER: US 6414149 B1

TITLE: Sorbitol dehydrogenase inhibitors

DATE-ISSUED: July 2, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Chu-Moyer; Margaret Y.	Old Lyme	CT		
Mylari; Banavara L.	Waterford	CT		
Zembrowski; William J.	Oakdale	CT		

US-CL-CURRENT: 544/295; 544/194, 544/242, 544/326

ABSTRACT:

This invention is directed to sorbitol dehydrogenase inhibitory compounds of the formula I, ##STR1##

wherein R.sup.1, R.sup.2 and R.sup.3 are as defined in the specification. This invention is also directed to pharmaceutical compositions containing those compounds and methods of treating or preventing diabetic complications, particularly diabetic neuropathy, diabetic nephropathy, diabetic microangiopathy, diabetic macroangiopathy and diabetic cardiomyopathy by administering such compounds to a mammal suffering from diabetes and therefore at risk for developing such complications. This invention is also directed to pharmaceutical compositions comprising a combination of a compound of formula I of this invention with an aldose reductase inhibitor and to methods of treating or preventing diabetic complications therewith. This invention is also directed to pharmaceutical compositions comprising a combination of a compound of formula I of this invention with an NHE-1 inhibitor and to methods of treating cardiomyopathy and other heart-related problems therewith. This invention is also directed to certain intermediates used in the synthesis of the compounds of formula I

and to processes for preparing those intermediates.

117 Claims, 0 Drawing figures
Exemplary Claim Number: 1

Full | Title | Citation | Front | Review | Classification | Date | Reference | Claims | KWIC | Draw. Desc

---

☐ 39. Document ID: US 6410736 B1

L8: Entry 39 of 94 File: USPT Jun 25, 2002

US-PAT-NO: 6410736
DOCUMENT-IDENTIFIER: US 6410736 B1

TITLE: Biaryl ether derivatives useful as monoamine reuptake inhibitors

DATE-ISSUED: June 25, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Howard, Jr.; Harry R.	Bristol	CT		
Adam; Mavis D.	East Lyme	CT		

US-CL-CURRENT: 546/216; 546/334, 548/205, 548/252, 548/255, 548/267.2, 548/371.7, 548/543, 549/491, 549/75, 564/337

ABSTRACT:

The present invention relates to compounds of formula I, ##STR1##

and to their pharmaceutically acceptable salts. Compounds of formula I exhibit activity as serotonin, norepinephrine, and dopamine reuptake inhibitors and can be used in the treatment of central nervous system and other disorders.

7 Claims, 0 Drawing figures
Exemplary Claim Number: 1

Full | Title | Citation | Front | Review | Classification | Date | Reference | Claims | KWIC | Draw. Desc

---

☐ 40. Document ID: US 6294538 B1

L8: Entry 40 of 94 File: USPT Sep 25, 2001

US-PAT-NO: 6294538
DOCUMENT-IDENTIFIER: US 6294538 B1

TITLE: Compounds for treating and preventing diabetic complications

DATE-ISSUED: September 25, 2001

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Mylari; Banavara L.	Waterford	CT		

US-CL-CURRENT: 514/252.14; 544/295

ABSTRACT:

This invention is directed to sorbitol dehydrogenase inhibitory compounds of the formula I, ##STR1##

wherein R is as defined in the specification. This invention is also directed to pharmaceutical compositions containing those compounds and methods of treating or preventing diabetic complications, particularly diabetic neuropathy, diabetic nephropathy and diabetic cardiomyopathy by administering such compounds to a mammal suffering from diabetes and therefore at risk for developing such complications. This invention is also directed to pharmaceutical compositions comprising a combination of a compound of formula I of this invention with an aldose reductase inhibitor and to methods of treating or preventing diabetic complications therewith. This invention is also directed to pharmaceutical compositions comprising a combination of a compound of formula I of this invention with an NHE-1 inhibitor and to methods of treating cardiomyopathy and other heart-related problems therewith. This invention is also directed to certain intermediates used in the synthesis of the compounds of formula I and to processes for preparing those intermediates.

46 Claims, 0 Drawing figures
Exemplary Claim Number: 1,6

☐ 41. Document ID: US 6096740 A

L8: Entry 41 of 94 File: USPT Aug 1, 2000

US-PAT-NO: 6096740
DOCUMENT-IDENTIFIER: US 6096740 A
**** See image for Certificate of Correction ****

TITLE: Dexanabinol derivatives and their use as neuroprotective pharmaceutical compositions

DATE-ISSUED: August 1, 2000

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Mechoulam; Raphael	Jerusalem			IL
Pop; Emil	Gainesville	FL		
Sokolovsky; Mordechai	Tel Aviv			IL
Kloog; Yoel	Hertzlyia			IL
Biegon; Anat	Tel Aviv			IL

US-CL-CURRENT: 514/236.8; 514/100, 514/254.11, 514/314, 514/325, 514/382, 514/455, 544/109, 544/375, 546/135, 546/282.7 , 548/252, 549/291

ABSTRACT:

The present invention relates to pharmaceutical compositions for preventing or alleviating neurotoxicity. Said pharmaceutical compositions comprise as their active ingredient the stereospecific (+) enantiomers, having (3S,4S) configuration, of .DELTA..sup.6 -tetrahydrocannabinol (THC) type compounds of general formula (I), as defined hereinbelow. ##STR1##

36 Claims, 10 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 7

Full | Title | Citation | Front | Review | Classification | Date | Reference | Claims | KWMC | Draw Des

---

☐ 42. Document ID: US 6093733 A

L8: Entry 42 of 94 File: USPT Jul 25, 2000

US-PAT-NO: 6093733
DOCUMENT-IDENTIFIER: US 6093733 A

TITLE: Muscarinic receptor agonists

DATE-ISSUED: July 25, 2000

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Villalobos; Anabella	Niantic	CT	06357	
Yohannes; Daniel	Groton	CT	06340	
Nowakowski; Jolanta	Old Saybrook	CT	06475	
Liston; Dane R.	Noank	CT	06340	

US-CL-CURRENT: 514/331; 514/183, 514/217.12, 514/228.8, 514/231.2, 514/318, 514/428, 540/450, 540/609, 544/105, 544/63, 546/193, 546/231

ABSTRACT:

This invention relates to a novel class of partial or full muscarinic receptor agonists intermediates for their preparation, and pharmaceutical compositions and methods of use for the treatment or prevention of diseases the treatment or prevention of which is mediated by muscarinic receptor agonism.

20 Claims, 0 Drawing figures
Exemplary Claim Number: 1

Full | Title | Citation | Front | Review | Classification | Date | Reference | Claims | KWMC | Draw Des

---

☐ 43. Document ID: US 6090945 A

L8: Entry 43 of 94 File: USPT Jul 18, 2000

US-PAT-NO: 6090945
DOCUMENT-IDENTIFIER: US 6090945 A

TITLE: Tetrahydro-beta-carbolines

DATE-ISSUED: July 18, 2000

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY

Audia; James E.	Indianapolis	IN
Nelson; David L.	Carmel	IN

US-CL-CURRENT: 546/290; 546/85

ABSTRACT:

The present invention provides novel tetrahydro-beta-carboline compounds having useful central nervous system activity. Further, there is provided 3-ethanamine and 3-ethanamine related compounds which are useful intermediates and have beneficial central nervous system activity. The invention provides formulations and methods for using the novel tetrahydro-beta-carboline and related compounds.

20 Claims, 0 Drawing figures
Exemplary Claim Number: 1

☐ 44. Document ID: US 5919897 A

L8: Entry 44 of 94 File: USPT Jul 6, 1999

US-PAT-NO: 5919897
DOCUMENT-IDENTIFIER: US 5919897 A
**** See image for Certificate of Correction ****

TITLE: MU opioid receptor ligands: agonists and antagonists

DATE-ISSUED: July 6, 1999

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Dooley; Colette T.	San Diego	CA		
Houghten; Richard A.	Del Mar	CA		

US-CL-CURRENT: 530/330; 260/998.2, 514/18, 514/19, 530/331, 530/345

ABSTRACT:

The present invention provides novel opioid peptides. Disclosed are opioid peptides having the general structures Ac-Phe-Arg-Trp-Trp-Tyr-Xaa-NH.sub.2 (SEQ ID NO. 1); Ac-Arg-Trp-Ile-Gly-Trp-Xaa-NH.sub.2 (SEQ ID NO. 2); Trp-Trp-Pro-Lys-His-Xaa-NH.sub.2 (SEQ ID NO. 3); and shorter versions of the latter, namely, Trp-Trp-Pro-Xaa-NH.sub.2 (SEQ ID NO. 4); Tyr-Pro-Phe-Gly-Phe-Xaa-NH.sub.2 (SEQ ID NO. 5); (D)Ile-(D)Met-(D)Ser-(D)Trp-(D)Trp-Gly.sub.n -Xaa-NH.sub.2 (SEQ ID NO. 6); and (D)Ile-(D)Met-(D)Thr-(D)Trp-Gly-Xaa-NH.sub.2 (SEQ ID NO. 7). Within each genus, Xaa is substituted by a specific amino acid. The invention also relates to an opioid peptide having the general structure Tyr-A1-B2-C3-NH.sub.2 (SEQ ID NO. 214), wherein A is D-Nve or D-Nle, B is Gly, Phe, or Trp, and C is Trp or Nap. Also included within the invention are opioid peptides of the general structure Me.sub.x H.sub.y N-Tyr-Tyr-Phe.sub.m -Pro.sub.n -NH.sub.2 (SEQ ID NO. 221) which are peptides modified by permethylation, perallylation, perethylation, perbenzylation and/or pernaphthylation and which can be further modified by reduction.

9 Claims, 7 Drawing figures
Exemplary Claim Number: 1

Number of Drawing Sheets: 7

Full | Title | Citation | Front | Review | Classification | Date | Reference | Claims | KWIC | Draw. Desc

☐ 45. Document ID: US 5869691 A

L8: Entry 45 of 94 File: USPT Feb 9, 1999

US-PAT-NO: 5869691
DOCUMENT-IDENTIFIER: US 5869691 A
**** See image for Certificate of Correction ****

TITLE: Aminoalkyl-indoles

DATE-ISSUED: February 9, 1999

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Audia; James E.	Indianapolis	IN		
Baker; Stephen Richard	Yateley			GB2
Carrera; Jesus Ezquerra	Madrid			ES
Peteira; Carlos Lamas	Madrid			ES
Tercero; Concepcion Pedregal	Madrid			ES

US-CL-CURRENT: 548/494; 548/426, 548/427, 548/504, 548/507

ABSTRACT:

The present invention provides novel tetrahydro-beta-carboline compounds having useful central nervous system activity. Further, there is provided tetrahydro-beta-carboline related compounds which are useful intermediates and have beneficial central nervous system activity. The invention provides formulations and methods for using the novel tetrahydro-beta-carboline and related compounds. Such compounds are particularly useful for the modulation of a 5-HT.sub.2B receptor.

3 Claims, 0 Drawing figures
Exemplary Claim Number: 1

Full | Title | Citation | Front | Review | Classification | Date | Reference | Claims | KWIC | Draw. Desc

☐ 46. Document ID: US 5861425 A

L8: Entry 46 of 94 File: USPT Jan 19, 1999

US-PAT-NO: 5861425
DOCUMENT-IDENTIFIER: US 5861425 A

TITLE: Indole-ethanamines

DATE-ISSUED: January 19, 1999

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Audia; James E.	Indianapolis	IN		
Droste; James J.	Indianapolis	IN		
Murdoch; Gwyn L.	Greenwood	IN		
Nelson; David L.	Carmel	IN		

US-CL-CURRENT: 514/411; 548/427

ABSTRACT:

The present invention provides 3-ethanamine and 3-ethanamine related compounds which are useful intermediates and have beneficial central nervous system activity.

8 Claims, 0 Drawing figures
Exemplary Claim Number: 1

☐ 47. Document ID: US 5861410 A

L8: Entry 47 of 94 File: USPT Jan 19, 1999

US-PAT-NO: 5861410
DOCUMENT-IDENTIFIER: US 5861410 A
**** See image for Certificate of Correction ****

TITLE: Tetrahydro-beta-carbolines

DATE-ISSUED: January 19, 1999

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Audia; James E.	Indianapolis	IN		
Baker; Stephen Richard	Camberley			GB2
Carrera; Jesus Ezquerra	Madrid			ES
Peteira; Carlos Lamas	Madrid			ES
Tercero; Concepcion Pedregal	Madrid			ES

US-CL-CURRENT: 514/285; 514/292, 546/70, 546/86, 546/87

ABSTRACT:

The present invention provides novel tetrahydro-beta-carboline compounds having useful central nervous system activity. Further, there is provided tetrahydro-beta-carboline related compounds which are useful intermediates and have beneficial central nervous system activity. The invention provides formulations and methods for using the novel tetrahydro-beta-carboline and related compounds. Such compounds are particularly useful for the modulation of a 5-HT.sub.2B receptor.

11 Claims, 0 Drawing figures
Exemplary Claim Number: 1

☐ 48. Document ID: US 5861409 A

L8: Entry 48 of 94 File: USPT Jan 19, 1999

US-PAT-NO: 5861409
DOCUMENT-IDENTIFIER: US 5861409 A
**** See image for Certificate of Correction ****

TITLE: Tetrahydro-beta-carbolines

DATE-ISSUED: January 19, 1999

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Audia; James E.	Indianapolis	IN		
Baker; Stephen Richard	Surrey			GB2
Carrera; Jesus Ezquerra	Madrid			ES
Peteira; Carlos Lamas	Madrid			ES
Tercero; Concepcion Pedregal	Madrid			ES

US-CL-CURRENT: 514/280; 546/18, 546/49

ABSTRACT:

The present invention provides novel tetrahydro-beta-carboline compounds having useful central nervous system activity. Further, there is provided tetrahydro-beta-carboline related compounds which are useful intermediates and have beneficial central nervous system activity. The invention provides formulations and methods for using the novel tetrahydro-beta-carboline and related compounds. Such compounds are particularly useful for the modulation of a 5-HT.sub.2B receptor.

6 Claims, 0 Drawing figures
Exemplary Claim Number: 1

☐ 49. Document ID: US 5861408 A

L8: Entry 49 of 94 File: USPT Jan 19, 1999

US-PAT-NO: 5861408
DOCUMENT-IDENTIFIER: US 5861408 A
**** See image for Certificate of Correction ****

TITLE: Tetrahydro-Beta-Carbolines

DATE-ISSUED: January 19, 1999

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Audia; James E.	Indianapolis	IN		
Baker; Stephen Richard	Surrey			GB2

Carrera; Jesus Ezquerra		Madrid	ES
Peteira; Carlos Lamas		Madrid	ES
Tercero; Concepcion Pedregal		Madrid	ES

US-CL-CURRENT: 514/278; 546/49, 546/70

ABSTRACT:

The present invention provides novel tetrahydro-beta-carboline compounds having useful central nervous system activity. Further, there is provided tetrahydro-beta-carboline related compounds which are useful intermediates and have beneficial central nervous system activity. The invention provides formulations and methods for using the novel tetrahydro-beta-carboline and related compounds. Such compounds are particularly useful for the modulation of a 5-HT.sub.2B receptor.

5 Claims, 0 Drawing figures
Exemplary Claim Number: 1

☐ 50. Document ID: US 5852029 A

L8: Entry 50 of 94 File: USPT Dec 22, 1998

US-PAT-NO: 5852029
DOCUMENT-IDENTIFIER: US 5852029 A
**** See image for Certificate of Correction ****

TITLE: Aza spiro compounds acting on the cholinergic system with muscarinic agonist activity

DATE-ISSUED: December 22, 1998

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Fisher; Abraham	Holon			IL
Karton; Yishal	Ness-Ziona			IL
Marciano; Daniele	Ramat-Hasharon			IL
Barak; Dov	Rehovot			IL
Meshulam; Haim	Bat Yam			IL

US-CL-CURRENT: 514/278; 546/16, 546/19, 546/20

ABSTRACT:

Compounds useful for treating diseases of the central or peripheral nervous system in mammals have formulae I-XII ##STR1## wherein ring A or A' together with the spiro-carbon atom constitutes a bridged or unbridged ring containing one or two ring nitrogen atoms; and the other symbols have specified values, subject to certain conditions.

9 Claims, 0 Drawing figures
Exemplary Claim Number: 1

☐ 51. Document ID: US 5847125 A

L8: Entry 51 of 94 File: USPT Dec 8, 1998

US-PAT-NO: 5847125
DOCUMENT-IDENTIFIER: US 5847125 A

TITLE: Amino acid derivatives with anticholecystokinin activity

DATE-ISSUED: December 8, 1998

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
McDonald; Iain Mair	Paddock Wood			GB

US-CL-CURRENT: 540/582; 546/16, 546/19, 560/16, 560/24, 560/38, 562/427

ABSTRACT:

Compounds of formula (II) wherein Ar is naphthyl, naphthylmethyl, 1,2,3,4-tetrahydronaphthyl, phenethyl, styryl, indanyl or a substituted derivative of any of the foregoing, or 3,4-dichlorophenyl, R.sub.1 is H, C.sub.1 to C.sub.6 alkyl, C.sub.1 to C.sub.6 alkenyl, cycloalkyl, --(CH.sub.2).sub.q aryl, --(CH.sub.2).sub.q (substituted aryl), --(CH.sub.2).sub.q heterocyclic or --(CH.sub.2).sub.q (substituted heterocyclic), wherein q is 0 to 4, R.sub.2 is H, methyl or ethyl, R.sub.3 is C.sub.1 to C.sub.3 alkylene or is absent, T is carboxyl, --CONR.sub.4 R.sub.5 (wherein R.sub.4 and R.sub.5 are independently H or C.sub.1 to C.sub.4 alkyl), --COOR.sub.13 (wherein R.sub.13 is C.sub.1 to C.sub.4 alkyl, benzyl or substituted benzyl) or tetrazolyl, X is --C(O)-- or --CH.sub.2 --, and Y is --NR.sub.6 R.sub.7 or --O--R.sub.6 (wherein R.sub.6 and R.sub.7 are independently H, C.sub.1 to C.sub.15 hydrocarbyl or halo-substituted C.sub.1 to C.sub.15 hydrocarbyl in which up to 6 carbon atoms may be replaced by --O--, --S--, or --NR.sub.8 -- (R.sub.8 being absent or selected from H, C.sub.1 to C.sub.12 hydrocarbyl, C.sub.1 to C.sub.12 hydrocarbylcarbonyl and C.sub.1 to C.sub.12 hydrocarbyloxycarbonyl), provided that neither R.sub.6 nor R.sub.7 contains a --O--O-- group, and wherein R.sub.6 and R.sub.7 may be linked by a single or double bond), and pharmaceutically acceptable salts thereof are ligands at CCK and/or gastrin receptors.

25 Claims, 0 Drawing figures
Exemplary Claim Number: 1

Full | Title | Citation | Front | Review | Classification | Date | Reference | Claims | KWMC | Draw Desc

☐ 52. Document ID: US 5760051 A

L8: Entry 52 of 94 File: USPT Jun 2, 1998

US-PAT-NO: 5760051
DOCUMENT-IDENTIFIER: US 5760051 A

TITLE: Tetrahydro-beta-carbolines

DATE-ISSUED: June 2, 1998

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Audia; James E.	Indianapolis	IN		
Droste; James J.	Indianapolis	IN		
Evrard; Deborah A.	Indianapolis	IN		
Fludzinski; Pawel	Indianapolis	IN		
Murdoch; Gwyn L.	Greenwood	IN		
Nelson; David L.	Carmel	IN		

US-CL-CURRENT: 514/292; 546/85, 546/86, 546/87

ABSTRACT:

Tetrahydro-beta-carboline compounds having useful central nervous system activity are enclosed.

20 Claims, 0 Drawing figures
Exemplary Claim Number: 1

Full | Title | Citation | Front | Review | Classification | Date | Reference | Claims | KWIC | Draw Des

---

☐ 53. Document ID: US 5736544 A

L8: Entry 53 of 94 File: USPT Apr 7, 1998

US-PAT-NO: 5736544
DOCUMENT-IDENTIFIER: US 5736544 A

TITLE: Naphthylpiperazinyl compounds useful for treating 5HT.sub.2B receptor mediated conditions

DATE-ISSUED: April 7, 1998

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Audia; James E.	Indianapolis	IN		
Cohen; Marlene L.	Carmel	IN		
Gidda; Jaswant S.	Carmel	IN		
Nelson; David L. G.	Carmel	IN		

US-CL-CURRENT: 514/247

ABSTRACT:

The present invention provides methods for binding a 5-HT.sub.2B receptor in mammals using both known and novel compounds. Further, the invention provides a method for treating or preventing 5-HT.sub.2B related conditions. Finally, the invention provides an article of manufacture.

7 Claims, 0 Drawing figures
Exemplary Claim Number: 1

Full | Title | Citation | Front | Review | Classification | Date | Reference | Claims | KWIC | Draw Des

☐ 54. Document ID: US 5705519 A

L8: Entry 54 of 94 File: USPT Jan 6, 1998

US-PAT-NO: 5705519
DOCUMENT-IDENTIFIER: US 5705519 A
**** See image for Certificate of Correction ****

TITLE: Method for treating 5-HT.sub.2B receptor related conditions

DATE-ISSUED: January 6, 1998

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Audia; James E.	Indianapolis	IN		
Cohen; Marlene	Carmel	IN		
Gidda; Jaswant S.	Carmel	IN		
Nelson; David L.	Carmel	IN		

US-CL-CURRENT: 514/415

ABSTRACT:

The present invention provides methods for binding a 5-HT.sub.2B receptor in mammals using a both known and novel compounds. Further, the invention provides a method for treating or preventing 5-HT.sub.2B related conditions. Finally, the invention provides an article of manufacture.

13 Claims, 0 Drawing figures
Exemplary Claim Number: 1

☐ 55. Document ID: US 5688807 A

L8: Entry 55 of 94 File: USPT Nov 18, 1997

US-PAT-NO: 5688807
DOCUMENT-IDENTIFIER: US 5688807 A
**** See image for Certificate of Correction ****

TITLE: Method for treating 5HT.sub.2B receptor related conditions

DATE-ISSUED: November 18, 1997

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Audia; James E.	Indianapolis	IN		
Cohen; Marlene L.	Carmel	IN		
Gidda; Jaswant S.	Carmel	IN		
Nelson; David L. G.	Carmel	IN		

US-CL-CURRENT: 514/285; 514/292, 546/86, 546/87

ABSTRACT:

The present invention provides methods for binding a 5-HT.sub.2B receptor in mammals using a both known and novel compounds. Further, the invention provides a method for treating or preventing 5-HT.sub.2B related conditions. Finally, the invention provides an article of manufacture.

13 Claims, 0 Drawing figures
Exemplary Claim Number: 1

☐ 56. Document ID: US 5663178 A

L8: Entry 56 of 94 File: USPT Sep 2, 1997

US-PAT-NO: 5663178
DOCUMENT-IDENTIFIER: US 5663178 A

TITLE: Tetrahydro-beta carbolines

DATE-ISSUED: September 2, 1997

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Audia; James E.	Indianapolis	IN		
Baker; Stephen Richard	Camberley			GB2
Carrera; Jesus Ezquerra	Madrid			ES
Peteira; Carlos Lamas	Madrid			ES
Tercero; Concepcion Pedregal	Madrid			ES

US-CL-CURRENT: 514/284; 546/70

ABSTRACT:

The present invention provides novel tetrahydro-beta-carboline compounds having useful central nervous system activity. Further, there is provided tetrahydro-beta-carboline related compounds which are useful intermediates and have beneficial central nervous system activity. The invention provides formulations and methods for using the novel tetrahydro-beta-carboline and related compounds. Such compounds are particularly useful for the modulation of a 5-HT.sub.2B receptor.

8 Claims, 0 Drawing figures
Exemplary Claim Number: 1

☐ 57. Document ID: US 5643916 A

L8: Entry 57 of 94 File: USPT Jul 1, 1997

US-PAT-NO: 5643916
DOCUMENT-IDENTIFIER: US 5643916 A
**** See image for Certificate of Correction ****

TITLE: Tetrahydro-beta-carbolines

DATE-ISSUED: July 1, 1997

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Audia; James E.	Indianapolis	IN		
Baker; Stephen Richard	Camberley			GB2
Carrera; Jesus Ezquerra	Madrid			ES
Peteira; Carlos Lamas	Madrid			ES
Tercero; Concepcion Pedregal	Madrid			ES

US-CL-CURRENT: 514/285; 514/292, 546/70, 546/86, 546/87

ABSTRACT:

The present invention provides novel tetrahydro-beta-carboline compounds having useful central nervous system activity. Further, there is provided tetrahydro-beta-carboline related compounds which are useful intermediates and have beneficial central nervous system activity. The invention provides formulations and methods for using the novel tetrahydro-beta-carboline and related compounds. Such compounds are particularly useful for the modulation of a 5-HT.sub.2B receptor.

11 Claims, 0 Drawing figures
Exemplary Claim Number: 1

☐ 58. Document ID: US 5641861 A

L8: Entry 58 of 94 File: USPT Jun 24, 1997

US-PAT-NO: 5641861
DOCUMENT-IDENTIFIER: US 5641861 A
**** See image for Certificate of Correction ****

TITLE: .mu.opioid receptor ligands: agonists and antagonists

DATE-ISSUED: June 24, 1997

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Dooley; Colette T.	San Diego	CA		
Houghten; Richard A.	Del Mar	CA		

US-CL-CURRENT: 530/329

ABSTRACT:

The present invention provides novel opioid peptides. Disclosed are opioid peptides having the general structures Ac-Phe-Arg-Trp-Trp-Tyr-Xaa--NH.sub.2 (SEQ ID NO. 1);

Ac-Arg-Trp-Ile-Gly-Trp-Xaa--NH.sub.2 (SEQ ID NO. 2); Trp-Trp-Pro-Lys-His-Xaa--NH.sub.2 (SEQ ID NO. 3); and shorter versions of the latter, namely, Trp-Trp-Pro-Xaa--NH.sub.2 (SEQ ID NO. 4); Tyr-Pro-Phe-Gly-Phe-Xaa--NH.sub.2 (SEQ ID NO. 5); (D)Ile-(D)Met-(D)Ser-(D)Trp-(D)Trp-Gly.sub.n -Xaa--NH.sub.2 (SEQ ID NO. 6); and (D)Ile-(D)Met-(D)Thr-(D)Trp-Gly-Xaa--NH.sub.2 (SEQ ID NO. 7). Within each genus, Xaa is substituted by a specific amino acid. The invention also relates to an opioid peptide having the general structure Tyr-A1-B2-C3--NH.sub.2 (SEQ ID NO. 214), wherein A is D-Nve or D-Nle, B is Gly, Phe, or Trp, and C is Trp or Nap. Also included within the invention are opioid peptides of the general structure Pm and red {Me.sub.x H.sub.y N-Tyr-(NMe).sub.z -Tyr-Xaa.sub.z --NH.sub.2 } (SEQ ID NO. 221), wherein Xaa is substituted by a specific amino acid.

10 Claims, 7 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 7

☐ 59. Document ID: US 5635528 A

L8: Entry 59 of 94 File: USPT Jun 3, 1997

US-PAT-NO: 5635528
DOCUMENT-IDENTIFIER: US 5635528 A

TITLE: Intermediates to tetrahydro-beta-carbolines

DATE-ISSUED: June 3, 1997

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Audia; James E.	Indianapolis	IN		
Droste; James J.	Indianapolis	IN		
Evrard; Deborah A.	Indianapolis	IN		
Fludzinski; Pawel	Indianapolis	IN		
Murdoch; Gwyn L.	Greenwood	IN		
Nelson; David L.	Carmel	IN		

US-CL-CURRENT: 514/415; 514/419, 548/504, 548/507

ABSTRACT:

3-Ethanamine and 3-ethanamine related compounds are provided that are useful intermediates and have beneficial central nervous system activity.

9 Claims, 0 Drawing figures
Exemplary Claim Number: 1

☐ 60. Document ID: US 5631265 A

L8: Entry 60 of 94 File: USPT May 20, 1997

US-PAT-NO: 5631265
DOCUMENT-IDENTIFIER: US 5631265 A

TITLE: 8-substituted tetrahydro-beta-carbolines

DATE-ISSUED: May 20, 1997

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Audia; James E.	Indianapolis	IN		
Droste; James J.	Indianapolis	IN		
Nissen; Jeffrey S.	Indianapolis	IN		

US-CL-CURRENT: 514/292; 546/85, 546/86, 546/87

ABSTRACT:

The present invention provides novel tetrahydro-beta-carboline compounds and intermediates having useful central nervous system activity. The invention provides formulations and methods for using the tetrahydro-beta-carboline and related intermediate compounds. Finally, the invention provides an article of manufacture.

25 Claims, 0 Drawing figures
Exemplary Claim Number: 1,23

☐ 61. Document ID: US 5629317 A

L8: Entry 61 of 94 File: USPT May 13, 1997

US-PAT-NO: 5629317
DOCUMENT-IDENTIFIER: US 5629317 A
**** See image for Certificate of Correction ****

TITLE: Tetrahydro-beta-carbolines

DATE-ISSUED: May 13, 1997

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Audia; James E.	Indianapolis	IN		
Baker; Stephen R.	Camberley			GB2
Carrera; Jesus E.	Madrid			ES
Peteira; Carlos L.	Madrid			ES
Tercero; Concepcion P.	Madrid			ES

US-CL-CURRENT: 514/278; 514/279, 514/280, 514/292, 546/18, 546/41, 546/49, 546/53, 546/70, 546/85, 546/86, 546/87

ABSTRACT:

The present invention provides novel tetrahydro-beta-carboline compounds having useful central nervous system activity. Further, there is provided tetrahydro-beta-

carboline related compounds which are useful intermediates and have beneficial central nervous system activity. The invention provides formulations and methods for using the novel tetrahydro-beta-carboline and related compounds. Such compounds are particularly useful for the modulation of a 5-HT.sub.2B receptor.

18 Claims, 0 Drawing figures
Exemplary Claim Number: 1

Full | Title | Citation | Front | Review | Classification | Date | Reference | Claims | KWMC | Draw Desc

---

☐ 62. Document ID: US 5610174 A

L8: Entry 62 of 94 File: USPT Mar 11, 1997

US-PAT-NO: 5610174
DOCUMENT-IDENTIFIER: US 5610174 A
**** See image for Certificate of Correction ****

TITLE: Use of .alpha..sub.1A -selective adrenoceptor agonists for the treatment of urinary incontinence

DATE-ISSUED: March 11, 1997

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Craig; Douglas A.	Fair Lawn	NJ		
Forray; Carlos C.	Paramus	NJ		
Gluchowski; Charles	Wayne	NJ		
Branchek; Theresa A.	Teaneck	NJ		

US-CL-CURRENT: 514/401; 514/394, 514/396, 514/400, 514/402, 514/414, 514/415, 514/418, 514/452, 514/466, 514/605

ABSTRACT:

The present invention provides a method of treating urinary incontinence in a subject which comprises administering to the subject a therapeutically effective amount of a compound having the following structure: ##STR1## wherein each of the substiutents for the compound is as defined in the specification.

3 Claims, 16 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 6

Full | Title | Citation | Front | Review | Classification | Date | Reference | Claims | KWMC | Draw Desc

---

☐ 63. Document ID: US 5538981 A

L8: Entry 63 of 94 File: USPT Jul 23, 1996

US-PAT-NO: 5538981
DOCUMENT-IDENTIFIER: US 5538981 A

TITLE: Tetrahydro-pyrido-indole

DATE-ISSUED: July 23, 1996

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Audia; James E.	Indianapolis	IN		
Droste; James J.	Indianapolis	IN		
Evrard; Deborah A.	Cambridge	MA		

US-CL-CURRENT: 514/292; 546/85, 546/86, 546/87

ABSTRACT:

The present invention provides novel tetrahydrobeta-carboline compounds and intermediates having useful central nervous system activity. The invention further provides formulations and methods for using the novel tetrahydrobeta-carboline compounds.

18 Claims, 0 Drawing figures
Exemplary Claim Number: 1

☐ 64. Document ID: US 5538980 A

L8: Entry 64 of 94 File: USPT Jul 23, 1996

US-PAT-NO: 5538980
DOCUMENT-IDENTIFIER: US 5538980 A

TITLE: Tetrahydro-pyrido-indole

DATE-ISSUED: July 23, 1996

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Audia; James E.	Indianapolis	IN		
Droste; James J.	Indianapolis	IN		
Evrard; Deborah A.	Cambridge	MA		

US-CL-CURRENT: 514/285; 546/70

ABSTRACT:

The present invention provides novel tetrahydro-beta-carboline compounds and intermediates having useful central nervous system activity.

17 Claims, 0 Drawing figures
Exemplary Claim Number: 1

☐ 65. Document ID: US 5534520 A

L8: Entry 65 of 94 File: USPT Jul 9, 1996

US-PAT-NO: 5534520
DOCUMENT-IDENTIFIER: US 5534520 A

TITLE: Spiro compounds containing five-membered rings

DATE-ISSUED: July 9, 1996

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Fisher; Abraham	Holon			IL
Karton; Yishai	Ness-Ziona			IL
Marciano; Daniele	Ramat-Hasharon			IL
Barak; Dov	Removot			IL
Meshulam; Haim	Bat-Yam			IL

US-CL-CURRENT: 514/278; 546/16, 546/19, 546/20

ABSTRACT:

Compounds useful for treating diseases of the central or peripheral nervous system in mammals have formulae I-XIII: ##STR1## wherein ring A or A' together with the spiro-carbon atom constitutes a bridged or unbridged ring containing one or two ring nitrogen atoms; and the other symbols have specified values, subject to certain conditions.

32 Claims, 0 Drawing figures
Exemplary Claim Number: 1

☐ 66. Document ID: US 5508284 A

L8: Entry 66 of 94 File: USPT Apr 16, 1996

US-PAT-NO: 5508284
DOCUMENT-IDENTIFIER: US 5508284 A

TITLE: Tetrahydro-beta-carbolines

DATE-ISSUED: April 16, 1996

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Audia; James E.	Indianapolis	IN		
Droste; James J.	Indianapolis	IN		
Evrard; Deborah A.	Cambridge	MA		
Fludzinski; Pawel	Berkshire			GB
Murdoch; Gwyn L.	Greenwood	IN		
Nelson; David L.	Carmel	IN		

US-CL-CURRENT: 514/285; 546/70

ABSTRACT:

The present invention provides novel tetrahydro-beta-carboline compounds having useful central nervous system activity. Further, there is provided 3-ethanamine and 3-ethanamine related compounds which are useful intermediates and have beneficial central nervous system activity. The invention provides formulations and methods for using the novel tetrahydro-beta-carboline and related compounds.

9 Claims, 0 Drawing figures
Exemplary Claim Number: 1

☐ 67. Document ID: US 5500431 A

L8: Entry 67 of 94 File: USPT Mar 19, 1996

US-PAT-NO: 5500431
DOCUMENT-IDENTIFIER: US 5500431 A

TITLE: Tetrahydro-.beta.-carbolines

DATE-ISSUED: March 19, 1996

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Audia; James E.	Indianapolis	IN		
Droste; James J.	Indianapolis	IN		
Evrard; Deborah A.	Cambridge	MA		
Fludzinski; Pawel	Berkshire			GB
Murdoch; Gwyn L.	Greenwood	IN		
Nelson; David L.	Carmel	IN		

US-CL-CURRENT: 514/280; 546/49

ABSTRACT:

The present invention provides tetrahydro-betacarboline compounds having useful central nervous system activity.

9 Claims, 0 Drawing figures
Exemplary Claim Number: 1

☐ 68. Document ID: US 5494923 A

L8: Entry 68 of 94 File: USPT Feb 27, 1996

US-PAT-NO: 5494923
DOCUMENT-IDENTIFIER: US 5494923 A

TITLE: Method of ameliorating cerebral circulation

DATE-ISSUED: February 27, 1996

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Nishikibe; Masaru	Urayasu			JP
Kamei; Kazuo	Fuchu			JP
Nagura; Jun	Ichikawa			JP
Fukuroda; Takahiro	Tokyo			JP

US-CL-CURRENT: 514/356

ABSTRACT:

An ameliorant of cerebral circulation which contains 2-carbamoyloxymethyl-4-(2,3-dichlorophenyl)-6-methyl-1,4-dihydropyridine-3 ,5-dicarboxylic acid 3-isopropyl ester 5-methyl ester as an active ingredient.

2 Claims, 0 Drawing figures
Exemplary Claim Number: 1

☐ 69. Document ID: US 5488053 A

L8: Entry 69 of 94 File: USPT Jan 30, 1996

US-PAT-NO: 5488053
DOCUMENT-IDENTIFIER: US 5488053 A
**** See image for Certificate of Correction ****

TITLE: Tetrahydro-pyrido-indole

DATE-ISSUED: January 30, 1996

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Audia; James E.	Indianapolis	IN		
Droste; James J.	Indianapolis	IN		
Evrard; Deborah A.	Cambridge	MA		

US-CL-CURRENT: 514/280; 546/49

ABSTRACT:

The present invention provides pentacyclic pyrido[3,4-b]indoles having useful central nervous system activity.

14 Claims, 0 Drawing figures
Exemplary Claim Number: 1

☐ 70. Document ID: US 5444077 A

L8: Entry 70 of 94 File: USPT Aug 22, 1995

US-PAT-NO: 5444077
DOCUMENT-IDENTIFIER: US 5444077 A

TITLE: Ameliorant of cerebral circulation and optical isomer of NB-818, processes for its use

DATE-ISSUED: August 22, 1995

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Nishikibe; Masaru	Urayasu			JP
Kamei; Kazuo	Fuchu			JP
Nagura; Jun	Ichikawa			JP
Fukuroda; Takahiro	Tokyo			JP

US-CL-CURRENT: 514/356; 546/321

ABSTRACT:

An ameliorant of cerebral circulation which contains 2-carbamoyloxymethyl-4-(2,3-dichlorophenyl)-6-methyl-1,4-dihydropyridine-3,5-dicarboxylic acid 3-isopropyl ester 5-methyl ester as an active ingredient.

3 Claims, 0 Drawing figures
Exemplary Claim Number: 1

Full | Title | Citation | Front | Review | Classification | Date | Reference | Claims | KWIC | Draw. Des

☐ 71. Document ID: US 5360822 A

L8: Entry 71 of 94 File: USPT Nov 1, 1994

US-PAT-NO: 5360822
DOCUMENT-IDENTIFIER: US 5360822 A
** See image for Certificate of Correction **

TITLE: Sulfonanilide derivatives and medicine

DATE-ISSUED: November 1, 1994

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Morino; Akira	Kyoto			JP
Morita; Iwao	Kyoto			JP
Tada; Shin-ichi	Shiga			JP

US-CL-CURRENT: 514/605; 564/99

ABSTRACT:

An object of the present invention is to offer an agent for curing urinary incontinence with high selectivity for the urethra.

One of the compounds of the present invention is a sulfonanilide derivative having the following formula (I). ##STR1## The compounds of the present invention exhibit selective contracting action to smooth muscle of the urethra tract whereupon they have useful effect as remedies for urinary incontinence.

3 Claims, 0 Drawing figures
Exemplary Claim Number: 1

Full | Title | Citation | Front | Review | Classification | Date | Reference | Claims | KWIC | Draw. Desc

---

☐ 72. Document ID: US 5324726 A

L8: Entry 72 of 94 File: USPT Jun 28, 1994

US-PAT-NO: 5324726
DOCUMENT-IDENTIFIER: US 5324726 A

TITLE: Benzodiazepine analogs

DATE-ISSUED: June 28, 1994

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Bock; Mark G.	Hatfield	PA		
Evans; Ben E.	Lansdale	PA		
Freidinger; Roger M.	Lansdale	PA		

US-CL-CURRENT: 514/221; 540/504, 540/505, 540/509, 540/510, 540/512, 540/513, 540/514, 540/572, 540/573

ABSTRACT:

Benzodiazepine analogs of the formula: ##STR1## wherein: R.sup.3 is ##STR2## --NH(CH.sub.2).sub.2 --.sub.3 NHCOR.sup.7, ##STR3## or --X.sup.11 NR.sup.18 SO.sub.2(CH.sub.2).sub.q R.sup.7 ; R.sup.7 is O,S,HH, or NR.sup.15 with the proviso that X.sup.7 can be NR.sup.15 only when R.sup.1 is not H.

are disclosed which are antagonists of gastrin and cholecystokinin (CCK) with enhanced aqueous solubility and have properties useful in the treatment of disorders of gastric secretion, appetite regulation, gastrointestinal motility, pancreatic secretion, and dopaminergic function, as well as in treatment producing potentiation of morphine and other opiate analgesics.

4 Claims, 0 Drawing figures
Exemplary Claim Number: 1

Full | Title | Citation | Front | Review | Classification | Date | Reference | Claims | KWIC | Draw. Desc

---

☐ 73. Document ID: US 5223509 A

L8: Entry 73 of 94 File: USPT Jun 29, 1993

US-PAT-NO: 5223509
DOCUMENT-IDENTIFIER: US 5223509 A

TITLE: .beta.-carbolines as cholecystokinin and gastrin antagonists

DATE-ISSUED: June 29, 1993

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Evans; Ben E.	Lansdale	PA		

US-CL-CURRENT: 514/292; 514/255.05, 514/542, 514/599, 514/79, 514/81, 546/85, 546/86, 546/87

ABSTRACT:

This invention relates to certain .beta.-carbolines, which are antagonists of the functions of cholecystokinin (CCK) and gastrin, to pharmaceutical compositions comprising these compounds, and to the use of these compounds in the prevention and treatment of disorders of the gastrointestinal, central nervous and appetite-regulatory systems of mammals, especially of humans.

6 Claims, 0 Drawing figures
Exemplary Claim Number: 1

☐ 74. Document ID: US 5220068 A

L8: Entry 74 of 94 File: USPT Jun 15, 1993

US-PAT-NO: 5220068
DOCUMENT-IDENTIFIER: US 5220068 A

TITLE: Psychostimulant agent

DATE-ISSUED: June 15, 1993

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Knoll; Jozsef	Budapest			HU
Simay; Antal	Budapest			HU
Szinnyei; Eva	Budapest			HU
Somfai; Eva	Budapest			HU
Torok; Zoltan	Budapest			HU
Mozsolits; Karoly	Sopron			HU
Bergmann; Janos	Visergad			HU

US-CL-CURRENT: 564/381; 564/374, 564/375, 564/376, 564/382

ABSTRACT:

The present invention relates to a pharmaceutical composition comprising as active ingredient a compound of the Formula I ##STR1## wherein R.sup.1 stands for straight or branched chain alkyl comprising 1 to 8 carbon atoms; phenyl alkyl having 7 to 10 carbon atoms; phenyl; or cycloalkyl comprising 3 to 8 carbon atoms;

R.sup.2 stands for straight or branched chain alkyl comprising 1 to 8 carbon atoms; alkyl comprising 1 to 8 carbon atoms substituted by halogen, hydroxy, alkoxy having 1 to 4 carbon atoms or by one or two phenyl groups; phenyl; or cycloalkyl having 3 to 8 carbon atoms,

with the proviso that groups R.sup.1 and R.sup.2 together contain at least three carbon atoms. The invention also relates to a process for the preparation of compounds of the Formula I by methods known per se. The compounds of the Formula I are phychostimulants having a new spectrum of effect which can be used in therapy for increasing psychical activity (learning and retention) and for treating clinical patterns of depression and deficiencies of learning and retention like in Alzheimer's disease, and are void of side effects (e.g. due to catecholamine release) of known stimulants.

4 Claims, 0 Drawing figures
Exemplary Claim Number: 1

☐ 75. Document ID: US 5210082 A

L8: Entry 75 of 94 File: USPT May 11, 1993

US-PAT-NO: 5210082
DOCUMENT-IDENTIFIER: US 5210082 A

TITLE: 2-benzazepines with 5- and 6-membered heterocyclic rings to treat pain and anxiety disorders

DATE-ISSUED: May 11, 1993

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Bock; Mark G.	Hatfield	PA		
Evans; Ben E.	Lansdale	PA		
Freidinger; Roger M.	Lansdale	PA		

US-CL-CURRENT: 514/215; 514/217

ABSTRACT:

Pharmaceutical compositions containing aromatic 2-benzazepines with fused 5- or 6-membered heterocyclic rings are disclosed which are useful in the treatment of panic disorder or anxiety disorder.

3 Claims, 0 Drawing figures
Exemplary Claim Number: 1

☐ 76. Document ID: US 5206238 A

L8: Entry 76 of 94 File: USPT Apr 27, 1993

US-PAT-NO: 5206238
DOCUMENT-IDENTIFIER: US 5206238 A

TITLE: Cholecystokinin antagonists

DATE-ISSUED: April 27, 1993

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Bock; Mark G.	Hatfield	PA		
Freidinger; Roger M.	Lansdale	PA		

US-CL-CURRENT: 514/221

ABSTRACT:

Compounds of the formula: ##STR1## are disclosed which are antagonists of gastrin and cholecycstokinin (CCK) and have properties useful for treating panic disorder and for directly inducing anlagesia.

6 Claims, 0 Drawing figures
Exemplary Claim Number: 1

Full | Title | Citation | Front | Review | Classification | Date | Reference | Claims | KWIC | Draw. Desc

☐ 77. Document ID: US 5206237 A

L8: Entry 77 of 94 File: USPT Apr 27, 1993

US-PAT-NO: 5206237
DOCUMENT-IDENTIFIER: US 5206237 A

TITLE: Benzodiazepine analogs

DATE-ISSUED: April 27, 1993

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Freidinger; Roger M.	Lansdale	PA		
Bock; Mark G.	Hatfield	PA		
Evans; Ben E.	Lansdale	PA		

US-CL-CURRENT: 514/219; 514/221

ABSTRACT:

Pharmaceutical compositions containing benzodiazepines of the formula: ##STR1## are

disclosed which are useful in the treatment of panic disorder or anxiety disorder.

3 Claims, 0 Drawing figures
Exemplary Claim Number: 1

Full | Title | Citation | Front | Review | Classification | Date | Reference | Claims | KWIC | Draw. Des

---

☐ 78. Document ID: US 5206234 A

L8: Entry 78 of 94 File: USPT Apr 27, 1993

US-PAT-NO: 5206234
DOCUMENT-IDENTIFIER: US 5206234 A

TITLE: Benzolactam analogs as antagonists of CCK

DATE-ISSUED: April 27, 1993

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Bock; Mark G.	Hatfield	PA		
Freidinger; Roger M.	Lansdale	PA		
Evans; Ben E.	Lansdale	PA		

US-CL-CURRENT: 514/212.07; 514/183, 514/312, 514/414, 514/415, 540/523, 546/157, 548/438, 548/465

ABSTRACT:

Benzolactam analogs of the formula: ##STR1## are disclosed which are antagonists of gastrin and cholecystokinin (CCK).

34 Claims, 0 Drawing figures
Exemplary Claim Number: 1,2

Full | Title | Citation | Front | Review | Classification | Date | Reference | Claims | KWIC | Draw. Des

---

☐ 79. Document ID: US 5185331 A

L8: Entry 79 of 94 File: USPT Feb 9, 1993

US-PAT-NO: 5185331
DOCUMENT-IDENTIFIER: US 5185331 A

TITLE: Triazolobenzodiazepines

DATE-ISSUED: February 9, 1993

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Freidinger; Roger M.	Lansdale	PA		
Bock; Mark G.	Hatfield	PA		

Evans; Ben E. Lansdale PA

US-CL-CURRENT: 514/220

ABSTRACT:

Pharmaceutical compositions containing Triazolobenzodiazepines of the formula: ##STR1## are disclosed which are useful in the treatment of panic disorder or anxiety disorder.

6 Claims, 0 Drawing figures
Exemplary Claim Number: 1

Full | Title | Citation | Front | Review | Classification | Date | Reference | Claims | KWIC | Draw. Des

---

☐ 80. Document ID: US 5177071 A

L8: Entry 80 of 94 File: USPT Jan 5, 1993

US-PAT-NO: 5177071
DOCUMENT-IDENTIFIER: US 5177071 A

TITLE: 1,4-benzodiazepines with 6-membered heterocyclic rings to treat panic and anxiety disorder

DATE-ISSUED: January 5, 1993

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Freidinger; Roger M.	Lansdale	PA		
Evans; Ben E.	Lansdale	PA		
Bock; Mark G.	Hatfield	PA		

US-CL-CURRENT: 514/220

ABSTRACT:

Pharmaceutical compositions containing 6-membered heterocyclic rings are disclosed which are useful in the treatment of panic disorder or anxiety disorder.

3 Claims, 0 Drawing figures
Exemplary Claim Number: 1

Full | Title | Citation | Front | Review | Classification | Date | Reference | Claims | KWIC | Draw. Des

---

☐ 81. Document ID: US 5166151 A

L8: Entry 81 of 94 File: USPT Nov 24, 1992

US-PAT-NO: 5166151
DOCUMENT-IDENTIFIER: US 5166151 A

TITLE: 2-Benzazepines with 5- and 6-membered heterocyclic rings, compositions and

medical methods of use thereof

DATE-ISSUED: November 24, 1992

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Freidinger; Roger M.	Hatfield	PA		
Evans; Ben E.	Lansdale	PA		
Bock; Mark G.	Hatfield	PA		

US-CL-CURRENT: 514/215; 514/217, 540/578

ABSTRACT:

Aromatic 2-benzazepines with fused 5- or 6-membered heterocyclic rings which are antagonists of cholecystokinins and/or gastrin, and are useful in the treatment or prevention of CCK-related and/or gastrin-related disorders of the gastrointestinal, central nervous and appetite regulatory systems; compositions comprising these compounds; and methods of treatment of mammals or of increasing food intake of animals employing these compounds.

16 Claims, 0 Drawing figures
Exemplary Claim Number: 1

☐ 82. Document ID: US 5137878 A

L8: Entry 82 of 94 File: USPT Aug 11, 1992

US-PAT-NO: 5137878
DOCUMENT-IDENTIFIER: US 5137878 A
**** See image for Certificate of Correction ****

TITLE: Composition and method for treatment of senile dementia

DATE-ISSUED: August 11, 1992

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Pang; Peter K. T.	Sherwood Park, Alberta			CA
Wang; Lawrence C. H.	Edmonton, Alberta			CA
Benishin; Christina G.	Ardressan, Alberta			CA
Liu; Hsing J.	Edmonton, Alberta			CA

US-CL-CURRENT: 514/54; 424/728, 514/879, 536/127, 536/128, 536/5

ABSTRACT:

Ginsenosides Rb.sub.1 and Rg.sub.1 enhance the availability of acetylcholine in the cortical and hippocampal regions of the brain and alleviaate the symptoms of Alzheimer-type senile dementia. The Rb.sub.1 or Rg.sub.1 may be administered together with a metabolic precursor for acetylcholine and/or with a cholinesterase inhibitor.

Pure Rb.sub.1 is located from a mixture of ginsenosides by a process involving vacuum

chromatography on silica gel. Preferably, the mixture of ginsenosides is enriched in Rb.sub.1 by partition between an aqueous system and water ethyl acetatebutanol.

11 Claims, 19 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 15

Full | Title | Citation | Front | Review | Classification | Date | Reference | Claims | KWIC | Draw. Des.

☐ 83. Document ID: US 5106834 A

L8: Entry 83 of 94 File: USPT Apr 21, 1992

US-PAT-NO: 5106834
DOCUMENT-IDENTIFIER: US 5106834 A

TITLE: Linear free-sulfhydryl-containing oligopeptide derivatives as antihypertensive agents

DATE-ISSUED: April 21, 1992

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Bovy; Philippe R.	St. Louis	MO		
Manning; Robert E.	St. Louis	MO		
O'Neal; Joan M.	St. Louis	MO		

US-CL-CURRENT: 514/15; 514/13, 514/14, 530/326, 530/327, 530/328

ABSTRACT:

Synthesis and use of novel oligopeptides are described, many of which peptides contain one or several unnatural amino acids. These short linear peptide derivatives are characterized by the presence of a free sulfhydryl function. These compounds have a high affinity for the Atrial Natriuretic Peptide (ANP) receptor coupled to particulate guanylate cyclase. Such peptides are full agonists at the ANP receptor as demonstrated by the ability of the peptides to stimulate the production of cGMP and to relax smooth muscles in vitro. In accord with these observations, the compounds of the invention lower blood pressure in mammals. Preferred peptides are the following:

Cys-Cha-Gly-Gly-Arg-Ile-Asp-Arg-Ile-GlyNH.sub.2 ; D-Cys-Cha-Gly-Gly-Arg-Ile-Asp-Arg-Ile-GlyNH.sub.2 ; L-Pen-Cha-Gly-Gly-Arg-Ile-Asp-Arg-Ile-GlyNH.sub.2 ; and Cys-Cha-Gly-Gly-Arg-Ile-Asp-Arg-IleNH.sub.2.

14 Claims, 5 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 5

Full | Title | Citation | Front | Review | Classification | Date | Reference | Claims | KWIC | Draw. Des.

☐ 84. Document ID: US 5089638 A

L8: Entry 84 of 94 File: USPT Feb 18, 1992

US-PAT-NO: 5089638
DOCUMENT-IDENTIFIER: US 5089638 A

TITLE: Amino acid analogs as CCK-antagonists

DATE-ISSUED: February 18, 1992

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Freidinger; Roger M.	Hatfield	PA		

US-CL-CURRENT: 549/468; 544/106, 546/168, 546/192, 546/225, 548/483, 548/492, 548/571, 549/436, 549/462, 549/57, 564/169 , 564/183

ABSTRACT:

Analogs of glutamic acid and related amino acids and pharmaceutically-acceptable salts thereof which antagonize the function of cholecystokinins and gastrin disease states in animals and compositions for and methods of preventing or treating disorders of the gastrointestinal, central nervous and appetite regulatory systems of mammals, especially of humans.

5 Claims, 0 Drawing figures
Exemplary Claim Number: 1

☐ 85. Document ID: US 5075338 A

L8: Entry 85 of 94 File: USPT Dec 24, 1991

US-PAT-NO: 5075338
DOCUMENT-IDENTIFIER: US 5075338 A

TITLE: Method of treatment of learning deficiency

DATE-ISSUED: December 24, 1991

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Knoll; Jozsef	Budapest			HU
Simay; Antal	Budapest			HU
Szinnyei; Eva	Budapest			HU
Somfai; Eva	Budapest			HU
Torok; Zoltan	Budapest			HU
Mozsolits; Karoly	Sopron			HU
Bergmann; Janos	Visegrad			HU

US-CL-CURRENT: 514/654

ABSTRACT:

A method of treating a learning deficiency is disclosed wherein a patient in need of stimulating learning ability is treated with a therapeutically effective amount of a

compound of the Formula (I) ##STR1## wherein R.sup.1 is C.sub.1 to C.sub.8 straight or branched chain alkyl, C.sub.7 to C.sub.10 phenylalkyl, phenyl, or C.sub.3 to C.sub.8 cycloalkyl; and

R.sup.2 is C.sub.1 to C.sub.8 straight or branched chain alkyl, unsubstituted or substituted by halogen, hydroxy, C.sub.1 to C.sub.4 alkoxy or by 1 or 2 phenyl groups; or is C.sub.3 to C.sub.8 cycloalkyl;

with the proviso that R.sup.1 and R.sup.2 together contain at least 3 carbon atoms; or a pharmaceutically acceptable salt thereof.

8 Claims, 0 Drawing figures
Exemplary Claim Number: 1

☐ 86. Document ID: US 5004741 A

L8: Entry 86 of 94 File: USPT Apr 2, 1991

US-PAT-NO: 5004741
DOCUMENT-IDENTIFIER: US 5004741 A

TITLE: Methods of antagonizing CCK or gastrin with benzodiazepine analogs

DATE-ISSUED: April 2, 1991

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Evans; Ben E.	Lansdale	PA		
Bock; Mark G.	Hatfield	PA		
Freidinger; Roger M.	Hatfield	PA		

US-CL-CURRENT: 514/221; 514/925, 514/926, 514/927

ABSTRACT:

Methods of antagonizing gastrin and/or cholecystokinin (CCK) with benzodiazepine analogs are disclosed, as well as related pharmaceutical compositions, which are useful in treating disorders of the gastrointestinal tract, central nervous system, and of the appetite.

15 Claims, 0 Drawing figures
Exemplary Claim Number: 1

☐ 87. Document ID: US 4966893 A

L8: Entry 87 of 94 File: USPT Oct 30, 1990

US-PAT-NO: 4966893
DOCUMENT-IDENTIFIER: US 4966893 A

TITLE: Method for treatment of senile dementia

DATE-ISSUED: October 30, 1990

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Pang; Peter K. T.	Sherwood Park, Alberta			CA
Wang; Lawrence C. H.	Edmonton, Alberta			CA
Benishin; Christina G.	Androssan, Alberta			CA
Liu; Hsing J.	Edmonton Alta.			CA

US-CL-CURRENT: 514/54; 424/728, 514/879, 536/5

ABSTRACT:

Ginsenosides Rb.sub.1 and Rg.sub.1 enhance the avaiability of acetylcholine in the cortical and hippocampal regions of the brain and alleviate the symptoms of Alzheimer-type senile dementia.

Pure Rb.sub.1 is isolated from a mixture of ginsenosides by a process involving vacuum chromatography on silica gel. Preferably, the mixture of ginsenosides is enriched in Rb.sub.1 by partition between an aqueous system and water ethyl acetatebutanol.

3 Claims, 8 Drawing figures
Exemplary Claim Number: 1
Number of Drawing Sheets: 3

☐ 88. Document ID: US 4880938 A

L8: Entry 88 of 94 File: USPT Nov 14, 1989

US-PAT-NO: 4880938
DOCUMENT-IDENTIFIER: US 4880938 A

TITLE: Amino acid analogs

DATE-ISSUED: November 14, 1989

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Freidinger; Roger M.	Hatfield	PA		

US-CL-CURRENT: 548/492; 544/106, 546/168, 546/225, 548/483, 548/571, 549/436, 549/57, 564/169, 564/183

ABSTRACT:

Analogs of glutamic acid and related amino acids and pharmaceutically-acceptable salts thereof which antagonize the function of cholecystokinins and gastrin disease states in animals and compositions for and methods of preventing or treating disorders of the gastrointestinal, central nervous and appetite regulatory systems of mammals, especially of humans.

6 Claims, 0 Drawing figures
Exemplary Claim Number: 1

Full | Title | Citation | Front | Review | Classification | Date | Reference | Claims | KWMC | Draw Desc

---

☐ 89. Document ID: US 4847248 A

L8: Entry 89 of 94 File: USPT Jul 11, 1989

US-PAT-NO: 4847248
DOCUMENT-IDENTIFIER: US 4847248 A

TITLE: 1,4-Benzodiazepines with 5- and 6-membered heterocyclic rings and their use as cholecystokinins and gastrin antagonists

DATE-ISSUED: July 11, 1989

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Freidinger; Roger M.	Hatfield	PA		
Evans; Ben E.	Lansdale	PA		
Bock; Mark G.	Hatfield	PA		

US-CL-CURRENT: 514/220; 540/558, 540/561, 540/562

ABSTRACT:

Aromatic 1,4-benzodiazepines with fused 5- or 6-membered heterocyclic rings which are antagonists of cholecystokinins and/or gastrin, and are useful in the treatment or prevention of CCK-related and/or gastrin-related disorders of the gastrointestinal, central nervous and appetite regulatory systems; compositions comprising these compounds; and methods of treatment employing these compounds.

12 Claims, 0 Drawing figures
Exemplary Claim Number: 1,9

Full | Title | Citation | Front | Review | Classification | Date | Reference | Claims | KWMC | Draw Desc

---

☐ 90. Document ID: US 4820834 A

L8: Entry 90 of 94 File: USPT Apr 11, 1989

US-PAT-NO: 4820834
DOCUMENT-IDENTIFIER: US 4820834 A

TITLE: Benzodiazepine analogs

DATE-ISSUED: April 11, 1989

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Evans; Ben E.	Lansdale	PA		

Freidinger; Roger M.	Hatfield	PA
Bock; Mark G.	Hatfield	PA

US-CL-CURRENT: 540/504; 540/505, 540/506, 540/507, 540/508, 540/509, 540/510, 540/512, 540/513, 540/514, 540/564, 540/570, 540/571, 540/572, 540/573

ABSTRACT:

Benzodiazepine analogs of the formula: ##STR1## are disclosed which are antagonists of gastrin and cholecystokinin (CCK).

13 Claims, 0 Drawing figures
Exemplary Claim Number: 1

Full | Title | Citation | Front | Review | Classification | Date | Reference | Claims | KWIC | Draw. Des

---

☐ 91. Document ID: US 4755508 A

L8: Entry 91 of 94 File: USPT Jul 5, 1988

US-PAT-NO: 4755508
DOCUMENT-IDENTIFIER: US 4755508 A

TITLE: Benzodiazepine analogs and use as antogonists of gastrin and cholecystokinin

DATE-ISSUED: July 5, 1988

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Bock; Mark G.	Hatfield	PA		
Evans; Ben E.	Lansdale	PA		
Freidinger; Roger M.	Hatfield	PA		

US-CL-CURRENT: 514/221; 540/542, 540/570, 540/571, 540/572

ABSTRACT:

Benzodiazepines of the formula: ##STR1## are disclosed which are antagonists of gastrin and cholecystokinin (CCK).

9 Claims, 0 Drawing figures
Exemplary Claim Number: 1,8

Full | Title | Citation | Front | Review | Classification | Date | Reference | Claims | KWIC | Draw. Des

---

☐ 92. Document ID: US 4735941 A

L8: Entry 92 of 94 File: USPT Apr 5, 1988

US-PAT-NO: 4735941
DOCUMENT-IDENTIFIER: US 4735941 A

TITLE: 1,4-benzodiazepines with 5- and 6-membered heterocyclic rings, useful as gastrointestinal and CNS agents

DATE-ISSUED: April 5, 1988

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Freidinger; Roger M.	Hatfield	PA		
Bock; Mark G.	Hatfield	PA		
Evans; Ben E.	Lansdale	PA		

US-CL-CURRENT: 514/220; 540/559

ABSTRACT:

Aromatic 1,4-benxodiazepines with fused 5- or 6-membered heterocyclic rings which are antagonists of cholecystokinins and/or gastrin, and are useful in the treatment or prevention of CCK-related and/or gastrin-related disorders of the gastrointestinal, central nervous and appetite regulatory systems; compositions comprising these compounds; and methods of treatment employing these compounds.

15 Claims, 0 Drawing figures
Exemplary Claim Number: 1,9

☐ 93. Document ID: US 4663321 A

L8: Entry 93 of 94 File: USPT May 5, 1987

US-PAT-NO: 4663321
DOCUMENT-IDENTIFIER: US 4663321 A

TITLE: Triazolobenzodiazepines and pharmaceutical use

DATE-ISSUED: May 5, 1987

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Bock; Mark G.	Hatfield	PA		
Evans; Ben E.	Lansdale	PA		
Freidinger; Roger M.	Hatfield	PA		

US-CL-CURRENT: 514/220; 540/542, 540/563, 540/564, 540/565, 540/566

ABSTRACT:

Triazolobenzodiazepines of the formula: ##STR1## are disclosed which are antagonists of cholecystokinin (CCK).

12 Claims, 0 Drawing figures
Exemplary Claim Number: 1,11

☐ 94. Document ID: US 4525360 A

L8: Entry 94 of 94 File: USPT Jun 25, 1985

US-PAT-NO: 4525360
DOCUMENT-IDENTIFIER: US 4525360 A
**** See image for Certificate of Correction ****

TITLE: Anti-psychotic phenylindene derivatives and acid addition salts thereof

DATE-ISSUED: June 25, 1985

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Perregaard; Jens K.	Olstykke			DK

US-CL-CURRENT: 514/277; 514/340, 514/341, 514/342, 514/357, 544/267, 546/205, 546/206, 546/269.7, 546/271.4, 546/274.4, 546/284.4, 546/330, 546/339, 546/344, 546/348, 546/350

ABSTRACT:

The present invention relates to novel phenylindene derivatives having interesting pharmacodynamic properties which make them useful as psychopharmacologicals in the treatment especially of psychoses such as schizophrenia, having a low degree of undesired side effects such as cataleptic effects, methods for the preparation of said phenylindene derivatives, pharmaceutical compositions containing same, and methods for the treatment of psychic disorders, such as psychoses and depressions and pain, by administering a therapeutically active amount of one of said derivatives to a living animal body, including human beings.

12 Claims, 0 Drawing figures
Exemplary Claim Number: 1,11

Full | Title | Citation | Front | Review | Classification | Date | Reference | Claims | KWMC | Draw. Desc

Clear | Generate Collection | Print | Fwd Refs | Bkwd Refs | Generate OACS

Terms	Documents
L7 AND L1	94

Display Format: - Change Format

Previous Page Next Page Go to Doc#

About Entrez

Text Version

Entrez PubMed
Overview
Help | FAQ
Tutorial
New/Noteworthy
E-Utilities

PubMed Services
Journals Database
MeSH Database
Single Citation Matcher
Batch Citation Matcher
Clinical Queries
LinkOut
Cubby

Related Resources
Order Documents
NLM Catalog
NLM Gateway
TOXNET
Consumer Health
Clinical Alerts
ClinicalTrials.gov
PubMed Central

Items 1 - 124 of 124 One page.

1: Gironacci MM, Yujnovsky I, Gorzalczany S, Taira C, Pena C. Related Articles, Links

Angiotensin-(1-7) inhibits the angiotensin II-enhanced norepinephrine release in coarcted hypertensive rats.
Regul Pept. 2004 Apr 15;118(1-2):45-9.
PMID: 14759556 [PubMed - indexed for MEDLINE]

2: Ohia SE, Opere CA, LeDay AM, Bagchi M, Bagchi D, Stohs SJ. Related Articles, Links

Safety and mechanism of appetite suppression by a novel hydroxycitric acid extract (HCA-SX).
Mol Cell Biochem. 2002 Sep;238(1-2):89-103.
PMID: 12349913 [PubMed - indexed for MEDLINE]

3: Gozali M, Pavia JM, Morris MJ. Related Articles, Links

Involvement of neuropeptide Y in glucose sensing in the dorsal hypothalamus of streptozotocin diabetic rats - in vitro and in vivo studies of transmitter release.
Diabetologia. 2002 Sep;45(9):1332-9. Epub 2002 Jul 12.
PMID: 12242467 [PubMed - indexed for MEDLINE]

4: Adachi YU, Watanabe K, Higuchi H, Satoh T, Zsilla G. Related Articles, Links

Halothane enhances acetylcholine release by decreasing dopaminergic activity in rat striatal slices.
Neurochem Int. 2002 Mar;40(3):189-93.
PMID: 11741001 [PubMed - indexed for MEDLINE]

5: Hwang LL, Chen CT, Dun NJ. Related Articles, Links

Mechanisms of orexin-induced depolarizations in rat dorsal motor nucleus of vagus neurones in vitro.
J Physiol. 2001 Dec 1;537(Pt 2):511-20.
PMID: 11731582 [PubMed - indexed for MEDLINE]

6: Zhan RZ, Qi S, Wu C, Fujihara H, Taga K, Shimoji K. Related Articles, Links

Intravenous anesthetics differentially reduce neurotransmission damage caused by oxygen-glucose deprivation in rat hippocampal slices in correlation with N-methyl-D-aspartate receptor inhibition.
Crit Care Med. 2001 Apr;29(4):808-13.
PMID: 11373474 [PubMed - indexed for MEDLINE]

7: Gao LZ, Zhang WH, Ju G. Related Articles, Links

Suppression of adrenocorticotropic hormone release by stimulation of the nerve fibres in the anterior pituitary.
J Neuroendocrinol. 2000 Aug;12(8):753-7.
PMID: 10929087 [PubMed - indexed for MEDLINE]

8: SanMartin S, Menendez L, Gutierrez M, Hidalgo A, Baamonde A. Related Articles, Links

Effects of DAGO on the rodent hippocampal evoked potentials using

different perfusion solutions.
Acta Neurobiol Exp (Wars). 2000;60(2):187-93.
PMID: 10909174 [PubMed - indexed for MEDLINE]

☐ **9:** Iizuka M. Related Articles, Links

Intercostal expiratory activity in an in vitro brainstem-spinal cord-rib preparation from the neonatal rat.
J Physiol. 1999 Oct 1;520 Pt 1:293-302.
PMID: 10517820 [PubMed - indexed for MEDLINE]

☐ **10:** Williams CA, Wu SY, Dun SL, Kwok EH, Dun NJ. Related Articles, Links

Release of endomorphin-2 like substances from the rat spinal cord.
Neurosci Lett. 1999 Sep 24;273(1):25-8.
PMID: 10505643 [PubMed - indexed for MEDLINE]

☐ **11:** Colamussi P, Calo G, Sbrenna S, Uccelli L, Bianchi C, Cittanti C, Siniscalchi A, Giganti M, Roveri R, Piffanelli A. Related Articles, Links

New insights on flow-independent mechanisms of 99mTc-HMPAO retention in nervous tissue: in vitro study.
J Nucl Med. 1999 Sep;40(9):1556-62.
PMID: 10492379 [PubMed - indexed for MEDLINE]

☐ **12:** Zhan RZ, Fujiwara N, Yamakura T, Taga K, Fukuda S, Shimoji K. Related Articles, Links

Differential inhibitory effects of thiopental, thiamylal and phenobarbital on both voltage-gated calcium channels and NMDA receptors in rat hippocampal slices.
Br J Anaesth. 1998 Dec;81(6):932-9.
PMID: 10211022 [PubMed - indexed for MEDLINE]

☐ **13:** Gladwell SJ, Coote JH. Related Articles, Links

Inhibitory and indirect excitatory effects of dopamine on sympathetic preganglionic neurones in the neonatal rat spinal cord in vitro.
Brain Res. 1999 Feb 13;818(2):397-407.
PMID: 10082825 [PubMed - indexed for MEDLINE]

☐ **14:** Nakai T, Milusheva E, Baranyi M, Uchihashi Y, Satoh T, Vizi ES. Related Articles, Links

Excessive release of [3H]noradrenaline and glutamate in response to simulation of ischemic conditions in rat spinal cord slice preparation: effect of NMDA and AMPA receptor antagonists.
Eur J Pharmacol. 1999 Feb 5;366(2-3):143-50.
PMID: 10082194 [PubMed - indexed for MEDLINE]

☐ **15:** Yamaguchi S, Endo K, Kitajima T, Ogata H, Hori Y. Related Articles, Links

Involvement of the glutamate transporter and the sodium-calcium exchanger in the hypoxia-induced increase in intracellular Ca2+ in rat hippocampal slices.
Brain Res. 1998 Dec 7;813(2):351-8.
PMID: 9838190 [PubMed - indexed for MEDLINE]

☐ **16:** Zhan RZ, Fujiwara N, Endoh H, Yamakura T, Taga K, Fukuda S, Shimoji K. Related Articles, Links

Thiopental inhibits increases in [Ca2+]i induced by membrane depolarization, NMDA receptor activation, and ischemia in rat hippocampal and cortical slices.
Anesthesiology. 1998 Aug;89(2):456-66.
PMID: 9710405 [PubMed - indexed for MEDLINE]

☐ **17:** Williams CA, Wu SY, Cook J, Dun NJ. Related Articles, Links

Release of nociceptin-like substances from the rat spinal cord dorsal horn.
Neurosci Lett. 1998 Mar 20;244(3):141-4.
PMID: 9593509 [PubMed - indexed for MEDLINE]

☐ **18:** Moret C, Briley M. Related Articles, Links

5-HT autoreceptors in the regulation of 5-HT release from guinea pig raphe nucleus and hypothalamus.
Neuropharmacology. 1997 Nov-Dec;36(11-12):1713-23.
PMID: 9517443 [PubMed - indexed for MEDLINE]

☐ **19:** Shang Y, Dluzen DE. Related Articles, Links

Castration reduces olfactory bulb norepinephrine transporter function as indicated by responses to noradrenergic uptake blockers.
Brain Res. 1998 Jan 1;779(1-2):119-24.
PMID: 9473620 [PubMed - indexed for MEDLINE]

☐ **20:** Kimura C, Oike M, Kashiwagi S, Ito Y. Related Articles, Links

Effects of acute glucose overload on histamine H2 receptor-mediated Ca2+ mobilization in bovine cerebral endothelial cells.
Diabetes. 1998 Jan;47(1):104-12.
PMID: 9421382 [PubMed - indexed for MEDLINE]

☐ **21:** Wilson WR, Phillips KS, Leslie SW. Related Articles, Links

Ethanol and glutamate effects on intracellular magnesium.
Alcohol. 1997 Nov-Dec;14(6):533-6.
PMID: 9401666 [PubMed - indexed for MEDLINE]

☐ **22:** Shorte SL. Related Articles, Links

N-methyl-D-aspartate evokes rapid net depolymerization of filamentous actin in cultured rat cerebellar granule cells.
J Neurophysiol. 1997 Aug;78(2):1135-43.
PMID: 9307140 [PubMed - indexed for MEDLINE]

☐ **23:** Yamaguchi S, Endo K, Kitajima T, Hori Y. Related Articles, Links

Extracellular sodium concentration has diverse effects on the hypoxia-induced increase in intracellular Ca2+ in rat hippocampal slices.
Neurosci Lett. 1997 Sep 5;232(3):163-6.
PMID: 9310305 [PubMed - indexed for MEDLINE]

☐ **24:** Johnson SM, Luo X, Bywood PT. Related Articles, Links

Neurotoxic effects of kainic acid on substantia nigra neurons in rat brain slices.
Exp Neurol. 1997 Aug;146(2):546-52.
PMID: 9270066 [PubMed - indexed for MEDLINE]

☐ **25:** Akasu T, Tsurusaki M, Shoji S. Related Articles, Links

Depletion of glucose causes presynaptic inhibition of neuronal transmission in the rat dorsolateral septal nucleus.
Synapse. 1996 Oct;24(2):125-34.
PMID: 8890454 [PubMed - indexed for MEDLINE]

☐ **26:** Momiyama T, Sim JA, Brown DA. Related Articles, Links

Dopamine D1-like receptor-mediated presynaptic inhibition of excitatory transmission onto rat magnocellular basal forebrain neurones.
J Physiol. 1996 Aug 15;495 (Pt 1):97-106.
PMID: 8866354 [PubMed - indexed for MEDLINE]

☐ **27:** Morin-Surun MP, Boudinot E, Schafer T, Denavit-Saubie M. Related Articles, Links

Localization of chemosensitive structures in the isolated brainstem of adult guinea-pig.
J Physiol. 1995 May 15;485 (Pt 1):203-12.
PMID: 7658374 [PubMed - indexed for MEDLINE]

☐ **28:** Laffling AJ, Scherr P, McGivern JG, Patmore L, Sheridan RD. Related Articles, Links

Electrophysiological actions of phenytoin on N-methyl-D-aspartate receptor-mediated responses in rat hippocampus in vitro.
Br J Pharmacol. 1995 May;115(1):67-72.
PMID: 7647985 [PubMed - indexed for MEDLINE]

☐ **29:** Vannucchi MG, Pepeu G. Related Articles, Links

Muscarinic receptor modulation of acetylcholine release from rat cerebral cortex and hippocampus.
Neurosci Lett. 1995 Apr 28;190(1):53-6.
PMID: 7624055 [PubMed - indexed for MEDLINE]

☐ **30:** Moret C, Briley M. Related Articles, Links

In vitro and in vivo activity of 1-(1-naphthyl)piperazine at terminal 5-HT autoreceptors in guinea-pig brain.
Naunyn Schmiedebergs Arch Pharmacol. 1995 Apr;351(4):377-84.
PMID: 7630428 [PubMed - indexed for MEDLINE]

☐ **31:** Barber WD, Yuan CS, Burks TF, Feldman JL, Greer JJ. Related Articles, Links

In vitro brainstem-gastric preparation with intact vagi for study of primary visceral afferent input to dorsal vagal complex in caudal medulla.
J Auton Nerv Syst. 1995 Mar 2;51(3):181-9.
PMID: 7769151 [PubMed - indexed for MEDLINE]

☐ **32:** Akasu T, Shoji S. Related Articles, Links

cAMP-dependent inward rectifier current in neurons of the rat suprachiasmatic nucleus.
Pflugers Arch. 1994 Nov;429(1):117-25.
PMID: 7535916 [PubMed - indexed for MEDLINE]

☐ **33:** Fink K, Zentner J, Gothert M. Related Articles, Links

Increased GABA release in the human brain cortex as a potential pathogenetic basis of hyperosmolar diabetic coma.
J Neurochem. 1994 Apr;62(4):1476-81.
PMID: 8133276 [PubMed - indexed for MEDLINE]

☐ **34:** Shen E, Wu SY, Dun NJ. Related Articles, Links

Spontaneous and transmitter-induced rhythmic activity in neonatal rat sympathetic preganglionic neurons in vitro.
J Neurophysiol. 1994 Mar;71(3):1197-205.
PMID: 7911161 [PubMed - indexed for MEDLINE]

☐ **35:** Morin-Surun MP, Boudinot E, Schafer T, Denavit-Saubie M. Related Articles, Links

Brain stem chemosensitivity: its implication in central respiratory regulation.
Biol Neonate. 1994;65(3-4):166-70.
PMID: 8038278 [PubMed - indexed for MEDLINE]

☐ **36:** Tsurusaki M, Akasu T, Shoji S. Related Articles, Links

Patch-clamp analysis of hypoglycemia-induced inhibition of synaptic

transmission in the rat dorsolateral septal nucleus.
Kurume Med J. 1994;41(2):65-72.
PMID: 7967441 [PubMed - indexed for MEDLINE]

☐ **37:** Ayala CA, Jaffe EH. Related Articles, Links

Pharmacological modulation of endogenous dopamine and DOPAC outflow from nucleus accumbens.
Neuropharmacology. 1993 Dec;32(12):1401-9.
PMID: 7512235 [PubMed - indexed for MEDLINE]

☐ **38:** Latini S, Pedata F, Pepeu G. Related Articles, Links

Effect of idebenone on adenosine outflow and adenine nucleotide level in hippocampal slices under ischemia-like conditions.
Eur J Pharmacol. 1993 Nov 2;249(1):65-70.
PMID: 8282020 [PubMed - indexed for MEDLINE]

☐ **39:** Pinco M, Lev-Tov A. Related Articles, Links

Modulation of monosynaptic excitation in the neonatal rat spinal cord.
J Neurophysiol. 1993 Sep;70(3):1151-8.
PMID: 8229164 [PubMed - indexed for MEDLINE]

☐ **40:** Schafer T, Morin-Surun MP, Denavit-Saubie M. Related Articles, Links

Oxygen supply and respiratory-like activity in the isolated perfused brainstem of the adult guinea pig.
Brain Res. 1993 Aug 6;618(2):246-50.
PMID: 8374755 [PubMed - indexed for MEDLINE]

☐ **41:** Pedata F, Latini S, Pugliese AM, Pepeu G. Related Articles, Links

Investigations into the adenosine outflow from hippocampal slices evoked by ischemia-like conditions.
J Neurochem. 1993 Jul;61(1):284-9.
PMID: 8515275 [PubMed - indexed for MEDLINE]

☐ **42:** Kubo T, Amano M, Ishizuka T, Ozaki S. Related Articles, Links

beta-Alanine and taurine microinjected into the rat caudal ventrolateral medulla increase blood pressure.
Clin Exp Hypertens. 1993 May;15(3):585-97.
PMID: 8387853 [PubMed - indexed for MEDLINE]

☐ **43:** Tatsumi H, Katayama Y. Related Articles, Links

Regulation of the intracellular free calcium concentration in acutely dissociated neurones from rat nucleus basalis.
J Physiol. 1993 May;464:165-81.
PMID: 8229797 [PubMed - indexed for MEDLINE]

☐ **44:** Tatsumi H, Sasaki H, Katayama Y. Related Articles, Links

Elongation of growth cone filopodia observed with video-enhanced differential interference contrast microscopy.
Jpn J Physiol. 1993;43 Suppl 1:S221-3.
PMID: 8271499 [PubMed - indexed for MEDLINE]

☐ **45:** Elenkov IJ, Kovacs K, Duda E, Stark E, Vizi ES. Related Articles, Links

Presynaptic inhibitory effect of TNF-alpha on the release of noradrenaline in isolated median eminence.
J Neuroimmunol. 1992 Nov;41(1):117-20.
PMID: 1460089 [PubMed - indexed for MEDLINE]

☐ **46:** Carla V, Moroni F. Related Articles, Links

General anaesthetics inhibit the responses induced by glutamate receptor agonists in the mouse cortex.
Neurosci Lett. 1992 Oct 26;146(1):21-4.
PMID: 1282227 [PubMed - indexed for MEDLINE]

☐ **47:** Tsuda K, Tsuda S, Masuyama Y. Related Articles, Links

Effects of calcium-antagonists on dopamine release in the central nervous system--possible interactions with D2-autoreceptors and guanosine triphosphate-binding proteins.
Jpn Circ J. 1992 Mar;56(3):248-54.
PMID: 1552653 [PubMed - indexed for MEDLINE]

☐ **48:** Takei M, Kawano Y, Yamada K. Related Articles, Links

Phosphorus nuclear magnetic resonance studies on the calcium-dependent energy metabolism of rat cerebrum under conditions of increased potassium in vitro.
Neurosci Res. 1992 Jan;12(5):596-605.
PMID: 1313954 [PubMed - indexed for MEDLINE]

☐ **49:** Tarasiuk A, Grossman Y. Related Articles, Links

High pressure reduces pH sensitivity of respiratory center in isolated rat brainstem.
Respir Physiol. 1991 Dec;86(3):369-79.
PMID: 1788496 [PubMed - indexed for MEDLINE]

☐ **50:** Tsuda K, Tsuda S, Masuyama Y, Goldstein M. Related Articles, Links

Alterations in catecholamine release in the central nervous system of spontaneously hypertensive rats.
Jpn Heart J. 1991 Sep;32(5):701-9.
PMID: 1774831 [PubMed - indexed for MEDLINE]

☐ **51:** Velasco A, Duenas-Laita A, Molina A. Related Articles, Links

Effects of dimethylsulfoxide on the oxidative metabolism of certain tissues in rats in vitro.
Methods Find Exp Clin Pharmacol. 1991 Sep;13(7):471-4.
PMID: 1664474 [PubMed - indexed for MEDLINE]

☐ **52:** Franklin TG, Traynor JR. Related Articles, Links

Alkylation with beta-funaltrexamine suggests differences between mu-opioid receptor systems in guinea-pig brain and myenteric-plexus.
Br J Pharmacol. 1991 Mar;102(3):718-22.
PMID: 1364844 [PubMed - indexed for MEDLINE]

☐ **53:** Chahl LA. Related Articles, Links

Morphine produces release of substance P-like immunoreactivity from guinea-pig central nervous system.
Neurosci Lett. 1990 Oct 2;118(1):88-90.
PMID: 1701871 [PubMed - indexed for MEDLINE]

☐ **54:** Pedata F, Pazzagli M, Tilli S, Pepeu G. Related Articles, Links

Regional differences in the electrically stimulated release of endogenous and radioactive adenosine and purine derivatives from rat brain slices.
Naunyn Schmiedebergs Arch Pharmacol. 1990 Oct;342(4):447-53.
PMID: 2255336 [PubMed - indexed for MEDLINE]

Vannucchi MG, Casamenti F, Pepeu G. Related Articles, Links

☐ **55:**

Decrease of acetylcholine release from cortical slices in aged rats: investigations into its reversal by phosphatidylserine.
J Neurochem. 1990 Sep;55(3):819-25.
PMID: 2384755 [PubMed - indexed for MEDLINE]

☐ **56:** Shen E, Mo N, Dun NJ. Related Articles, Links

APV-sensitive dorsal root afferent transmission to neonate rat sympathetic preganglionic neurons in vitro.
J Neurophysiol. 1990 Sep;64(3):991-9.
PMID: 1977894 [PubMed - indexed for MEDLINE]

☐ **57:** Siniscalchi A, Bertelli MG, Bianchi C, Beani L. Related Articles, Links

Effect of opioid antagonists on acetylcholine release from guinea-pig brain slices: influence of peptidase inhibition.
Pharmacol Res. 1990 Jul-Aug;22(4):493-501.
PMID: 2402481 [PubMed - indexed for MEDLINE]

☐ **58:** Berger AJ, Takahashi T. Related Articles, Links

Serotonin enhances a low-voltage-activated calcium current in rat spinal motoneurons.
J Neurosci. 1990 Jun;10(6):1922-8.
PMID: 2355258 [PubMed - indexed for MEDLINE]

☐ **59:** Zajac JM, Bigeard A, Delay-Goyet P, Roques BP. Related Articles, Links

Affinity states of rat brain opioid receptors in different tissue preparations.
J Neurochem. 1990 Mar;54(3):992-9.
PMID: 2154555 [PubMed - indexed for MEDLINE]

☐ **60:** Kullama LK, Balaraman V, Claybaugh JR, Ichimura WM, Nakamura KT. Related Articles, Links

Ontogeny of vasoconstrictor neurohypophysial hormone function in rats.
Am J Physiol. 1990 Jan;258(1 Pt 2):R263-8.
PMID: 2301639 [PubMed - indexed for MEDLINE]

☐ **61:** Zheng QA, Higashi H, Inokuchi H, Nishi S. Related Articles, Links

[Electrical membrane properties of neurones of mesencephalic nucleus of fifth nerve in rats]
Sheng Li Xue Bao. 1989 Dec;41(6):543-54. Chinese.
PMID: 2626682 [PubMed - indexed for MEDLINE]

☐ **62:** Minota S, Miyazaki T, Wang MY, Read HL, Dun NJ. Related Articles, Links

Glycine potentiates NMDA responses in rat hippocampal CA1 neurons.
Neurosci Lett. 1989 May 22;100(1-3):237-42.
PMID: 2569702 [PubMed - indexed for MEDLINE]

☐ **63:** Kerr DI, Ong J, Johnston GA, Berthelot P, Debaert M, Vaccher C. Related Articles, Links

Benzofuran analogues of baclofen: a new class of central and peripheral GABAB-receptor antagonists.
Eur J Pharmacol. 1989 May 19;164(2):361-4.
PMID: 2547638 [PubMed - indexed for MEDLINE]

☐ **64:** Stapelfeldt WH, Szurszewski JH. Related Articles, Links

Neurotensin facilitates release of substance P in the guinea-pig inferior mesenteric ganglion.
J Physiol. 1989 Apr;411:325-45.
PMID: 2482356 [PubMed - indexed for MEDLINE]

☐ **65:** Yu JG, Lee TJ. Related Articles, Links

5-Hydroxytryptamine-containing fibers in cerebral arteries of the cat, rat and guinea pig.
Blood Vessels. 1989;26(1):33-43.
PMID: 2653470 [PubMed - indexed for MEDLINE]

☐ **66:** Middlemiss DN, Bremer ME, Smith SM. Related Articles, Links

A pharmacological analysis of the 5-HT receptor mediating inhibition of 5-HT release in the guinea-pig frontal cortex.
Eur J Pharmacol. 1988 Nov 15;157(1):101-7.
PMID: 3234493 [PubMed - indexed for MEDLINE]

☐ **67:** Boakes RJ, Burns BD, Webb AC. Related Articles, Links

Transmission of burst responses through slices of rat cerebral cortex.
J Physiol. 1988 Oct;404:467-78.
PMID: 2855350 [PubMed - indexed for MEDLINE]

☐ **68:** Kerr DI, Ong J, Johnston GA, Abbenante J, Prager RH. Related Articles, Links

2-Hydroxy-saclofen: an improved antagonist at central and peripheral GABAB receptors.
Neurosci Lett. 1988 Sep 23;92(1):92-6.
PMID: 2847092 [PubMed - indexed for MEDLINE]

☐ **69:** Carroll PT, Ivy MT. Related Articles, Links

Effect of 2-(4-phenylpiperidino)cyclohexanol (AH 5183) on the veratridine-induced increase in acetylcholine synthesis by rat hippocampal tissue.
J Neurochem. 1988 Sep;51(3):808-19.
PMID: 3411328 [PubMed - indexed for MEDLINE]

☐ **70:** Mihic SJ, Wu PH, Kalant H. Related Articles, Links

Buffer systems variably affect the interaction of norepinephrine with brain Na+-K+ ATPase.
Can J Physiol Pharmacol. 1988 Aug;66(8):1035-40.
PMID: 2846134 [PubMed - indexed for MEDLINE]

☐ **71:** Schiavone MT, Santos RA, Brosnihan KB, Khosla MC, Ferrario CM. Related Articles, Links

Release of vasopressin from the rat hypothalamo-neurohypophysial system by angiotensin-(1-7) heptapeptide.
Proc Natl Acad Sci U S A. 1988 Jun;85(11):4095-8.
PMID: 3375255 [PubMed - indexed for MEDLINE]

☐ **72:** Pedata F, Magnani M, Pepeu G. Related Articles, Links

Muscarinic modulation of purine release from electrically stimulated rat cortical slices.
J Neurochem. 1988 Apr;50(4):1074-9.
PMID: 3346668 [PubMed - indexed for MEDLINE]

☐ **73:** Racke K, Hering B, Hochgesand U. Related Articles, Links

Effects of gadolinium and cadmium on the electrically evoked release of 45calcium from the isolated rat neurohypophysis.
Naunyn Schmiedebergs Arch Pharmacol. 1988 Mar;337(3):301-7.
PMID: 3393232 [PubMed - indexed for MEDLINE]

☐ **74:** Ryu PD, Gerber G, Murase K, Randic M. Related Articles, Links

Actions of calcitonin gene-related peptide on rat spinal dorsal horn neurons.

Brain Res. 1988 Feb 16;441(1-2):357-61.
PMID: 3258783 [PubMed - indexed for MEDLINE]

☐ **75:** Brown L, Amedro J, Williams G, Smith D. Related Articles, Links

A pharmacological analysis of the rat spinal cord serotonin (5-HT) autoreceptor.
Eur J Pharmacol. 1988 Jan 12;145(2):163-71.
PMID: 2965026 [PubMed - indexed for MEDLINE]

☐ **76:** Giovannelli L, Giovannini MG, Pedata F, Pepeu G. Related Articles, Links

Purinergic modulation of cortical acetylcholine release is decreased in aging rats.
Exp Gerontol. 1988;23(3):175-81.
PMID: 3203718 [PubMed - indexed for MEDLINE]

☐ **77:** Shibata S, Newman GC, Moore RY. Related Articles, Links

Effects of calcium ions on glucose utilization in the rat suprachiasmatic nucleus in vitro.
Brain Res. 1987 Nov 24;426(2):332-8.
PMID: 3690326 [PubMed - indexed for MEDLINE]

☐ **78:** Forloni G, Bidzinski A, Fusi R, Ladinsky H, Consolo S. Related Articles, Links

Striatal cholinergic function reflects differences in D-2 dopaminergic receptor activation.
Life Sci. 1987 Oct 5;41(14):1717-23.
PMID: 2958667 [PubMed - indexed for MEDLINE]

☐ **79:** Siniscalchi A, Cristofori P, Veratti E. Related Articles, Links

Influence of N-allyl-normetazocine on acetylcholine release from brain slices: involvement of muscarinic receptors.
Naunyn Schmiedebergs Arch Pharmacol. 1987 Oct;336(4):425-9.
PMID: 3431597 [PubMed - indexed for MEDLINE]

☐ **80:** Widmann R, Sperk G. Related Articles, Links

Cysteamine-induced decrease of somatostatin in rat brain synaptosomes in vitro.
Endocrinology. 1987 Oct;121(4):1383-9.
PMID: 2888645 [PubMed - indexed for MEDLINE]

☐ **81:** Vannucchi MG, Pepeu G. Related Articles, Links

Effect of phosphatidylserine on acetylcholine release and content in cortical slices from aging rats.
Neurobiol Aging. 1987 Sep-Oct;8(5):403-7.
PMID: 3683721 [PubMed - indexed for MEDLINE]

☐ **82:** Yoshimura M, Polosa C, Nishi S. Related Articles, Links

Afterdepolarization mechanism in the in vitro, cesium-loaded, sympathetic preganglionic neuron of the cat.
J Neurophysiol. 1987 May;57(5):1325-37.
PMID: 3585470 [PubMed - indexed for MEDLINE]

☐ **83:** Budai D, Szerdahelyi P, Kasa P. Related Articles, Links

Isolation of choline and choline esters from Krebs-Ringer solution for gas chromatographic determination.
Anal Biochem. 1986 Dec;159(2):260-6.
PMID: 3826615 [PubMed - indexed for MEDLINE]

☐ **84:** Schiavone MT, Brosnihan KB, Husain A, Ferrario CM. Related Articles, Links

Basal and potassium-evoked release of angiotensin II from the rat hypothalamus.
Brain Res. 1986 Nov 5;397(1):193-6.
PMID: 3801861 [PubMed - indexed for MEDLINE]

☐ **85:** Spencer P, Lynch MA, Bliss TV. Related Articles, Links

In-vitro release of [14C]glutamate from dentate gyrus is modulated by GABA.
J Pharm Pharmacol. 1986 May;38(5):393-5.
PMID: 2872320 [PubMed - indexed for MEDLINE]

☐ **86:** Chen CC, Lin-Shiau SY. Related Articles, Links

Decreased Na+-K+-ATPase activity and [3H]ouabain binding sites in various tissues of spontaneously hypertensive rats.
Eur J Pharmacol. 1986 Apr 2;122(3):311-9.
PMID: 3011446 [PubMed - indexed for MEDLINE]

☐ **87:** Shibata S, Liou SY, Ueki S. Related Articles, Links

Influence of excitatory amino acid receptor antagonists and of baclofen on synaptic transmission in the optic nerve to the suprachiasmatic nucleus in slices of rat hypothalamus.
Neuropharmacology. 1986 Apr;25(4):403-9.
PMID: 3012400 [PubMed - indexed for MEDLINE]

☐ **88:** Shibata S, Liou SY, Ueki S, Oomura Y. Related Articles, Links

Inhibitory action of insulin on suprachiasmatic nucleus neurons in rat hypothalamic slice preparations.
Physiol Behav. 1986 Jan;36(1):79-81.
PMID: 3513217 [PubMed - indexed for MEDLINE]

☐ **89:** Storm-Mathisen J, Ottersen OP, Fu-Long T, Gundersen V, Laake JH, Nordbo G. Related Articles, Links

Metabolism and transport of amino acids studied by immunocytochemistry.
Med Biol. 1986;64(2-3):127-32.
PMID: 2875229 [PubMed - indexed for MEDLINE]

☐ **90:** Starr MS. Related Articles, Links

Multiple opiate receptors may be involved in suppressing gamma-aminobutyrate release in substantia nigra.
Life Sci. 1985 Dec 16;37(24):2249-55.
PMID: 2999545 [PubMed - indexed for MEDLINE]

☐ **91:** Kitazawa T, Saito K, Ohga A. Related Articles, Links

Effects of catecholamines on spinal motoneurones and spinal reflex discharges in the isolated spinal cord of the newborn rat.
Brain Res. 1985 Mar;351(1):31-6.
PMID: 3995339 [PubMed - indexed for MEDLINE]

☐ **92:** Pedata F, Giovannelli L, Spignoli G, Giovannini MG, Pepeu G. Related Articles, Links

Phosphatidylserine increases acetylcholine release from cortical slices in aged rats.
Neurobiol Aging. 1985 Winter;6(4):337-9.
PMID: 4088427 [PubMed - indexed for MEDLINE]

☐ **93:** Hill DR. Related Articles, Links

GABAB receptor modulation of adenylate cyclase activity in rat brain

slices.
Br J Pharmacol. 1985 Jan;84(1):249-57.
PMID: 2579700 [PubMed - indexed for MEDLINE]

☐ **94:** Shibata S, Shiratsuchi A, Liou SY, Ueki S. Related Articles, Links

The role of calcium ions in circadian rhythm of suprachiasmatic nucleus neuron activity in rat hypothalamic slices.
Neurosci Lett. 1984 Nov 23;52(1-2):181-4.
PMID: 6098875 [PubMed - indexed for MEDLINE]

☐ **95:** Fournier E, Crepel F. Related Articles, Links

Electrophysiological properties of in vitro hippocampal pyramidal cells from normal and staggerer mutant mice.
Brain Res. 1984 Oct 8;311(1):87-96.
PMID: 6488047 [PubMed - indexed for MEDLINE]

☐ **96:** Fournier E, Crepel F. Related Articles, Links

Electrophysiological properties of dentate granule cells in mouse hippocampal slices maintained in vitro.
Brain Res. 1984 Oct 8;311(1):75-86.
PMID: 6488046 [PubMed - indexed for MEDLINE]

☐ **97:** Pedata F, Pepeu G, Spignoli G. Related Articles, Links

Biphasic effect of methylxanthines on acetylcholine release from electrically-stimulated brain slices.
Br J Pharmacol. 1984 Sep;83(1):69-73.
PMID: 6487897 [PubMed - indexed for MEDLINE]

☐ **98:** Suzue T. Related Articles, Links

Respiratory rhythm generation in the in vitro brain stem-spinal cord preparation of the neonatal rat.
J Physiol. 1984 Sep;354:173-83.
PMID: 6148410 [PubMed - indexed for MEDLINE]

☐ **99:** Middlemiss DN. Related Articles, Links

8-Hydroxy-2-(di-n-propylamino) tetralin is devoid of activity at the 5-hydroxytryptamine autoreceptor in rat brain. Implications for the proposed link between the autoreceptor and the [3H] 5-HT recognition site.
Naunyn Schmiedebergs Arch Pharmacol. 1984 Aug;327(1):18-22.
PMID: 6238235 [PubMed - indexed for MEDLINE]

☐ **100:** Carroll PT, Benishin CG. Related Articles, Links

Depolarization of mouse forebrain minces with veratridine and high K+: failure to stimulate the Ca2+ independent, spontaneous release of acetylcholine from the cytoplasm due to hydrolysis of the acetylcholine stored there.
Brain Res. 1984 Jan 23;291(2):261-72.
PMID: 6697191 [PubMed - indexed for MEDLINE]

☐ **101:** Williams J, Davies JA. Related Articles, Links

The involvement of 5-hydroxytryptamine in the release of dendritic dopamine from slices of rat substantia nigra.
J Pharm Pharmacol. 1983 Nov;35(11):734-7.
PMID: 6139455 [PubMed - indexed for MEDLINE]

☐ **102:** Holzbauer M, Racke K, Muscholl E, Sharman D. Related Articles, Links

Dopamine release and synthesis in the neurointermediate lobe of the rat

hypophysis in vitro after electrical stimulation of the pituitary stalk.
Brain Res. 1983 Oct 24;277(1):47-54.
PMID: 6640294 [PubMed - indexed for MEDLINE]

☐ **103:** Pedata F, Antonelli T, Lambertini L, Beani L, Pepeu G. Related Articles, Links

Effect of adenosine, adenosine triphosphate, adenosine deaminase, dipyridamole and aminophylline on acetylcholine release from electrically-stimulated brain slices.
Neuropharmacology. 1983 May;22(5):609-14.
PMID: 6877538 [PubMed - indexed for MEDLINE]

☐ **104:** Brown DA, Griffith WH. Related Articles, Links

Persistent slow inward calcium current in voltage-clamped hippocampal neurones of the guinea-pig.
J Physiol. 1983 Apr;337:303-20.
PMID: 6875932 [PubMed - indexed for MEDLINE]

☐ **105:** Abe H, Inoue M, Matsuo T, Ogata N. Related Articles, Links

The effects of vasopressin on electrical activity in the guinea-pig supraoptic nucleus in vitro.
J Physiol. 1983 Apr;337:665-85.
PMID: 6308238 [PubMed - indexed for MEDLINE]

☐ **106:** Galzin AM, Langer SZ. Related Articles, Links

Presynaptic alpha 2-adrenoceptor antagonism by verapamil but not by diltiazem in rabbit hypothalamic slices.
Br J Pharmacol. 1983 Mar;78(3):571-7.
PMID: 6132643 [PubMed - indexed for MEDLINE]

☐ **107:** Kato K, Goto M, Fukuda H. Related Articles, Links

Regulation by divalent cations of 3H-baclofen binding to GABAB sites in rat cerebellar membranes.
Life Sci. 1983 Feb 21;32(8):879-87.
PMID: 6827916 [PubMed - indexed for MEDLINE]

☐ **108:** Pedata F, Slavikova J, Kotas A, Pepeu G. Related Articles, Links

Acetylcholine release from rat cortical slices during postnatal development and aging.
Neurobiol Aging. 1983 Spring;4(1):31-5.
PMID: 6877485 [PubMed - indexed for MEDLINE]

☐ **109:** Racke K, Rothlander M, Muscholl E. Related Articles, Links

Isoprenaline and forskolin increase evoked vasopressin release from rat pituitary.
Eur J Pharmacol. 1982 Aug 13;82(1-2):97-100.
PMID: 6889972 [PubMed - indexed for MEDLINE]

☐ **110:** Beani L, Bianchi C, Siniscalchi A. Related Articles, Links

The effect of naloxone on opioid-induced inhibition and facilitation of acetylcholine release in brain slices.
Br J Pharmacol. 1982 Jul;76(3):393-401.
PMID: 7104516 [PubMed - indexed for MEDLINE]

☐ **111:** Abe H, Ogata N. Related Articles, Links

Ionic mechanism for the osmotically-induced depolarization in neurones of the guinea-pig supraoptic nucleus in vitro.
J Physiol. 1982 Jun;327:157-71.

PMID: 7120136 [PubMed - indexed for MEDLINE]

☐ **112:** Bianchi C, Tanganelli S, Marzola G, Beani L. Related Articles, Links

GABA induced changes in acetylcholine release from slices of guinea-pig brain.
Naunyn Schmiedebergs Arch Pharmacol. 1982 Mar;318(4):253-8.
PMID: 6281665 [PubMed - indexed for MEDLINE]

☐ **113:** Collard KJ, Evans TN, Suter HA, Wilkinson LS. Related Articles, Links

The stimulus-induced release of 5-hydroxytryptamine and tryptophan from superfused rat brain synaptosomes.
J Neural Transm. 1982;53(2-3):223-30.
PMID: 6176682 [PubMed - indexed for MEDLINE]

☐ **114:** Miletic V, Randic M. Related Articles, Links

Neonatal rat spinal cord slice preparation: postsynaptic effects of neuropeptides on dorsal horn neurons.
Brain Res. 1981 Oct;254(3):432-8.
PMID: 6169414 [PubMed - indexed for MEDLINE]

☐ **115:** Jeftinija S, Miletic V, Randic M. Related Articles, Links

Cholecystokinin octapeptide excites dorsal horn neurons both in vivo and in vitro.
Brain Res. 1981 May 25;213(1):231-6.
PMID: 6263412 [PubMed - indexed for MEDLINE]

☐ **116:** Tamir H, Gershon MD. Related Articles, Links

Intracellular proteins that bind serotonin in neurons, paraneurons and platelets.
J Physiol (Paris). 1981;77(2-3):283-6.
PMID: 7288645 [PubMed - indexed for MEDLINE]

☐ **117:** Brandt L, Andersson KE, Edvinsson L, Ljunggren B. Related Articles, Links

Effects of extracellular calcium and of calcium antagonists on the contractile responses of isolated human pial and mesenteric arteries.
J Cereb Blood Flow Metab. 1981;1(3):339-47.
PMID: 6948814 [PubMed - indexed for MEDLINE]

☐ **118:** Akagi H, Otsuka M, Yanagisawa M. Related Articles, Links

Identification by high-performance liquid chromatography of immunoreactive substance P released from isolated rat spinal cord.
Neurosci Lett. 1980 Dec;20(3):259-63.
PMID: 6160430 [PubMed - indexed for MEDLINE]

☐ **119:** Lansdown MJ, Nash HL, Preston PR, Wallis DI, Williams RG. Related Articles, Links

Antagonism of 5-hydroxytryptamine receptors by quipazine.
Br J Pharmacol. 1980 Mar;68(3):525-32.
PMID: 7052342 [PubMed - indexed for MEDLINE]

☐ **120:** Garthwaite J, Woodhams PL, Collins MJ, Balazs R. Related Articles, Links

A morphological study of incubated slices of rat cerebellum in relation to postnatal age.
Dev Neurosci. 1980;3(2):90-9.
PMID: 7418633 [PubMed - indexed for MEDLINE]

☐ **121:** Roth SH, Williams PJ. Related Articles, Links

The non-specific membrane binding properties of delta9-

tetrahydrocannabinol and the effects of various solubilizers.
J Pharm Pharmacol. 1979 Apr;31(4):224-30.
PMID: 36461 [PubMed - indexed for MEDLINE]

☐ **122:** Casamenti F, Mantovani P, Pepeu G. Related Articles, Links

Stimulation of acetylcholine output from brain slices caused by the ionophores BrX-537A and A23187.
Br J Pharmacol. 1978 Jun;63(2):259-65.
PMID: 96898 [PubMed - indexed for MEDLINE]

☐ **123:** Hadhazy P, Szerb JC. Related Articles, Links

The effect of cholinergic drugs on [3H]acetylcholine release from slices of rat hippocampus, striatum and cortex.
Brain Res. 1977 Mar 11;123(2):311-22.
PMID: 843927 [PubMed - indexed for MEDLINE]

☐ **124:** Desmedt JE, Robertson D. Related Articles, Links

Ionic mechanism of the efferent olivo-cochlear inhibition studied by cochlear perfusion in the cat.
J Physiol. 1975 May;247(2):407-28.
PMID: 1097639 [PubMed - indexed for MEDLINE]

Display Summary Show: 500 Sort Send to Text

☐ 9:

Albumin enhances superoxide production in cultured microglia.
Glia. 1997 Dec;21(4):413-8.
PMID: 9419017 [PubMed - indexed for MEDLINE]

☐ 10: Ezan E, Laplante E, Bluet-Pajot MT, Mounier F, Mamas S, Grouselle D, Grognet JM, Kordon C. Related Articles, Links

An enzyme immunoassay for rat growth hormone: validation and application to the determination of plasma levels and in vitro release.
J Immunoassay. 1997 Nov;18(4):335-56.
PMID: 9358340 [PubMed - indexed for MEDLINE]

☐ 11: Leitner B, Kaufmann WA, Marksteiner J, Hoflehner J, Traurig H, Saria A, Fischer-Colbrie R, Winkler H. Related Articles, Links

Ontogenic development of secretogranin II and of its processing to secretoneurin in rat brain.
Brain Res Dev Brain Res. 1997 Jun 18;100(2):161-8.
PMID: 9205807 [PubMed - indexed for MEDLINE]

☐ 12: Leblanc P, L'Heritier A, Kordon C. Related Articles, Links

Cryptic gonadotropin-releasing hormone receptors of rat pituitary cells in culture are unmasked by epidermal growth factor.
Endocrinology. 1997 Feb;138(2):574-9.
PMID: 9002988 [PubMed - indexed for MEDLINE]

☐ 13: D'Sa CM, Arthur RE Jr, Kuhn DM. Related Articles, Links

Expression and deletion mutagenesis of tryptophan hydroxylase fusion proteins: delineation of the enzyme catalytic core.
J Neurochem. 1996 Sep;67(3):917-26.
PMID: 8752096 [PubMed - indexed for MEDLINE]

☐ 14: Leach L, Firth JA. Related Articles, Links

Advances in understanding permeability in fetal capillaries of the human placenta: a review of organization of the endothelial paracellular clefts and their junctional complexes.
Reprod Fertil Dev. 1995;7(6):1451-6. Review.
PMID: 8743146 [PubMed - indexed for MEDLINE]

☐ 15: Lin LF, Zhang TJ, Collins F, Armes LG. Related Articles, Links

Purification and initial characterization of rat B49 glial cell line-derived neurotrophic factor.
J Neurochem. 1994 Aug;63(2):758-68.
PMID: 8035200 [PubMed - indexed for MEDLINE]

☐ 16: Nichol KA, Everett AW, Schulz M, Bennett MR. Related Articles, Links

Retinal ganglion cell survival in vitro maintained by a chondroitin sulfate proteoglycan from the superior colliculus carrying the HNK-1 epitope.
J Neurosci Res. 1994 Apr 1;37(5):623-32.
PMID: 7518009 [PubMed - indexed for MEDLINE]

☐ 17: Liepnieks JJ, Ghetti B, Farlow M, Roses AD, Benson MD. Related Articles, Links

Characterization of amyloid fibril beta-peptide in familial Alzheimer's disease with APP717 mutations.
Biochem Biophys Res Commun. 1993 Dec 15;197(2):386-92.
PMID: 8267572 [PubMed - indexed for MEDLINE]

☐ 18: Lee C, Dineen TE, Brack M, Kirsch JE, Runge VM. Related Articles, Links

The mucopolysaccharidoses: characterization by cranial MR imaging.
AJNR Am J Neuroradiol. 1993 Nov-Dec;14(6):1285-92.
PMID: 8279321 [PubMed - indexed for MEDLINE]

☐ **19:** Guo M, Dow KE, Kisilevsky R, Riopelle RJ. Related Articles, Links

Novel neurite growth-inhibitory properties of an astrocyte proteoglycan.
J Chem Neuroanat. 1993 Jul-Aug;6(4):239-45.
PMID: 8397923 [PubMed - indexed for MEDLINE]

☐ **20:** Levy L, Bourdais J, Mouhieddine B, Benlot C, Villares S, Cohen P, Peillon F, Joubert D. Related Articles, Links

Presence and characterization of the somatostatin precursor in normal human pituitaries and in growth hormone secreting adenomas.
J Clin Endocrinol Metab. 1993 Jan;76(1):85-90.
PMID: 8093621 [PubMed - indexed for MEDLINE]

☐ **21:** Bulant M, Ladram A, Montagne JJ, Delfour A, Nicolas P. Related Articles, Links

Isolation and amino acid sequence of the TRH-potentiating peptide from bovine hypothalamus.
Biochem Biophys Res Commun. 1992 Dec 15;189(2):1110-8.
PMID: 1472021 [PubMed - indexed for MEDLINE]

☐ **22:** Smyth MJ, Wiltrout T, Trapani JA, Ottaway KS, Sowder R, Henderson LE, Kam CM, Powers JC, Young HA, Sayers TJ. Related Articles, Links

Purification and cloning of a novel serine protease, RNK-Met-1, from the granules of a rat natural killer cell leukemia.
J Biol Chem. 1992 Dec 5;267(34):24418-25.
PMID: 1447189 [PubMed - indexed for MEDLINE]

☐ **23:** Timerman AP, Mayrleitner MM, Lukas TJ, Chadwick CC, Saito A, Watterson DM, Schindler H, Fleischer S. Related Articles, Links

Inositol polyphosphate receptor and clathrin assembly protein AP-2 are related proteins that form potassium-selective ion channels in planar lipid bilayers.
Proc Natl Acad Sci U S A. 1992 Oct 1;89(19):8976-80.
PMID: 1329085 [PubMed - indexed for MEDLINE]

☐ **24:** Hanson VG, Horowitz M, Rosenbluth D, Spiera H, Puszkin S. Related Articles, Links

Systemic lupus erythematosus patients with central nervous system involvement show autoantibodies to a 50-kD neuronal membrane protein.
J Exp Med. 1992 Aug 1;176(2):565-73.
PMID: 1500860 [PubMed - indexed for MEDLINE]

☐ **25:** D'Agrosa RM, Hubbes M, Zhang S, Shankaran R, Callahan JW. Related Articles, Links

Characteristics of the beta-galactosidase-carboxypeptidase complex in GM1-gangliosidosis and beta-galactosialidosis fibroblasts.
Biochem J. 1992 Aug 1;285 (Pt 3):833-8.
PMID: 1497621 [PubMed - indexed for MEDLINE]

☐ **26:** Lai Z, Roos P, Olsson Y, Larsson C, Nyberg F. Related Articles, Links

Characterization of prolactin receptors in human choroid plexus.
Neuroendocrinology. 1992 Aug;56(2):225-33.
PMID: 1407377 [PubMed - indexed for MEDLINE]

☐ **27:** Bar-Sinai A, Marbach I, Shorr RG, Levitzki A. Related Articles, Links

The GppNHp-activated adenylyl cyclase complex from turkey erythrocyte membranes can be isolated with its beta gamma subunits.
Eur J Biochem. 1992 Jul 15;207(2):703-8.

PMID: 1633821 [PubMed - indexed for MEDLINE]

☐ **28:** Halper J, Parnell PG, Carter BJ, Ren P, Scheithauer BW. Related Articles, Links

Presence of growth factors in human pituitary.
Lab Invest. 1992 May;66(5):639-45.
PMID: 1573857 [PubMed - indexed for MEDLINE]

☐ **29:** Chadwick CC, Timerman AP, Saito A, Mayrleitner M, Schindler H, Fleischer S. Related Articles, Links

Structural and functional characterization of an inositol polyphosphate receptor from cerebellum.
J Biol Chem. 1992 Feb 15;267(5):3473-81.
PMID: 1371119 [PubMed - indexed for MEDLINE]

☐ **30:** Seno H, Ishino H, Inagaki T, Yamamori C, Iijima M, Tanaka S, Ideshita H, Yoshinaga J, Hikiji A. Related Articles, Links

[An autopsy case of ataxic form of Creutzfeldt-Jakob disease]
No To Shinkei. 1992 Feb;44(2):177-81. Japanese.
PMID: 1567739 [PubMed - indexed for MEDLINE]

☐ **31:** Lai ZN, Emtner M, Roos P, Nyberg F. Related Articles, Links

Characterization of putative growth hormone receptors in human choroid plexus.
Brain Res. 1991 Apr 19;546(2):222-6.
PMID: 2070259 [PubMed - indexed for MEDLINE]

☐ **32:** DeBin JA, Strichartz GR. Related Articles, Links

Chloride channel inhibition by the venom of the scorpion Leiurus quinquestriatus.
Toxicon. 1991;29(11):1403-8.
PMID: 1726031 [PubMed - indexed for MEDLINE]

☐ **33:** Lucas D, Yaksh TL. Related Articles, Links

Release in vivo of Met-enkephalin and encrypted forms of Met-enkephalin from brain and spinal cord of the anesthetized cat.
Peptides. 1990 Nov-Dec;11(6):1119-25.
PMID: 2087436 [PubMed - indexed for MEDLINE]

☐ **34:** Brezinschek HP, Faessler R, Klocker H, Kroemer G, Sgonc R, Dietrich H, Jakober R, Wick G. Related Articles, Links

Analysis of the immune-encodrine feedback loop in the avian system and its alteration in chickens with spontaneous autoimmune thyroiditis.
Eur J Immunol. 1990 Oct;20(10):2155-9.
PMID: 2242753 [PubMed - indexed for MEDLINE]

☐ **35:** Bulant M, Beauvillain JC, Delfour A, Vaudry H, Nicolas P. Related Articles, Links

Processing of thyrotropin-releasing hormone (TRH) prohormone in the rat olfactory bulb generates novel TRH-related peptides.
Endocrinology. 1990 Oct;127(4):1978-85.
PMID: 2119297 [PubMed - indexed for MEDLINE]

☐ **36:** Luthman M, Jonsdottir I, Skoog B, Wivall IL, Roos P, Werner S. Related Articles, Links

Monoclonal antibodies reveal circulating growth hormone of high molecular weight not detectable by conventional assays.
Acta Endocrinol (Copenh). 1990 Sep;123(3):317-25.
PMID: 2239080 [PubMed - indexed for MEDLINE]

☐ **37:** Schulz M, Raju T, Ralston G, Bennett MR. Related Articles, Links

A retinal ganglion cell neurotrophic factor purified from the superior colliculus.
J Neurochem. 1990 Sep;55(3):832-41.
PMID: 2200848 [PubMed - indexed for MEDLINE]

☐ **38:** Mor A, Pradelles P, Delfour A, Montagne JJ, Quintero FL, Conrath M, Nicolas P. Related Articles, Links

Evidence for Pro-dermorphin processing products in rat tissues.
Biochem Biophys Res Commun. 1990 Jul 16;170(1):30-8.
PMID: 2196877 [PubMed - indexed for MEDLINE]

☐ **39:** Huang KP, Huang FL. Related Articles, Links

Differential sensitivity of protein kinase C isozymes to phospholipid-induced inactivation.
J Biol Chem. 1990 Jan 15;265(2):738-44.
PMID: 2295617 [PubMed - indexed for MEDLINE]

☐ **40:** Marks MS, Chi-Rosso G, Toole BP. Related Articles, Links

Hyaluronate-binding proteins of murine brain.
J Neurochem. 1990 Jan;54(1):171-80.
PMID: 1688375 [PubMed - indexed for MEDLINE]

☐ **41:** Takimoto K, Okada M, Nakagawa H. Related Articles, Links

Purification and characterization of membrane-bound inositolpolyphosphate 5-phosphatase.
J Biochem (Tokyo). 1989 Oct;106(4):684-90.
PMID: 2558114 [PubMed - indexed for MEDLINE]

☐ **42:** Martin TF, Walent JH. Related Articles, Links

A new method for cell permeabilization reveals a cytosolic protein requirement for Ca2+ -activated secretion in GH3 pituitary cells.
J Biol Chem. 1989 Jun 15;264(17):10299-308.
PMID: 2722869 [PubMed - indexed for MEDLINE]

☐ **43:** Delree P, Leprince P, Schoenen J, Moonen G. Related Articles, Links

Purification and culture of adult rat dorsal root ganglia neurons.
J Neurosci Res. 1989 Jun;23(2):198-206.
PMID: 2754765 [PubMed - indexed for MEDLINE]

☐ **44:** Meigan G, Sasaki A, Yoshinaga K. Related Articles, Links

Immunoreactive growth hormone-releasing hormone in rat placenta.
Endocrinology. 1988 Aug;123(2):1098-102.
PMID: 2899497 [PubMed - indexed for MEDLINE]

☐ **45:** Sussman I, Carson MP, McCall AL, Schultz V, Ruderman NB, Tornheim K. Related Articles, Links

Energy state of bovine cerebral microvessels: comparison of isolation methods.
Microvasc Res. 1988 Mar;35(2):167-78.
PMID: 2897072 [PubMed - indexed for MEDLINE]

☐ **46:** Lynch SS, Reay P, Bluck M. Related Articles, Links

The extraction and purification of human pituitary follicle-stimulating hormone and luteinizing hormone.
Acta Endocrinol Suppl (Copenh). 1988;288:12-9.
PMID: 3138863 [PubMed - indexed for MEDLINE]

☐ **47:** Riss TL, Sirbasku DA. Related Articles, Links

Purification and identification of transferrin as a major pituitary-derived mitogen for MTW9/PL2 rat mammary tumor cells.
In Vitro Cell Dev Biol. 1987 Dec;23(12):841-9.
PMID: 3693252 [PubMed - indexed for MEDLINE]

☐ **48:** Sasaki A, Sato S, Go MG, Shimizu Y, Murakami O, Hanew K, Yumita S, Andoh N, Sasano N, Yoshinaga K. Related Articles, Links

Distribution, plasma concentration, and in vivo prolactin-releasing activity of peptide histidine methionine in humans.
J Clin Endocrinol Metab. 1987 Oct;65(4):683-8.
PMID: 3654914 [PubMed - indexed for MEDLINE]

☐ **49:** Brown RE, Thompson TE. Related Articles, Links

Spontaneous transfer of ganglioside GM1 between phospholipid vesicles.
Biochemistry. 1987 Aug 25;26(17):5454-60.
PMID: 3676263 [PubMed - indexed for MEDLINE]

☐ **50:** van Amerongen A, Helms JB, van der Krift TP, Schutgens RB, Wirtz KW. Related Articles, Links

Purification of nonspecific lipid transfer protein (sterol carrier protein 2) from human liver and its deficiency in livers from patients with cerebro-hepato-renal (Zellweger) syndrome.
Biochim Biophys Acta. 1987 Jun 2;919(2):149-55.
PMID: 3555624 [PubMed - indexed for MEDLINE]

☐ **51:** Noteborn HP, Burbach JP, Ebels I. Related Articles, Links

Modified forms of vasopressin and oxytocin in a bovine pineal preparation.
FEBS Lett. 1987 Jun 1;216(2):200-6.
PMID: 3582672 [PubMed - indexed for MEDLINE]

☐ **52:** Colon A, Berl S, Clarke DD. Related Articles, Links

Acetylation of synaptosomal protein: effect of Na+.
Neurochem Res. 1987 May;12(5):431-8.
PMID: 3587502 [PubMed - indexed for MEDLINE]

☐ **53:** Matsuo K, Moss L, Hommes FA. Related Articles, Links

Properties of the 3'-phosphoadenosine-5'-phosphosulfate (PAPS) synthesizing systems of brain and liver.
Neurochem Res. 1987 Apr;12(4):345-9.
PMID: 3037402 [PubMed - indexed for MEDLINE]

☐ **54:** Motoyama N, Takimoto K, Okada M, Nakagawa H. Related Articles, Links

Phosphotyrosine phosphatase: a novel phosphatase specific for phosphotyrosine, 2'-AMP and p-nitrophenylphosphate in rat brain.
J Biochem (Tokyo). 1987 Apr;101(4):939-47.
PMID: 2440857 [PubMed - indexed for MEDLINE]

☐ **55:** Liu KP, Tamir H, Hsiung S, Adlersberg M, Gershon MD. Related Articles, Links

Prenatal development of serotonin binding protein in relation to other transmitter-related characteristics of central serotonergic neurons.
Brain Res. 1987 Mar;429(1):31-41.
PMID: 2436719 [PubMed - indexed for MEDLINE]

☐ **56:** Roos P, Nyberg F, Brostedt P, Jansson JO, Isaksson O. Related Articles, Links

Isolation of three electrophoretic variants of rat pituitary growth hormone.
Prep Biochem. 1987;17(1):25-49.
PMID: 3588553 [PubMed - indexed for MEDLINE]

☐ **57:** Underhill CB, Tarone G, Kausz AT. Related Articles, Links

The hyaluronate-binding site from the plasma membrane is distinct from the binding protein present in brain.
Connect Tissue Res. 1987;16(3):225-35.
PMID: 2440638 [PubMed - indexed for MEDLINE]

☐ **58:** Hannun YA, Loomis CR, Bell RM. Related Articles, Links

Protein kinase C activation in mixed micelles. Mechanistic implications of phospholipid, diacylglycerol, and calcium interdependencies.
J Biol Chem. 1986 Jun 5;261(16):7184-90.
PMID: 3711083 [PubMed - indexed for MEDLINE]

☐ **59:** Gautron JP, Pattou E, Kordon C. Related Articles, Links

[Different immunoreactive forms of hypothalamic LHRH]
Ann Endocrinol (Paris). 1986;47(1):28-34. French.
PMID: 3532926 [PubMed - indexed for MEDLINE]

☐ **60:** Drouva SV, Gautron JP, Pattou E, Laplante E, Kordon C. Related Articles, Links

Effects of estradiol and progesterone on immunoreactive forms of hypothalamic luteinizing hormone-releasing hormone.
Neuroendocrinology. 1986;43(1):32-7.
PMID: 3520372 [PubMed - indexed for MEDLINE]

☐ **61:** Rapoport SI, Robinson PJ. Related Articles, Links

Tight-junctional modification as the basis of osmotic opening of the blood-brain barrier.
Ann N Y Acad Sci. 1986;481:250-67.
PMID: 3468860 [PubMed - indexed for MEDLINE]

☐ **62:** Krisch B. Related Articles, Links

The functional and structural borders between the CSF- and blood-dominated milieus in the choroid plexuses and the area postrema of the rat.
Cell Tissue Res. 1986;245(1):101-15.
PMID: 2425979 [PubMed - indexed for MEDLINE]

☐ **63:** Nye JS, Seltzman HH, Pitt CG, Snyder SH. Related Articles, Links

High-affinity cannabinoid binding sites in brain membranes labeled with [3H]-5'-trimethylammonium delta 8-tetrahydrocannabinol.
J Pharmacol Exp Ther. 1985 Sep;234(3):784-91.
PMID: 2993595 [PubMed - indexed for MEDLINE]

☐ **64:** Hannun YA, Loomis CR, Bell RM. Related Articles, Links

Activation of protein kinase C by Triton X-100 mixed micelles containing diacylglycerol and phosphatidylserine.
J Biol Chem. 1985 Aug 25;260(18):10039-43.
PMID: 3160705 [PubMed - indexed for MEDLINE]

☐ **65:** Takimoto K, Okada M, Matsuda Y, Nakagawa H. Related Articles, Links

Purification and properties of myo-inositol-1-phosphatase from rat brain.
J Biochem (Tokyo). 1985 Aug;98(2):363-70.
PMID: 2999094 [PubMed - indexed for MEDLINE]

☐ **66:** Brown RE, Sugar IP, Thompson TE. Related Articles, Links

Spontaneous transfer of gangliotetraosylceramide between phospholipid vesicles.
Biochemistry. 1985 Jul 16;24(15):4082-91.

PMID: 4052384 [PubMed - indexed for MEDLINE]

☐ **67:** Somjen GG, Aitken PG. Related Articles, Links

The ionic and metabolic responses associated with neuronal depression of Leao's type in cerebral cortex and in hippocampal formation.
An Acad Bras Cienc. 1984 Dec;56(4):495-504. Review.
PMID: 6442833 [PubMed - indexed for MEDLINE]

☐ **68:** Wilson JE, Smith AD. Related Articles, Links

A gel electrophoresis method for epitope mapping studies with monoclonal antibodies.
Anal Biochem. 1984 Nov 15;143(1):179-87.
PMID: 6084963 [PubMed - indexed for MEDLINE]

☐ **69:** Gluschankof P, Morel A, Gomez S, Nicolas P, Fahy C, Cohen P. Related Articles, Links

Enzymes processing somatostatin precursors: an Arg-Lys esteropeptidase from the rat brain cortex converting somatostatin-28 into somatostatin-14.
Proc Natl Acad Sci U S A. 1984 Nov;81(21):6662-6.
PMID: 6149550 [PubMed - indexed for MEDLINE]

☐ **70:** Nowak RA, Wiseman BS, Bahr JM. Related Articles, Links

Identification of a gonadotropin-releasing hormone-like factor in the rabbit fetal placenta.
Biol Reprod. 1984 Aug;31(1):67-75.
PMID: 6380602 [PubMed - indexed for MEDLINE]

☐ **71:** Lauber M, Clavreul C, Vaudry H, Cohen P. Related Articles, Links

Immunological detection of pro-corticotropin releasing factor (CRF) in rat hypothalamus and pancreatic extracts. Evidence for in vitro conversion into CRF.
FEBS Lett. 1984 Jul 23;173(1):222-6.
PMID: 6611275 [PubMed - indexed for MEDLINE]

☐ **72:** Mullikin LJ, Helmkamp GM Jr. Related Articles, Links

Bovine brain phosphatidylinositol transfer protein. Selective inhibition by chlorpromazine and other amphiphilic amines.
J Biol Chem. 1984 Mar 10;259(5):2764-8.
PMID: 6698992 [PubMed - indexed for MEDLINE]

☐ **73:** Krakower GR, Kamen BA. Related Articles, Links

In situ methotrexate polyglutamate formation in rat tissues.
J Pharmacol Exp Ther. 1983 Dec;227(3):633-8.
PMID: 6197519 [PubMed - indexed for MEDLINE]

☐ **74:** Weisner B, Kauerz U. Related Articles, Links

The influence of the choroid plexus on the concentration of prealbumin in CSF.
J Neurol Sci. 1983 Sep;61(1):27-35.
PMID: 6631451 [PubMed - indexed for MEDLINE]

☐ **75:** Morel A, Nicolas P, Cohen P. Related Articles, Links

Evidence for a predominant form of Mr = 15,000 prosomatostatin in the mouse hypothalamus. Relationship with somatostatin-14 and -28.
J Biol Chem. 1983 Jul 10;258(13):8273-6.
PMID: 6134727 [PubMed - indexed for MEDLINE]

☐ **76:** Cahill CA, Matthews JD, Akil H. Related Articles, Links

Human plasma beta-endorphin-like peptides: a rapid, high recovery extraction technique and validation of radioimmunoassay.
J Clin Endocrinol Metab. 1983 May;56(5):992-7.
PMID: 6300182 [PubMed - indexed for MEDLINE]

☐ **77:** Stoffel W, Hillen H, Schroder W, Deutzmann R. Related Articles, Links

Lipophilin (proteolipid apoprotein) of brain white matter. Purification and amino acid sequence studies of the four tryptophan fragments.
Hoppe Seylers Z Physiol Chem. 1982 Nov;363(11):1397-407.
PMID: 7173828 [PubMed - indexed for MEDLINE]

☐ **78:** Boileau G, Lariviere N, Hsi KL, Seidah NG, Chretien M. Related Articles, Links

Characterization of multiple forms of porcine anterior pituitary proopiomelanocortin amino-terminal glycopeptide.
Biochemistry. 1982 Oct 12;21(21):5341-6.
PMID: 7171563 [PubMed - indexed for MEDLINE]

☐ **79:** Stoffel W, Schroder W, Hillen H, Deutzmann R. Related Articles, Links

Analysis of the primary structure of the strongly hydrophobic brain myelin proteolipid apoprotein (lipophilin). Isolation and amino acid sequence determination of proteolytic fragments.
Hoppe Seylers Z Physiol Chem. 1982 Sep;363(9):1117-31.
PMID: 7141416 [PubMed - indexed for MEDLINE]

☐ **80:** Gilbert JA, Knodel EL, Stenstrom SD, Richelson E. Related Articles, Links

Function and regulation of methionine5-enkephalin and its receptors in murine neuroblastoma cells.
J Biol Chem. 1982 Feb 10;257(3):1274-81.
PMID: 6276378 [PubMed - indexed for MEDLINE]

☐ **81:** Fazekas S, Ovary I, Horvath E, Szekessy-Hermann V, Juhasz P. Related Articles, Links

Isolation, properties and P content of the human brain myosin.
Acta Physiol Acad Sci Hung. 1982;59(2):101-17.
PMID: 7158365 [PubMed - indexed for MEDLINE]

☐ **82:** Nyberg F, Roos P, Isaksson O. Related Articles, Links

Isolation of rat pituitary prolactin isohormones differing in charge, size, and specific immunological activity.
Prep Biochem. 1982;12(2):153-73.
PMID: 7122424 [PubMed - indexed for MEDLINE]

☐ **83:** Gautron JP, Pattou E, Kordon C. Related Articles, Links

Occurrence of higher molecular forms of LHRH in fractionated extracts from rat hypothalamus, cortex and placenta.
Mol Cell Endocrinol. 1981 Oct;24(1):1-15.
PMID: 7035249 [PubMed - indexed for MEDLINE]

☐ **84:** Lees MB, Macklin WB, Chao BH. Related Articles, Links

A study of elastase peptides from bovine white matter proteolipid.
Neurochem Res. 1981 Oct;6(10):1091-104.
PMID: 6917041 [PubMed - indexed for MEDLINE]

☐ **85:** Bulinski JC, Borisy GG. Related Articles, Links

Microtubule-associated proteins from cultured HeLa cells. Analysis of molecular properties and effects on microtubule polymerization.
J Biol Chem. 1980 Dec 10;255(23):11570-6.
PMID: 7440558 [PubMed - indexed for MEDLINE]

☐ **86:** Tamir H, Bebirian R, Muller F, Casper D. Related Articles, Links

Differences between intracellular platelet and brain proteins that bind serotonin.
J Neurochem. 1980 Nov;35(5):1033-44.
PMID: 7452303 [PubMed - indexed for MEDLINE]

☐ **87:** Tamura T, Shiraki H, Nakagawa H. Related Articles, Links

Purification and characterization of adenylate kinase isozymes from rat muscle and liver.
Biochim Biophys Acta. 1980 Mar 14;612(1):56-66.
PMID: 6244854 [PubMed - indexed for MEDLINE]

☐ **88:** Boyd WH, Peters A. Related Articles, Links

Low molecular weight protein in bovine anterior pituitary similar to immunoglobulin M.
Endocrinol Exp. 1980;14(2):83-90.
PMID: 6967014 [PubMed - indexed for MEDLINE]

☐ **89:** Roos P, Nyberg F, Wide L. Related Articles, Links

Isolation of human pituitary prolactin.
Biochim Biophys Acta. 1979 Dec 11;588(3):368-79.
PMID: 508811 [PubMed - indexed for MEDLINE]

☐ **90:** Bernd P, Gershon MD, Nunez EA, Tamir H. Related Articles, Links

Localization of a highly specific neuronal protein, serotonin binding protein, in thyroid parafollicular cells.
Anat Rec. 1979 Feb;193(2):257-67.
PMID: 426298 [PubMed - indexed for MEDLINE]

☐ **91:** Kuczmarski ER, Rosenbaum JL. Related Articles, Links

Chick brain actin and myosin. Isolation and characterization.
J Cell Biol. 1979 Feb;80(2):341-55.
PMID: 156729 [PubMed - indexed for MEDLINE]

☐ **92:** Binder LI, Rosenbaum JL. Related Articles, Links

The in vitro assembly of flagellar outer doublet tubulin.
J Cell Biol. 1978 Nov;79(2 Pt 1):500-15.
PMID: 569158 [PubMed - indexed for MEDLINE]

☐ **93:** Liotta AS, Suda T, Krieger DT. Related Articles, Links

beta-Lipotropin is the major opioid-like peptide of human pituitary and rat pars distalis: lack of significant beta-endorphin.
Proc Natl Acad Sci U S A. 1978 Jun;75(6):2950-4.
PMID: 208078 [PubMed - indexed for MEDLINE]

☐ **94:** Meier E, Jorgensen OS. Related Articles, Links

Proteins from disassembled microtubules characterized by oligospecific antisera.
Biochim Biophys Acta. 1977 Oct 26;494(2):354-66.
PMID: 911877 [PubMed - indexed for MEDLINE]

☐ **95:** Dons RF, Doughty CC. Related Articles, Links

Isolation and characterization of aldose reductase from calf brain.
Biochim Biophys Acta. 1976 Nov 8;452(1):1-12.
PMID: 10990 [PubMed - indexed for MEDLINE]

☐ **96:** Pert CB, Pert A, Tallman JF. Related Articles, Links

Isolation of a novel endogenous opiate analgesic from human blood.
Proc Natl Acad Sci U S A. 1976 Jul;73(7):2226-30.
PMID: 1065871 [PubMed - indexed for MEDLINE]

☐ **97:** Monreal J. Related Articles, Links

The application of acetylated Sephadex for the separation of proteolipids.
Biochim Biophys Acta. 1976 Mar 18;427(1):15-9.
PMID: 1259996 [PubMed - indexed for MEDLINE]

☐ **98:** LeBeux YJ, Willemot J. Related Articles, Links

An ultrastructural study of the microfilaments in rat brain by means of E-PTA staining and heavy meromyosin labeling. II. The synapses.
Cell Tissue Res. 1975 Jun 27;160(1):37-68.
PMID: 50140 [PubMed - indexed for MEDLINE]

☐ **99:** Mosavy SH, Sajadieh V, Vakhshuri P. Related Articles, Links

Echinococcal cyst beyond the pulmonary sieve.
Surgery. 1975 Feb;77(2):194-200.
PMID: 124095 [PubMed - indexed for MEDLINE]

Display Summary Show: 500 Sort Send to Text

1: J Biochem (Tokyo). 1985 Aug;98(2):363-70.

Purification and properties of myo-inositol-1-phosphatase from rat brain.

Takimoto K, Okada M, Matsuda Y, Nakagawa H.

myo-Inositol-1-phosphatase [EC 3.1.3.25] was purified from a cytosolic fraction of rat brain. The purified enzyme appeared homogeneous on SDS-polyacrylamide gel electrophoresis and its molecular weight was estimated to be 29,000. The molecular weight of the native enzyme was 55,000 as determined by molecular sieve chromatography. These values indicated that the native enzyme was composed of two identical subunits. The isoelectric point of the enzyme was 4.6. The enzyme hydrolyzed inositol-1-phosphate, 2'-AMP, 2'-GMP, beta-glycerophosphate, and alpha-glycerophosphate; the ratio of the reaction rates was 100 : 84 : 73 : 64 : 32. The Km values for inositol-1-phosphate, 2'-AMP, and beta-glycerophosphate were 1.2 X 10(-4) M, 1.9 X 10(-4) M, and 7.7 X 10(-4) M, respectively. Mn2+ and Ca2+ were strong competitive inhibitors against Mg2+, with Ki values of 3 microM and 20 microM, respectively. This result suggests that myo-inositol-1-phosphatase might be regulated by intracellular Ca2+ and/or Mn2+. Li+, which is known to show a therapeutic effect on manic-depressive disease and also to prolong the intrinsic periods of circadian rhythms in various organisms, was a potent uncompetitive inhibitor and inhibited 50% of the activity at 1 mM. The possibility that myo-inositol-1-phosphatase and inositol phospholipid metabolism are involved in circadian rhythm oscillation is discussed in terms of Li actions.

PMID: 2999094 [PubMed - indexed for MEDLINE]

About Entrez

Text Version

Entrez PubMed
Overview
Help | FAQ
Tutorial
New/Noteworthy
E-Utilities

PubMed Services
Journals Database
MeSH Database
Single Citation Matcher
Batch Citation Matcher
Clinical Queries
LinkOut
Cubby

Related Resources
Order Documents
NLM Catalog
NLM Gateway
TOXNET
Consumer Health
Clinical Alerts
ClinicalTrials.gov
PubMed Central

Items 1 - 87 of 87 One page

1: Pesen D, Hoh JH. Related Articles, Links

Micromechanical architecture of the endothelial cell cortex.
Biophys J. 2004 Oct 15; [Epub ahead of print]
PMID: 15489304 [PubMed - as supplied by publisher]

2: Feneberg W, Aepfelbacher M, Sackmann E. Related Articles, Links

Microviscoelasticity of the apical cell surface of human umbilical vein endothelial cells (HUVEC) within confluent monolayers.
Biophys J. 2004 Aug;87(2):1338-50.
PMID: 15298936 [PubMed - in process]

3: Golaszewski SM, Siedentopf CM, Koppelstaetter F, Rhomberg P, Guendisch GM, Schlager A, Gallasch E, Eisner W, Felber SR, Mottaghy FM. Related Articles, Links

Modulatory effects on human sensorimotor cortex by whole-hand afferent electrical stimulation.
Neurology. 2004 Jun 22;62(12):2262-9.
PMID: 15210892 [PubMed - in process]

4: Zhang L, Zhao Y, Zhou JW. Related Articles, Links

The three-dimensional structure and the relationship between external and internal vascularizations in the brain of rat embryos.
Chin Med J (Engl). 2004 Feb;117(2):280-5.
PMID: 14975217 [PubMed - indexed for MEDLINE]

5: Xu M, Thompson PM, Toga AW. Related Articles, Links

An adaptive level set segmentation on a triangulated mesh.
IEEE Trans Med Imaging. 2004 Feb;23(2):191-201.
PMID: 14964564 [PubMed - indexed for MEDLINE]

6: Jariyapongskul A, Nakano A, Yamaguchi S, Nageswari K, Niimi H. Related Articles, Links

Maturity of pericytes in cerebral neocapillaries induced by growth factors: fluorescence immuno-histochemical analysis using confocal laser microscopy.
Clin Hemorheol Microcirc. 2003;29(3-4):417-21.
PMID: 14724369 [PubMed - indexed for MEDLINE]

7: Kruggel F, Bruckner MK, Arendt T, Wiggins CJ, von Cramon DY. Related Articles, Links

Analyzing the neocortical fine-structure.
Med Image Anal. 2003 Sep;7(3):251-64.
PMID: 12946467 [PubMed - indexed for MEDLINE]

8: Levitt JG, Blanton RE, Smalley S, Thompson PM, Guthrie D, McCracken JT, Sadoun T, Heinichen L, Toga AW. Related Articles, Links

Cortical sulcal maps in autism.
Cereb Cortex. 2003 Jul;13(7):728-35.
PMID: 12816888 [PubMed - indexed for MEDLINE]

☐ **9:** Nageswari K, Yamaguchi S, Yamakawa T, Niimi H. Related Articles, Links

Quantitative assessment of cerebral neocapillary network and its remodeling in mice using intravital fluorescence videomicroscopy.
Angiogenesis. 2002;5(1-2):99-105.
PMID: 12549866 [PubMed - indexed for MEDLINE]

☐ **10:** Trifaro JM, Lejen T, Rose SD, Pene TD, Barkar ND, Seward EP. Related Articles, Links

Pathways that control cortical F-actin dynamics during secretion.
Neurochem Res. 2002 Nov;27(11):1371-85. Review.
PMID: 12512942 [PubMed - indexed for MEDLINE]

☐ **11:** Moores KA, Clark CR, Hadfield JL, Brown GC, Taylor DJ, Fitzgibbon SP, Lewis AC, Weber DL, Greenblatt R. Related Articles, Links

Investigating the generators of the scalp recorded visuo-verbal P300 using cortically constrained source localization.
Hum Brain Mapp. 2003 Jan;18(1):53-77.
PMID: 12454912 [PubMed - indexed for MEDLINE]

☐ **12:** Rose SD, Lejen T, Casaletti L, Larson RE, Pene TD, Trifaro JM. Related Articles, Links

Molecular motors involved in chromaffin cell secretion.
Ann N Y Acad Sci. 2002 Oct;971:222-31. Review.
PMID: 12438122 [PubMed - indexed for MEDLINE]

☐ **13:** Freire E, Gomes FC, Linden R, Neto VM, Coelho-Sampaio T. Related Articles, Links

Structure of laminin substrate modulates cellular signaling for neuritogenesis.
J Cell Sci. 2002 Dec 15;115(Pt 24):4867-76.
PMID: 12432074 [PubMed - indexed for MEDLINE]

☐ **14:** Matthews RT, Kelly GM, Zerillo CA, Gray G, Tiemeyer M, Hockfield S. Related Articles, Links

Aggrecan glycoforms contribute to the molecular heterogeneity of perineuronal nets.
J Neurosci. 2002 Sep 1;22(17):7536-47.
PMID: 12196577 [PubMed - indexed for MEDLINE]

☐ **15:** Mouatt JG. Related Articles, Links

Acrylic cranioplasty and axial pattern flap following calvarial and cerebral mass excision in a dog.
Aust Vet J. 2002 Apr;80(4):211-5.
PMID: 12054283 [PubMed - indexed for MEDLINE]

☐ **16:** Hoehn BD, Harik SI, Hudetz AG. Related Articles, Links

VEGF mRNA expressed in microvessels of neonatal and adult rat cerebral cortex.
Brain Res Mol Brain Res. 2002 May 30;101(1-2):103-8.
PMID: 12007837 [PubMed - indexed for MEDLINE]

☐ **17:** Roberts S, Creamer K, Shoupe B, Flores Y, Robie D. Related Articles, Links

Unique management of stage 4S neuroblastoma complicated by massive hepatomegaly: case report and review of the literature.
J Pediatr Hematol Oncol. 2002 Feb;24(2):142-4. Review.
PMID: 11990702 [PubMed - indexed for MEDLINE]

☐ **18:** Ala Eddine T, Remy F, Chantelot C, Giraud F, Migaud H, Duquennoy A. Related Articles, Links

[Anterior iliopsoas impingement after total hip arthroplasty: diagnosis and

conservative treatment in 9 cases].
Rev Chir Orthop Reparatrice Appar Mot. 2001 Dec;87(8):815-9. French.
PMID: 11845085 [PubMed - indexed for MEDLINE]

☐ **19:** Sowell ER, Thompson PM, Rex D, Kornsand D, Tessner KD, Jernigan TL, Toga AW. Related Articles, Links

Mapping sulcal pattern asymmetry and local cortical surface gray matter distribution in vivo: maturation in perisylvian cortices.
Cereb Cortex. 2002 Jan;12(1):17-26.
PMID: 11734529 [PubMed - indexed for MEDLINE]

☐ **20:** Matsumoto K, Nakamura T, Fukuda S, Sekine T, Ueda H, Shimizu Y. Related Articles, Links

A gelatin coated collagen-polyglycolic acid composite membrane as a dural substitute.
ASAIO J. 2001 Nov-Dec;47(6):641-5.
PMID: 11730203 [PubMed - indexed for MEDLINE]

☐ **21:** Yokoyama M, Karahara I. Related Articles, Links

Radial widening of the Casparian strip follows induced radial expansion of endodermal cells.
Planta. 2001 Jul;213(3):474-7.
PMID: 11506371 [PubMed - indexed for MEDLINE]

☐ **22:** Blanton RE, Levitt JG, Thompson PM, Narr KL, Capetillo-Cunliffe L, Nobel A, Singerman JD, McCracken JT, Toga AW. Related Articles, Links

Mapping cortical asymmetry and complexity patterns in normal children.
Psychiatry Res. 2001 Jul 1;107(1):29-43.
PMID: 11472862 [PubMed - indexed for MEDLINE]

☐ **23:** Kriegeskorte N, Goebel R. Related Articles, Links

An efficient algorithm for topologically correct segmentation of the cortical sheet in anatomical mr volumes.
Neuroimage. 2001 Aug;14(2):329-46.
PMID: 11467907 [PubMed - indexed for MEDLINE]

☐ **24:** Niimi H, Nageswari K, Ranade G, Yamaguchi S, Yamakawa T. Related Articles, Links

Microcirculatory characterization of cerebral angiogenesis in mice using intravital videomicroscopy.
Clin Hemorheol Microcirc. 2000;23(2-4):293-301.
PMID: 11321454 [PubMed - indexed for MEDLINE]

☐ **25:** Boyne PJ. Related Articles, Links

Application of bone morphogenetic proteins in the treatment of clinical oral and maxillofacial osseous defects.
J Bone Joint Surg Am. 2001;83-A Suppl 1(Pt 2):S146-50.
PMID: 11314792 [PubMed - indexed for MEDLINE]

☐ **26:** Friel KM, Heddings AA, Nudo RJ. Related Articles, Links

Effects of postlesion experience on behavioral recovery and neurophysiologic reorganization after cortical injury in primates.
Neurorehabil Neural Repair. 2000;14(3):187-98.
PMID: 11272475 [PubMed - indexed for MEDLINE]

☐ **27:** Strehl R, Minuth WW. Related Articles, Links

Nephron induction--the epithelial mesenchymal interface revisited.
Pediatr Nephrol. 2001 Jan;16(1):38-40.
PMID: 11198601 [PubMed - indexed for MEDLINE]

☐ **28:** Narr K, Thompson P, Sharma T, Moussai J, Zoumalan C, Rayman J, Toga A. Related Articles, Links

Three-dimensional mapping of gyral shape and cortical surface asymmetries in schizophrenia: gender effects.
Am J Psychiatry. 2001 Feb;158(2):244-55.
PMID: 11156807 [PubMed - indexed for MEDLINE]

☐ **29:** Wainwright P. Related Articles, Links

Thermal effects of radiation from cellular telephones.
Phys Med Biol. 2000 Aug;45(8):2363-72.
PMID: 10958200 [PubMed - indexed for MEDLINE]

☐ **30:** Atoji Y, Yamamoto Y, Suzuki Y. Related Articles, Links

Parvalbumin in cortical epithelial cells of the pigeon thymus.
J Anat. 2000 Apr;196 (Pt 3):305-11.
PMID: 10853953 [PubMed - indexed for MEDLINE]

☐ **31:** Kelly MK, Carvell GE, Kodger JM, Simons DJ. Related Articles, Links

Sensory loss by selected whisker removal produces immediate disinhibition in the somatosensory cortex of behaving rats.
J Neurosci. 1999 Oct 15;19(20):9117-25.
PMID: 10516329 [PubMed - indexed for MEDLINE]

☐ **32:** Preuss TM, Qi H, Kaas JH. Related Articles, Links

Distinctive compartmental organization of human primary visual cortex.
Proc Natl Acad Sci U S A. 1999 Sep 28;96(20):11601-6.
PMID: 10500223 [PubMed - indexed for MEDLINE]

☐ **33:** Golaszewski S, Kremser C, Wagner M, Felber S, Aichner F, Dimitrijevic MM. Related Articles, Links

Functional magnetic resonance imaging of the human motor cortex before and after whole-hand afferent electrical stimulation.
Scand J Rehabil Med. 1999 Sep;31(3):165-73.
PMID: 10458314 [PubMed - indexed for MEDLINE]

☐ **34:** De-Carvalho MC, Chimelli LM, Quirico-Santos T. Related Articles, Links

Modulation of fibronectin expression in the central nervous system of Lewis rats with experimental autoimmune encephalomyelitis.
Braz J Med Biol Res. 1999 May;32(5):583-92.
PMID: 10412570 [PubMed - indexed for MEDLINE]

☐ **35:** Thompson PM, Moussai J, Zohoori S, Goldkorn A, Khan AA, Mega MS, Small GW, Cummings JL, Toga AW. Related Articles, Links

Cortical variability and asymmetry in normal aging and Alzheimer's disease.
Cereb Cortex. 1998 Sep;8(6):492-509.
PMID: 9758213 [PubMed - indexed for MEDLINE]

☐ **36:** Zaoui P, Barro C, Maynard C, Descotes JL, Maurizi-Balzan J, Cordonnier DJ, Morel F. Related Articles, Links

Inter-regulated balance between gelatinases and tissue inhibitor (TIMP-1) in isolated human glomeruli.
Ren Fail. 1998 Mar;20(2):201-9.
PMID: 9574444 [PubMed - indexed for MEDLINE]

☐ **37:** Bal BS, Maurer BT, Harris WH. Related Articles, Links

Trochanteric union following revision total hip arthroplasty.
J Arthroplasty. 1998 Jan;13(1):29-33.

PMID: 9493535 [PubMed - indexed for MEDLINE]

☐ **38:** Lonstein JS, Simmons DA, Swann JM, Stern JM. Related Articles, Links

Forebrain expression of c-fos due to active maternal behaviour in lactating rats.
Neuroscience. 1998 Jan;82(1):267-81.
PMID: 9483519 [PubMed - indexed for MEDLINE]

☐ **39:** Klein GJ, Teng X, Jagust WJ, Eberling JL, Acharya A, Reutter BW, Huesman RH. Related Articles, Links

A methodology for specifying PET VOI's using multimodality techniques.
IEEE Trans Med Imaging. 1997 Aug;16(4):405-15.
PMID: 9262998 [PubMed - indexed for MEDLINE]

☐ **40:** Apkarian RP. Related Articles, Links

The fine structure of fenestrated adrenocortical capillaries revealed by in-lens field-emission scanning electron microscopy and scanning transmission electron microscopy.
Scanning. 1997 Aug;19(5):361-7.
PMID: 9262021 [PubMed - indexed for MEDLINE]

☐ **41:** Gard DL, Cha BJ, King E. Related Articles, Links

The organization and animal-vegetal asymmetry of cytokeratin filaments in stage VI Xenopus oocytes is dependent upon F-actin and microtubules.
Dev Biol. 1997 Apr 1;184(1):95-114.
PMID: 9142987 [PubMed - indexed for MEDLINE]

☐ **42:** Kiyotani T, Teramachi M, Takimoto Y, Nakamura T, Shimizu Y, Endo K. Related Articles, Links

Nerve regeneration across a 25-mm gap bridged by a polyglycolic acid-collagen tube: a histological and electrophysiological evaluation of regenerated nerves.
Brain Res. 1996 Nov 18;740(1-2):66-74.
PMID: 8973799 [PubMed - indexed for MEDLINE]

☐ **43:** Meyer KL, Kim K, Li T, Tulipano PK, Lee KM, DeLaPaz R, Hirsch J, Ballon D. Related Articles, Links

Sensitivity-enhanced echo-planar MRI at 1.5T using a 5 x 5 mesh dome resonator.
Magn Reson Med. 1996 Oct;36(4):606-12.
PMID: 8892214 [PubMed - indexed for MEDLINE]

☐ **44:** Nagumo K, Shinotoh H, Arai K, Furumoto H, Hirayama K. Related Articles, Links

[Frontal type adrenoleukodystrophy: the progress of the white matter lesion--a neuroradiological and pathological study]
Rinsho Shinkeigaku. 1995 Sep;35(9):983-90. Japanese.
PMID: 8565349 [PubMed - indexed for MEDLINE]

☐ **45:** Tamura T, Kishi S. Related Articles, Links

[Scanning electron microscopic findings of the premacular vitreous in eyes without posterior vitreous detachment]
Nippon Ganka Gakkai Zasshi. 1993 Oct;97(10):1197-202. Japanese.
PMID: 7504879 [PubMed - indexed for MEDLINE]

☐ **46:** McLean JH, Darby-King A, Sullivan RM, King SR. Related Articles, Links

Serotonergic influence on olfactory learning in the neonate rat.
Behav Neural Biol. 1993 Sep;60(2):152-62.
PMID: 7906939 [PubMed - indexed for MEDLINE]

☐ **47:** Widmaier EP, Kunz TH. Related Articles, Links

Basal, diurnal, and stress-induced levels of glucose and glucocorticoids in captive bats.
J Exp Zool. 1993 Apr 1;265(5):533-40.
PMID: 8468542 [PubMed - indexed for MEDLINE]

☐ **48:** Larabell CA. Related Articles, Links

A new technique for isolation and visualization of the Xenopus egg cortex reveals a complex cytoskeleton.
J Struct Biol. 1993 Mar-Apr;110(2):154-9.
PMID: 8338718 [PubMed - indexed for MEDLINE]

☐ **49:** Hamon GA, Hunt TK, Spencer EM. Related Articles, Links

In vivo effects of systemic insulin-like growth factor-I alone and complexed with insulin-like growth factor binding protein-3 on corticosteroid suppressed wounds.
Growth Regul. 1993 Mar;3(1):53-6.
PMID: 7683531 [PubMed - indexed for MEDLINE]

☐ **50:** Mutoh K, Ito M, Tsuda H, Shiraishi H, Oguro K, Shirasaka Y, Okuno T, Mikawa H. Related Articles, Links

Depth EEG in mutant epileptic E1 mice: demonstration of secondary generalization of the seizure from the hippocampus.
Electroencephalogr Clin Neurophysiol. 1993 Mar;86(3):205-12.
PMID: 7680997 [PubMed - indexed for MEDLINE]

☐ **51:** Suh DY, Hunt TK, Spencer EM. Related Articles, Links

Insulin-like growth factor-I reverses the impairment of wound healing induced by corticosteroids in rats.
Endocrinology. 1992 Nov;131(5):2399-403.
PMID: 1425438 [PubMed - indexed for MEDLINE]

☐ **52:** Meddings N, Scott R, Bullock R, French DA, Hide TA, Gorham SD. Related Articles, Links

Collagen vicryl--a new dural prosthesis.
Acta Neurochir (Wien). 1992;117(1-2):53-8.
PMID: 1514429 [PubMed - indexed for MEDLINE]

☐ **53:** Bignami A, Asher R. Related Articles, Links

Some observations on the localization of hyaluronic acid in adult, newborn and embryonal rat brain.
Int J Dev Neurosci. 1992;10(1):45-57.
PMID: 1376955 [PubMed - indexed for MEDLINE]

☐ **54:** Georgiev V, Tanaka M, Tsuda A, Koga C, Takeda S, Yokoo H, Yoshida M. Related Articles, Links

Effects of angiotensin II on regional brain noradrenaline metabolism in non-stressed and stressed rats.
Kurume Med J. 1992;39(4):235-44.
PMID: 1305906 [PubMed - indexed for MEDLINE]

☐ **55:** Hashimura T, Kimura T, Miyakawa T. Related Articles, Links

Morphological changes of blood vessels in the brain with Alzheimer's disease.
Jpn J Psychiatry Neurol. 1991 Sep;45(3):661-5.
PMID: 1800813 [PubMed - indexed for MEDLINE]

☐ **56:** Hisanaga K, Sharp FR. Related Articles, Links

Marked neurotrophic effects of diffusible substances released from non-target cerebellar cells on thalamic neurons in culture.
Brain Res Dev Brain Res. 1990 Jul 1;54(2):151-60.
PMID: 2397583 [PubMed - indexed for MEDLINE]

☐ **57:** Delree P, Leprince P, Schoenen J, Moonen G. Related Articles, Links

Purification and culture of adult rat dorsal root ganglia neurons.
J Neurosci Res. 1989 Jun;23(2):198-206.
PMID: 2754765 [PubMed - indexed for MEDLINE]

☐ **58:** Hirokawa N. Related Articles, Links

The arrangement of actin filaments in the postsynaptic cytoplasm of the cerebellar cortex revealed by quick-freeze deep-etch electron microscopy.
Neurosci Res. 1989 Feb;6(3):269-75.
PMID: 2710429 [PubMed - indexed for MEDLINE]

☐ **59:** Jasty M, Harris WH. Related Articles, Links

Results of total hip reconstruction using acetabular mesh in patients with central acetabular deficiency.
Clin Orthop. 1988 Dec;(237):142-9.
PMID: 3191622 [PubMed - indexed for MEDLINE]

☐ **60:** Pickering SJ, Johnson MH, Braude PR, Houliston E. Related Articles, Links

Cytoskeletal organization in fresh, aged and spontaneously activated human oocytes.
Hum Reprod. 1988 Nov;3(8):978-89.
PMID: 3204153 [PubMed - indexed for MEDLINE]

☐ **61:** Nishiye H, Obata K, Ozaki T, Uchizono K. Related Articles, Links

A new method for electron microscopic observation of isolated synaptic vesicles labelled with monoclonal antibody.
Neurosci Res. 1988 Aug;5(6):567-76.
PMID: 3173813 [PubMed - indexed for MEDLINE]

☐ **62:** Schutzer SF, Harris WH. Related Articles, Links

Trochanteric osteotomy for revision total hip arthroplasty. 97% union rate using a comprehensive approach.
Clin Orthop. 1988 Feb;227:172-83.
PMID: 3338206 [PubMed - indexed for MEDLINE]

☐ **63:** Bignami A, Dahl D. Related Articles, Links

Expression of brain-specific hyaluronectin (BHN), a hyaluronate-binding protein, in dog postnatal development.
Exp Neurol. 1988 Jan;99(1):107-17.
PMID: 2446903 [PubMed - indexed for MEDLINE]

☐ **64:** Kato S, Schoefl GI. Related Articles, Links

The vasculature of the guinea-pig thymus: topographic studies by light and electron microscopy.
Arch Histol Jpn. 1987 Jul;50(3):299-314.
PMID: 3662758 [PubMed - indexed for MEDLINE]

☐ **65:** Johnson MH, Pickering SJ. Related Articles, Links

The effect of dimethylsulphoxide on the microtubular system of the mouse oocyte.
Development. 1987 Jun;100(2):313-24.
PMID: 3652973 [PubMed - indexed for MEDLINE]

☐ **66:** Gentile AM, Beheshti Z, Held JM. Related Articles, Links

Enrichment versus exercise effects on motor impairments following cortical removals in rats.
Behav Neural Biol. 1987 May;47(3):321-32.
PMID: 3606531 [PubMed - indexed for MEDLINE]

☐ **67:** Voormolen JH, Ringers J, Bots GT, van der Heide A, Hermans J. Related Articles, Links

Hemostatic agents: brain tissue reaction and effectiveness. A comparative animal study using collagen fleece and oxidized cellulose.
Neurosurgery. 1987 May;20(5):702-9.
PMID: 3601016 [PubMed - indexed for MEDLINE]

☐ **68:** Joos L, Gicquaud C. Related Articles, Links

Effect of phalloidin and viroisin on Acanthamoeba castellanii after permeabilization of the cell.
Biochem Cell Biol. 1987 Mar;65(3):261-70.
PMID: 3580176 [PubMed - indexed for MEDLINE]

☐ **69:** Yuen TG, Agnew WF, Bullara LA. Related Articles, Links

Tissue response to potential neuroprosthetic materials implanted subdurally.
Biomaterials. 1987 Mar;8(2):138-41.
PMID: 3555632 [PubMed - indexed for MEDLINE]

☐ **70:** Silverberg M, Singh M, Sreekanth S, Gans BJ. Related Articles, Links

Use of polyglycolic acid mesh to confine particulate hydroxylapatite for augmentation of bone in the rat.
J Oral Maxillofac Surg. 1986 Nov;44(11):877-86.
PMID: 2430083 [PubMed - indexed for MEDLINE]

☐ **71:** Bignami A, Dahl D. Related Articles, Links

Brain-specific hyaluronate-binding protein. A product of white matter astrocytes?
J Neurocytol. 1986 Oct;15(5):671-9.
PMID: 2430070 [PubMed - indexed for MEDLINE]

☐ **72:** Lombardi T, Montesano R, Furie MB, Silverstein SC, Orci L. Related Articles, Links

Endothelial diaphragmed fenestrae: in vitro modulation by phorbol myristate acetate.
J Cell Biol. 1986 May;102(5):1965-70.
PMID: 3700479 [PubMed - indexed for MEDLINE]

☐ **73:** Chahwala SB, Harpur ES. Related Articles, Links

The use of renal tubule fragments isolated from the rat to investigate aspects of gentamicin nephrotoxicity.
J Pharmacol Methods. 1986 Feb;15(1):21-34.
PMID: 3081763 [PubMed - indexed for MEDLINE]

☐ **74:** Hirokawa K, Utsuyama M, Moriizumi E, Handa S. Related Articles, Links

Analysis of the thymic microenvironment by monoclonal antibodies with special reference to thymic nurse cells.
Thymus. 1986;8(6):349-60.
PMID: 3101237 [PubMed - indexed for MEDLINE]

☐ **75:** Bearer EL, Orci L. Related Articles, Links

Endothelial fenestral diaphragms: a quick-freeze, deep-etch study.
J Cell Biol. 1985 Feb;100(2):418-28.

PMID: 3968170 [PubMed - indexed for MEDLINE]

☐ **76:** Ben Hamida C, Bisconte JC, Margules S. Related Articles, Links

Postnatal maturation of the vascularisation of the suprasylvian gyrus of the cat.
J Anat. 1983 Sep;137 (Pt 2):371-85.
PMID: 6630047 [PubMed - indexed for MEDLINE]

☐ **77:** Frank HJ, Pardridge WM. Related Articles, Links

A direct in vitro demonstration of insulin binding to isolated brain microvessels.
Diabetes. 1981 Sep;30(9):757-61.
PMID: 7021274 [PubMed - indexed for MEDLINE]

☐ **78:** Irvine AR. Related Articles, Links

Extracapsular cataract extraction and pseudophakos implantation in primates: a clinico-pathologic study.
Ophthalmic Surg. 1981 Jan;12(1):27-38.
PMID: 7231866 [PubMed - indexed for MEDLINE]

☐ **79:** Martin-Dupont P, Cambar J. Related Articles, Links

[Demonstration of 2 distinct glomerular populations by a sieving technic in the kidney cortex of the pig]
C R Seances Soc Biol Fil. 1981;175(6):787-91. French.
PMID: 6459823 [PubMed - indexed for MEDLINE]

☐ **80:** Ranawat CS, Dorr LD, Inglis AE. Related Articles, Links

Total hip arthroplasty in protrusio acetabuli of rheumatoid arthritis.
J Bone Joint Surg Am. 1980 Oct;62(7):1059-65.
PMID: 7430191 [PubMed - indexed for MEDLINE]

☐ **81:** Irvine AR. Related Articles, Links

Extracapsular cataract extraction and pseudophakos implantation in primates: a clinico-pathologic study.
Trans Am Ophthalmol Soc. 1980;78:780-807.
PMID: 7257072 [PubMed - indexed for MEDLINE]

☐ **82:** Bullara LA, Agnew WF, Yuen TG, Jacques S, Pudenz RH. Related Articles, Links

Evaluation of electrode array material for neural prostheses.
Neurosurgery. 1979 Dec;5(6):681-6.
PMID: 160513 [PubMed - indexed for MEDLINE]

☐ **83:** Reddy PV, Sastry PS. Related Articles, Links

Studies on neurotransmitter-stimulated phospholipid metabolism with cerebral tissue suspensions: a possible biochemical correlate of synaptogenesis in normal and undernourished rats.
Brain Res. 1979 May 25;168(2):287-98.
PMID: 36206 [PubMed - indexed for MEDLINE]

☐ **84:** Harris WH, Crothers OD. Related Articles, Links

Reattachment of the greater trochanter in total hip-replacement arthroplasty. A new technique.
J Bone Joint Surg Am. 1978 Mar;60(2):211-3.
PMID: 641086 [PubMed - indexed for MEDLINE]

☐ **85:** Diem E, Wittels W, Konrad K. Related Articles, Links

[Local therapy of extensive severe burns: an illustrative review (author's

transl)]
Wien Klin Wochenschr. 1975 Oct 17;87(19):621-7. German.
PMID: 775796 [PubMed - indexed for MEDLINE]

☐ **86:** Ferchmin PA, Bennett EL. Related Articles, Links

Direct contact with enriched environment is required to alter cerebral weights in rats.
J Comp Physiol Psychol. 1975 Jan;88(1):360-7.
PMID: 1120811 [PubMed - indexed for MEDLINE]

☐ **87:** Sirota MN. Related Articles, Links

[Inflatable polyethylene dilator-sound with a nylon mesh cover for dilating the esophagus and for the local use of corticosteroids and antibiotics in the treatment of severe chemical burns of the esophagus]
Zh Ushn Nos Gorl Bolezn. 1973 Nov-Dec;33(6):86-7. Russian. No abstract available.
PMID: 4786992 [PubMed - indexed for MEDLINE]

Display Summary Show: 500 Sort Send to Text

Nov 23 2004 06:26:50

About Entrez

Text Version

Entrez PubMed
Overview
Help | FAQ
Tutorial
New/Noteworthy
E-Utilities

PubMed Services
Journals Database
MeSH Database
Single Citation Matcher
Batch Citation Matcher
Clinical Queries
LinkOut
Cubby

Related Resources
Order Documents
NLM Catalog
NLM Gateway
TOXNET
Consumer Health
Clinical Alerts
ClinicalTrials.gov
PubMed Central

☐ **1:** J Neurophysiol. 1997 Aug;78(2):1135-43.

Related Articles, Links

N-methyl-D-aspartate evokes rapid net depolymerization of filamentous actin in cultured rat cerebellar granule cells.

Shorte SL.

Institut National de la Sante et de la Recherche Medicale (INSERM), Unite 29, Laboratoire de Neurobiologie et Physiopathologie du Developpement, Hopital de Port-Royal, Paris, France.

Filamentous actin (F-actin) was measured in cultured rat cerebellum granule neurons with the use of fluorescently labeled phallotoxin as a site-specific probe for F-actin, and fluorescence microscopy. The averaged apparent intensity of soma-associated F-actin-derived fluorescence (F(app)) was measured from fixed cells after incubation in either 1) normal Krebs solution containing 2 mM extracellular calcium ([Ca2+]ex) or 2) normal Krebs solution plus N-methyl-D-aspartate (NMDA) for 2 min immediately before fixation. NMDA (10, 50, and 100 microM) decreased F(app) to 63 +/- 5% (mean +/- SE), 53 +/- 4%, and 47 +/- 2%, respectively, of that measured from control cells. This effect was mimicked by treatment of cells with ionomycin. The ability of NMDA to reduce the F(app) in the presence of [Ca2+]ex was abolished when cells were maintained in [Ca2+]ex-free medium. Cells first treated with NMDA for 2 min and then left in normal medium for 30 min before fixation gave F(app) fluorescence similar to control values (91 +/- 12%). However, if the F-actin polymerization inhibitor cytochalasin D was added to cells immediately after NMDA was removed, the F(app) did not recover with time (36 +/- 3%). Cells treated for 30 min with cytochalasin D alone showed a small reduction in staining (approximately 20%). It is concluded that the actin polymerization state of rat cerebellar granule neurons is sensitive to changes in intracellular calcium, and that NMDA receptor activation evokes an initial rapid depolymerization of F-actin.

PMID: 9307140 [PubMed - indexed for MEDLINE]

Items 1 - 31 of 31 One page

1: Ohia SE, Opere CA, LeDay AM, Bagchi M, Bagchi D, Stohs SJ. Related Articles, Links

Safety and mechanism of appetite suppression by a novel hydroxycitric acid extract (HCA-SX).
Mol Cell Biochem. 2002 Sep;238(1-2):89-103.
PMID: 12349913 [PubMed - indexed for MEDLINE]

2: Harvey BJ, Higgins M. Related Articles, Links

Nongenomic effects of aldosterone on Ca2+ in M-1 cortical collecting duct cells.
Kidney Int. 2000 Apr;57(4):1395-403.
PMID: 10760073 [PubMed - indexed for MEDLINE]

3: Zhan RZ, Fujiwara N, Endoh H, Yamakura T, Taga K, Fukuda S, Shimoji K. Related Articles, Links

Thiopental inhibits increases in [Ca2+]i induced by membrane depolarization, NMDA receptor activation, and ischemia in rat hippocampal and cortical slices.
Anesthesiology. 1998 Aug;89(2):456-66.
PMID: 9710405 [PubMed - indexed for MEDLINE]

4: Clifton VL, Read MA, Boura AL, Robinson PJ, Smith R. Related Articles, Links

Adrenocorticotropin causes vasodilatation in the human fetal-placental circulation.
J Clin Endocrinol Metab. 1996 Apr;81(4):1406-10.
PMID: 8636342 [PubMed - indexed for MEDLINE]

5: Vannucchi MG, Pepeu G. Related Articles, Links

Muscarinic receptor modulation of acetylcholine release from rat cerebral cortex and hippocampus.
Neurosci Lett. 1995 Apr 28;190(1):53-6.
PMID: 7624055 [PubMed - indexed for MEDLINE]

6: Fink K, Zentner J, Gothert M. Related Articles, Links

Increased GABA release in the human brain cortex as a potential pathogenetic basis of hyperosmolar diabetic coma.
J Neurochem. 1994 Apr;62(4):1476-81.
PMID: 8133276 [PubMed - indexed for MEDLINE]

7: Carla V, Moroni F. Related Articles, Links

General anaesthetics inhibit the responses induced by glutamate receptor agonists in the mouse cortex.
Neurosci Lett. 1992 Oct 26;146(1):21-4.
PMID: 1282227 [PubMed - indexed for MEDLINE]

8: Takei M, Kawano Y, Yamada K. Related Articles, Links

Phosphorus nuclear magnetic resonance studies on the calcium-dependent

energy metabolism of rat cerebrum under conditions of increased potassium in vitro.
Neurosci Res. 1992 Jan;12(5):596-605.
PMID: 1313954 [PubMed - indexed for MEDLINE]

☐ 9: Pedata F, Pazzagli M, Tilli S, Pepeu G. Related Articles, Links

Regional differences in the electrically stimulated release of endogenous and radioactive adenosine and purine derivatives from rat brain slices.
Naunyn Schmiedebergs Arch Pharmacol. 1990 Oct;342(4):447-53.
PMID: 2255336 [PubMed - indexed for MEDLINE]

☐ 10: Vannucchi MG, Casamenti F, Pepeu G. Related Articles, Links

Decrease of acetylcholine release from cortical slices in aged rats: investigations into its reversal by phosphatidylserine.
J Neurochem. 1990 Sep;55(3):819-25.
PMID: 2384755 [PubMed - indexed for MEDLINE]

☐ 11: Siniscalchi A, Bertelli MG, Bianchi C, Beani L. Related Articles, Links

Effect of opioid antagonists on acetylcholine release from guinea-pig brain slices: influence of peptidase inhibition.
Pharmacol Res. 1990 Jul-Aug;22(4):493-501.
PMID: 2402481 [PubMed - indexed for MEDLINE]

☐ 12: Kerr DI, Ong J, Johnston GA, Berthelot P, Debaert M, Vaccher C. Related Articles, Links

Benzofuran analogues of baclofen: a new class of central and peripheral GABAB-receptor antagonists.
Eur J Pharmacol. 1989 May 19;164(2):361-4.
PMID: 2547638 [PubMed - indexed for MEDLINE]

☐ 13: Middlemiss DN, Bremer ME, Smith SM. Related Articles, Links

A pharmacological analysis of the 5-HT receptor mediating inhibition of 5-HT release in the guinea-pig frontal cortex.
Eur J Pharmacol. 1988 Nov 15;157(1):101-7.
PMID: 3234493 [PubMed - indexed for MEDLINE]

☐ 14: Boakes RJ, Burns BD, Webb AC. Related Articles, Links

Transmission of burst responses through slices of rat cerebral cortex.
J Physiol. 1988 Oct;404:467-78.
PMID: 2855350 [PubMed - indexed for MEDLINE]

☐ 15: Kerr DI, Ong J, Johnston GA, Abbenante J, Prager RH. Related Articles, Links

2-Hydroxy-saclofen: an improved antagonist at central and peripheral GABAB receptors.
Neurosci Lett. 1988 Sep 23;92(1):92-6.
PMID: 2847092 [PubMed - indexed for MEDLINE]

☐ 16: Pedata F, Magnani M, Pepeu G. Related Articles, Links

Muscarinic modulation of purine release from electrically stimulated rat cortical slices.
J Neurochem. 1988 Apr;50(4):1074-9.
PMID: 3346668 [PubMed - indexed for MEDLINE]

☐ 17: Siniscalchi A, Cristofori P, Veratti E. Related Articles, Links

Influence of N-allyl-normetazocine on acetylcholine release from brain slices: involvement of muscarinic receptors.
Naunyn Schmiedebergs Arch Pharmacol. 1987 Oct;336(4):425-9.
PMID: 3431597 [PubMed - indexed for MEDLINE]

☐ **18:** Vannucchi MG, Pepeu G. Related Articles, Links

Effect of phosphatidylserine on acetylcholine release and content in cortical slices from aging rats.
Neurobiol Aging. 1987 Sep-Oct;8(5):403-7.
PMID: 3683721 [PubMed - indexed for MEDLINE]

☐ **19:** Chen CC, Lin-Shiau SY. Related Articles, Links

Decreased Na+-K+-ATPase activity and [3H]ouabain binding sites in various tissues of spontaneously hypertensive rats.
Eur J Pharmacol. 1986 Apr 2;122(3):311-9.
PMID: 3011446 [PubMed - indexed for MEDLINE]

☐ **20:** Pedata F, Giovannelli L, Spignoli G, Giovannini MG, Pepeu G. Related Articles, Links

Phosphatidylserine increases acetylcholine release from cortical slices in aged rats.
Neurobiol Aging. 1985 Winter;6(4):337-9.
PMID: 4088427 [PubMed - indexed for MEDLINE]

☐ **21:** Hill DR. Related Articles, Links

GABAB receptor modulation of adenylate cyclase activity in rat brain slices.
Br J Pharmacol. 1985 Jan;84(1):249-57.
PMID: 2579700 [PubMed - indexed for MEDLINE]

☐ **22:** Pedata F, Pepeu G, Spignoli G. Related Articles, Links

Biphasic effect of methylxanthines on acetylcholine release from electrically-stimulated brain slices.
Br J Pharmacol. 1984 Sep;83(1):69-73.
PMID: 6487897 [PubMed - indexed for MEDLINE]

☐ **23:** Middlemiss DN. Related Articles, Links

8-Hydroxy-2-(di-n-propylamino) tetralin is devoid of activity at the 5-hydroxytryptamine autoreceptor in rat brain. Implications for the proposed link between the autoreceptor and the [3H] 5-HT recognition site.
Naunyn Schmiedebergs Arch Pharmacol. 1984 Aug;327(1):18-22.
PMID: 6238235 [PubMed - indexed for MEDLINE]

☐ **24:** Diz DI, Baer PG, Nasjletti A. Related Articles, Links

Angiotensin II-induced hypertension in the rat. Effects on the plasma concentration, renal excretion, and tissue release of prostaglandins.
J Clin Invest. 1983 Aug;72(2):466-77.
PMID: 6575977 [PubMed - indexed for MEDLINE]

☐ **25:** Pedata F, Antonelli T, Lambertini L, Beani L, Pepeu G. Related Articles, Links

Effect of adenosine, adenosine triphosphate, adenosine deaminase, dipyridamole and aminophylline on acetylcholine release from electrically-stimulated brain slices.
Neuropharmacology. 1983 May;22(5):609-14.
PMID: 6877538 [PubMed - indexed for MEDLINE]

☐ **26:** Pedata F, Slavikova J, Kotas A, Pepeu G. Related Articles, Links

Acetylcholine release from rat cortical slices during postnatal development and aging.
Neurobiol Aging. 1983 Spring;4(1):31-5.
PMID: 6877485 [PubMed - indexed for MEDLINE]

Beani L, Bianchi C, Siniscalchi A. Related Articles, Links

☐ 27:

The effect of naloxone on opioid-induced inhibition and facilitation of acetylcholine release in brain slices.
Br J Pharmacol. 1982 Jul;76(3):393-401.
PMID: 7104516 [PubMed - indexed for MEDLINE]

☐ 28: Spokas EG, Wong PY, McGiff JC. Related Articles, Links

Prostaglandin-related renin release from rabbit renal cortical slices.
Hypertension. 1982 May-Jun;4(3 Pt 2):96-100.
PMID: 7040243 [PubMed - indexed for MEDLINE]

☐ 29: Bianchi C, Tanganelli S, Marzola G, Beani L. Related Articles, Links

GABA induced changes in acetylcholine release from slices of guinea-pig brain.
Naunyn Schmiedebergs Arch Pharmacol. 1982 Mar;318(4):253-8.
PMID: 6281665 [PubMed - indexed for MEDLINE]

☐ 30: Casamenti F, Mantovani P, Pepeu G. Related Articles, Links

Stimulation of acetylcholine output from brain slices caused by the ionophores BrX-537A and A23187.
Br J Pharmacol. 1978 Jun;63(2):259-65.
PMID: 96898 [PubMed - indexed for MEDLINE]

☐ 31: Hadhazy P, Szerb JC. Related Articles, Links

The effect of cholinergic drugs on [3H]acetylcholine release from slices of rat hippocampus, striatum and cortex.
Brain Res. 1977 Mar 11;123(2):311-22.
PMID: 843927 [PubMed - indexed for MEDLINE]

Display Summary Show: 500 Sort Send to Text

Nov 23 2004 06:26:50

About Entrez

Text Version

Entrez PubMed
Overview
Help | FAQ
Tutorial
New/Noteworthy
E-Utilities

PubMed Services
Journals Database
MeSH Database
Single Citation Matcher
Batch Citation Matcher
Clinical Queries
LinkOut
Cubby

Related Resources
Order Documents
NLM Catalog
NLM Gateway
TOXNET
Consumer Health
Clinical Alerts
ClinicalTrials.gov
PubMed Central

Items 1 - 4 of 4 One page

1: Arata A, Ito M. Related Articles, Links

Purkinje cell functions in the in vitro cerebellum isolated from neonatal rats in a block with the pons and medulla.
Neurosci Res. 2004 Nov;50(3):361-7.
PMID: 15488299 [PubMed - in process]

2: Shorte SL. Related Articles, Links

N-methyl-D-aspartate evokes rapid net depolymerization of filamentous actin in cultured rat cerebellar granule cells.
J Neurophysiol. 1997 Aug;78(2):1135-43.
PMID: 9307140 [PubMed - indexed for MEDLINE]

3: Kato K, Goto M, Fukuda H. Related Articles, Links

Regulation by divalent cations of 3H-baclofen binding to GABAB sites in rat cerebellar membranes.
Life Sci. 1983 Feb 21;32(8):879-87.
PMID: 6827916 [PubMed - indexed for MEDLINE]

4: Garthwaite J, Woodhams PL, Collins MJ, Balazs R. Related Articles, Links

A morphological study of incubated slices of rat cerebellum in relation to postnatal age.
Dev Neurosci. 1980;3(2):90-9.
PMID: 7418633 [PubMed - indexed for MEDLINE]

About Entrez

Text Version

Entrez PubMed
Overview
Help | FAQ
Tutorial
New/Noteworthy
E-Utilities

PubMed Services
Journals Database
MeSH Database
Single Citation Matcher
Batch Citation Matcher
Clinical Queries
LinkOut
Cubby

Related Resources
Order Documents
NLM Catalog
NLM Gateway
TOXNET
Consumer Health
Clinical Alerts
ClinicalTrials.gov
PubMed Central

☐ 1: Neurosci Lett. 1995 Apr 28;190(1):53-6.

Related Articles, Links

Muscarinic receptor modulation of acetylcholine release from rat cerebral cortex and hippocampus.

Vannucchi MG, Pepeu G.

Department of Preclinical and Clinical Pharmacology, University of Florence, Italy.

An attempt to identify the muscarinic receptor subtypes involved in presynaptic modulation of acetylcholine (ACh) release from cortical and hippocampal slices was made by means of several muscarinic antagonists. Cortical and hippocampal slices prepared from adult rats were superfused with Krebs solution containing physostigmine; ACh content of the superfusate at rest and after electrical stimulation (1 Hz) was quantified by high performance liquid chromatography. The antagonists were added to the Krebs at the concentration of 1 microM. ACh release at rest was enhanced only in the cortex by (+/-)-5,11-dihydro-11-([(2-[2-[(dipropylamino)methyl]-1-piperidinyl)ethyl)amino]carbonyl)-6H-pyrido[2,3-b](1,4)- benzodiazepine-6-one (AFDX384), an M2/M4 selective antagonist. The evoked ACh release from the cerebral cortex was significantly increased by AFDX384, methoctramine, pirenzepine, M2/M4, M2 and M1 selective antagonists, respectively, and scopolamine. This finding suggests that M1, M2 and M4 presynaptic receptor subtypes could regulate evoked ACh release in the cortex. In hippocampal slices, the evoked ACh release was enhanced by AFDX384, pirenzepine and scopolamine but not by methoctramine. In this region ACh release seems therefore regulated only by M1 and M4 receptor subtypes. The M3 antagonist (+/-)-p-fluorohexahydro-sila-difenidol hydrochloride did not affect ACh release.

PMID: 7624055 [PubMed - indexed for MEDLINE]

1: Brain Res. 1984 Oct 8;311(1):87-96.

Electrophysiological properties of in vitro hippocampal pyramidal cells from normal and staggerer mutant mice.

Fournier E, Crepel F.

Electrophysiological properties of intracellularly recorded CA1 pyramidal cells from normal and staggerer mice were compared by using hippocampal slices maintained in vitro. In staggerer mice, the passive membrane properties of these neurons as well as their synaptic potentials elicited by stratum radiatum stimulation were very similar to those observed in normal mice. In control and mutant mice and in standard Krebs solution, CA1 pyramidal cells mainly fired tetrodoxin (TTX)-sensitive fast spikes but could also generate slow spikes. In both groups, replacement of calcium (Ca) by barium (Ba) or introduction of TEA in the bathing medium prolonged the repolarization of the fast spikes and suppressed the brief spike afterhyperpolarization which normally followed them, thus suggesting that both events involve fast potassium conductances. Furthermore, in both groups of animals, TEA and Ba enhanced the slow spikes and induced the appearance of prolonged depolarizations. These slow events were TTX-resistant and were abolished by the Ca channel blockers cadmium or cobalt, thus suggesting that they are Ca-dependent. On the whole, the present results indicate that the staggerer mutation which yields marked abnormalities in the bioelectrical properties of cerebellar Purkinje cells has no such effect on CA1 pyramidal cells.

PMID: 6488047 [PubMed - indexed for MEDLINE]

```
Welcome to STN International!  Enter x:x
* * * * * * * * * *   Welcome to STN International   * * * * * * * * * *
* * * * * * * * * * * * * STN  Columbus  * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 17:14:06 ON 02 DEC 2004

=> file BIOSCIENCE
FILE 'DRUGMONOG' ACCESS NOT AUTHORIZED
FILE 'ADISCTI' ENTERED AT 17:14:15 ON 02 DEC 2004
COPYRIGHT (C) 2004 Adis Data Information BV

FILE 'ADISINSIGHT' ENTERED AT 17:14:15 ON 02 DEC 2004
COPYRIGHT (C) 2004 Adis Data Information BV

FILE 'ADISNEWS' ENTERED AT 17:14:15 ON 02 DEC 2004
COPYRIGHT (C) 2004 Adis Data Information BV

FILE 'AGRICOLA' ENTERED AT 17:14:15 ON 02 DEC 2004

FILE 'ANABSTR' ENTERED AT 17:14:15 ON 02 DEC 2004
COPYRIGHT (c) 2004 THE ROYAL SOCIETY OF CHEMISTRY (RSC)

FILE 'ANTE' ENTERED AT 17:14:15 ON 02 DEC 2004
COPYRIGHT (C) 2004 Cambridge Scientific Abstracts (CSA)

FILE 'AQUALINE' ENTERED AT 17:14:15 ON 02 DEC 2004
COPYRIGHT (C) 2004 Cambridge Scientific Abstracts (CSA)

FILE 'AQUASCI' ENTERED AT 17:14:15 ON 02 DEC 2004
COPYRIGHT 2004 FAO (On behalf of the ASFA Advisory Board). All rights reserved.

FILE 'BIOBUSINESS' ENTERED AT 17:14:15 ON 02 DEC 2004
Copyright (c) 1998 The Thomson Corporation.

FILE 'BIOCOMMERCE' ENTERED AT 17:14:15 ON 02 DEC 2004
COPYRIGHT (C) 2004 BioCommerce Data Ltd. Richmond Surrey, United Kingdom. All r:

FILE 'BIOENG' ENTERED AT 17:14:15 ON 02 DEC 2004
COPYRIGHT (C) 2004 Cambridge Scientific Abstracts (CSA)

FILE 'BIOSIS' ENTERED AT 17:14:15 ON 02 DEC 2004
Copyright (c) 2004 The Thomson Corporation.

FILE 'BIOTECHABS' ACCESS NOT AUTHORIZED

FILE 'BIOTECHDS' ENTERED AT 17:14:15 ON 02 DEC 2004
COPYRIGHT (C) 2004 THE THOMSON CORPORATION

FILE 'BIOTECHNO' ENTERED AT 17:14:15 ON 02 DEC 2004
COPYRIGHT (C) 2004 Elsevier Science B.V., Amsterdam. All rights reserved.

FILE 'CABA' ENTERED AT 17:14:15 ON 02 DEC 2004
COPYRIGHT (C) 2004 CAB INTERNATIONAL (CABI)

FILE 'CANCERLIT' ENTERED AT 17:14:15 ON 02 DEC 2004

FILE 'CAPLUS' ENTERED AT 17:14:15 ON 02 DEC 2004
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'CEABA-VTB' ENTERED AT 17:14:15 ON 02 DEC 2004
COPYRIGHT (c) 2004 DECHEMA eV

FILE 'CEN' ENTERED AT 17:14:15 ON 02 DEC 2004
COPYRIGHT (C) 2001 American Chemical Society (ACS)

FILE 'CIN' ENTERED AT 17:14:15 ON 02 DEC 2004
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2004 American Chemical Society (ACS)

FILE 'CONFSCI' ENTERED AT 17:14:15 ON 02 DEC 2004
COPYRIGHT (C) 2004 Cambridge Scientific Abstracts (CSA)
```

COPYRIGHT (C) 2004 THE THOMSON CORPORATION

FILE 'CROPU' ENTERED AT 17:14:15 ON 02 DEC 2004
COPYRIGHT (C) 2004 THE THOMSON CORPORATION

FILE 'DDFB' ENTERED AT 17:14:15 ON 02 DEC 2004
COPYRIGHT (C) 2004 THE THOMSON CORPORATION

FILE 'DDFU' ACCESS NOT AUTHORIZED

FILE 'DGENE' ENTERED AT 17:14:15 ON 02 DEC 2004
COPYRIGHT (C) 2004 THE THOMSON CORPORATION

FILE 'DISSABS' ENTERED AT 17:14:15 ON 02 DEC 2004
COPYRIGHT (C) 2004 ProQuest Information and Learning Company; All Rights Reserve

FILE 'DRUGB' ENTERED AT 17:14:15 ON 02 DEC 2004
COPYRIGHT (C) 2004 THE THOMSON CORPORATION

FILE 'DRUGMONOG2' ENTERED AT 17:14:15 ON 02 DEC 2004
COPYRIGHT (C) 2004 IMSWORLD Publications Ltd

FILE 'DRUGU' ENTERED AT 17:14:15 ON 02 DEC 2004
COPYRIGHT (C) 2004 THE THOMSON CORPORATION

FILE 'EMBAL' ENTERED AT 17:14:15 ON 02 DEC 2004
COPYRIGHT (C) 2004 Elsevier Inc. All rights reserved.

FILE 'EMBASE' ENTERED AT 17:14:15 ON 02 DEC 2004
COPYRIGHT (C) 2004 Elsevier Inc. All rights reserved.

FILE 'ESBIOBASE' ENTERED AT 17:14:15 ON 02 DEC 2004
COPYRIGHT (C) 2004 Elsevier Science B.V., Amsterdam. All rights reserved.

FILE 'FEDRIP' ENTERED AT 17:14:15 ON 02 DEC 2004

FILE 'FOMAD' ENTERED AT 17:14:15 ON 02 DEC 2004
COPYRIGHT (C) 2004 Leatherhead Food Research Association

FILE 'FOREGE' ENTERED AT 17:14:15 ON 02 DEC 2004
COPYRIGHT (C) 2004 Leatherhead Food Research Association

FILE 'FROSTI' ENTERED AT 17:14:15 ON 02 DEC 2004
COPYRIGHT (C) 2004 Leatherhead Food Research Association

FILE 'FSTA' ENTERED AT 17:14:15 ON 02 DEC 2004
COPYRIGHT (C) 2004 International Food Information Service

FILE 'GENBANK' ENTERED AT 17:14:15 ON 02 DEC 2004

FILE 'HEALSAFE' ENTERED AT 17:14:15 ON 02 DEC 2004
COPYRIGHT (C) 2004 Cambridge Scientific Abstracts (CSA)

FILE 'IFIPAT' ENTERED AT 17:14:15 ON 02 DEC 2004
COPYRIGHT (C) 2004 IFI CLAIMS(R) Patent Services (IFI)

FILE 'IMSDRUGNEWS' ENTERED AT 17:14:15 ON 02 DEC 2004
COPYRIGHT (C) 2004 IMSWORLD Publications Ltd

FILE 'IMSPRODUCT' ENTERED AT 17:14:15 ON 02 DEC 2004
COPYRIGHT (C) 2004 IMSWORLD Publications Ltd

FILE 'IMSRESEARCH' ENTERED AT 17:14:15 ON 02 DEC 2004
COPYRIGHT (C) 2004 IMSWORLD Publications Ltd

FILE 'JICST-EPLUS' ENTERED AT 17:14:15 ON 02 DEC 2004
COPYRIGHT (C) 2004 Japan Science and Technology Agency (JST)

FILE 'KOSMET' ENTERED AT 17:14:15 ON 02 DEC 2004
COPYRIGHT (C) 2004 International Federation of the Societies of Cosmetics Chemi

FILE 'LIFESCI' ENTERED AT 17:14:15 ON 02 DEC 2004
COPYRIGHT (C) 2004 Cambridge Scientific Abstracts (CSA)

FILE 'MEDICONF' ENTERED AT 17:14:15 ON 02 DEC 2004

FILE 'MEDLINE' ENTERED AT 17:14:15 ON 02 DEC 2004

FILE 'NIOSHTIC' ENTERED AT 17:14:15 ON 02 DEC 2004
COPYRIGHT (C) 2004 U.S. Secretary of Commerce on Behalf of the U.S. Government

FILE 'NTIS' ENTERED AT 17:14:15 ON 02 DEC 2004
Compiled and distributed by the NTIS, U.S. Department of Commerce.
It contains copyrighted material.
All rights reserved. (2004)

FILE 'NUTRACEUT' ENTERED AT 17:14:15 ON 02 DEC 2004
Copyright 2004 (c) MARKETLETTER Publications Ltd. All rights reserved.

FILE 'OCEAN' ENTERED AT 17:14:15 ON 02 DEC 2004
COPYRIGHT (C) 2004 Cambridge Scientific Abstracts (CSA)

FILE 'PASCAL' ENTERED AT 17:14:15 ON 02 DEC 2004
Any reproduction or dissemination in part or in full,
by means of any process and on any support whatsoever
is prohibited without the prior written agreement of INIST-CNRS.
COPYRIGHT (C) 2004 INIST-CNRS. All rights reserved.

FILE 'PCTGEN' ENTERED AT 17:14:15 ON 02 DEC 2004
COPYRIGHT (C) 2004 WIPO

FILE 'PHAR' ENTERED AT 17:14:15 ON 02 DEC 2004
COPYRIGHT (C) 2004 PJB Publications Ltd. (PJB)

FILE 'PHARMAML' ENTERED AT 17:14:15 ON 02 DEC 2004
Copyright 2004 (c) MARKETLETTER Publications Ltd. All rights reserved.

FILE 'PHIC' ENTERED AT 17:14:15 ON 02 DEC 2004
COPYRIGHT (C) 2004 PJB Publications Ltd. (PJB)

FILE 'PHIN' ENTERED AT 17:14:15 ON 02 DEC 2004
COPYRIGHT (C) 2004 PJB Publications Ltd. (PJB)

FILE 'PROMT' ENTERED AT 17:14:15 ON 02 DEC 2004
COPYRIGHT (C) 2004 Gale Group. All rights reserved.

FILE 'PROUSDDR' ENTERED AT 17:14:15 ON 02 DEC 2004
COPYRIGHT (C) 2004 Prous Science

FILE 'PS' ENTERED AT 17:14:15 ON 02 DEC 2004
COPYRIGHT (C) 2004 Thieme on STN

FILE 'RDISCLOSURE' ENTERED AT 17:14:15 ON 02 DEC 2004
COPYRIGHT (C) 2004 Kenneth Mason Publications Ltd.

FILE 'SCISEARCH' ENTERED AT 17:14:15 ON 02 DEC 2004
Copyright (c) 2004 The Thomson Corporation.

FILE 'SYNTHLINE' ENTERED AT 17:14:15 ON 02 DEC 2004
COPYRIGHT (C) 2004 Prous Science

FILE 'TOXCENTER' ENTERED AT 17:14:15 ON 02 DEC 2004
COPYRIGHT (C) 2004 ACS

FILE 'USPATFULL' ENTERED AT 17:14:15 ON 02 DEC 2004
CA INDEXING COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'USPAT2' ENTERED AT 17:14:15 ON 02 DEC 2004
CA INDEXING COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'VETB' ENTERED AT 17:14:15 ON 02 DEC 2004
COPYRIGHT (C) 2004 THE THOMSON CORPORATION

FILE 'VETU' ENTERED AT 17:14:15 ON 02 DEC 2004
COPYRIGHT (C) 2004 THE THOMSON CORPORATION

FILE 'WATER' ENTERED AT 17:14:15 ON 02 DEC 2004
COPYRIGHT (C) 2004 Cambridge Scientific Abstracts (CSA)

FILE 'WPIDS' ENTERED AT 17:14:15 ON 02 DEC 2004

```
FILE 'WPIFV' ENTERED AT 17:14:15 ON 02 DEC 2004
COPYRIGHT (C) 2004 THOMSON DERWENT

FILE 'WPINDEX' ACCESS NOT AUTHORIZED

=> s grid OR sieve OR mesh
  22 FILES SEARCHED...
  50 FILES SEARCHED...
L1      2885366 GRID OR SIEVE OR MESH

=> S cortex OR cerebellum
  29 FILES SEARCHED...
  56 FILES SEARCHED...
L2      1869897 CORTEX OR CEREBELLUM

=> S Krebs solution
  29 FILES SEARCHED...
  54 FILES SEARCHED...
L3        11629 KREBS SOLUTION

=> S L1 AND L2 AND L3
  45 FILES SEARCHED...
L4           98 L1 AND L2 AND L3

=> DUP REM L4
DUPLICATE IS NOT AVAILABLE IN 'ADISINSIGHT, ADISNEWS, BIOCOMMERCE, DGENE,
DRUGMONOG2, FEDRIP, FOREGE, GENBANK, IMSPRODUCT, IMSRESEARCH, KOSMET,
MEDICONF, NUTRACEUT, PCTGEN, PHAR, PHARMAML, PROUSDDR, RDISCLOSURE, SYNTHLINE'.
ANSWERS FROM THESE FILES WILL BE CONSIDERED UNIQUE
PROCESSING COMPLETED FOR L4
L5            95 DUP REM L4 (3 DUPLICATES REMOVED)

=> D L5 1-95

L5   ANSWER 1 OF 95  USPATFULL on STN
AN      2004:255163  USPATFULL
TI      Compounds for the treatment of ischemia
IN      DeNinno, Michael P., Gales Ferry, CT, UNITED STATES
        Masamune, Hiroko, Noank, CT, UNITED STATES
        Scott, Robert W., Mystic, CT, UNITED STATES
PI      US 2004198693       A1   20041007
AI      US 2004-822411      A1   20040412 (10)
RLI     Continuation of Ser. No. US 2000-640530, filed on 17 Aug 2000, PENDING
PRAI    US 1999-156828P      19990930 (60)
DT      Utility
FS      APPLICATION
LN.CNT 7516
INCL    INCLM: 514/046.000
        INCLS: 514/303.000; 544/277.000; 546/119.000; 514/263.230; 536/027.300;
               514/263.400
NCL     NCLM:  514/046.000
        NCLS:  514/303.000; 544/277.000; 546/119.000; 514/263.230; 536/027.300;
               514/263.400
IC      [7]
        ICM: C07H019-16
        ICS: C07D487-14; C07D473-14; A61K031-52
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5   ANSWER 2 OF 95  USPATFULL on STN
AN      2004:222026  USPATFULL
TI      Nicotinamide acids, amides, and their mimetics active as inhibitors of
        PDE4 isozymes
IN      Magee, Thomas V., Mystic, CT, UNITED STATES
        Marfat, Anthony, Mystic, CT, UNITED STATES
        Chambers, Robert J., Mystic, CT, UNITED STATES
PA      Pfizer Inc (U.S. corporation)
PI      US 2004171798       A1   20040902
AI      US 2004-781062      A1   20040217 (10)
RLI     Continuation of Ser. No. US 2002-62811, filed on 31 Jan 2002, ABANDONED
PRAI    US 2001-265240P      20010131 (60)
DT      Utility
FS      APPLICATION
LN.CNT 7725
INCL    INCLM: 530/331.000
```

NCL NCLM: 530/331.000
NCLS: 546/315.000
IC [7]
ICM: C07K005-04
ICS: C07D213-46
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 3 OF 95 USPATFULL on STN
AN 2004:209882 USPATFULL
TI Combination treatment for alcoholism and alcohol dependence
IN Howard, Harry R., JR., Bristol, CT, UNITED STATES
PA Pfizer Inc (U.S. corporation)
PI US 2004162316 A1 20040819
AI US 2004-783196 A1 20040220 (10)
RLI Continuation of Ser. No. US 2002-153379, filed on 22 May 2002, PENDING
PRAI US 2001-293088P 20010523 (60)
DT Utility
FS APPLICATION
LN.CNT 2247
INCL INCLM: 514/317.000
INCLS: 514/649.000
NCL NCLM: 514/317.000
NCLS: 514/649.000
IC [7]
ICM: A61K031-445
ICS: A61K031-137
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 4 OF 95 USPATFULL on STN
AN 2004:204037 USPATFULL
TI Method for increasing serotonin levels in a person by administration of a composition incorporating(-)hydroxycitric acid, and related compositions thereof
IN Ohia, Sunny E., Omaha, NE, UNITED STATES
Preuss, Harry G., Fairfax Station, VA, UNITED STATES
Bagchi, Debasis, Concord, CA, UNITED STATES
PI US 2004157929 A1 20040812
AI US 2004-473557 A1 20040406 (10)
WO 2002-US10368 20020401
DT Utility
FS APPLICATION
LN.CNT 511
INCL INCLM: 514/574.000
NCL NCLM: 514/574.000
IC [7]
ICM: A61K031-19
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 5 OF 95 USPATFULL on STN
AN 2004:101801 USPATFULL
TI Sorbitol dehydrogenase inhibitors
IN Chu-Moyer, Margaret Y., Old Lyme, CT, UNITED STATES
Murry, Jerry A., Mystic, CT, UNITED STATES
Mylari, Banavara L., Waterford, CT, UNITED STATES
Zembrowski, William J., Oakdale, CT, UNITED STATES
PI US 2004077671 A1 20040422
AI US 2003-645401 A1 20030821 (10)
RLI Division of Ser. No. US 2003-384424, filed on 10 Mar 2003, GRANTED, Pat. No. US 6660740 Division of Ser. No. US 2002-87869, filed on 28 Feb 2002, GRANTED, Pat. No. US 6602875 Division of Ser. No. US 2000-538039, filed on 29 Mar 2000, GRANTED, Pat. No. US 6414149
PRAI US 1999-127437P 19990401 (60)
DT Utility
FS APPLICATION
LN.CNT 11272
INCL INCLM: 514/275.000
INCLS: 544/331.000; 544/230.000
NCL NCLM: 514/275.000
NCLS: 544/331.000; 544/230.000
IC [7]
ICM: A61K031-506
ICS: C07D043-02
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 6 OF 95 USPATFULL on STN

TI Monoamine reuptake inhibitors for treatment of CNS disorders
IN Howard, Harry R., JR., Bristol, CT, UNITED STATES
Schmidt, Christopher J., Old Lyme, CT, UNITED STATES
Seeger, Thomas F., Mystic, CT, UNITED STATES
Elliott, Mark L., Canterbury, CT, UNITED STATES
PA Pfizer Inc (U.S. corporation)
PI US 2004048856 A1 20040311
AI US 2003-655404 A1 20030904 (10)
RLI Division of Ser. No. US 2001-845992, filed on 30 Apr 2001, GRANTED, Pat. No. US 6677378 Continuation-in-part of Ser. No. US 529207, ABANDONED A 371 of International Ser. No. WO 2000-IB108, filed on 2 Feb 2000, UNKNOWN
PRAI US 1999-121313P 19990223 (60)
DT Utility
FS APPLICATION
LN.CNT 2029
INCL INCLM: 514/227.500
INCLS: 514/650.000; 514/231.200; 514/252.120; 514/317.000; 544/059.000; 544/170.000; 544/399.000; 546/236.000; 564/365.000
NCL NCLM: 514/227.500
NCLS: 514/650.000; 514/231.200; 514/252.120; 514/317.000; 544/059.000; 544/170.000; 544/399.000; 546/236.000; 564/365.000
IC [7]
ICM: A61K031-54
ICS: A61K031-537; A61K031-495; C07D279-12; C07D265-32; A61K031-445; A61K031-137
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 7 OF 95 USPATFULL on STN
AN 2004:257013 USPATFULL
TI Compounds for the treatment of ischemia
IN DeNinno, Michael P., Gales Ferry, CT, United States
Masamune, Hiroko, Noank, CT, United States
Scott, Robert W., Mystic, CT, United States
PA Pfizer, Inc., New York, NY, United States (U.S. corporation)
PI US 6803457 B1 20041012
AI US 2000-640530 20000817 (9)
PRAI US 1999-156828P 19990930 (60)
DT Utility
FS GRANTED
LN.CNT 6557
INCL INCLM: 536/027.210
INCLS: 536/027.220; 536/027.230; 536/027.630; 514/046.000
NCL NCLM: 536/027.210
NCLS: 536/027.220; 536/027.230; 536/027.630; 514/046.000
IC [7]
ICM: C07H019-16
EXF 536/27.21; 536/27.22; 536/27.23; 536/27.63; 536/27.11; 514/46
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 8 OF 95 USPATFULL on STN DUPLICATE 1
AN 2003:93818 USPATFULL
TI Sorbitol dehydrogenase inhibitors
IN Chu-Moyer, Margaret Y., Old Lyme, CT, UNITED STATES
Murry, Jerry A, Mystic, CT, UNITED STATES
Mylari, Banavara L, Waterford, CT, UNITED STATES
Zembrowski, William J, Oakdale, CT, UNITED STATES
PI US 2003065179 A1 20030403
US 6602875 B2 20030805
AI US 2002-87869 A1 20020228 (10)
RLI Division of Ser. No. US 2000-538039, filed on 29 Mar 2000, PENDING
PRAI US 1999-127437P 19990401 (60)
DT Utility
FS APPLICATION
LN.CNT 10908
INCL INCLM: 544/295.000
INCLS: 544/279.000; 540/575.000; 544/324.000
NCL NCLM: 514/253.040
NCLS: 514/252.130; 514/252.160; 514/256.000; 514/275.000; 514/300.000; 544/242.000; 544/295.000; 544/330.000; 544/345.000; 544/358.000; 544/405.000
IC [7]
ICM: C07D487-02
ICS: C07D043-04
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 9 OF 95 USPATFULL on STN DUPLICATE 2
AN 2003:79111 USPATFULL
TI Novel biaryl ether derivatives useful as monoamine reuptake inhibitors
IN Howard, Harry R., Bristol, CT, UNITED STATES
Adam, Mavis D., East Lyme, CT, UNITED STATES
PA Pfizer Inc. (U.S. corporation)
PI US 2003055038 A1 20030320
US 6596741 B2 20030722
AI US 2002-153308 A1 20020522 (10)
RLI Division of Ser. No. US 2000-692335, filed on 19 Oct 2000, GRANTED, Pat. No. US 6410736 Continuation of Ser. No. WO 2000-IB1373, filed on 25 Sep 2000, UNKNOWN
PRAI US 1999-167761P 19991129 (60)
US 1999-167761P 19991129 (60)
US 1999-159276P 19991013 (60)
DT Utility
FS APPLICATION
LN.CNT 2110
INCL INCLM: 514/212.010
INCLS: 514/227.500; 514/231.200; 514/252.120; 514/317.000; 514/365.000; 514/385.000; 514/408.000; 514/374.000; 514/649.000
NCL NCLM: 514/357.000
NCLS: 514/327.000; 514/383.000; 514/406.000; 514/424.000; 514/438.000; 514/471.000; 514/650.000
IC [7]
ICM: A61K031-55
ICS: A61K031-54; A61K031-537; A61K031-496; A61K031-445; A61K031-426; A61K031-137
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 10 OF 95 USPATFULL on STN
AN 2003:266202 USPATFULL
TI Regulation of human alpha 1A adrenergic receptor-line G protein-coupled receptor
IN Ramakrishnan, Shyam, Brighton, MA, UNITED STATES
PI US 2003187219 A1 20031002
AI US 2003-276243 A1 20030505 (10)
WO 2001-EP5383 20010511
DT Utility
FS APPLICATION
LN.CNT 3419
INCL INCLM: 530/350.000
INCLS: 536/023.500; 435/069.100; 435/320.100; 435/325.000; 514/044.000
NCL NCLM: 530/350.000
NCLS: 536/023.500; 435/069.100; 435/320.100; 435/325.000; 514/044.000
IC [7]
ICM: C07K014-705
ICS: C07H021-04; A61K048-00; C12P021-02; C12N005-06
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 11 OF 95 USPATFULL on STN
AN 2003:244935 USPATFULL
TI Novel muscarinic receptor agonists
IN Villalobos, Anabella, Niantic, CT, UNITED STATES
Yohannes, Daniel, Groton, CT, UNITED STATES
Nowakowski, Jolanta, Old Saybrook, CT, UNITED STATES
Liston, Dane R., Noank, CT, UNITED STATES
PI US 2003171349 A1 20030911
AI US 2003-376138 A1 20030228 (10)
RLI Continuation of Ser. No. US 2000-504362, filed on 15 Feb 2000, PENDING
Continuation of Ser. No. US 1997-848359, filed on 30 Apr 1997, GRANTED, Pat. No. US 6093733
PRAI US 1996-16494P 19960430 (60)
DT Utility
FS APPLICATION
LN.CNT 2132
INCL INCLM: 514/210.010
INCLS: 514/227.500; 514/217.120; 514/237.800; 514/331.000; 514/408.000; 514/365.000; 540/609.000; 544/059.000; 544/167.000; 546/229.000; 548/205.000; 548/566.000; 548/950.000
NCL NCLM: 514/210.010
NCLS: 514/227.500; 514/217.120; 514/237.800; 514/331.000; 514/408.000; 514/365.000; 540/609.000; 544/059.000; 544/167.000; 546/229.000; 548/205.000; 548/566.000; 548/950.000
IC [7]

ICS: A61K031-54; A61K031-535; A61K031-445; A61K031-397
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 12 OF 95 USPATFULL on STN
AN 2003:244888 USPATFULL
TI Opioid derivative
IN Okada, Yoshio, Akashi-shi, JAPAN
Tsuda, Yuko, Akashi-shi, JAPAN
Yokoi, Toshio, Akashi-shi, JAPAN
Bryant, Sharon D., Chapel Hill, NC, UNITED STATES
Lazarus, Lawrence H., Durham, NC, UNITED STATES
PI US 2003171302 A1 20030911
AI US 2002-58192 A1 20020129 (10)
DT Utility
FS APPLICATION
LN.CNT 966
INCL INCLM: 514/019.000
INCLS: 564/157.000
NCL NCLM: 514/019.000
NCLS: 564/157.000
IC [7]
ICM: A61K038-04
ICS: C07K005-04
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 13 OF 95 USPATFULL on STN
AN 2003:220268 USPATFULL
TI Propenecarboxylic acid amidoxime derivatives, a process for the preparation thereof , and pharmaceutical compositions containing the same
IN Literati Nagy, Peter, Budapest, HUNGARY
Sumegi, Balazs, Pecs, HUNGARY
Takacs, Kalman, Budapest, HUNGARY
PI US 2003153559 A1 20030814
AI US 2002-239159 A1 20021120 (10)
WO 2001-HU29 20010313
PRAI HU 2000-P1178 20000320
HU 2001-P987 20010307
DT Utility
FS APPLICATION
LN.CNT 2556
INCL INCLM: 514/227.500
INCLS: 514/237.800; 514/252.120; 514/331.000; 514/365.000; 514/400.000; 514/406.000; 514/374.000; 514/408.000; 514/633.000; 544/059.000; 544/167.000; 544/398.000; 546/229.000; 548/203.000; 548/215.000; 548/221.000; 548/336.100; 548/370.100; 548/566.000; 564/229.000
NCL NCLM: 514/227.500
NCLS: 514/237.800; 514/252.120; 514/331.000; 514/365.000; 514/400.000; 514/406.000; 514/374.000; 514/408.000; 514/633.000; 544/059.000; 544/167.000; 544/398.000; 546/229.000; 548/203.000; 548/215.000; 548/221.000; 548/336.100; 548/370.100; 548/566.000; 564/229.000
IC [7]
ICM: A61K031-54
ICS: A61K031-537; A61K031-495; A61K031-445; A61K031-426; A61K031-421; A61K031-4172; A61K031-405; A61K031-40; A61K031-155
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 14 OF 95 USPATFULL on STN
AN 2003:214400 USPATFULL
TI N-[(substituted five-membered di-or triaza diunsaturated ring)carbonyl] guanidine derivatives for the treatment of ischemia
IN Hamanaka, Ernest S., Gales Ferry, CT, UNITED STATES
Guzman-Perez, Angel, Stonington, CT, UNITED STATES
Mularski, Christian J., Chester, CT, UNITED STATES
Ruggeri, Roger B., Waterford, CT, UNITED STATES
Wester, Ronald T., Ledyard, CT, UNITED STATES
PA Pfizer Inc. (U.S. corporation)
PI US 2003149043 A1 20030807
AI US 2002-315369 A1 20021209 (10)
RLI Division of Ser. No. US 1999-367731, filed on 18 Aug 1999, GRANTED, Pat. No. US 6492401
PRAI WO 1999-IB206 19990205
DT Utility
FS APPLICATION
LN.CNT 8827

INCLS: 514/249.000; 514/266.230; 514/307.000; 514/314.000; 514/406.000;
544/284.000; 544/237.000; 544/235.000; 544/355.000; 544/167.000;
546/146.000; 548/365.100; 548/374.100
NCL NCLM: 514/248.000
NCLS: 514/249.000; 514/266.230; 514/307.000; 514/314.000; 514/406.000;
544/284.000; 544/237.000; 544/235.000; 544/355.000; 544/167.000;
546/146.000; 548/365.100; 548/374.100
IC [7]
ICM: A61K031-517
ICS: A61K031-502; A61K031-4709; A61K031-498
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 15 OF 95 USPATFULL on STN
AN 2003:188529 USPATFULL
TI Combination treatment for alcoholism and alcohol dependence
IN Howard, Harry R., JR., Bristol, CT, UNITED STATES
PA Pfizer Inc. (U.S. corporation)
PI US 2003130322 A1 20030710
AI US 2002-153379 A1 20020522 (10)
PRAI US 2001-293088P 20010523 (60)
DT Utility
FS APPLICATION
LN.CNT 2246
INCL INCLM: 514/357.000
INCLS: 514/408.000; 514/649.000; 514/438.000; 546/334.000; 548/561.000;
549/074.000; 514/534.000; 558/418.000; 564/336.000
NCL NCLM: 514/357.000
NCLS: 514/408.000; 514/649.000; 514/438.000; 546/334.000; 548/561.000;
549/074.000; 514/534.000; 558/418.000; 564/336.000
IC [7]
ICM: A61K031-44
ICS: A61K031-381; A61K031-40; A61K031-277; A61K031-137
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 16 OF 95 USPATFULL on STN
AN 2003:174065 USPATFULL
TI Method for increasing serotonin levels in a person by administration of a composition incorporating (-)-hydroxycitric acid, and related compositions thereof
IN Ohia, Sunny E., Omaha, NE, UNITED STATES
Preuss, Harry G., Fairfax Station, VA, UNITED STATES
Bagchi, Debasis, Concord, CA, UNITED STATES
PI US 2003119913 A1 20030626
AI US 2002-115266 A1 20020402 (10)
PRAI US 2001-343473P 20011220 (60)
DT Utility
FS APPLICATION
LN.CNT 510
INCL INCLM: 514/574.000
NCL NCLM: 514/574.000
IC [7]
ICM: A61K031-19
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 17 OF 95 USPATFULL on STN
AN 2003:172701 USPATFULL
TI Methods and compositions for treating mammalian nerve tissue injuries
IN Shi, Riyi, West Lafayette, IN, UNITED STATES
Borgens, Richard B., Delphi, IN, UNITED STATES
Lee, Raphael C., Chicago, IL, UNITED STATES
PI US 2003118545 A1 20030626
AI US 2002-132542 A1 20020424 (10)
PRAI US 2001-286200P 20010424 (60)
DT Utility
FS APPLICATION
LN.CNT 4484
INCL INCLM: 424/078.370
NCL NCLM: 424/078.370
IC [7]
ICM: A61K031-765
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 18 OF 95 USPATFULL on STN
AN 2003:140566 USPATFULL
TI Creation of tissue engineered female reproductive organs

Yoo, James J., Brookline, MA, UNITED STATES
PI US 2003096407 A1 20030522
AI US 2002-298198 A1 20021115 (10)
PRAI US 2001-331503P 20011116 (60)
DT Utility
FS APPLICATION
LN.CNT 3022
INCL INCLM: 435/366.000
INCLS: 424/093.700
NCL NCLM: 435/366.000
NCLS: 424/093.700
IC [7]
ICM: C12N005-08
ICS: A61K045-00
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 19 OF 95 USPATFULL on STN
AN 2003:140565 USPATFULL
TI Tissue engineered uterus
IN Atala, Anthony, Weston, MA, UNITED STATES
Yoo, James J., Brookline, MA, UNITED STATES
PI US 2003096406 A1 20030522
AI US 2002-295812 A1 20021115 (10)
PRAI US 2001-331503P 20011116 (60)
DT Utility
FS APPLICATION
LN.CNT 2969
INCL INCLM: 435/366.000
INCLS: 424/093.700
NCL NCLM: 435/366.000
NCLS: 424/093.700
IC [7]
ICM: C12N005-08
ICS: A61K045-00
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 20 OF 95 USPATFULL on STN
AN 2003:80308 USPATFULL
TI NMP35 apoptosis inhibitor gene disruptions, compositions and methods related thereto
IN Reeder, Thadd C., San Carlos, CA, UNITED STATES
Phillips, Russell, Menlo Park, CA, UNITED STATES
PI US 2003056239 A1 20030320
AI US 2002-180917 A1 20020625 (10)
PRAI US 2001-301101P 20010626 (60)
US 2002-367236P 20020325 (60)
DT Utility
FS APPLICATION
LN.CNT 2767
INCL INCLM: 800/018.000
INCLS: 800/021.000; 435/354.000
NCL NCLM: 800/018.000
NCLS: 800/021.000; 435/354.000
IC [7]
ICM: A01K067-027
ICS: C12N005-06
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 21 OF 95 USPATFULL on STN
AN 2003:79094 USPATFULL
TI Compounds for the treatment of ischemia
IN DeNinno, Michael P., Gales Ferry, CT, UNITED STATES
Masamune, Hiroko, Noank, CT, UNITED STATES
PI US 2003055021 A1 20030320
AI US 2002-99620 A1 20020315 (10)
PRAI US 2001-276411P 20010316 (60)
DT Utility
FS APPLICATION
LN.CNT 3858
INCL INCLM: 514/045.000
INCLS: 514/046.000; 514/043.000; 514/263.230; 514/263.380; 514/263.400; 514/303.000; 544/276.000; 544/277.000; 546/118.000; 536/027.300; 536/027.130; 536/027.210
NCL NCLM: 514/045.000
NCLS: 514/046.000; 514/043.000; 514/263.230; 514/263.380; 514/263.400;

536/027.130; 536/027.210
IC [7]
ICM: A61K031-708
ICS: A61K031-7076; A61K031-522; A61K031-52; A61K031-4745
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 22 OF 95 USPATFULL on STN
AN 2003:321520 USPATFULL
TI Sorbitol dehydrogenase inhibitors
IN Chu-Moyer, Margaret Y., Old Lyme, CT, United States
Murry, Jerry A., Mystic, CT, United States
Mylari, Banavara L., Waterford, CT, United States
Zembrowski, William J., Oakdale, CT, United States
PA Pfizer Inc, New York, NY, United States (U.S. corporation)
PI US 6660740 B1 20031209
AI US 2003-384424 20030310 (10)
RLI Division of Ser. No. US 2002-87869, filed on 28 Feb 2002 Division of Ser. No. US 2000-538039, filed on 29 Mar 2000, now patented, Pat. No. US 6414149
PRAI US 1999-127437P 19990401 (60)
DT Utility
FS GRANTED
LN.CNT 8567
INCL INCLM: 514/253.040
INCLS: 514/183.000; 514/255.010; 544/295.000; 544/386.000; 544/319.000
NCL NCLM: 514/253.040
NCLS: 514/183.000; 514/255.010; 544/295.000; 544/319.000; 544/386.000
IC [7]
ICM: A61K031-495
ICS: C07D403-00
EXF 514/183; 514/253.04; 514/255.01; 544/295; 544/386; 544/319
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 23 OF 95 USPATFULL on STN DUPLICATE 3
AN 2002:259430 USPATFULL
TI Monoamine reuptake inhibitors for treatment of CNS disorders
IN Howard, Harry R., JR., Bristol, CT, UNITED STATES
Schmidt, Christopher J., Old Lyme, CT, UNITED STATES
Seeger, Thomas F., Mystic, CT, UNITED STATES
Elliott, Mark L., Canterbury, CT, UNITED STATES
PI US 2002143003 A1 20021003
US 6677378 B2 20040113
AI US 2001-845992 A1 20010430 (9)
RLI Continuation-in-part of Ser. No. US 529207, PENDING A 371 of International Ser. No. WO 2000-IB108, filed on 2 Feb 2000, UNKNOWN
PRAI US 1999-121313P 19990223 (60)
DT Utility
FS APPLICATION
LN.CNT 1999
INCL INCLM: 514/210.010
INCLS: 514/212.010; 514/317.000; 514/408.000; 514/649.000; 514/183.000; 540/484.000; 546/232.000; 548/570.000; 548/950.000; 564/336.000
NCL NCLM: 514/649.000
NCLS: 564/336.000
IC [7]
ICM: A61K031-55
ICS: A61K031-445; A61K031-397; A01N043-40; A61K031-137
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 24 OF 95 USPATFULL on STN
AN 2002:279667 USPATFULL
TI Methods for treating the inflammatory component of a brain disorder
IN Bolton, Anthony E., Tideswell, UNITED KINGDOM
Mandel, Arkady, North York, CANADA
PI US 2002155098 A1 20021024
AI US 2002-115943 A1 20020405 (10)
PRAI US 2001-282120P 20010406 (60)
DT Utility
FS APPLICATION
LN.CNT 1249
INCL INCLM: 424/093.700
NCL NCLM: 424/093.700
IC [7]
ICM: A01N063-00
ICS: A01N065-00

L5 ANSWER 25 OF 95 USPATFULL on STN
AN 2002:206794 USPATFULL
TI Nicotinamide acids, amides, and their mimetics active as inhibitors of PDE4 isozymes
IN Magee, Thomas Victor, Mystic, CT, UNITED STATES
Marfat, Anthony, Mystic, CT, UNITED STATES
Chambers, Robert James, Mystic, CT, UNITED STATES
PA Pfizer Inc. (U.S. corporation)
PI US 2002111495 A1 20020815
AI US 2002-62811 A1 20020131 (10)
PRAI US 2001-265240P 20010131 (60)
US 1997-43403P 19970404 (60)
US 1998-105120P 19981021 (60)
DT Utility
FS APPLICATION
LN.CNT 7710
INCL INCLM: 546/291.000
INCLS: 546/298.000; 546/315.000
NCL NCLM: 546/291.000
NCLS: 546/298.000; 546/315.000
IC [7]
ICM: C07D213-78
ICS: C07D213-63
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 26 OF 95 USPATFULL on STN
AN 2002:192123 USPATFULL
TI Novel muscarinic receptor agonists
IN Villalobos, Anabella, Niantic, CT, UNITED STATES
Yohannes, Daniel, Groton, CT, UNITED STATES
Nowakowski, Jolanta, Old Saybrook, CT, UNITED STATES
Liston, Dane, Noank, CT, UNITED STATES
PI US 2002103194 A1 20020801
AI US 2000-504362 A1 20000215 (9)
RLI Continuation of Ser. No. US 1997-848359, filed on 30 Apr 1997, PATENTED
DT Utility
FS APPLICATION
LN.CNT 2162
INCL INCLM: 514/231.800
INCLS: 514/237.200; 514/238.500; 514/217.030; 514/228.200; 514/231.200; 514/318.000; 514/428.000; 540/450.000; 540/609.000; 544/063.000; 544/105.000; 546/193.000; 546/231.000; 564/238.000
NCL NCLM: 514/231.800
NCLS: 514/237.200; 514/238.500; 514/217.030; 514/228.200; 514/231.200; 514/318.000; 514/428.000; 540/450.000; 540/609.000; 544/063.000; 544/105.000; 546/193.000; 546/231.000; 564/238.000
IC [7]
ICM: A61K031-5377
ICS: A61K031-454; C07D413-02; C07D043-02
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 27 OF 95 USPATFULL on STN
AN 2002:105951 USPATFULL
TI Zsig33-like peptides
IN Jaspers, Stephen R., Edmonds, WA, UNITED STATES
Sheppard, Paul O., Granite Falls, WA, UNITED STATES
Deisher, Theresa A., Seattle, WA, UNITED STATES
Bishop, Paul D., Fall City, WA, UNITED STATES
PI US 2002055156 A1 20020509
AI US 2001-853253 A1 20010510 (9)
PRAI US 2000-203300P 20000511 (60)
DT Utility
FS APPLICATION
LN.CNT 3022
INCL INCLM: 435/183.000
INCLS: 435/320.100; 435/325.000; 435/069.100; 536/023.200
NCL NCLM: 435/183.000
NCLS: 435/320.100; 435/325.000; 435/069.100; 536/023.200
IC [7]
ICM: C12N009-00
ICS: C07H021-04; C12P021-02; C12N005-06
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 28 OF 95 USPATFULL on STN

TI N-[(substituted five-membered di- or triaza diunsaturated ring)carbonyl] guanidine derivatives for the treatment of ischemia
IN Hamanaka, Ernest S., Gales Ferry, CT, United States
Guzman-Perez, Angel, Stonington, CT, United States
Ruggeri, Roger B., Waterford, CT, United States
Webster, Ronald T., Ledyard, CT, United States
Mularski, Christian J., Chester, CT, United States
PA Pfizer, Inc., New York, NY, United States (U.S. corporation)
PI US 6492401 B1 20021210
WO 9943663 19990902
AI US 1999-367731 19990818 (9)
WO 1999-IB206 19990205
PRAI US 1998-76362P 19980227 (60)
DT Utility
FS GRANTED
LN.CNT 8541
INCL INCLM: 514/359.000
INCLS: 514/406.000; 548/255.000; 548/362.500; 548/306.100; 546/165.000; 546/145.000; 546/175.000
NCL NCLM: 514/359.000
NCLS: 514/406.000; 546/145.000; 546/165.000; 546/175.000; 548/255.000; 548/306.100; 548/362.500
IC [7]
ICM: A61K031-41
ICS: A61K031-415; C07D249-04; C07D231-56; C07D403-02
EXF 548/255; 548/374.1; 548/262.2; 548/362.5; 548/306.1; 514/359; 514/406; 546/165; 546/145; 546/175
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 29 OF 95 USPATFULL on STN
AN 2002:297591 USPATFULL
TI Sodium channel drugs and uses
IN Marquess, Daniel, Half Moon Bay, CA, United States
Choi, Seok-Ki, Palo Alto, CA, United States
Beattie, David T., Belmont, CA, United States
Griffin, John H., Atherton, CA, United States
Armstrong, Scott, San Francisco, CA, United States
Church, Timothy J., San Mateo, CA, United States
Jenkins, Thomas E., La Honda, CA, United States
Green, David C., Pacifica, CA, United States
PA Theravance, Inc., South San Francisco, CA, United States (U.S. corporation)
PI US 6479498 B1 20021112
AI US 2001-39699 20011109 (10)
RLI Continuation of Ser. No. US 1999-458107, filed on 8 Dec 1999
Continuation-in-part of Ser. No. US 1999-325563, filed on 4 Jun 1999, now abandoned
DT Utility
FS GRANTED
LN.CNT 5629
INCL INCLM: 514/256.000
INCLS: 514/275.000; 544/325.000; 544/326.000; 544/327.000; 544/329.000
NCL NCLM: 514/256.000
NCLS: 514/275.000; 544/325.000; 544/326.000; 544/327.000; 544/329.000
IC [7]
ICM: C07D239-42
ICS: C07D239-48; A61K031-505
EXF 544/325; 544/326; 544/327; 544/329; 514/256; 514/275
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 30 OF 95 USPATFULL on STN
AN 2002:175137 USPATFULL
TI Sodium channel drugs and uses
IN Marquess, Daniel, Half Moon Bay, CA, United States
Choi, Seok-Ki, Palo Alto, CA, United States
Beattie, David T., Belmont, CA, United States
Griffin, John H., Atherton, CA, United States
Armstrong, Scott, San Francisco, CA, United States
Church, Timothy J., San Mateo, CA, United States
Jenkins, Thomas E., La Honda, CA, United States
PA Advanced Medicine, Inc., South San Francisco, CA, United States (U.S. corporation)
PI US 6420354 B1 20020716
AI US 1999-458107 19991208 (9)
RLI Continuation-in-part of Ser. No. US 1999-325563, filed on 4 Jun 1999,

PRAI US 1998-93068P 19980716 (60)
US 1998-88465P 19980608 (60)
DT Utility
FS GRANTED
LN.CNT 5797
INCL INCLM: 514/183.000
INCLS: 514/357.000; 514/438.000; 514/651.000; 540/470.000; 546/334.000; 549/075.000; 564/353.000
NCL NCLM: 514/183.000
NCLS: 514/357.000; 514/438.000; 514/651.000; 540/470.000; 546/334.000; 549/075.000; 564/353.000
IC [7]
ICM: C07D245-02
ICS: C07D211-70; C07D333-12; A61K031-33; A61K031-44
EXF 514/183; 514/357; 514/438; 514/651; 540/470; 546/334; 549/75; 564/353
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 31 OF 95 USPATFULL on STN
AN 2002:160876 USPATFULL
TI Sorbitol dehydrogenase inhibitors
IN Chu-Moyer, Margaret Y., Old Lyme, CT, United States
Mylari, Banavara L., Waterford, CT, United States
Zembrowski, William J., Oakdale, CT, United States
PA Pfizer Inc., New York, NY, United States (U.S. corporation)
PI US 6414149 B1 20020702
AI US 2000-538039 20000329 (9)
PRAI US 1999-127437P 19990401 (60)
DT Utility
FS GRANTED
LN.CNT 9305
INCL INCLM: 544/295.000
INCLS: 544/242.000; 544/326.000; 544/194.000; 514/241.000; 514/252.120; 514/252.130; 514/255.000; 514/256.000
NCL NCLM: 544/295.000
NCLS: 544/194.000; 544/242.000; 544/326.000
IC [7]
ICM: A61K031-53
ICS: A61K031-505; C07D251-00; C07D241-04; C07D403-00
EXF 514/241; 514/252.13; 514/255.05; 514/252.12; 514/256; 544/194; 544/242; 544/295; 544/326; 544/358
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 32 OF 95 USPATFULL on STN
AN 2002:152797 USPATFULL
TI Biaryl ether derivatives useful as monoamine reuptake inhibitors
IN Howard, Jr., Harry R., Bristol, CT, United States
Adam, Mavis D., East Lyme, CT, United States
PA Pfizer Inc., New York, NY, United States (U.S. corporation)
PI US 6410736 B1 20020625
AI US 2000-692335 20001019 (9)
RLI Continuation of Ser. No. WO 2000-IB1373, filed on 25 Sep 2000
PRAI US 1999-167761P 19991129 (60)
DT Utility
FS GRANTED
LN.CNT 1679
INCL INCLM: 546/216.000
INCLS: 549/491.000; 549/075.000; 546/334.000; 548/205.000; 548/252.000; 548/267.200; 548/371.700; 548/543.000; 548/255.000; 564/337.000
NCL NCLM: 546/216.000
NCLS: 546/334.000; 548/205.000; 548/252.000; 548/255.000; 548/267.200; 548/371.700; 548/543.000; 549/075.000; 549/491.000; 564/337.000
IC [7]
ICM: C07D211-76
ICS: C07D307-34
EXF 514/650; 514/471; 514/438; 514/357; 514/327; 514/407; 514/424; 514/381; 514/365; 514/383; 564/337; 549/491; 549/75; 546/334; 546/216; 548/371.1; 548/255; 548/543; 548/252; 548/205; 548/267.2
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 33 OF 95 BIOSIS COPYRIGHT (c) 2004 The Thomson Corporation. on STN
AN 2002:560088 BIOSIS
DN PREV200200560088
TI Safety and mechanism of appetite suppression by a novel hydroxycitric acid extract (HCA-SX).

Bagchi, Manashi; Bagchi, Debasis; Stohs, Sidney J.
CS Creighton University School of Pharmacy and Allied Health Professions, 2500 California Plaza, Omaha, NE, 68178, USA
seohia@creighton.edu
SO Molecular and Cellular Biochemistry, (September, 2002) Vol. 238, No. 1-2, pp. 89-103. print.
CODEN: MCBIB8. ISSN: 0300-8177.
DT Article
LA English
ED Entered STN: 30 Oct 2002
Last Updated on STN: 30 Oct 2002

L5 ANSWER 34 OF 95 USPATFULL on STN
AN 2001:163206 USPATFULL
TI Compounds for treating and preventing diabetic complications
IN Mylari, Banavara L., Waterford, CT, United States
PA Pfizer Inc., New York, NY, United States (U.S. corporation)
PI US 6294538 B1 20010925
AI US 2000-537254 20000329 (9)
PRAI US 1999-127430P 19990401 (60)
DT Utility
FS GRANTED
LN.CNT 2468
INCL INCLM: 514/252.140
INCLS: 540/295.000
NCL NCLM: 514/252.140
NCLS: 544/295.000
IC [7]
ICM: A01N043-58
EXF 574/255; 574/256; 574/252.14; 540/295
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 35 OF 95 BIOSIS COPYRIGHT (c) 2004 The Thomson Corporation. on STN
AN 2001:533296 BIOSIS
DN PREV200100533296
TI Optical imaging of excitation propagation in cortical and hippocampal slices of the gerbil after transient exposure to oxygen-glucose deprivation.
AU Fujiwara, N. [Reprint author]; Hirano, S. [Reprint author]; Taga, K.
CS Dept. Medical Technology, Niigata University School of Health Sciences, Niigata, Japan
SO Society for Neuroscience Abstracts, (2001) Vol. 27, No. 1, pp. 1395. print.
Meeting Info.: 31st Annual Meeting of the Society for Neuroscience. San Diego, California, USA. November 10-15, 2001.
ISSN: 0190-5295.
DT Conference; (Meeting)
Conference; Abstract; (Meeting Abstract)
LA English
ED Entered STN: 14 Nov 2001
Last Updated on STN: 23 Feb 2002

L5 ANSWER 36 OF 95 USPATFULL on STN
AN 2000:98425 USPATFULL
TI Dexanabinol derivatives and their use as neuroprotective pharmaceutical compositions
IN Mechoulam, Raphael, Jerusalem, Israel
Pop, Emil, Gainesville, FL, United States
Sokolovsky, Mordechai, Tel Aviv, Israel
Kloog, Yoel, Hertzlyia, Israel
Biegon, Anat, Tel Aviv, Israel
PA Ramot University Authority for Applied Research and Industrial Development Ltd., Tel Aviv, Israel (non-U.S. corporation)
Yissum Research Develpoment Company of the Hebrew University in Jersusalem, Jerusalem, Israel (non-U.S. corporation)
PI US 6096740 20000801
WO 9520958 19950810
AI US 1998-11814 19980928 (9)
WO 1995-US1470 19950206
19980928 PCT 371 date
19980928 PCT 102(e) date
RLI Continuation-in-part of Ser. No. US 1994-192886, filed on 7 Feb 1994, now patented, Pat. No. US 5521215 which is a continuation-in-part of Ser. No. US 1992-865088, filed on 8 Apr 1992, now patented, Pat. No. US

filed on 6 Nov 1990, now abandoned
DT Utility
FS Granted
LN.CNT 2533
INCL INCLM: 514/236.800
INCLS: 514/255.000; 514/314.000; 514/325.000; 514/382.000; 514/455.000; 544/109.000; 544/375.000; 546/135.000; 546/282.700; 548/252.000; 549/291.000
NCL NCLM: 514/236.800
NCLS: 514/100.000; 514/254.110; 514/314.000; 514/325.000; 514/382.000; 514/455.000; 544/109.000; 544/375.000; 546/135.000; 546/282.700; 548/252.000; 549/291.000
IC [7]
ICM: A61K031-352
ICS: A61K031-496; C07D295-037; C07D311-80; C07D453-04
EXF 514/236.8; 514/255; 514/314; 514/325; 514/382; 514/455; 544/109; 544/375; 546/135; 546/282.7; 548/252; 549/391
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 37 OF 95 USPATFULL on STN
AN 2000:95032 USPATFULL
TI Muscarinic receptor agonists
IN Villalobos, Anabella, 47 Greencliff Dr., Niantic, CT, United States 06357
Yohannes, Daniel, 600 Meridian St. Ext., Groton, CT, United States 06340
Nowakowski, Jolanta, 10 Otter Brook Dr., Old Saybrook, CT, United States 06475
Liston, Dane R., 68 Main St., Noank, CT, United States 06340
PI US 6093733 20000725
AI US 1997-848359 19970430 (8)
PRAI US 1996-16474P 19960430 (60)
DT Utility
FS Granted
LN.CNT 2295
INCL INCLM: 514/331.000
INCLS: 514/183.000; 514/212.000; 514/228.800; 514/231.200; 514/318.000; 514/428.000; 540/450.000; 540/609.000; 544/063.000; 544/105.000; 546/193.000; 546/231.000; 548/586.000
NCL NCLM: 514/331.000
NCLS: 514/183.000; 514/217.120; 514/228.800; 514/231.200; 514/318.000; 514/428.000; 540/450.000; 540/609.000; 544/063.000; 544/105.000; 546/193.000; 546/231.000
IC [7]
ICM: A61K031-445
ICS: C07D265-00; C07D211-28
EXF 540/450; 540/609; 544/63; 544/105; 546/193; 546/231; 548/586; 514/183; 514/212; 514/228.8; 514/231.2; 514/318; 514/331; 514/428
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 38 OF 95 USPATFULL on STN
AN 2000:92100 USPATFULL
TI Tetrahydro-beta-carbolines
IN Audia, James E., Indianapolis, IN, United States
Nelson, David L., Carmel, IN, United States
PA Eli Lilly and Company, Indianapolis, IN, United States (U.S. corporation)
PI US 6090945 20000718
AI US 1998-187066 19981105 (9)
RLI Division of Ser. No. US 1997-845053, filed on 18 Apr 1997, now patented, Pat. No. US 5861425 which is a division of Ser. No. US 1995-481714, filed on 7 Jun 1995, now patented, Pat. No. US 5760051 which is a continuation-in-part of Ser. No. US 1994-206839, filed on 11 Mar 1994, now patented, Pat. No. US 5500431 which is a continuation-in-part of Ser. No. US 1993-48544, filed on 14 Apr 1993, now abandoned
DT Utility
FS Granted
LN.CNT 3208
INCL INCLM: 546/290.000
INCLS: 546/085.000
NCL NCLM: 546/290.000
NCLS: 546/085.000
IC [7]
ICM: C07D211-72
ICS: C07D471-04; A61K031-44

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 39 OF 95 USPATFULL on STN
AN 1999:75753 USPATFULL
TI MU opioid receptor ligands: agonists and antagonists
IN Dooley, Colette T., San Diego, CA, United States
Houghten, Richard A., Del Mar, CA, United States
PA Torrey Pines Institute for Molecular Studies, San Diego, CA, United States (U.S. corporation)
PI US 5919897 19990706
AI US 1995-488659 19950607 (8)
DT Utility
FS Granted
LN.CNT 3436
INCL INCLM: 530/330.000
INCLS: 530/331.000; 530/345.000; 514/018.000; 514/019.000; 260/998.200
NCL NCLM: 530/330.000
NCLS: 260/998.200; 514/018.000; 514/019.000; 530/331.000; 530/345.000
IC [6]
ICM: C07K005-00
EXF 530/330; 530/331; 530/345; 514/18; 514/19; 260/998.2
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 40 OF 95 USPATFULL on STN
AN 1999:37117 USPATFULL
TI Methods of treating or ameliorating the symptoms of venomous bites and stings
IN Cohen, Marlene Lois, Carmel, IN, United States
Johnson, Kirk Willis, Camby, IN, United States
PA Eli Lilly and Company, Indianapolis, IN, United States (U.S. corporation)
PI US 5886003 19990323
AI US 1997-813131 19970307 (8)
PRAI US 1996-14039P 19960325 (60)
US 1996-14119P 19960325 (60)
DT Utility
FS Granted
LN.CNT 1286
INCL INCLM: 514/280.000
INCLS: 514/285.000; 514/292.000
NCL NCLM: 514/280.000
NCLS: 514/285.000; 514/292.000
IC [6]
ICM: A61K031-44
EXF 514/280; 514/292; 514/285
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 41 OF 95 USPATFULL on STN
AN 1999:19349 USPATFULL
TI Aminoalkyl-indoles
IN Audia, James E., Indianapolis, IN, United States
Baker, Stephen Richard, Yateley, England
Carrera, Jesus Ezquerra, Madrid, Spain
Peteira, Carlos Lamas, Madrid, Spain
Tercero, Concepcion Pedregal, Madrid, Spain
PA Eli Lilly and Company, Indianapolis, IN, United States (U.S. corporation)
PI US 5869691 19990209
AI US 1997-838377 19970408 (8)
RLI Division of Ser. No. US 1995-444449, filed on 19 May 1995, now patented, Pat. No. US 5643916
DT Utility
FS Granted
LN.CNT 1581
INCL INCLM: 548/494.000
INCLS: 548/504.000; 548/507.000; 548/426.000; 548/427.000
NCL NCLM: 548/494.000
NCLS: 548/426.000; 548/427.000; 548/504.000; 548/507.000
IC [6]
ICM: C07D209-18
ICS: C07D209-20; C07D209-10
EXF 546/79; 548/494; 548/504; 548/507
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 42 OF 95 USPATFULL on STN

TI Method of treating or ameliorating the symptoms of common cold or allergic rhinitis
IN Johnson, Kirk Willis, Camby, IN, United States
Nelson, David Lloyd Garver, Carmel, IN, United States
Phebus, Lee Alan, Fountaintown, IN, United States
PA Eli Lilly and Company, Indianapolis, IN, United States (U.S. corporation)
PI US 5869497 19990209
AI US 1997-813472 19970307 (8)
DT Utility
FS Granted
LN.CNT 1240
INCL INCLM: 514/278.000
INCLS: 514/300.000
NCL NCLM: 514/278.000
NCLS: 514/300.000
IC [6]
ICM: A61K031-44
EXF 514/300; 514/278
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 43 OF 95 USPATFULL on STN
AN 1999:7412 USPATFULL
TI Indole-ethanamines
IN Audia, James E., Indianapolis, IN, United States
Droste, James J., Indianapolis, IN, United States
Murdoch, Gwyn L., Greenwood, IN, United States
Nelson, David L., Carmel, IN, United States
PA Eli Lilly and Company, Indianapolis, IN, United States (U.S. corporation)
PI US 5861425 19990119
AI US 1997-845053 19970418 (8)
RLI Division of Ser. No. US 1995-481714, filed on 7 Jun 1995, now patented, Pat. No. US 5760051 which is a continuation-in-part of Ser. No. US 1994-206839, filed on 11 Mar 1994, now patented, Pat. No. US 5500431 which is a continuation-in-part of Ser. No. US 1993-48544, filed on 14 Apr 1993, now abandoned
DT Utility
FS Granted
LN.CNT 3152
INCL INCLM: 514/411.000
INCLS: 548/427.000
NCL NCLM: 514/411.000
NCLS: 548/427.000
IC [6]
ICM: A61K031-40
ICS: C07D209-60
EXF 514/411; 548/427
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 44 OF 95 USPATFULL on STN
AN 1999:7397 USPATFULL
TI Tetrahydro-beta-carbolines
IN Audia, James E., Indianapolis, IN, United States
Baker, Stephen Richard, Camberley, England
Carrera, Jesus Ezquerra, Madrid, Spain
Peteira, Carlos Lamas, Madrid, Spain
Tercero, Concepcion Pedregal, Madrid, Spain
PA Eli Lilly and Company, Indianapolis, IN, United States (U.S. corporation)
PI US 5861410 19990119
AI US 1997-833751 19970409 (8)
RLI Division of Ser. No. US 1995-444449, filed on 19 May 1995, now patented, Pat. No. US 5643916
DT Utility
FS Granted
LN.CNT 1628
INCL INCLM: 514/285.000
INCLS: 514/292.000; 546/070.000; 546/086.000; 546/087.000
NCL NCLM: 514/285.000
NCLS: 514/292.000; 546/070.000; 546/086.000; 546/087.000
IC [6]
ICM: A61K031-44
ICS: C07D471-04; C07D487-04
EXF 546/86; 546/87; 546/70; 514/292; 514/285

L5 ANSWER 45 OF 95 USPATFULL on STN
AN 1999:7396 USPATFULL
TI Tetrahydro-beta-carbolines
IN Audia, James E., Indianapolis, IN, United States
Baker, Stephen Richard, Surrey, England
Carrera, Jesus Ezquerra, Madrid, Spain
Peteira, Carlos Lamas, Madrid, Spain
Tercero, Concepcion Pedregal, Madrid, Spain
PA Eli Lilly and Company, Indianapolis, IN, United States (U.S. corporation)
PI US 5861409 19990119
AI US 1997-835774 19970408 (8)
RLI Division of Ser. No. US 1995-444449, filed on 19 May 1995, now patented, Pat. No. US 5643916
DT Utility
FS Granted
LN.CNT 1604
INCL INCLM: 514/280.000
INCLS: 546/018.000; 546/049.000
NCL NCLM: 514/280.000
NCLS: 546/018.000; 546/049.000
IC [6]
ICM: A61K031-44
ICS: C07D471-04
EXF 546/49; 514/280
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 46 OF 95 USPATFULL on STN
AN 1999:7395 USPATFULL
TI Tetrahydro-Beta-Carbolines
IN Audia, James E., Indianapolis, IN, United States
Baker, Stephen Richard, Surrey, England
Carrera, Jesus Ezquerra, Madrid, Spain
Peteira, Carlos Lamas, Madrid, Spain
Tercero, Concepcion Pedregal, Madrid, Spain
PA Eli Lilly and Company, Indianapolis, IN, United States (U.S. corporation)
PI US 5861408 19990119
AI US 1997-835452 19970408 (8)
RLI Division of Ser. No. US 1995-444449, filed on 19 May 1995, now patented, Pat. No. US 5643916
DT Utility
FS Granted
LN.CNT 1544
INCL INCLM: 514/278.000
INCLS: 546/049.000; 546/070.000
NCL NCLM: 514/278.000
NCLS: 546/049.000; 546/070.000
IC [6]
ICM: A61K031-44
ICS: C07D471-04; C07D471-10
EXF 546/86; 546/87; 546/49; 546/70; 546/18; 514/278
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 47 OF 95 USPATFULL on STN
AN 1998:159959 USPATFULL
TI Aza spiro compounds acting on the cholinergic system with muscarinic agonist activity
IN Fisher, Abraham, Holon, Israel
Karton, Yishal, Ness-Ziona, Israel
Marciano, Daniele, Ramat-Hasharon, Israel
Barak, Dov, Rehovot, Israel
Meshulam, Haim, Bat Yam, Israel
PA Israel Institute for Biological Research, Nessziona, Israel (non-U.S. corporation)
PI US 5852029 19981222
AI US 1996-627222 19960118 (8)
RLI Continuation-in-part of Ser. No. US 1993-94855, filed on 20 Jul 1993, now patented, Pat. No. US 5534520 which is a continuation-in-part of Ser. No. US 1991-685397, filed on 9 Apr 1991, now abandoned which is a continuation-in-part of Ser. No. US 1990-507708, filed on 10 Apr 1990, now abandoned
DT Utility
FS Granted

INCL INCLM: 514/278.000
INCLS: 546/016.000; 546/019.000; 546/020.000
NCL NCLM: 514/278.000
NCLS: 546/016.000; 546/019.000; 546/020.000
IC [6]
ICM: C07D491-10
ICS: C07D491-20; A61K031-445; A61K031-46
EXF 546/19; 546/16; 546/20; 514/278
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 48 OF 95 USPATFULL on STN
AN 1998:154423 USPATFULL
TI Amino acid derivatives with anticholecystokinin activity
IN McDonald, Iain Mair, Paddock Wood, United Kingdom
PA James Black Foundation Limited, London, England (non-U.S. corporation)
PI US 5847125 19981208
WO 9314066 19930722 ##STR1##
AI US 1994-256145 19940707 (8)
WO 1993-GB28 19930108
19940707 PCT 371 date
19940707 PCT 102(e) date
PRAI GB 1992-420 19920109
DT Utility
FS Granted
LN.CNT 1298
INCL INCLM: 540/582.000
INCLS: 546/016.000; 546/019.000; 560/016.000; 560/024.000; 560/038.000; 562/427.000
NCL NCLM: 540/582.000
NCLS: 546/016.000; 546/019.000; 560/016.000; 560/024.000; 560/038.000; 562/427.000
IC [6]
ICM: C07D223-32
ICS: C07D491-113; C07D317-10
EXF 540/582; 546/16; 546/19; 560/16; 562/427
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 49 OF 95 USPATFULL on STN
AN 1998:61666 USPATFULL
TI Tetrahydro-beta-carbolines
IN Audia, James E., Indianapolis, IN, United States
Droste, James J., Indianapolis, IN, United States
Evrard, Deborah A., Indianapolis, IN, United States
Fludzinski, Pawel, Indianapolis, IN, United States
Murdoch, Gwyn L., Greenwood, IN, United States
Nelson, David L., Carmel, IN, United States
PA Eli Lilly and Company, Indianapolis, IN, United States (U.S. corporation)
PI US 5760051 19980602
AI US 1995-481714 19950607 (8)
RLI Continuation-in-part of Ser. No. US 1994-206839, filed on 11 Mar 1994, now patented, Pat. No. US 5500431 which is a continuation-in-part of Ser. No. US 1993-48544, filed on 14 Apr 1993, now abandoned
DT Utility
FS Granted
LN.CNT 3163
INCL INCLM: 514/292.000
INCLS: 546/085.000; 546/086.000; 546/087.000
NCL NCLM: 514/292.000
NCLS: 546/085.000; 546/086.000; 546/087.000
IC [6]
ICM: A61K031-44
ICS: C07D471-04
EXF 514/292; 546/85; 546/86; 546/87
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 50 OF 95 USPATFULL on STN
AN 1998:36752 USPATFULL
TI Naphthylpiperazinyl compounds useful for treating 5HT.sub.2B receptor mediated conditions
IN Audia, James E., Indianapolis, IN, United States
Cohen, Marlene L., Carmel, IN, United States
Gidda, Jaswant S., Carmel, IN, United States
Nelson, David L. G., Carmel, IN, United States
PA Eli Lilly and Company, Indianapolis, IN, United States (U.S.

PI US 5736544 19980407
AI US 1996-621408 19960325 (8)
RLI Division of Ser. No. US 1995-380566, filed on 6 Feb 1995 which is a continuation-in-part of Ser. No. US 1994-212622, filed on 11 Mar 1994, now abandoned
DT Utility
FS Granted
LN.CNT 5339
INCL INCLM: 514/247.000
NCL NCLM: 514/247.000
IC [6]
ICM: A01N043-58
EXF 544/395; 514/247; 514/657
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 51 OF 95 USPATFULL on STN
AN 1998:1802 USPATFULL
TI Method for treating 5-HT.sub.2B receptor related conditions
IN Audia, James E., Indianapolis, IN, United States
Cohen, Marlene, Carmel, IN, United States
Gidda, Jaswant S., Carmel, IN, United States
Nelson, David L., Carmel, IN, United States
PA Eli Lilly and Company, Indianapolis, IN, United States (U.S. corporation)
PI US 5705519 19980106
AI US 1995-440013 19950512 (8)
RLI Division of Ser. No. US 1995-380566, filed on 6 Feb 1995 which is a continuation-in-part of Ser. No. US 1994-212622, filed on 11 Mar 1994, now abandoned
DT Utility
FS Granted
LN.CNT 5448
INCL INCLM: 514/415.000
NCL NCLM: 514/415.000
IC [6]
ICM: A01N043-38
EXF 514/415; 548/469; 548/509
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 52 OF 95 BIOSIS COPYRIGHT (c) 2004 The Thomson Corporation. on STN
AN 1998:437498 BIOSIS
DN PREV199800437498
TI Thiopental inhibits increases in (Ca2+)i induced by membrane depolarization, NMDA receptor activation, and ischemia in rat hippocampal and cortical slices.
AU Zhan, Ren-Zhi [Reprint author]; Fujiwara, Naoshi; Endoh, Hiroshi; Yamakura, Tomohiro; Taga, Kiichiro; Fukuda, Satoru; Shimoji, Koki
CS Dep Anesthesiol., Niigata Univ. Sch. Med., 1-757 Asahimachi-dori, Niigata 951-8510, Japan
SO Anesthesiology (Hagerstown), (Aug., 1998) Vol. 89, No. 2, pp. 456-466. print.
CODEN: ANESAV. ISSN: 0003-3022.
DT Article
LA English
ED Entered STN: 7 Oct 1998
Last Updated on STN: 7 Oct 1998

L5 ANSWER 53 OF 95 USPATFULL on STN
AN 97:107093 USPATFULL
TI Method for treating 5HT.sub.2B receptor related conditions
IN Audia, James E., Indianapolis, IN, United States
Cohen, Marlene L., Carmel, IN, United States
Gidda, Jaswant S., Carmel, IN, United States
Nelson, David L. G., Carmel, IN, United States
PA Eli Lilly and Company, Indianapolis, IN, United States (U.S. corporation)
PI US 5688807 19971118
AI US 1995-380566 19950206 (8)
RLI Continuation-in-part of Ser. No. US 1994-212622, filed on 11 Mar 1994, now abandoned
DT Utility
FS Granted
LN.CNT 5501
INCL INCLM: 514/285.000

NCL NCLM: 514/285.000
NCLS: 514/292.000; 546/086.000; 546/087.000
IC [6]
ICM: A61K031-435
EXF 546/78; 546/85; 546/86; 546/87; 514/285; 514/292
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 54 OF 95 USPATFULL on STN
AN 97:78447 USPATFULL
TI Tetrahydro-beta carbolines
IN Audia, James E., Indianapolis, IN, United States
Baker, Stephen Richard, Camberley, England
Carrera, Jesus Ezquerra, Madrid, Spain
Peteira, Carlos Lamas, Madrid, Spain
Tercero, Concepcion Pedregal, Madrid, Spain
PA Eli Lilly and Company, Indianapolis, IN, United States (U.S. corporation)
PI US 5663178 19970902
AI US 1995-380565 19950206 (8)
DT Utility
FS Granted
LN.CNT 1553
INCL INCLM: 514/284.000
INCLS: 546/070.000
NCL NCLM: 514/284.000
NCLS: 546/070.000
IC [6]
ICM: C07D471-04
ICS: A61K031-44
EXF 546/70; 514/284
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 55 OF 95 USPATFULL on STN
AN 97:56682 USPATFULL
TI Tetrahydro-beta-carbolines
IN Audia, James E., Indianapolis, IN, United States
Baker, Stephen Richard, Camberley, England
Carrera, Jesus Ezquerra, Madrid, Spain
Peteira, Carlos Lamas, Madrid, Spain
Tercero, Concepcion Pedregal, Madrid, Spain
PA Eli Lilly and Company, Indianapolis, IN, United States (U.S. corporation)
PI US 5643916 19970701
AI US 1995-444449 19950519 (8)
RLI Division of Ser. No. US 1995-380565, filed on 6 Feb 1995, now abandoned
DT Utility
FS Granted
LN.CNT 1562
INCL INCLM: 514/285.000
INCLS: 514/292.000; 546/070.000; 546/086.000; 546/087.000
NCL NCLM: 514/285.000
NCLS: 514/292.000; 546/070.000; 546/086.000; 546/087.000
IC [6]
ICM: A61K031-44
ICS: C07D471-04; C07D487-04
EXF 546/70; 546/86; 546/87; 514/285; 514/292
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 56 OF 95 USPATFULL on STN
AN 97:54311 USPATFULL
TI .mu.opioid receptor ligands: agonists and antagonists
IN Dooley, Colette T., San Diego, CA, United States
Houghten, Richard A., Del Mar, CA, United States
PA Torrey Pines Institute For Molecular Studies, San Diego, CA, United States (U.S. corporation)
PI US 5641861 19970624
AI US 1995-487006 19950607 (8)
DT Utility
FS Granted
LN.CNT 1822
INCL INCLM: 530/329.000
NCL NCLM: 530/329.000
IC [6]
ICM: A61K038-08
ICS: A61K038-04

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 57 OF 95 USPATFULL on STN
AN 97:47433 USPATFULL
TI Intermediates to tetrahydro-beta-carbolines
IN Audia, James E., Indianapolis, IN, United States
Droste, James J., Indianapolis, IN, United States
Evrard, Deborah A., Indianapolis, IN, United States
Fludzinski, Pawel, Indianapolis, IN, United States
Murdoch, Gwyn L., Greenwood, IN, United States
Nelson, David L., Carmel, IN, United States
PA Eli Lilly and Company, Indianapolis, IN, United States (U.S. corporation)
PI US 5635528 19970603
AI US 1995-481716 19950607 (8)
RLI Continuation-in-part of Ser. No. US 1994-206839, filed on 11 Mar 1994, now patented, Pat. No. US 5500431, issued on 19 Mar 1996 which is a continuation-in-part of Ser. No. US 1993-48544, filed on 14 Apr 1993, now abandoned
DT Utility
FS Granted
LN.CNT 3182
INCL INCLM: 514/415.000
INCLS: 514/419.000; 548/504.000; 548/507.000
NCL NCLM: 514/415.000
NCLS: 514/419.000; 548/504.000; 548/507.000
IC [6]
ICM: A61K031-405
ICS: C07D209-16
EXF 514/415; 514/419; 548/494; 548/504; 548/507
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 58 OF 95 USPATFULL on STN
AN 97:42890 USPATFULL
TI 8-substituted tetrahydro-beta-carbolines
IN Audia, James E., Indianapolis, IN, United States
Droste, James J., Indianapolis, IN, United States
Nissen, Jeffrey S., Indianapolis, IN, United States
PA Eli Lilly and Company, Indianapolis, IN, United States (U.S. corporation)
PI US 5631265 19970520
AI US 1995-380564 19950206 (8)
RLI Continuation-in-part of Ser. No. US 1994-358644, filed on 19 Dec 1994, now abandoned which is a continuation of Ser. No. US 1994-212404, filed on 11 Mar 1994, now abandoned
DT Utility
FS Granted
LN.CNT 1457
INCL INCLM: 514/292.000
INCLS: 546/085.000; 546/086.000; 546/087.000
NCL NCLM: 514/292.000
NCLS: 546/085.000; 546/086.000; 546/087.000
IC [6]
ICM: A61K031-395
ICS: C07D471-04
EXF 514/292; 546/85; 546/86; 546/87
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 59 OF 95 USPATFULL on STN
AN 97:40795 USPATFULL
TI Tetrahydro-beta-carbolines
IN Audia, James E., Indianapolis, IN, United States
Baker, Stephen R., Camberley, England
Carrera, Jesus E., Madrid, Spain
Peteira, Carlos L., Madrid, Spain
Tercero, Concepcion P., Madrid, Spain
PA Eli Lilly and Company, Indianapolis, IN, United States (U.S. corporation)
PI US 5629317 19970513
AI US 1995-444450 19950519 (8)
RLI Division of Ser. No. US 1995-380565, filed on 6 Feb 1995, now abandoned
DT Utility
FS Granted
LN.CNT 1594
INCL INCLM: 514/278.000

546/049.000; 546/053.000; 546/085.000; 546/086.000; 546/087.000; 546/070.000
NCL NCLM: 514/278.000
NCLS: 514/279.000; 514/280.000; 514/292.000; 546/018.000; 546/041.000; 546/049.000; 546/053.000; 546/070.000; 546/085.000; 546/086.000; 546/087.000
IC [6]
ICM: A61K031-44
ICS: C07D471-10; C07D487-04; C07D487-10
EXF 546/18; 546/70; 546/41; 546/49; 546/53; 546/85; 546/87; 514/278; 514/285; 514/279; 514/280; 514/292
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 60 OF 95 USPATFULL on STN
AN 97:20543 USPATFULL
TI Use of .alpha..sub.1A -selective adrenoceptor agonists for the treatment of urinary incontinence
IN Craig, Douglas A., Fair Lawn, NJ, United States
Forray, Carlos C., Paramus, NJ, United States
Gluchowski, Charles, Wayne, NJ, United States
Branchek, Theresa A., Teaneck, NJ, United States
PA Synaptic Pharmaceutical Corporation, Paramus, NJ, United States (U.S. corporation)
PI US 5610174 19970311
AI US 1995-459410 19950602 (8)
DT Utility
FS Granted
LN.CNT 1626
INCL INCLM: 514/401.000
INCLS: 514/402.000; 514/400.000; 514/396.000; 514/605.000; 514/394.000; 514/414.000; 514/415.000; 514/418.000; 514/452.000; 514/466.000
NCL NCLM: 514/401.000
NCLS: 514/394.000; 514/396.000; 514/400.000; 514/402.000; 514/414.000; 514/415.000; 514/418.000; 514/452.000; 514/466.000; 514/605.000
IC [6]
ICM: A61K031-415
ICS: A61K031-18; A61K031-40; A61K031-405
EXF 514/400; 514/396; 514/402; 514/605; 514/394; 514/414; 514/415; 514/418; 514/452; 514/466; 514/401
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 61 OF 95 USPATFULL on STN
AN 97:16051 USPATFULL
TI Bicyclic heterocyclic derivatives having .alpha..sub.1 adrenergic and 5HT.sub.1A activities
IN Leonardi, Amedeo, Milan, Italy
Motta, Gianni, Barlassina, Italy
Riva, Carlo, Varese, Italy
Testa, Rodolfo, Milan, Italy
PA Recordati S.A., Chemical and Pharmaceutical Company, Chiasso, Switzerland (non-U.S. corporation)
PI US 5605896 19970225
AI US 1994-299188 19940831 (8)
RLI Continuation-in-part of Ser. No. US 1993-67861, filed on 26 May 1993, now patented, Pat. No. US 5474994 which is a continuation-in-part of Ser. No. US 1992-888775, filed on 26 May 1992, now patented, Pat. No. US 5403842
PRAI IT 1992-MI408 19920225
DT Utility
FS Granted
LN.CNT 8029
INCL INCLM: 514/218.000
INCLS: 546/153.000; 546/169.000; 546/170.000; 546/171.000; 546/176.000; 546/174.000; 546/175.000; 546/196.000; 546/202.000; 546/204.000; 548/304.400; 548/491.000; 549/023.000; 549/049.000; 549/362.000; 549/398.000; 549/401.000; 549/403.000; 549/405.000; 514/234.500; 514/232.200; 514/233.500; 514/253.000; 514/314.000; 514/414.000; 514/443.000; 514/452.000; 514/394.000; 514/456.000; 514/469.000; 540/575.000; 544/143.000; 544/144.000; 544/146.000; 544/148.000; 544/151.000; 544/153.000; 544/363.000; 544/373.000; 544/376.000; 544/377.000
NCL NCLM: 514/218.000
NCLS: 514/232.200; 514/233.500; 514/234.500; 514/252.130; 514/253.070; 514/253.080; 514/254.110; 514/314.000; 514/394.000; 514/414.000; 514/443.000; 514/452.000; 514/456.000; 514/469.000; 540/575.000;

544/153.000; 544/363.000; 544/373.000; 544/376.000; 544/377.000;
546/121.000; 546/153.000; 546/169.000; 546/170.000; 546/174.000;
546/175.000; 546/176.000; 546/196.000; 546/202.000; 546/204.000;
548/304.400; 548/491.000; 549/023.000; 549/049.000; 549/362.000;
549/398.000; 549/401.000; 549/403.000; 549/405.000
IC [6]
ICM: C07D243-08
ICS: C07D413-00; C07D215-16; C07D235-04; A61K031-395; A61K031-47;
A61K031-38; A61K031-335
EXF 540/575; 544/143; 544/144; 544/146; 544/148; 544/151; 544/153; 544/363;
544/373; 544/376; 544/377; 546/153; 546/169; 546/170; 546/121; 546/176;
546/174; 546/175; 546/196; 546/202; 546/204; 548/304.4; 548/991; 549/23;
549/49; 549/362; 549/398; 549/401; 549/403; 549/405; 514/218; 514/234.5;
514/232.2; 514/233.5; 514/253; 514/314; 514/414; 514/443; 514/452;
514/394; 514/456; 514/469
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 62 OF 95 USPATFULL on STN
AN 96:65572 USPATFULL
TI Tetrahydro-pyrido-indole
IN Audia, James E., Indianapolis, IN, United States
Droste, James J., Indianapolis, IN, United States
Evrard, Deborah A., Cambridge, MA, United States
PA Eli Lilly and Company, Indianapolis, IN, United States (U.S.
corporation)
PI US 5538981 19960723
AI US 1995-438595 19950510 (8)
RLI Division of Ser. No. US 1994-206830, filed on 11 Mar 1994, now abandoned
which is a continuation-in-part of Ser. No. US 1993-48392, filed on 14
Apr 1993, now patented, Pat. No. US 5300645
DT Utility
FS Granted
LN.CNT 2043
INCL INCLM: 514/292.000
INCLS: 546/085.000; 546/086.000; 546/087.000
NCL NCLM: 514/292.000
NCLS: 546/085.000; 546/086.000; 546/087.000
IC [6]
ICM: A61K031-44
ICS: C07D471-04
EXF 546/85; 546/86; 546/87; 514/292
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 63 OF 95 USPATFULL on STN
AN 96:65571 USPATFULL
TI Tetrahydro-pyrido-indole
IN Audia, James E., Indianapolis, IN, United States
Droste, James J., Indianapolis, IN, United States
Evrard, Deborah A., Cambridge, MA, United States
PA Eli Lilly and Company, Indianapolis, IN, United States (U.S.
corporation)
PI US 5538980 19960723
AI US 1995-437912 19950510 (8)
RLI Division of Ser. No. US 1994-206830, filed on 11 Mar 1994, now abandoned
which is a continuation-in-part of Ser. No. US 1993-48392, filed on 14
Apr 1993, now patented, Pat. No. US 5300645
DT Utility
FS Granted
LN.CNT 2020
INCL INCLM: 514/285.000
INCLS: 546/070.000
NCL NCLM: 514/285.000
NCLS: 546/070.000
IC [6]
ICM: A61K031-44
ICS: C07D471-04
EXF 514/285; 546/70
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 64 OF 95 USPATFULL on STN
AN 96:60705 USPATFULL
TI Spiro compounds containing five-membered rings
IN Fisher, Abraham, 4717 David Elazar Street, Holon, Israel
Karton, Yishai, 8 Ben-Gurion Street, Ness-Ziona, Israel
Marciano, Daniele, 22 Usichkin Street, Ramat-Hasharon, Israel

Meshulam, Haim, 13 Harishohim Street, Bat-Yam, Israel
PI US 5534520 19960709
AI US 1993-94855 19930720 (8)
RLI Continuation-in-part of Ser. No. US 1991-685397, filed on 9 Apr 1991, now abandoned which is a continuation-in-part of Ser. No. US 1990-507708, filed on 10 Apr 1990, now abandoned
DT Utility
FS Granted
LN.CNT 2865
INCL INCLM: 514/278.000
INCLS: 546/016.000; 546/019.000; 546/020.000
NCL NCLM: 514/278.000
NCLS: 546/016.000; 546/019.000; 546/020.000
IC [6]
ICM: A61K031-445
ICS: C07D221-20; C07D491-10; C07D491-20
EXF 546/16; 546/19; 546/20; 514/278
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 65 OF 95 USPATFULL on STN
AN 96:31833 USPATFULL
TI Tetrahydro-beta-carbolines
IN Audia, James E., Indianapolis, IN, United States
Droste, James J., Indianapolis, IN, United States
Evrard, Deborah A., Cambridge, MA, United States
Fludzinski, Pawel, Berkshire, United Kingdom
Murdoch, Gwyn L., Greenwood, IN, United States
Nelson, David L., Carmel, IN, United States
PA Eli Lilly and Company, Indianapolis, IN, United States (U.S. corporation)
PI US 5508284 19960416
AI US 1995-448005 19950523 (8)
RLI Division of Ser. No. US 1994-206839, filed on 11 Mar 1994 which is a continuation-in-part of Ser. No. US 1993-48544, filed on 14 Apr 1993, now abandoned
DT Utility
FS Granted
LN.CNT 3037
INCL INCLM: 514/285.000
INCLS: 546/070.000
NCL NCLM: 514/285.000
NCLS: 546/070.000
IC [6]
ICM: A61K031-44
ICS: C07D471-04
EXF 514/285; 546/70
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 66 OF 95 USPATFULL on STN
AN 96:23114 USPATFULL
TI Tetrahydro-.beta.-carbolines
IN Audia, James E., Indianapolis, IN, United States
Droste, James J., Indianapolis, IN, United States
Evrard, Deborah A., Cambridge, MA, United States
Fludzinski, Pawel, Berkshire, United Kingdom
Murdoch, Gwyn L., Greenwood, IN, United States
Nelson, David L., Carmel, IN, United States
PA Eli Lilly and Company, Indianapolis, IN, United States (U.S. corporation)
PI US 5500431 19960319
AI US 1994-206839 19940311 (8)
RLI Continuation-in-part of Ser. No. US 1993-48544, filed on 14 Apr 1993, now abandoned
DT Utility
FS Granted
LN.CNT 3023
INCL INCLM: 514/280.000
INCLS: 546/049.000
NCL NCLM: 514/280.000
NCLS: 546/049.000
IC [6]
ICM: A61K031-44
ICS: C07D471-04
EXF 514/280; 546/49; 546/56
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 67 OF 95 USPATFULL on STN
AN 96:17000 USPATFULL
TI Method of ameliorating cerebral circulation
IN Nishikibe, Masaru, Urayasu, Japan
Kamei, Kazuo, Fuchu, Japan
Nagura, Jun, Ichikawa, Japan
Fukuroda, Takahiro, Tokyo, Japan
PA Banyu Pharmaceutical Co., Ltd., Tokyo, Japan (non-U.S. corporation)
PI US 5494923 19960227
AI US 1995-409669 19950324 (8)
RLI Division of Ser. No. US 1994-282657, filed on 29 Jul 1994, now patented, Pat. No. US 5444077 which is a continuation of Ser. No. US 1991-645309, filed on 24 Jan 1991, now abandoned which is a continuation of Ser. No. US 1988-254106, filed on 6 Oct 1988, now abandoned
PRAI JP 1987-251988 19871006
JP 1988-43526 19880226
DT Utility
FS Granted
LN.CNT 950
INCL INCLM: 514/356.000
NCL NCLM: 514/356.000
IC [6]
ICM: A81K031-44
EXF 514/356; 546/321

L5 ANSWER 68 OF 95 USPATFULL on STN
AN 96:9427 USPATFULL
TI Tetrahydro-pyrido-indole
IN Audia, James E., Indianapolis, IN, United States
Droste, James J., Indianapolis, IN, United States
Evrard, Deborah A., Cambridge, MA, United States
PA Eli Lilly and Company, Indianapolis, IN, United States (U.S. corporation)
PI US 5488053 19960130
AI US 1994-206830 19940311 (8)
RLI Continuation-in-part of Ser. No. US 1993-48392, filed on 14 Apr 1993, now patented, Pat. No. US 5300645
DT Utility
FS Granted
LN.CNT 1999
INCL INCLM: 514/280.000
INCLS: 546/049.000
NCL NCLM: 514/280.000
NCLS: 546/049.000
IC [6]
ICM: A61K031-44
ICS: C07D471-04
EXF 546/49; 546/56; 514/280
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 69 OF 95 USPATFULL on STN
AN 95:110442 USPATFULL
TI Bicyclic heterocyclic derivatives having .alpha..sub.1 -adrenergic and 5HT.sub.1A
IN Leonardi, Amedeo, Milan, Italy
Motta, Gianni, Barlassina, Italy
Riva, Carlo, Varese, Italy
Testa, Rodolfo, Milan, Italy
PA Recordati S.A., Chemical and Pharmaceutical Company, Chiasso, Switzerland (non-U.S. corporation)
PI US 5474994 19951212
AI US 1993-67861 19930526 (8)
RLI Continuation-in-part of Ser. No. US 1992-888775, filed on 26 May 1992, now patented, Pat. No. US 5403842
PRAI EP 1993-301264 19930222
DT Utility
FS Granted
LN.CNT 6301
INCL INCLM: 514/218.000
INCLS: 514/253.000; 514/320.000; 514/324.000; 514/433.000; 514/456.000; 540/575.000; 544/295.000; 544/376.000; 546/196.000; 546/202.000; 546/204.000; 546/181.000; 546/169.000; 546/170.000; 546/176.000; 549/401.000; 549/403.000; 549/405.000; 549/023.000
NCL NCLM: 514/218.000
NCLS: 514/254.110; 514/320.000; 514/324.000; 514/433.000; 514/456.000;

546/176.000; 546/181.000; 546/196.000; 546/202.000; 546/204.000;
549/023.000; 549/401.000; 549/403.000; 549/405.000
IC [6]
ICM: C07D307-30
ICS: C07D409-02; A61K031-50; A61K031-445
EXF 540/575; 544/295; 544/376; 546/196; 546/202; 546/204; 546/181; 546/169;
546/170; 546/176; 549/401; 549/403; 549/405; 549/23; 514/253; 514/218;
514/320; 514/324; 514/433; 514/456
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 70 OF 95 USPATFULL on STN
AN 95:75986 USPATFULL
TI Ameliorant of cerebral circulation and optical isomer of NB-818, processes for its use
IN Nishikibe, Masaru, Urayasu, Japan
Kamei, Kazuo, Fuchu, Japan
Nagura, Jun, Ichikawa, Japan
Fukuroda, Takahiro, Tokyo, Japan
PA Banyu Pharmaceutical Co., Ltd., Tokyo, Japan (non-U.S. corporation)
PI US 5444077 19950822
AI US 1994-282657 19940729 (8)
RLI Continuation of Ser. No. US 1991-645309, filed on 24 Jan 1991, now abandoned which is a continuation of Ser. No. US 1988-254106, filed on 6 Oct 1988, now abandoned
PRAI JP 1987-251988 19871006
JP 1988-43526 19880226
DT Utility
FS Granted
LN.CNT 980
INCL INCLM: 514/356.000
INCLS: 546/321.000
NCL NCLM: 514/356.000
NCLS: 546/321.000
IC [6]
ICM: A61K031-44
ICS: C07D211-90
EXF 514/356; 546/321
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 71 OF 95 USPATFULL on STN
AN 95:29644 USPATFULL
TI Benzopyran and benzothiopyran derivatives
IN Leonardi, Amedeo, Milan, Italy
Motta, Gianni, Barlassina, Italy
Riva, Carlo, Varese, Italy
Testa, Rodolfo, Milan, Italy
PA Recordati S.A., Chemical and Pharmaceutical Company, Chiasso, Switzerland (non-U.S. corporation)
PI US 5403842 19950404
AI US 1992-888775 19920526 (7)
PRAI IT 1992-408 19920225
DT Utility
FS Granted
LN.CNT 3226
INCL INCLM: 514/252.000
INCLS: 524/253.000; 544/295.000; 544/359.000; 546/196.000; 546/202.000;
549/023.000; 549/400.000; 549/403.000
NCL NCLM: 514/252.130
NCLS: 514/043.000; 514/252.200; 514/254.110; 544/295.000; 544/359.000;
546/196.000; 546/202.000; 549/023.000; 549/400.000; 549/403.000
IC [6]
ICM: A61K031-495
ICS: A61K031-50; C07D403-00
EXF 544/295; 544/359; 514/253; 514/252
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 72 OF 95 USPATFULL on STN
AN 94:95436 USPATFULL
TI Sulfonanilide derivatives and medicine
IN Morino, Akira, Kyoto, Japan
Morita, Iwao, Kyoto, Japan
Tada, Shin-ichi, Shiga, Japan
PA Nippon Shinyaku Co. Ltd., Japan (non-U.S. corporation)
PI US 5360822 19941101
AI US 1993-171195 19931221 (8)

abandoned
PRAI JP 1990-227675 19900207
JP 1990-2136360 19900525
JP 1990-2278041 19901016
DT Utility
FS Granted
LN.CNT 976
INCL INCLM: 514/605.000
INCLS: 564/099.000
NCL NCLM: 514/605.000
NCLS: 564/099.000
IC [5]
ICM: C07C311-08
ICS: A61K031-18
EXF 514/605; 564/99
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 73 OF 95 USPATFULL on STN
AN 94:55545 USPATFULL
TI Benzodiazepine analogs
IN Bock, Mark G., Hatfield, PA, United States
Evans, Ben E., Lansdale, PA, United States
Freidinger, Roger M., Lansdale, PA, United States
PA Merck & Co., Inc., Rahway, NJ, United States (U.S. corporation)
PI US 5324726 19940628
AI US 1992-968624 19921029 (7)
RLI Continuation-in-part of Ser. No. US 1992-824764, filed on 17 Jan 1992, now abandoned which is a continuation of Ser. No. US 1990-621500, filed on 7 Dec 1990, now abandoned which is a continuation-in-part of Ser. No. US 1989-452012, filed on 18 Dec 1989, now abandoned
DT Utility
FS Granted
LN.CNT 1217
INCL INCLM: 514/221.000
INCLS: 540/504.000; 540/505.000; 540/509.000; 540/510.000; 540/512.000; 540/513.000; 540/514.000; 540/572.000; 540/573.000
NCL NCLM: 514/221.000
NCLS: 540/504.000; 540/505.000; 540/509.000; 540/510.000; 540/512.000; 540/513.000; 540/514.000; 540/572.000; 540/573.000
IC [5]
ICM: A61K031-55
ICS: C07D243-24; C07D243-22; C07D243-16
EXF 514/221; 540/504; 540/505; 540/509; 540/510; 540/512; 540/513; 540/514; 540/572; 540/573
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 74 OF 95 USPATFULL on STN
AN 93:52587 USPATFULL
TI .beta.-carbolines as cholecystokinin and gastrin antagonists
IN Evans, Ben E., Lansdale, PA, United States
PA Merck & Co., Inc., Rahway, NJ, United States (U.S. corporation)
PI US 5223509 19930629
AI US 1992-841231 19920221 (7)
RLI Continuation of Ser. No. US 1990-593547, filed on 2 Oct 1990, now abandoned which is a continuation of Ser. No. US 1989-363357, filed on 2 Jun 1989, now abandoned which is a continuation of Ser. No. US 1988-244583, filed on 13 Sep 1988, now abandoned which is a continuation of Ser. No. US 1987-86134, filed on 17 Aug 1987, now abandoned
DT Utility
FS Granted
LN.CNT 814
INCL INCLM: 514/292.000
INCLS: 514/210.000; 514/211.000; 514/255.000; 514/542.000; 514/599.000; 546/085.000; 546/086.000; 546/087.000
NCL NCLM: 514/292.000
NCLS: 514/079.000; 514/081.000; 514/255.050; 514/542.000; 514/599.000; 546/085.000; 546/086.000; 546/087.000
IC [5]
ICM: A61K031-435
ICS: C07D471-04
EXF 514/210; 514/211; 514/255; 514/292; 514/542; 514/599; 546/85; 546/86; 546/87
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 75 OF 95 USPATFULL on STN

TI Psychostimulant agent
IN Knoll, Jozsef, Budapest, Hungary
Simay, Antal, Budapest, Hungary
Szinnyei, Eva, Budapest, Hungary
Somfai, Eva, Budapest, Hungary
Torok, Zoltan, Budapest, Hungary
Mozsolits, Karoly, Sopron, Hungary
Bergmann, Janos, Visergad, Hungary
PA Chinoin Gyogyszer - es Vegyeszeti Termekek Gyara Rt., Buadpest, Hungary (non-U.S. corporation)
PI US 5220068 19930615
AI US 1991-649239 19910129 (7)
RLI Continuation of Ser. No. US 1988-269665, filed on 15 Jul 1988, now abandoned
PRAI HU 1986-4101 19860925
DT Utility
FS Granted
LN.CNT 677
INCL INCLM: 564/381.000
INCLS: 564/375.000; 564/376.000; 564/382.000
NCL NCLM: 564/381.000
NCLS: 564/374.000; 564/375.000; 564/376.000; 564/382.000
IC [5]
ICM: C07C211-27
ICS: A61K031-135
EXF 564/381; 564/382; 564/374; 514/654
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 76 OF 95 USPATFULL on STN
AN 93:37716 USPATFULL
TI 2-benzazepines with 5- and 6-membered heterocyclic rings to treat pain and anxiety disorders
IN Bock, Mark G., Hatfield, PA, United States
Evans, Ben E., Lansdale, PA, United States
Freidinger, Roger M., Lansdale, PA, United States
PA Merck & Co., Inc., Rahway, NJ, United States (U.S. corporation)
PI US 5210082 19930511
AI US 1991-701275 19910516 (7)
DT Utility
FS Granted
LN.CNT 849
INCL INCLM: 514/213.000
INCLS: 514/217.000
NCL NCLM: 514/215.000
NCLS: 514/217.000
IC [5]
ICM: A61K031-55
EXF 514/217; 514/213
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 77 OF 95 USPATFULL on STN
AN 93:33491 USPATFULL
TI Cholecystokinin antagonists
IN Bock, Mark G., Hatfield, PA, United States
Freidinger, Roger M., Lansdale, PA, United States
PA Merck & Co., Inc., Rahway, NJ, United States (U.S. corporation)
PI US 5206238 19930427
AI US 1992-870157 19920415 (7)
RLI Continuation of Ser. No. US 1990-612646, filed on 13 Nov 1990, now abandoned
DT Utility
FS Granted
LN.CNT 1004
INCL INCLM: 514/221.000
NCL NCLM: 514/221.000
IC [5]
ICM: A01K031-55
EXF 514/221
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 78 OF 95 USPATFULL on STN
AN 93:33490 USPATFULL
TI Benzodiazepine analogs
IN Freidinger, Roger M., Lansdale, PA, United States
Bock, Mark G., Hatfield, PA, United States

PA Merck & Co., Inc., Rahway, NJ, United States (U.S. corporation)
PI US 5206237 19930427
AI US 1991-699849 19910514 (7)
DT Utility
FS Granted
LN.CNT 1706
INCL INCLM: 514/219.000
INCLS: 514/221.000
NCL NCLM: 514/219.000
NCLS: 514/221.000
IC [5]
ICM: A61U031-55
EXF 514/219; 514/222; 514/221
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 79 OF 95 USPATFULL on STN
AN 93:33487 USPATFULL
TI Benzolactam analogs as antagonists of CCK
IN Bock, Mark G., Hatfield, PA, United States
Freidinger, Roger M., Lansdale, PA, United States
Evans, Ben E., Lansdale, PA, United States
PA Merck & Co., Inc., Rahway, NJ, United States (U.S. corporation)
PI US 5206234 19930427
AI US 1991-718075 19910620 (7)
RLI Continuation-in-part of Ser. No. US 1990-602031, filed on 22 Oct 1990, now abandoned
DT Utility
FS Granted
LN.CNT 1114
INCL INCLM: 514/213.000
INCLS: 540/523.000; 546/157.000; 548/465.000; 548/438.000; 514/312.000; 514/414.000; 514/415.000
NCL NCLM: 514/212.070
NCLS: 514/183.000; 514/312.000; 514/414.000; 514/415.000; 540/523.000; 546/157.000; 548/438.000; 548/465.000
IC [5]
ICM: A61K031-55
ICS: C07D223-16
EXF 540/523; 546/157; 548/465; 548/438; 514/213; 514/312; 514/414; 514/415
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 80 OF 95 USPATFULL on STN
AN 93:10514 USPATFULL
TI Triazolobenzodiazepines
IN Freidinger, Roger M., Lansdale, PA, United States
Bock, Mark G., Hatfield, PA, United States
Evans, Ben E., Lansdale, PA, United States
PA Merck & Co., Inc., Rahway, NJ, United States (U.S. corporation)
PI US 5185331 19930209
AI US 1991-699850 19910514 (7)
DT Utility
FS Granted
LN.CNT 2540
INCL INCLM: 514/220.000
NCL NCLM: 514/220.000
IC [5]
ICM: A61K031-55
EXF 514/220
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 81 OF 95 USPATFULL on STN
AN 93:1372 USPATFULL
TI 1,4-benzodiazepines with 6-membered heterocyclic rings to treat panic and anxiety disorder
IN Freidinger, Roger M., Lansdale, PA, United States
Evans, Ben E., Lansdale, PA, United States
Bock, Mark G., Hatfield, PA, United States
PA Merck & Co., Inc., Rahway, NJ, United States (U.S. corporation)
PI US 5177071 19930105
AI US 1991-716589 19910617 (7)
DT Utility
FS Granted
LN.CNT 783
INCL INCLM: 514/220.000
NCL NCLM: 514/220.000

ICM: A61U031-55
EXF 514/220
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 82 OF 95 USPATFULL on STN
AN 92:92760 USPATFULL
TI 2-Benzazepines with 5- and 6-membered heterocyclic rings, compositions and medical methods of use thereof
IN Freidinger, Roger M., Hatfield, PA, United States
Evans, Ben E., Lansdale, PA, United States
Bock, Mark G., Hatfield, PA, United States
PA Merck & Co., Inc., Rahway, NJ, United States (U.S. corporation)
PI US 5166151 19921124
AI US 1991-668353 19910311 (7)
RLI Continuation of Ser. No. US 1989-353224, filed on 15 May 1989, now abandoned which is a continuation of Ser. No. US 1988-175641, filed on 25 Mar 1988, now abandoned
DT Utility
FS Granted
LN.CNT 930
INCL INCLM: 514/215.000
INCLS: 514/217.000; 540/578.000
NCL NCLM: 514/215.000
NCLS: 514/217.000; 540/578.000
IC [5]
ICM: C07D471-04
ICS: A61K031-44; A61K031-55
EXF 548/578; 544/216; 544/217
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 83 OF 95 USPATFULL on STN
AN 92:65956 USPATFULL
TI Composition and method for treatment of senile dementia
IN Pang, Peter K. T., 52225 Range Road, 205 Carriage Lane, Sherwood Park, Alberta, Canada T8A 2A6
Wang, Lawrence C. H., 406 Rooney Crescent, Edmonton, Alberta, Canada T6R 1C8
Benishin, Christina G., 218-53431 Range Rd., 221, Ardressan, Alberta, Canada T0B 0E0
Liu, Hsing J., 3543-105B St., Edmonton, Alberta, Canada T6J 2K9
PI US 5137878 19920811
WO 9008315 19900726
AI US 1991-768423 19910913 (7)
WO 1990-US121 19900112
19910913 PCT 371 date
19910913 PCT 102(e) date
RLI Continuation-in-part of Ser. No. US 1989-297021, filed on 13 Jan 1989, now patented, Pat. No. US 4966893
DT Utility
FS Granted
LN.CNT 456
INCL INCLM: 514/054.000
INCLS: 514/879.000; 424/195.100; 536/005.000; 536/127.000; 536/128.000
NCL NCLM: 514/054.000
NCLS: 424/728.000; 514/879.000; 536/005.000; 536/127.000; 536/128.000
IC [5]
ICM: A61K031-751
ICS: A01N031-00; G01N031-00
EXF 514/54; 514/879; 424/195.1; 536/5; 536/127; 536/128
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 84 OF 95 USPATFULL on STN
AN 92:31856 USPATFULL
TI Linear free-sulfhydryl-containing oligopeptide derivatives as antihypertensive agents
IN Bovy, Philippe R., St. Louis, MO, United States
Manning, Robert E., St. Louis, MO, United States
O'Neal, Joan M., St. Louis, MO, United States
PA G. D. Searle & Co., Chicago, IL, United States (U.S. corporation)
PI US 5106834 19920421
AI US 1988-290667 19881227 (7)
DT Utility
FS Granted
LN.CNT 1361
INCL INCLM: 514/015.000

NCL NCLM: 514/015.000
NCLS: 514/013.000; 514/014.000; 530/326.000; 530/327.000; 530/328.000
IC [5]
ICM: A61K037-02
ICS: C07K007-06
EXF 530/328; 530/327; 530/326; 514/15; 514/14; 514/13
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 85 OF 95 USPATFULL on STN
AN 92:13094 USPATFULL
TI Amino acid analogs as CCK-antagonists
IN Freidinger, Roger M., Hatfield, PA, United States
PA Merck & Co., Inc., Rahway, NJ, United States (U.S. corporation)
PI US 5089638 19920218
AI US 1989-400608 19890830 (7)
RLI Division of Ser. No. US 1986-874928, filed on 16 Jun 1986, now patented, Pat. No. US 4880938
DT Utility
FS Granted
LN.CNT 739
INCL INCLM: 549/468.000
INCLS: 548/492.000; 548/571.000; 548/483.000; 549/462.000; 549/436.000; 549/057.000; 546/192.000; 546/225.000; 546/168.000; 544/106.000; 564/169.000; 564/183.000
NCL NCLM: 549/468.000
NCLS: 544/106.000; 546/168.000; 546/192.000; 546/225.000; 548/483.000; 548/492.000; 548/571.000; 549/057.000; 549/436.000; 549/462.000; 564/169.000; 564/183.000
IC [5]
ICM: C07D307-82
EXF 549/468
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 86 OF 95 USPATFULL on STN
AN 91:104215 USPATFULL
TI Method of treatment of learning deficiency
IN Knoll, Jozsef, Budapest, Hungary
Simay, Antal, Budapest, Hungary
Szinnyei, Eva, Budapest, Hungary
Somfai, Eva, Budapest, Hungary
Torok, Zoltan, Budapest, Hungary
Mozsolits, Karoly, Sopron, Hungary
Bergmann, Janos, Visegrad, Hungary
PA Chinoin Gyogyszer- es Vergyeszeti Termekek Gyara Rt., Budapest, Hungary (non-U.S. corporation)
PI US 5075338 19911224
AI US 1989-420058 19891011 (7)
RLI Division of Ser. No. US 1988-269665, filed on 9 Nov 1988
PRAI HU 1986-4101 19860925
DT Utility
FS Granted
LN.CNT 685
INCL INCLM: 514/654.000
NCL NCLM: 514/654.000
IC [5]
ICM: A61K031-135
EXF 514/654
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 87 OF 95 USPATFULL on STN
AN 91:26615 USPATFULL
TI Methods of antagonizing CCK or gastrin with benzodiazepine analogs
IN Evans, Ben E., Lansdale, PA, United States
Bock, Mark G., Hatfield, PA, United States
Freidinger, Roger M., Hatfield, PA, United States
PA Merck & Co., Inc., Rahway, NJ, United States (U.S. corporation)
PI US 5004741 19910402
AI US 1988-269212 19881109 (7)
RLI Division of Ser. No. US 1987-26420, filed on 16 Mar 1987, now patented, Pat. No. US 4820834 which is a continuation-in-part of Ser. No. US 1985-741972, filed on 10 Jun 1985, now abandoned which is a continuation-in-part of Ser. No. US 1985-705272, filed on 25 Feb 1985, now abandoned which is a continuation-in-part of Ser. No. US 1984-624854, filed on 26 Jun 1984, now abandoned
DT Utility

LN.CNT 8800
INCL INCLM: 514/221.000
INCLS: 514/925.000; 514/926.000; 514/927.000
NCL NCLM: 514/221.000
NCLS: 514/925.000; 514/926.000; 514/927.000
IC [5]
ICM: A61K031-55
EXF 514/221; 514/925; 514/926; 514/927
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 88 OF 95 USPATFULL on STN
AN 90:83617 USPATFULL
TI Method for treatment of senile dementia
IN Pang, Peter K. T., 52225 Range Road 232, 205 Carriage Lane, Sherwood Park, Alberta, Canada T8A 2A6
Wang, Lawrence C. H., 5012-144 St., Edmonton, Alberta, Canada T6G 2E9
Benishin, Christina G., 218-53431 Range Rd 221, Androssan, Alberta, Canada T0B 0E0
Liu, Hsing J., 3543-105 B St., Edmonton Alta., Canada T6J 2K9
PI US 4966893 19901030
AI US 1989-297012 19890113 (7)
DT Utility
FS Granted
LN.CNT 287
INCL INCLM: 514/054.000
INCLS: 536/005.000; 514/879.000; 424/195.100
NCL NCLM: 514/054.000
NCLS: 424/728.000; 514/879.000; 536/005.000
IC [5]
ICM: A61K035-78
ICS: C07H015-20
EXF 023/230R; 536/5; 536/127; 536/128; 514/54; 514/879; 424/195.1
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 89 OF 95 USPATFULL on STN
AN 89:92644 USPATFULL
TI Amino acid analogs
IN Freidinger, Roger M., Hatfield, PA, United States
PA Merck & Co., Inc., Rahway, NJ, United States (U.S. corporation)
PI US 4880938 19891114
AI US 1986-874928 19860616 (6)
DT Utility
FS Granted
LN.CNT 759
INCL INCLM: 548/492.000
INCLS: 564/183.000; 564/169.000; 549/436.000; 549/057.000; 548/483.000; 548/571.000; 546/225.000; 546/168.000; 544/106.000
NCL NCLM: 548/492.000
NCLS: 544/106.000; 546/168.000; 546/225.000; 548/483.000; 548/571.000; 549/057.000; 549/436.000; 564/169.000; 564/183.000
IC [4]
ICM: C07D209-18
EXF 548/492; 548/483; 514/419
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 90 OF 95 USPATFULL on STN
AN 89:56397 USPATFULL
TI 1,4-Benzodiazepines with 5- and 6-membered heterocyclic rings and their use as cholecystokinins and gastrin antagonists
IN Freidinger, Roger M., Hatfield, PA, United States
Evans, Ben E., Lansdale, PA, United States
Bock, Mark G., Hatfield, PA, United States
PA Merck & Co., Inc., Rahway, NJ, United States (U.S. corporation)
PI US 4847248 19890711
AI US 1988-141435 19880106 (7)
RLI Division of Ser. No. US 1986-946392, filed on 23 Dec 1986, now patented, Pat. No. US 4735941
DT Utility
FS Granted
LN.CNT 859
INCL INCLM: 514/214.000
INCLS: 540/558.000; 540/561.000; 540/562.000
NCL NCLM: 514/220.000
NCLS: 540/558.000; 540/561.000; 540/562.000
IC [4]

ICS: C07D487-04
EXF 540/561; 540/562; 514/214
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 91 OF 95 USPATFULL on STN
AN 89:28036 USPATFULL
TI Benzodiazepine analogs
IN Evans, Ben E., Lansdale, PA, United States
Freidinger, Roger M., Hatfield, PA, United States
Bock, Mark G., Hatfield, PA, United States
PA Merck & Co., Inc., Rahway, NJ, United States (U.S. corporation)
PI US 4820834 19890411
AI US 1987-26420 19870316 (7)
RLI Continuation-in-part of Ser. No. US 1985-741972, filed on 10 Jun 1985, now abandoned which is a continuation-in-part of Ser. No. US 1985-705272, filed on 25 Feb 1985, now abandoned which is a continuation-in-part of Ser. No. US 1984-624854, filed on 26 Jun 1984, now abandoned
DT Utility
FS Granted
LN.CNT 8808
INCL INCLM: 540/504.000
INCLS: 540/505.000; 540/506.000; 540/507.000; 540/508.000; 540/509.000; 540/510.000; 540/512.000; 540/513.000; 540/514.000; 540/564.000; 540/570.000; 540/571.000; 540/572.000; 540/573.000
NCL NCLM: 540/504.000
NCLS: 540/505.000; 540/506.000; 540/507.000; 540/508.000; 540/509.000; 540/510.000; 540/512.000; 540/513.000; 540/514.000; 540/564.000; 540/570.000; 540/571.000; 540/572.000; 540/573.000
IC [4]
ICM: C07D243-24
ICS: C07D243-22; C07D243-20; A61K031-55
EXF 540/504; 540/505; 540/506; 540/507; 540/508; 540/509; 540/510; 540/512; 540/513; 540/514; 540/569; 540/570; 540/571; 540/572; 540/573
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 92 OF 95 USPATFULL on STN
AN 88:42346 USPATFULL
TI Benzodiazepine analogs and use as antogonists of gastrin and cholecystokinin
IN Bock, Mark G., Hatfield, PA, United States
Evans, Ben E., Lansdale, PA, United States
Freidinger, Roger M., Hatfield, PA, United States
PA Merck & Co., Inc., Rahway, NJ, United States (U.S. corporation)
PI US 4755508 19880705
AI US 1987-20261 19870227 (7)
RLI Continuation-in-part of Ser. No. US 1985-741973, filed on 10 Jul 1985, now abandoned which is a continuation-in-part of Ser. No. US 1984-624852, filed on 26 Jun 1984, now abandoned
DT Utility
FS Granted
LN.CNT 1686
INCL INCLM: 514/221.000
INCLS: 540/542.000; 540/570.000; 540/571.000; 540/572.000
NCL NCLM: 514/221.000
NCLS: 540/542.000; 540/570.000; 540/571.000; 540/572.000
IC [4]
ICM: A61K031-55
ICS: C07D243-20; C07D243-16
EXF 514/221; 540/542; 540/570; 540/571; 540/572
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 93 OF 95 USPATFULL on STN
AN 88:21134 USPATFULL
TI 1,4-benzodiazepines with 5- and 6-membered heterocyclic rings, useful as gastrointestinal and CNS agents
IN Freidinger, Roger M., Hatfield, PA, United States
Bock, Mark G., Hatfield, PA, United States
Evans, Ben E., Lansdale, PA, United States
PA Merck & Co., Inc., Rahway, NJ, United States (U.S. corporation)
PI US 4735941 19880405
AI US 1986-946392 19861223 (6)
DT Utility
FS Granted
LN.CNT 915

```
       INCLS: 540/559.000
NCL    NCLM:  514/220.000
       NCLS:  540/559.000
IC     [4]
       ICM: A61K031-55
       ICS: C07D487-04
EXF    540/559; 544/184; 514/220
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5   ANSWER 94 OF 95  USPATFULL on STN
AN     87:32233  USPATFULL
TI     Triazolobenzodiazepines and pharmaceutical use
IN     Bock, Mark G., Hatfield, PA, United States
       Evans, Ben E., Lansdale, PA, United States
       Freidinger, Roger M., Hatfield, PA, United States
PA     Merck & Co., Inc., Rahway, NJ, United States (U.S. corporation)
PI     US 4663321              19870505
AI     US 1985-741971          19850610 (6)
RLI    Continuation-in-part of Ser. No. US 1984-624850, filed on 26 Jun 1984,
       now abandoned
DT     Utility
FS     Granted
LN.CNT 2439
INCL   INCLM: 514/220.000
       INCLS: 540/563.000; 540/564.000; 540/565.000; 540/566.000; 540/542.000
NCL    NCLM:  514/220.000
       NCLS:  540/542.000; 540/563.000; 540/564.000; 540/565.000; 540/566.000
IC     [4]
       ICM: A61K031-55
       ICS: C07D487-04
EXF    260/245.5; 260/244.4; 260/243.3; 514/220; 540/563; 540/564; 540/565;
       540/566; 540/542
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5   ANSWER 95 OF 95  USPATFULL on STN
AN     85:37213  USPATFULL
TI     Anti-psychotic phenylindene derivatives and acid addition salts thereof
IN     Perregaard, Jens K., Olstykke, Denmark
PA     Kefalas A/S, Copenhagen, Denmark (non-U.S. corporation)
PI     US 4525360              19850625
AI     US 1983-539308          19831005 (6)
PRAI   GB 1982-28729       19821007
DT     Utility
FS     Granted
LN.CNT 896
INCL   INCLM: 514/277.000
       INCLS: 514/340.000; 546/205.000; 546/206.000; 546/277.000; 546/278.000;
              546/330.000; 546/339.000; 546/344.000; 546/348.000; 546/350.000;
              514/341.000; 514/342.000; 514/357.000
NCL    NCLM:  514/277.000
       NCLS:  514/340.000; 514/341.000; 514/342.000; 514/357.000; 544/267.000;
              546/205.000; 546/206.000; 546/269.700; 546/271.400; 546/274.400;
              546/284.400; 546/330.000; 546/339.000; 546/344.000; 546/348.000;
              546/350.000
IC     [3]
       ICM: A61K031-44
       ICS: A61K031-445; C07D401-06; C07D211-08
EXF    546/205; 546/206; 546/277; 546/278; 546/330; 546/339; 546/344; 546/348;
       546/350; 424/263; 424/267
CAS INDEXING IS AVAILABLE FOR THIS PATENT.


=> S L2 AND L3
  36 FILES SEARCHED...
L6          472 L2 AND L3

=> DUP REM L6
DUPLICATE IS NOT AVAILABLE IN 'ADISINSIGHT, ADISNEWS, BIOCOMMERCE, DGENE,
DRUGMONOG2, FEDRIP, FOREGE, GENBANK, IMSPRODUCT, IMSRESEARCH, KOSMET,
MEDICONF, NUTRACEUT, PCTGEN, PHAR, PHARMAML, PROUSDDR, RDISCLOSURE, SYNTHLINE'.
ANSWERS FROM THESE FILES WILL BE CONSIDERED UNIQUE
PROCESSING COMPLETED FOR L6
L7           291 DUP REM L6 (181 DUPLICATES REMOVED)

=> S L7 AND PY<=1999
```

```
   4 FILES SEARCHED...
   8 FILES SEARCHED...
  12 FILES SEARCHED...
  15 FILES SEARCHED...
  20 FILES SEARCHED...
'1999' NOT A VALID FIELD CODE
  27 FILES SEARCHED...
  31 FILES SEARCHED...
'1999' NOT A VALID FIELD CODE
'1999' NOT A VALID FIELD CODE
  44 FILES SEARCHED...
'1999' NOT A VALID FIELD CODE
  48 FILES SEARCHED...
  53 FILES SEARCHED...
'1999' NOT A VALID FIELD CODE
  59 FILES SEARCHED...
'1999' NOT A VALID FIELD CODE
  65 FILES SEARCHED...
  71 FILES SEARCHED...
L8          188 L7 AND PY<=1999

=> D L8 1-888

L8   ANSWER 1 OF 188  BIOSIS  COPYRIGHT (c) 2004 The Thomson Corporation.  on
     STN
AN   1998:437498  BIOSIS
DN   PREV199800437498
TI   Thiopental inhibits increases in (Ca2+)i induced by membrane
     depolarization, NMDA receptor activation, and ischemia in rat hippocampal
     and cortical slices.
AU   Zhan, Ren-Zhi [Reprint author]; Fujiwara, Naoshi; Endoh, Hiroshi;
     Yamakura, Tomohiro; Taga, Kiichiro; Fukuda, Satoru; Shimoji, Koki
CS   Dep Anesthesiol., Niigata Univ. Sch. Med., 1-757 Asahimachi-dori, Niigata
     951-8510, Japan
SO   Anesthesiology (Hagerstown), (Aug., 1998) Vol. 89, No. 2, pp. 456-466.
     print.
     CODEN: ANESAV. ISSN: 0003-3022.
DT   Article
LA   English
ED   Entered STN: 7 Oct 1998
     Last Updated on STN: 7 Oct 1998

L8   ANSWER 2 OF 188  BIOSIS  COPYRIGHT (c) 2004 The Thomson Corporation.  on
     STN
AN   1997:460045  BIOSIS
DN   PREV199799759248
TI   Effects of selective h5-HT-1B (SB-216641) and h5-HT-1D (BRL-15572)
     receptor ligands on guinea-pig and human 5-HT auto- and heteroreceptors.
AU   Schlicker, E.; Fink, K.; Molderings, G. J.; Price, G. W.; Duckworth, M.;
     Gaster, L.; Middlemiss, D. N.; Zentner, J.; Likungu, J.; Goethert, M.
     [Reprint author]
CS   Institut fuer Pharmakologie und Toxikologie, Universitaet Bonn,
     Reuterstrasse 2 b, D-53113 Bonn, Germany
SO   Naunyn-Schmiedeberg's Archives of Pharmacology, (1997) Vol. 356, No. 3,
     pp. 321-327.
     CODEN: NSAPCC. ISSN: 0028-1298.
DT   Article
LA   English
ED   Entered STN: 27 Oct 1997
     Last Updated on STN: 10 Dec 1997

L8   ANSWER 3 OF 188  BIOSIS  COPYRIGHT (c) 2004 The Thomson Corporation.  on
     STN
AN   1997:442513  BIOSIS
DN   PREV199799741716
TI   N-methyl-D-aspartate evokes rapid net depolymerization of filamentous
     actin in cultured rat cerebellar granule cells.
AU   Shorte, Spencer L.
CS   INSERM Unit 261, Neurobiol. Cell. Mol., Batiment Biotechnol., Inst.
     Pasteur, 28 rue Docteur Roux, 75274 Paris Cedex 15, France
SO   Journal of Neurophysiology (Bethesda), (1997) Vol. 78, No. 2, pp.
     1135-1143.
     CODEN: JONEA4. ISSN: 0022-3077.
DT   Article
LA   English
```

Last Updated on STN: 8 Oct 1997

L8 ANSWER 4 OF 188 BIOSIS COPYRIGHT (c) 2004 The Thomson Corporation. on STN
AN 1997:170765 BIOSIS
DN PREV199799477368
TI Tetrahydroprotoberberine analogs antagonize alpha-1-adrenoceptors and inhibit mobilization of intracellular calcium.
AU Han, Chide [Reprint author]; Lu, Zhizheng; Wei, Xuan; Jin, Guozhang
CS Inst. Vasc. Med., Third Hosp., Beijing Med. Univ., Beijing 100083, China
SO Drug Development Research, (1996) Vol. 39, No. 2, pp. 191-196.
CODEN: DDREDK. ISSN: 0272-4391.
DT Article
LA English
ED Entered STN: 24 Apr 1997
Last Updated on STN: 24 Apr 1997

L8 ANSWER 5 OF 188 BIOSIS COPYRIGHT (c) 2004 The Thomson Corporation. on STN
AN 1996:272615 BIOSIS
DN PREV199698828744
TI Presynaptic 5-HT autoreceptors modulate N-methyl-D-aspartate-evoked 5-hydroxytryptamine release in the guinea-pig brain ***cortex***.
AU Fink, Klaus; Boeing, Carsten; Goethert, Manfred [Reprint author]
CS Inst. Pharmakol. Toxikologie, Univ. Bonn, Reuterstrasse 2b, D-53113 Bonn, Germany
SO European Journal of Pharmacology, (1996) Vol. 300, No. 1-2, pp. 79-82.
CODEN: EJPHAZ. ISSN: 0014-2999.
DT Article
LA English
ED Entered STN: 10 Jun 1996
Last Updated on STN: 11 Jul 1996

L8 ANSWER 6 OF 188 BIOSIS COPYRIGHT (c) 2004 The Thomson Corporation. on STN
AN 1996:264111 BIOSIS
DN PREV199698820240
TI Adrenocorticotropin causes vasodilatation in the human fetal-placental circulation.
AU Clifton, Vicki L.; Read, Mark A.; Boura, Alan L. A.; Robinson, Phillip J.; Smith, Roger [Reprint author]
CS Dep. Endocrinol., John Hunter Hospital, Locked Bag 1, Hunter Region Mail Center, Newcastle, 2310 New South Wales, Australia
SO Journal of Clinical Endocrinology and Metabolism, (1996) Vol. 81, No. 4, pp. 1406-1410.
CODEN: JCEMAZ. ISSN: 0021-972X.
DT Article
LA English
ED Entered STN: 10 Jun 1996
Last Updated on STN: 10 Jun 1996

L8 ANSWER 7 OF 188 BIOSIS COPYRIGHT (c) 2004 The Thomson Corporation. on STN
AN 1995:302822 BIOSIS
DN PREV199598317122
TI Muscarinic receptor modulation of acetylcholine release from rat cerebral ***cortex*** and hippocampus.
AU Vannucchi, Maria Giuliana; Pepeu, Giancarlo [Reprint author]
CS Dep. Preclinical Clinical Pharmacol., Univ. Florence, Viale Morgagni 65, 50134 Florence, Italy
SO Neuroscience Letters, (1995) Vol. 190, No. 1, pp. 53-56.
CODEN: NELED5. ISSN: 0304-3940.
DT Article
LA English
ED Entered STN: 11 Jul 1995
Last Updated on STN: 11 Jul 1995

L8 ANSWER 8 OF 188 BIOSIS COPYRIGHT (c) 2004 The Thomson Corporation. on STN
AN 1994:214059 BIOSIS
DN PREV199497227059
TI Increased GABA release in the human brain ***cortex*** as a potential pathogenetic basis of hyperosmolar diabetic coma.
AU Fink, K.; Zentner, J.; Goethert, M. [Reprint author]
CS Inst. Pharmacol. Toxicol., Univ. Bonn, Reuterstrasse 2b, D-53113 Bonn,

SO Journal of Neurochemistry, (1994) Vol. 62, No. 4, pp. 1476-1481.
CODEN: JONRA9. ISSN: 0022-3042.
DT Article
LA English
ED Entered STN: 10 May 1994
Last Updated on STN: 11 May 1994

L8 ANSWER 9 OF 188 BIOSIS COPYRIGHT (c) 2004 The Thomson Corporation. on STN
AN 1993:435867 BIOSIS
DN PREV199396090492
TI High D-glucose concentrations increase GABA release but inhibit release of norepinephrine and 5-hydroxytryptamine in rat cerebral ***cortex*** .
AU Fink, Klaus; Goethert, Manfred [Reprint author]
CS Inst. Pharmacol. Toxicol., Univ. Bonn, Reuterstr. 2b, D-53113 Bonn, Germany
SO Brain Research, (1993) Vol. 618, No. 2, pp. 220-226.
CODEN: BRREAP. ISSN: 0006-8993.
DT Article
LA English
ED Entered STN: 22 Sep 1993
Last Updated on STN: 23 Sep 1993

L8 ANSWER 10 OF 188 BIOSIS COPYRIGHT (c) 2004 The Thomson Corporation. on STN
AN 1993:78316 BIOSIS
DN PREV199395042816
TI General anaesthetics inhibit the responses induced by glutamate receptor agonists in the mouse ***cortex*** .
AU Carla, Vincenzo; Moroni, Flavio [Reprint author]
CS Dep. Preclinical Clinical Pharmacology, Univ. Florence, Viale Morgagni 65, 50134 Florence, Italy
SO Neuroscience Letters, (1992) Vol. 146, No. 1, pp. 21-24.
CODEN: NELED5. ISSN: 0304-3940.
DT Article
LA English
ED Entered STN: 26 Jan 1993
Last Updated on STN: 17 Mar 1993

L8 ANSWER 11 OF 188 BIOSIS COPYRIGHT (c) 2004 The Thomson Corporation. on STN
AN 1991:298884 BIOSIS
DN PREV199192019899; BA92:19899
TI OPPOSING EFFECTS OF DOPAMINE D-2 RECEPTOR STIMULATION ON THE SPONTANEOUS AND THE ELECTRICALLY EVOKED RELEASE OF TRITIATED GABA ON RAT PREFRONTAL ***CORTEX*** SLICES.
AU RETAUX S [Reprint author]; BESSON M J; PENIT-SORIA J
CS LAB DE NEUROCHIMIE-ANATOMIE, INST DES NEUROSCIENCES, UNIVERSITE PIERRE ET MARIE CURIE, 9 QUAI ST BERNARD, 75005 PARIS, FRANCE
SO Neuroscience, (1991) Vol. 42, No. 1, pp. 61-72.
CODEN: NRSCDN. ISSN: 0306-4522.
DT Article
FS BA
LA ENGLISH
ED Entered STN: 25 Jun 1991
Last Updated on STN: 13 Aug 1991

L8 ANSWER 12 OF 188 BIOSIS COPYRIGHT (c) 2004 The Thomson Corporation. on STN
AN 1990:520453 BIOSIS
DN PREV199090137729; BA90:137729
TI REGIONAL DIFFERENCES IN THE ELECTRICALLY STIMULATED RELEASE OF ENDOGENOUS AND RADIOACTIVE ADENOSINE AND PURINE DERIVATIVES FROM RAT BRAIN SLICES.
AU PEDATA F [Reprint author]; PAZZAGLI M; TILLI S; PEPEU G
CS DIP FARMACOLOGIA PRECLINICA CLINICA, UNIV FIRENZE, VIALE MORGAGNI 65, 50134 FIRENZE, ITALY
SO Naunyn-Schmiedeberg's Archives of Pharmacology, (1990) Vol. 342, No. 4, pp. 447-453.
CODEN: NSAPCC. ISSN: 0028-1298.
DT Article
FS BA
LA ENGLISH
ED Entered STN: 19 Nov 1990
Last Updated on STN: 20 Nov 1990

STN
AN 1990:452741 BIOSIS
DN PREV199090103381; BA90:103381
TI EFFECT OF OPIOID ANTAGONISTS ON ACETYLCHOLINE RELEASE FROM GUINEA-PIG BRAIN SLICE INFLUENCE OF PEPTIDASE INHIBITION.
AU SINISCALCHI A [Reprint author]; BERTELLI M G; BIANCHI C; BEANI L
CS DEP PHARMACOL, UNIV FERRARA, VIA FOSSATO DI MORTARA, 23, 4410 FERRARA, ITALY
SO Pharmacological Research, (1990) Vol. 22, No. 4, pp. 493-502.
CODEN: PHMREP. ISSN: 1043-6618.
DT Article
FS BA
LA ENGLISH
ED Entered STN: 7 Oct 1990
Last Updated on STN: 4 Jan 1991

L8 ANSWER 14 OF 188 BIOSIS COPYRIGHT (c) 2004 The Thomson Corporation. on STN
AN 1989:140172 BIOSIS
DN PREV198987074825; BA87:74825
TI A PHARMACOLOGICAL ANALYSIS OF THE 5-HT RECEPTOR MEDIATING INHIBITION OF 5-HT RELEASE IN THE GUINEA-PIG FRONTAL ***CORTEX*** .
AU MIDDLEMISS D N [Reprint author]; BREMER M E; SMITH S M
CS MERCK SHARPE AND DOHME RES LABORATORIES, NEUROSCI RES CENTRE, TERLINGS PARK, EASTWICK ROAD, HARLOW, ESSEX CM20 2QR, UK
SO European Journal of Pharmacology, (1988) Vol. 157, No. 1, pp. 101-108.
CODEN: EJPHAZ. ISSN: 0014-2999.
DT Article
FS BA
LA ENGLISH
ED Entered STN: 10 Mar 1989
Last Updated on STN: 10 Mar 1989

L8 ANSWER 15 OF 188 BIOSIS COPYRIGHT (c) 2004 The Thomson Corporation. on STN
AN 1988:506729 BIOSIS
DN PREV198886127413; BA86:127413
TI TRANSMISSION OF BURST RESPONSES THROUGH SLICES OF RAT CEREBRAL ***CORTEX*** .
AU BOAKES R J [Reprint author]; BURNS B D; WEBB A C
CS MRC NEUROENDOCRINOL UNIT, NEWCASTLE GEN HOSP, UK
SO Journal of Physiology (Cambridge), (1988) Vol. 404, pp. 467-478.
CODEN: JPHYA7. ISSN: 0022-3751.
DT Article
FS BA
LA ENGLISH
ED Entered STN: 22 Nov 1988
Last Updated on STN: 22 Nov 1988

L8 ANSWER 16 OF 188 BIOSIS COPYRIGHT (c) 2004 The Thomson Corporation. on STN
AN 1988:224839 BIOSIS
DN PREV198885114074; BA85:114074
TI MUSCARINIC MODULATION OF PURINE RELEASE FROM ELECTRICALLY STIMULATED RAT CORTICAL SLICES.
AU PEDATA F [Reprint author]; MAGNANI M; PEPEU G
CS DEP PRECLIN CLIN PHARMACOL, UNIV FLORENCE, VIALE MORGAGNI 65, 50134 FLORENCE, ITALY
SO Journal of Neurochemistry, (1988) Vol. 50, No. 4, pp. 1074-1079.
CODEN: JONRA9. ISSN: 0022-3042.
DT Article
FS BA
LA ENGLISH
ED Entered STN: 4 May 1988
Last Updated on STN: 4 May 1988

L8 ANSWER 17 OF 188 BIOSIS COPYRIGHT (c) 2004 The Thomson Corporation. on STN
AN 1988:153454 BIOSIS
DN PREV198885077107; BA85:77107
TI INHIBITION OF GUINEA-PIG ILEUM CONTRACTIONS MEDIATED BY A CLASS OF HISTAMINE RECEPTOR RESEMBLING THE H-3 SUBTYPE.
AU TRZECIAKOWSKI J P [Reprint author]
CS DEP MED PHARMACOL TOXICOL, ROOM 304 MED SCI BUILD, TEX A AND M UNIV, COLLEGE STATION, TEX 77843, USA

No. 3, pp. 874-880.
CODEN: JPETAB. ISSN: 0022-3565.
DT Article
FS BA
LA ENGLISH
ED Entered STN: 22 Mar 1988
Last Updated on STN: 22 Mar 1988

L8 ANSWER 18 OF 188 BIOSIS COPYRIGHT (c) 2004 The Thomson Corporation. on STN
AN 1988:74626 BIOSIS
DN PREV198885040925; BA85:40925
TI INFLUENCE OF N ALLYL-NORMETAZOCINE ON ACETYLCHOLINE RELEASE FROM BRAIN SLICES INVOLVEMENT OF MUSCARINIC RECEPTORS.
AU SINISCALCHI A [Reprint author]; CRISTOFORI P; VERATTI E
CS DEP PHARMACOL, UNIV FERRARA, VIA FOSSATO MORTARA, 23, I-44100 FERRARA, ITALY
SO Naunyn-Schmiedeberg's Archives of Pharmacology, (1987) Vol. 336, No. 4, pp. 425-429.
CODEN: NSAPCC. ISSN: 0028-1298.
DT Article
FS BA
LA ENGLISH
ED Entered STN: 27 Jan 1988
Last Updated on STN: 27 Jan 1988

L8 ANSWER 19 OF 188 BIOSIS COPYRIGHT (c) 2004 The Thomson Corporation. on STN
AN 1986:276936 BIOSIS
DN PREV198682020799; BA82:20799
TI DECREASED SODIUM POTASSIUM ATPASE ACTIVITY AND TRITIATED OUABAIN BINDING SITES IN VARIOUS TISSUES OF SPONTANEOUSLY HYPERTENSIVE RATS.
AU CHEN C-C [Reprint author]; LIN-SHIAU S-Y
CS PHARMACOL INST, COLL MED, NATIONAL TAIWAN UNIV, TAIPEI, TAIWAN 100
SO European Journal of Pharmacology, (1986) Vol. 122, No. 3, pp. 311-320.
CODEN: EJPHAZ. ISSN: 0014-2999.
DT Article
FS BA
LA ENGLISH
ED Entered STN: 4 Jul 1986
Last Updated on STN: 4 Jul 1986

L8 ANSWER 20 OF 188 BIOSIS COPYRIGHT (c) 2004 The Thomson Corporation. on STN
AN 1985:309293 BIOSIS
DN PREV198579089289; BA79:89289
TI GAMMA AMINOBUTYRIC-ACID-B RECEPTOR MODULATION OF ADENYLATE CYCLASE ACTIVITY IN RAT BRAIN SLICES.
AU HILL D R [Reprint author]
CS DEP PHARMACOL, SCH PHARMACY, UNIV LONDON, 29-39 BRUNSWICK SQUARE, LONDON, WC1N 1AX, UK
SO British Journal of Pharmacology, (1985) Vol. 84, No. 1, pp. 249-258.
CODEN: BJPCBM. ISSN: 0007-1188.
DT Article
FS BA
LA ENGLISH

L8 ANSWER 21 OF 188 BIOSIS COPYRIGHT (c) 2004 The Thomson Corporation. on STN
AN 1985:281877 BIOSIS
DN PREV198579061873; BA79:61873
TI 8 HYDROXY-2-DI-N-PROPYLAMINO TETRALIN IS DEVOID OF ACTIVITY AT THE 5 HYDROXYTRYPTAMINE AUTORECEPTOR IN RAT BRAIN IMPLICATIONS FOR THE PROPOSED LINK BETWEEN THE AUTORECEPTOR AND THE TRITIUM-LABELED 5 HYDROXYTRYPTAMINE RECOGNITION SITE.
AU MIDDLEMISS D N [Reprint author]
CS MERRELL DOW RESEARCH INSTITUTE-STRASBOURG CENTER, 16 RUE D'ANKARA, F-67084 STRASBOURG CEDEX, FRANCE
SO Naunyn-Schmiedeberg's Archives of Pharmacology, (1984) Vol. 327, No. 1, pp. 18-22.
CODEN: NSAPCC. ISSN: 0028-1298.
DT Article
FS BA
LA ENGLISH

STN
AN 1985:281852 BIOSIS
DN PREV198579061848; BA79:61848
TI BIPHASIC EFFECT OF METHYLXANTHINES ON ACETYLCHOLINE RELEASE FROM ELECTRICALLY-STIMULATED BRAIN SLICES.
AU PEDATA F [Reprint author]; PEPEU G; SPIGNOLI G
CS DEPARTMENT OF PHARMACOLOGY, UNIVERSITY OF FLORENCE, VIALE MORGAGNI 65, 50134, FLORENCE, ITALY
SO British Journal of Pharmacology, (1984) Vol. 83, No. 1, pp. 69-74.
CODEN: BJPCBM. ISSN: 0007-1188.
DT Article
FS BA
LA ENGLISH

L8 ANSWER 23 OF 188 BIOSIS COPYRIGHT (c) 2004 The Thomson Corporation. on STN
AN 1984:264563 BIOSIS
DN PREV198478001043; BA78:1043
TI ANGIOTENSIN II INDUCED HYPERTENSION IN THE RAT EFFECTS ON PLASMA CONCENTRATION RENAL EXCRETION AND TISSUE RELEASE OF PROSTAGLANDINS.
AU DIZ D I [Reprint author]; BAER P G; NASJLETTI A
CS BUILD 10, ROOM 3D-48, NATL INST MENTAL HEALTH, BETHESDA, MD 20205, USA
SO Journal of Clinical Investigation, (1983) Vol. 72, No. 2, pp. 466-477.
CODEN: JCINAO. ISSN: 0021-9738.
DT Article
FS BA
LA ENGLISH

L8 ANSWER 24 OF 188 BIOSIS COPYRIGHT (c) 2004 The Thomson Corporation. on STN
AN 1983:317552 BIOSIS
DN PREV198376075044; BA76:75044
TI EFFECT OF ADENOSINE ATP ADENOSINE DEAMINASE DIPYRIDAMOLE AND AMINOPHYLLINE ON ACETYL CHOLINE RELEASE FROM ELECTRICALLY STIMULATED BRAIN SLICES.
AU PEDATA F [Reprint author]; ANTONELLI T; LAMBERTINI L; BEANI L; PEPEU G
CS DEP PHARMACOL, UNIV FLORENCE, VIALE MORGAGNI 65, 50134 FLORENCE, ITALY
SO Neuropharmacology, (1983) Vol. 22, No. 5, pp. 609-614.
CODEN: NEPHBW. ISSN: 0028-3908.
DT Article
FS BA
LA ENGLISH

L8 ANSWER 25 OF 188 BIOSIS COPYRIGHT (c) 2004 The Thomson Corporation. on STN
AN 1983:247962 BIOSIS
DN PREV198376005454; BA76:5454
TI THE EFFECT OF NALOXONE ON OPIOID INDUCED INHIBITION AND FACILITATION OF ACETYL CHOLINE RELEASE IN BRAIN SLICES.
AU BEANI L [Reprint author]; BIANCHI C; SINISCALCHI A
CS DEP PHARMACOL, UNIV FERRARA, VIA FOSSATO MORTARA, 64/B, 44100 FERRARA, ITALY
SO British Journal of Pharmacology, (1982) Vol. 76, No. 3, pp. 393-402.
CODEN: BJPCBM. ISSN: 0007-1188.
DT Article
FS BA
LA ENGLISH

L8 ANSWER 26 OF 188 BIOSIS COPYRIGHT (c) 2004 The Thomson Corporation. on STN
AN 1982:291006 BIOSIS
DN PREV198274063486; BA74:63486
TI GAMMA AMINO BUTYRIC-ACID INDUCED CHANGES IN ACETYL CHOLINE RELEASE FROM SLICES OF GUINEA-PIG BRAIN.
AU BIANCHI C [Reprint author]; TANGANELLI S; MARZOLA G; BEANI L
CS DEP PHARMACOL, UNIV FERRARA, VIA FOSSATO DI MORTARA, 23, I-44100 FERRARA, ITALY
SO Naunyn-Schmiedeberg's Archives of Pharmacology, (1982) Vol. 318, No. 4, pp. 253-258.
CODEN: NSAPCC. ISSN: 0028-1298.
DT Article
FS BA
LA ENGLISH

L8 ANSWER 27 OF 188 BIOSIS COPYRIGHT (c) 2004 The Thomson Corporation. on STN

DN PREV198274026338; BA74:26338
TI IN-VIVO HIGH AFFINITY UPTAKE AND AXONAL TRANSPORT OF TRITIUM LABELED D ASPARTATE IN EXCITATORY NEURONS.
AU STORM-MATHISEN J [Reprint author]; WOLD J E
CS ANATOMICAL INSTITUTE, UNIV OF OSLO, KARL JOHANSGT 47, OSLO 1, NORWAY
SO Brain Research, (1981) Vol. 230, No. 1-2, pp. 427-433.
CODEN: BRREAP. ISSN: 0006-8993.
DT Article
FS BA
LA ENGLISH

L8 ANSWER 28 OF 188 BIOSIS COPYRIGHT (c) 2004 The Thomson Corporation. on STN
AN 1981:227239 BIOSIS
DN PREV198172012223; BA72:12223
TI INTERACTIONS BETWEEN IONOPHORES MAGNESIUM AND CALCIUM ON ACETYL CHOLINE FORMATION AND RELEASE IN BRAIN SLICES.
AU MANTOVANI P [Reprint author]; PEPEU G
CS DEP OF PHARMACOL, UNIV OF FLORENCE, VIALE MORGAGNI 65, 50134 FLORENCE, ITALY
SO Pharmacological Research Communications, (1981) Vol. 13, No. 2, pp. 175-184.
CODEN: PLRCAT. ISSN: 0031-6989.
DT Article
FS BA
LA ENGLISH

L8 ANSWER 29 OF 188 BIOSIS COPYRIGHT (c) 2004 The Thomson Corporation. on STN
AN 1980:246224 BIOSIS
DN PREV198070038720; BA70:38720
TI A MORPHOLOGICAL STUDY OF INCUBATED SLICES OF RAT ***CEREBELLUM*** IN RELATION TO POST NATAL AGE.
AU GARTHWAITE J [Reprint author]; WOODHAMS P L; COLLINS M J; BALAZS R
CS MED RES COUNC DEV NEUROBIOL UNIT, INST NEUROL, 33 JOHN'S MEWS, LONDON WC1, ENGL, UK
SO Developmental Neuroscience, (1980) Vol. 3, No. 2, pp. 90-99.
CODEN: DENED7. ISSN: 0378-5866.
DT Article
FS BA
LA ENGLISH

L8 ANSWER 30 OF 188 BIOSIS COPYRIGHT (c) 2004 The Thomson Corporation. on STN
AN 1977:200145 BIOSIS
DN PREV197764022509; BA64:22509
TI THE EFFECT OF CHOLINERGIC DRUGS ON TRITIATED ACETYL CHOLINE RELEASE FROM SLICES OF RAT HIPPOCAMPUS STRIATUM AND ***CORTEX***.
AU HADHAZY P; SZERB J C
SO Brain Research, (1977) Vol. 123, No. 2, pp. 311-322.
CODEN: BRREAP. ISSN: 0006-8993.
DT Article
FS BA
LA Unavailable

L8 ANSWER 31 OF 188 BIOSIS COPYRIGHT (c) 2004 The Thomson Corporation. on STN
AN 1977:133610 BIOSIS
DN PREV197763028474; BA63:28474
TI EFFECT OF HISTAMINE AND ANTI HISTAMINES ON RENAL HEMODYNAMICS AND FUNCTIONS IN THE ISOLATED PERFUSED CANINE KIDNEY.
AU CAMPBELL W B; ITSKOVITZ H D
SO Journal of Pharmacology and Experimental Therapeutics, (1976) Vol. 198, No. 3, pp. 661-667.
CODEN: JPETAB. ISSN: 0022-3565.
DT Article
FS BA
LA Unavailable

L8 ANSWER 32 OF 188 CAPLUS COPYRIGHT 2004 ACS on STN
AN 1999:637905 CAPLUS
DN 132:134166
TI New insights on flow-independent mechanisms of 99mTc-HMPAO retention in nervous tissue: In vitro study
AU Colamussi, Paolo; Calo, Girolamo; Sbrenna, Simone; Uccelli, Licia;

Melchiore; Roveri, Raffaele; Piffanelli, Adriano
CS Department of Experimental and Clinical Medicine, Sections of Nuclear, University of Ferrara, Ferrara, 44100, Italy
SO Journal of Nuclear Medicine (***1999***), 40(9), 1556-1562
CODEN: JNMEAQ; ISSN: 0161-5505
PB Society of Nuclear Medicine, Inc.
DT Journal
LA English
RE.CNT 40 THERE ARE 40 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 33 OF 188 CAPLUS COPYRIGHT 2004 ACS on STN
AN 1998:566404 CAPLUS
DN 129:310787
TI Thiopental inhibits increases in [Ca2+]i induced by membrane depolarization, NMDA receptor activation, and ischemia in rat hippocampal and cortical slices
AU Zhan, Ren-Zhi; Fujiwara, Naoshi; Endoh, Hiroshi; Yamakura, Tomohiro; Taga, Kiichiro; Fukuda, Satoru; Shimoji, Koki
CS Department of Anesthesiology, Niigata University School of Medicine, Niigata, 951-8510, Japan
SO Anesthesiology (***1998***), 89(2), 454-466
CODEN: ANESAV; ISSN: 0003-3022
PB Lippincott-Raven Publishers
DT Journal
LA English
RE.CNT 42 THERE ARE 42 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 34 OF 188 CAPLUS COPYRIGHT 2004 ACS on STN
AN 1998:29233 CAPLUS
DN 128:136747
TI Effects of acute glucose overload on histamine H2 receptor-mediated Ca2+ mobilization in bovine cerebral endothelial cells
AU Kimura, Chiwaka; Oike, Masahiro; Kashiwagi, Seizaburo; Ito, Yushi
CS Department of Pharmacology, Faculty of Medicine, Kyushu University, Fukuoka, 812-82, Japan
SO Diabetes (***1998***), 47(1), 104-112
CODEN: DIAEAZ; ISSN: 0012-1797
PB American Diabetes Association
DT Journal
LA English
RE.CNT 41 THERE ARE 41 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L8 ANSWER 35 OF 188 CAPLUS COPYRIGHT 2004 ACS on STN
AN 1997:3487 CAPLUS
DN 126:54402
TI Screening for drug-induced alterations in the production and release of steroid hormones by porcine adrenocortical cells in vitro
AU Jager, L. P.; De Graaf, G. J.; Widjaja-Greefkes, H. C. A.
CS Dep. Biochem. and Toxicology, D.L.O.-Central Veterinary Inst. (CDI-DLO), Leylstad, 8200 AB, Neth.
SO Toxicology in Vitro (***1996***), 10(5), 595-608
CODEN: TIVIEQ; ISSN: 0887-2333
PB Elsevier
DT Journal
LA English

L8 ANSWER 36 OF 188 CAPLUS COPYRIGHT 2004 ACS on STN
AN 1995:522114 CAPLUS
DN 123:780
TI In vitro and in vivo activity of 1-(1-naphthyl)piperazine at terminal 5-HT autoreceptors in guinea-pig brain
AU Moret, C.; Briley, M.
CS Centre Recherche Pierre Fabre, Castres, F-81100, Fr.
SO Naunyn-Schmiedeberg's Archives of Pharmacology (***1995***), 351(4), 377-84
CODEN: NSAPCC; ISSN: 0028-1298
PB Springer
DT Journal
LA English

L8 ANSWER 37 OF 188 CAPLUS COPYRIGHT 2004 ACS on STN
AN 1990:527011 CAPLUS

TI Decrease of acetylcholine release from cortical slices in aged rats: investigations into its reversal by phosphatidylserine
AU Vannucchi, Maria Giuliana; Casamenti, Fiorella; Pepeu, Giancarlo
CS Dep. Preclin. Clin. Pharmacol., Univ. Florence, Florence, 50134, Italy
SO Journal of Neurochemistry (***1990***), 55(3), 819-25
CODEN: JONRA9; ISSN: 0022-3042
DT Journal
LA English

L8 ANSWER 38 OF 188 CAPLUS COPYRIGHT 2004 ACS on STN
AN 1989:33635 CAPLUS
DN 110:33635
TI Cognitive deficits and cholinergic mechanisms in aging brain: investigations on potentially useful drugs
AU Pepeu, G.; Vannucchi, M. G.; Spignoli, G.
CS Dep. Preclin. Clin. Pharmacol., Univ. Florence, Florence, Italy
SO Annali dell'Istituto Superiore di Sanita (***1988***), 24(3), 411-16
CODEN: AISSAW; ISSN: 0021-2571
DT Journal
LA English

L8 ANSWER 39 OF 188 CAPLUS COPYRIGHT 2004 ACS on STN
AN 1988:449047 CAPLUS
DN 109:49047
TI Purinergic modulation of cortical acetylcholine release is decreased in aging rats
AU Giovannelli, Lisa; Giovannini, Maria Grazia; Pedata, Felicita; Pepeu, Giancarlo
CS Clin. Pharmacol., Univ. Florence, Florence, 50134, Italy
SO Experimental Gerontology (***1988***), 23(3), 175-81
CODEN: EXGEAB; ISSN: 0531-5565
DT Journal
LA English

L8 ANSWER 40 OF 188 CAPLUS COPYRIGHT 2004 ACS on STN
AN 1988:418507 CAPLUS
DN 109:18507
TI Carbadox-induced inhibition of aldosterone production in porcine adrenals in vitro
AU Spierenburg, T. J.; Baars, A. J.; De Graaf, G. J.; Jager, L. P.
CS Cent. Vet. Inst., Lelystad, 8219 PH, Neth.
SO Toxicology in Vitro (***1988***), 2(2), 141-3
CODEN: TIVIEQ; ISSN: 0887-2333
DT Journal
LA English

L8 ANSWER 41 OF 188 CAPLUS COPYRIGHT 2004 ACS on STN
AN 1988:1060 CAPLUS
DN 108:1060
TI Effect of phosphatidylserine on acetylcholine release and content in cortical slices from aging rats
AU Vannucchi, Maria Giuliana; Pepeu, Giancarlo
CS Dep. Preclin. Clin. Pharmacol., Univ. Florence, Florence, 50134, Italy
SO Neurobiology of Aging (***1987***), 8(5), 403-7
CODEN: NEAGDO; ISSN: 0197-4580
DT Journal
LA English

L8 ANSWER 42 OF 188 CAPLUS COPYRIGHT 2004 ACS on STN
AN 1986:45675 CAPLUS
DN 104:45675
TI Phosphatidylserine increases acetylcholine release from cortical slices in aged rats
AU Pedata, F.; Giovannelli, L.; Spignoli, G.; Giovannini, M. G.; Pepeu, G.
CS Dep. Preclin. Clin. Pharmacol., Univ. Florence, Florence, 50134, Italy
SO Neurobiology of Aging (***1985***), 6(4), 337-9
CODEN: NEAGDO; ISSN: 0197-4580
DT Journal
LA English

L8 ANSWER 43 OF 188 CAPLUS COPYRIGHT 2004 ACS on STN
AN 1984:115395 CAPLUS
DN 100:115395
TI Depolarization of mouse forebrain minces with veratridine and high potassium: failure to stimulate the calcium independent, spontaneous

acetylcholine stored there
AU Carroll, Paul T.; Benishin, Christina G.
CS Health Sci. Cent., Texas Tech Univ., Lubbock, TX, 79430, USA
SO Brain Research (***1984***), 291(2), 261-72
CODEN: BRREAP; ISSN: 0006-8993
DT Journal
LA English

L8 ANSWER 44 OF 188 CAPLUS COPYRIGHT 2004 ACS on STN
AN 1983:464895 CAPLUS
DN 99:64895
TI Acetylcholine release from rat cortical slices during postnatal development and aging
AU Pedata, Felicita; Slavikova, Jana; Kotas, Andrzej; Pepeu, Giancarlo
CS Dep. Pharmacol., Univ. Florence, Florence, I-50134, Italy
SO Neurobiology of Aging (***1983***), 4(1), 31-5
CODEN: NEAGDO; ISSN: 0197-4580
DT Journal
LA English

L8 ANSWER 45 OF 188 CAPLUS COPYRIGHT 2004 ACS on STN
AN 1983:84097 CAPLUS
DN 98:84097
TI Regulation by divalent cations of 3H-baclofen binding to GABAB sites in rat cerebellar membranes
AU Kato, Koki; Goto, Masayoshi; Fukuda, Hideomi
CS Fac. Pharm. Sci., Univ. Tokyo, Tokyo, 113, Japan
SO Life Sciences (***1983***), 32(8), 879-87
CODEN: LIFSAK; ISSN: 0024-3205
DT Journal
LA English

L8 ANSWER 46 OF 188 CAPLUS COPYRIGHT 2004 ACS on STN
AN 1980:15133 CAPLUS
DN 92:15133
TI 1,1-Dimethyl-3-acetoxypiperidine, a new cholinergic transmitter
AU Hemsworth, B. A.; Shreeve, S. M.; Veitch, G. B. A.
CS Dep. Pharm., Univ. Aston, Birmingham, B4 7ET, UK
SO British Journal of Pharmacology (***1979***), 66(3), 465P
CODEN: BJPCBM; ISSN: 0007-1188
DT Journal
LA English

L8 ANSWER 47 OF 188 CAPLUS COPYRIGHT 2004 ACS on STN
AN 1978:504815 CAPLUS
DN 89:104815
TI Comparative polarographic measurement of QO2 in rat tissues maintained in Ringer-Krebs phosphate and bicarbonate solutions
AU Colleoni, M. P.; Grazzini, R.
CS Fac. Sci., Univ. Milano, Milan, Italy
SO Rivista di Farmacologia e Terapia (***1977***), 8(2), 185-91
CODEN: RVFTBB; ISSN: 0302-1750
DT Journal
LA Italian

L8 ANSWER 48 OF 188 CAPLUS COPYRIGHT 2004 ACS on STN
AN 1978:485056 CAPLUS
DN 89:85056
TI The effects of gamma-hydroxybutyrate and gamma-butyrolactone upon the energy metabolism of the normoxic and hypoxic rat brain
AU Macmillan, V.
CS Dep. Med., Univ. Toronto, Toronto, ON, Can.
SO Brain Research (***1978***), 146(1), 177-87
CODEN: BRREAP; ISSN: 0006-8993
DT Journal
LA English

L8 ANSWER 49 OF 188 CAPLUS COPYRIGHT 2004 ACS on STN
AN 1977:436366 CAPLUS
DN 87:36366
TI Acetyltriethylcholine: a cholinergic false transmitter in cat superior cervical ganglion and rat cerebral ***cortex***
AU Ilson, D.; Collier, B.; Boksa, P.
CS Dep. Pharmacol. Ther., McGill Univ., Montreal, QC, Can.
SO Journal of Neurochemistry (***1977***), 28(2), 371-81

DT Journal
LA English

L8 ANSWER 50 OF 188 CAPLUS COPYRIGHT 2004 ACS on STN
AN 1975:2242 CAPLUS
DN 82:2242
TI Evoked surface-positive potentials in mammalian olfactory ***cortex***
AU Harvey, John A.; Sholfield, C. N.; Brown, David A.
CS Dep. Psychol., Univ. Iowa, Iowa City, IA, USA
SO Brain Research (***1974***), 76(2), 235-45
CODEN: BRREAP; ISSN: 0006-8993
DT Journal
LA English

L8 ANSWER 51 OF 188 CAPLUS COPYRIGHT 2004 ACS on STN
AN 1972:535701 CAPLUS
DN 77:135701
TI Effect of lithium on acetylcholine release and synthesis
AU Vizi, E. S.; Illes, P.; Ronai, A.; Knoll, J.
CS Dep. Pharmacol., Semmelweis Med. Univ., Budapest, Hung.
SO Neuropharmacology (***1972***), 11(4), 521-30
CODEN: NEPHBW; ISSN: 0028-3908
DT Journal
LA English

L8 ANSWER 52 OF 188 CAPLUS COPYRIGHT 2004 ACS on STN
AN 1971:538589 CAPLUS
DN 75:138589
TI Observations on [3H].gamma.-aminobutyric acid accumulation and efflux in isolated sympathetic ganglia
AU Bowery, N. G.; Brown, D. A.
CS Dep. Pharmacol., St. Bartholomew's Hosp. Med. Coll., London, UK
SO Journal of Physiology (Cambridge, United Kingdom) (***1971***), 218(1), 32p-33p
CODEN: JPHYA7; ISSN: 0022-3751
DT Journal
LA English

L8 ANSWER 53 OF 188 CAPLUS COPYRIGHT 2004 ACS on STN
AN 1971:459209 CAPLUS
DN 75:59209
TI Further research into the method of in vitro penetration of [3H] testosterone into the anterior hypophysis, the hypothalamus, and the cerebral ***cortex*** of normal and castrated rats
AU Samperez, Suzanne; Thieulant, Marie L.; Jouan, Pierre
CS Lab. Neurobiol. Mol., Fac. Sci., Rennes, Fr.
SO Annales d'Endocrinologie (***1971***), 32(1), 31-42
CODEN: ANENAG; ISSN: 0003-4266
DT Journal
LA French

L8 ANSWER 54 OF 188 CAPLUS COPYRIGHT 2004 ACS on STN
AN 1967:419311 CAPLUS
DN 67:19311
TI Effects of the bovine brain lipids extracted from the hypothalamus and the ***cortex*** on smooth muscle
AU Turkulin, K.; Atanackovic, D.
CS Dep. Pharmacol., Fac. Med., Rijeka-Univ., Zagreb, Yugoslavia
SO Biochimica e Biologia Sperimentale (***1966***), 5(3), 345-51
CODEN: BBSPAJ; ISSN: 0006-2995
DT Journal
LA English

L8 ANSWER 55 OF 188 CAPLUS COPYRIGHT 2004 ACS on STN
AN 1966:95987 CAPLUS
DN 64:95987
OREF 64:18122f-h
TI Alterations in the phosphorus to nitrogen ratio in lipids of the brain following exhaustion of the animal and incubation of brain slices
AU Gotsiridze, E. G.
SO Vopr. Biokhim. Nervn. i Myshechn. Sistem (Tbilisi; Metsniereba) Sb. (***1965***) 87-91
From: Ref. Zh., Biol. Khim. 1965, Abstr. No. 22F1050.
DT Journal
LA Russian

L8 ANSWER 56 OF 188 CAPLUS COPYRIGHT 2004 ACS on STN
AN 1966:38100 CAPLUS
DN 64:38100
OREF 64:7119d-h,7120a
TI Distribution of oxidative enzymes in glial and nerve cells in the temporal ***cortex*** of the rabbit brain
AU Kul'tas, K. N.
CS Inst. Exptl. Biol., Acad. Sci. Estonian S.S.R., Tallin
SO Folia Morphologica (Warsaw) (***1965***), 13(1), 43-50
CODEN: FOMOAJ; ISSN: 0015-5659
DT Journal
LA English

L8 ANSWER 57 OF 188 CAPLUS COPYRIGHT 2004 ACS on STN
AN 1965:24334 CAPLUS
DN 62:24334
OREF 62:4401h,4402a
TI Vitamin A and adrenal ***cortex*** secretion. Effect of hypophyseal stimulation in vitro
AU Nicol, M.; Le Gall, M.; Grangaud, R.
CS Fac. Med. Pharm., Rennes, Fr.
SO Comptes Rendus des Seances de la Societe de Biologie et de Ses Filiales (***1964***), 158(6), 1270-2
CODEN: CRSBAW; ISSN: 0037-9026
DT Journal
LA French

L8 ANSWER 58 OF 188 CAPLUS COPYRIGHT 2004 ACS on STN
AN 1964:63137 CAPLUS
DN 60:63137
OREF 60:11145g-h,11146a-b
TI Evolution of the acetylcholine system in the vertebrate brain
AU Verzhbinskaya, N. A.
CS Inst. Evol. Physiol., Acad. Sci. U.S.S.R., Leningrad
SO Tret'ya Vses. Konf. po Biokhim. Nervnoi Sistemy, Akad. Nauk Arm. SSR, Inst. Biokhim., Sb. Dokl., Erevan (***1963***), 1962, 503-15
DT Journal
LA Unavailable

L8 ANSWER 59 OF 188 CAPLUS COPYRIGHT 2004 ACS on STN
AN 1963:417369 CAPLUS
DN 59:17369
OREF 59:3162f-h,3163a-c
TI Metabolism and functional survival of cervical sympathetic ganglion isolated from the rat
AU Roch-Ramel, F.
CS Univ. Lausanne Switz.
SO Helvetica Physiologica et Pharmacologica Acta, Supplementum (***1962***), No. 13, 64 pp.
CODEN: HPASAY; ISSN: 0367-6226
DT Journal
LA French

L8 ANSWER 60 OF 188 CAPLUS COPYRIGHT 2004 ACS on STN
AN 1963:84492 CAPLUS
DN 58:84492
OREF 58:14532h,14533a
TI Effects of potassium and of electrical stimulation on the turnover of phospholipids in brain slices of guinea pigs
AU Kai, Mutsuoki; Hayashi, Kohei
CS Gunma Univ., Maebashi, Japan
SO Gunma Journal of Medical Sciences (***1962***), 11, 150-8
CODEN: GJMSA7; ISSN: 0017-565X
DT Journal
LA English

L8 ANSWER 61 OF 188 CAPLUS COPYRIGHT 2004 ACS on STN
AN 1959:40398 CAPLUS
DN 53:40398
OREF 53:7294a-c
TI Microscopic histochemical demonstration of steroid-3-.beta.-ol dehydrogenase in tissue sections
AU Wattenburg, Lee W.
CS Univ. of Minnesota School Med., Minneapolis
SO Journal of Histochemistry and Cytochemistry (***1958***), 6, 225-32

DT Journal
LA Unavailable

L8 ANSWER 62 OF 188 CAPLUS COPYRIGHT 2004 ACS on STN
AN 1953:73166 CAPLUS
DN 47:73166
OREF 47:12471a-e
TI Metabolism in slices of brain ***cortex*** . The level of adenosine triphosphate and its changes under the influence of glutamic acid
AU Ac, G.; Balaz, R.; Straub, F. B.
CS Med. Inst., Budapest
SO Ukrains'kii Biokhimichnii Zhurnal (1946-1977) (***1953***), 25(No. 1), 17-27
CODEN: UBZHAZ; ISSN: 0372-3909
DT Journal
LA Unavailable

L8 ANSWER 63 OF 188 CAPLUS COPYRIGHT 2004 ACS on STN
AN 1949:41979 CAPLUS
DN 43:41979
OREF 43:7588d-i
TI The influence of magnesium on respiration, glycolysis, and cholinesterase activity in rat brain
AU Peiss, C. N.; Hall, V. E.; Field, J.
SO Journal of Physiology (Cambridge, United Kingdom) (***1949***), 108, 365-73
CODEN: JPHYA7; ISSN: 0022-3751
DT Journal
LA Unavailable

L8 ANSWER 64 OF 188 DISSABS COPYRIGHT (C) 2004 ProQuest Information and Learning Company; All Rights Reserved on STN
AN 94:33917 DISSABS Order Number: AARC360032 (not available for sale by UMI)
TI ACTIONS OF ADENOSINE AND ANOXIA IN RAT BRAIN
AU DONAGHY, KEVIN MICHAEL [PH.D.]
CS QUEEN'S UNIVERSITY OF BELFAST (NORTHERN IRELAND) (0725)
SO Dissertation Abstracts International, (***1993***) Vol. 55, No. 3C, p. 780. Order No.: AARC360032 (not available for sale by UMI). 180 pages. THE QUEEN'S UNIVERSITY OF BELFAST, SCIENCE LIBRARY, CHLORINE GARDENS, BELFAST BT9 5AG, NORTHERN IRELAND.
DT Dissertation
FS DAI
LA English
ED Entered STN: 19940830
Last Updated on STN: 19940830

L8 ANSWER 65 OF 188 DRUGU COPYRIGHT 2004 THE THOMSON CORP on STN
AN 1998-02211 DRUGU P
TI Importance of constrictor ET-A receptors in pial artery from human brain revealed by potent nonpeptide endothelin antagonists.
AU Pierre L N; Davenport A P
CS Univ.Cambridge
LO Cambridge, U.K.
SO Br.J.Pharmacol. (122, Proc. Suppl., 15P, 1997) 1 Fig. 4 Ref.
CODEN: BJPCBM ISSN: 0007-1188
AV Clinical Pharmacology Unit, University of Cambridge, Box 110, Addenbrooke's Hospital, Cambridge, CB2 2QQ, England.
LA English
DT Journal
FA AB; LA; CT
FS Literature

L8 ANSWER 66 OF 188 DRUGU COPYRIGHT 2004 THE THOMSON CORP on STN
AN 1997-16978 DRUGU P
TI Effects of SB 216641 and BRL 15572 (selective h5-HT1B and h5-HT1D receptor antagonists, respectively) on guinea-pig and human 5-HT auto- and hetero-receptors.
AU Schlicker E; Fink K; Molderings G J; Price G W; Middlemiss D N; Zentner J; Likungu J; Gothert M
CS Univ.Bonn-Inst.Pharmacol.+Toxicol.; SK-Beecham
LO Bonn, Ger.; Harlow, U.K.
SO Br.J.Pharmacol. (120, Proc.Suppl., 143P, 1997) 1 Ref.
CODEN: BJPCBM ISSN: 0007-1188
AV Institute of Pharmacology and Toxicology, University of Bonn,

LA English
DT Journal
FA AB; LA; CT
FS Literature

L8 ANSWER 67 OF 188 DRUGU COPYRIGHT 2004 THE THOMSON CORP on STN
AN 1994-34317 DRUGU P E
TI Effect of the N-glucuronide conjugate of GR117289 at angiotensin AT1 and AT2 receptors in the rabbit aorta and bovine ***cerebellum*** .
AU Hilditch A; Pierre L; Manchee G R; Eddershaw P M; Mitchell H A
CS Glaxo
LO Ware, United Kingdom
SO Br.J.Pharmacol. (112, July, Proc.Suppl., 636P, 1994) 1 Ref.
CODEN: BJPCBM ISSN: 0007-1188
AV Pharmacology 2, Glaxo Research and Development Ltd., Ware, Herts, SG12 0DP.
LA English
DT Journal
FA AB; LA; CT; MPC
FS Literature

L8 ANSWER 68 OF 188 DRUGU COPYRIGHT 2004 THE THOMSON CORP on STN
AN 1994-34277 DRUGU P
TI UK-84,149: A novel gut-selective spasmolytic with calcium antagonist activity.
AU Wallis R M; Alker D; Burges R A; Cross P E; Greengrass P M; McIntyre P
CS Pfizer
LO Sandwich, United Kingdom
SO Br.J.Pharmacol. (112, July, Proc.Suppl., 574P, 1994) 1 Tab. 1 Ref.
CODEN: BJPCBM ISSN: 0007-1188
AV Pfizer Central Research, Sandwich, Kent CT13 9NJ, England. (7 authors).
LA English
DT Journal
FA AB; LA; CT
FS Literature

L8 ANSWER 69 OF 188 DRUGU COPYRIGHT 2004 THE THOMSON CORP on STN
AN 1992-03630 DRUGU P S
TI Doxofylline Differs from Methylxanthines in its Movement of Cytosolic Calcium.
AU Franzone J S; Cirillo R; Reboani M C
CS ABC
LO Turin, Italy
SO Int.J.Tissue React. (13. No. 3, 131-38, 1991) 3 Fig. 34 Ref.
CODEN: IJTEDP ISSN: 0250-0868
AV "ABC" Pharmaco-Toxicological Research Laboratories, 25 Via Crescentino, 10154 Torino, Italy.
LA English
DT Journal
FA AB; LA; CT
FS Literature

L8 ANSWER 70 OF 188 DRUGU COPYRIGHT 2004 THE THOMSON CORP on STN
AN 1991-09825 DRUGU P
TI Effect of the alpha-2-Adrenoceptor Antagonist GR50360A on (3H)-Noradrenaline Overflow from Brain Slices.
AU Beattie D T; Skingle M
CS Glaxo
LO Ware, United Kingdom
SO J.Psychopharmacol.(Oxford) (4, No. 4, 303, 1990) 2 Ref.
CODEN: JOPSEQ ISSN: 0269-8811
AV Dept. of Neuropharmacology, Glaxo Group Research, Park Road, Ware, Herts. SG12 0DP, England.
LA English
DT Journal
FA AB; LA; CT
FS Literature

L8 ANSWER 71 OF 188 DRUGU COPYRIGHT 2004 THE THOMSON CORP on STN
AN 1990-04208 DRUGU P
TI Pravadoline and Aminoalkylindole (AAI) Analogues: Actions Which Suggest a Receptor Interaction.
AU Ward S J; Childers S R; Pacheco M
CS Sterling-Winthrop
LO New York, New York, Gainesville, Florida, United States

CODEN: BJPCBM ISSN: 0007-1188
AV Department of Pharmacy, Sterling Research Group, Rensl., NY 12144, U.S.A.
LA English
DT Journal
FA AB; LA; CT
FS Literature

L8 ANSWER 72 OF 188 DRUGU COPYRIGHT 2004 THE THOMSON CORP on STN
AN 1989-44530 DRUGU P
TI The 5-HT Uptake Inhibitor SL 81.0385 Enhances the Electrically-Evoked Release of (3H)5-HT in Slices of Human Frontal ***Cortex*** .
AU Galzin A M; Langer S Z
CS Synthelabo
LO Paris, France
SO Fundam.Clin.Pharmacol. (3, No. 4, 425-26, 1989) 2 Ref.
CODEN: FCPHEZ ISSN: 0767-3981
AV Laboratoires d'Etudes et de Recherches Synthelabo (L.E.R.S.), 58, rue de la Glaciere, 75013 Paris, France.
LA English
DT Journal
FA AB; LA; CT
FS Literature

L8 ANSWER 73 OF 188 DRUGU COPYRIGHT 2004 THE THOMSON CORP on STN
AN 1989-32265 DRUGU P E
TI Barbiturates but not Steroids Modulate the GABA Autoreceptor.
AU Ennis C; Minchin M C W
CS Wyeth
LO Maidenhead, United Kingdom
SO Br.J.Pharmacol. (97, Suppl., 489P, 1989) 3 Ref.
CODEN: BJPCBM ISSN: 0007-1188
AV Wyeth Research, Huntercombe Lane South, Maidenhead, Berkshire, SL6 OPH, England.
LA English
DT Journal
FA AB; LA; CT
FS Literature

L8 ANSWER 74 OF 188 DRUGU COPYRIGHT 2004 THE THOMSON CORP on STN
AN 1988-17180 DRUGU P
TI Modulation of the Electrically-Evoked Release of (3H)-5-HT from Slices of Human Frontal ***Cortex*** .
AU Galzin A M; Chodkiewicz J P; Poirier M F; Loo H; Roux F X; Redondo A
CS Synthelabo
LO Paris, France
SO Br.J.Pharmacol. (93, Mar. Suppl., 14P, 1988) 4 Ref.
CODEN: BJPCBM ISSN: 0007-1188
AV Department of Biology, Laboratoires d'Etudes et de Recherches Synthelabo (L.E.R.S.), 58 rue de la Glaciere, 75013 Paris, France.
LA English
DT Journal
FA AB; LA; CT
FS Literature

L8 ANSWER 75 OF 188 DRUGU COPYRIGHT 2004 THE THOMSON CORP on STN
AN 1988-05112 DRUGU P
TI The Terminal 5-HT Autoreceptor in the Guinea-Pig Frontal ***Cortex*** : A Pharmacological Analysis.
AU Middlemiss D N; Bremer M E
CS Searle
LO St. Louis, Missouri, United States
SO Br.J.Pharmacol. (92, Dec, Suppl., 559P, 1987) 1 Tab. 5 Ref.
CODEN: BJPCBM ISSN: 0007-1188
AV Central Nervous System Diseases Research, G. D. Searle, 700 Chesterfield Village Parkway, St. Louis, MO 63198, U.S.A.
LA English
DT Journal
FA AB; LA; CT
FS Literature

L8 ANSWER 76 OF 188 DRUGU COPYRIGHT 2004 THE THOMSON CORP on STN
AN 1988-05091 DRUGU P
TI Benzodiazepines Enhance the Effect of GABA Autoreceptor Agonists.
AU Ennis C; Minchin M C W
CS Wyeth

SO Br.J.Pharmacol. (92, Dec, Suppl., 535P, 1987) 4 Ref.
CODEN: BJPCBM ISSN: 0007-1188
AV Dept. of Biomedical Res., Wyeth Research (UK), Huntercombe Lane South, Maidenhead, Berks, SL6 0PH, England.
LA English
DT Journal
FA AB; LA; CT
FS Literature

L8 ANSWER 77 OF 188 DRUGU COPYRIGHT 2004 THE THOMSON CORP on STN
AN 1987-50634 DRUGU P
TI Some 5-Hydroxytryptamine Derivatives may Discriminate between 5-HT High Affinity Binding Site Subtypes: A Quantitative Autoradiographic Study.
AU Segu L; Lanoir J; Puizillout J J
LO Marseille, France
SO Neuroscience(Oxford) (22, Suppl., S74, 1987)
CODEN: NRSCDN ISSN: 0306-4522
AV Laboratoire de Neurobiologie E6, 31 Ch. J. Aiguier, Inserm-U6, France.
LA English
DT Journal
FA AB; LA; CT; MPC
FS Literature

L8 ANSWER 78 OF 188 DRUGU COPYRIGHT 2004 THE THOMSON CORP on STN
AN 1987-50625 DRUGU P
TI Inhibition of High Affinity Choline Uptake by Ethylcholine Mustard and Phenoxybenzamine Aziridiniums.
AU Ormandy G C; Darling D L; Prince A K
LO London, United Kingdom
SO Neuroscience(Oxford) (22, Suppl., S64, 1987) 2 Ref.
CODEN: NRSCDN ISSN: 0306-4522
AV Dept. Pharmacology, King's College, London WC2R 2LS, England.
LA English
DT Journal
FA AB; LA; CT; MPC
FS Literature

L8 ANSWER 79 OF 188 DRUGU COPYRIGHT 2004 THE THOMSON CORP on STN
AN 1986-36321 DRUGU P
TI Quantification of the Effects of Muscarinic Antagonists on the Release of (3H)-Acetylcholine from Rat Cerebral ***Cortex*** Slices.
AU Roberts F; Tutty C
CS Glaxo
LO Ware, United Kingdom
SO Br.J.Pharmacol. (88, June Suppl., 358jP, 1986) 3 Ref.
CODEN: BJPCBM ISSN: 0007-1188
AV Department of Neuropharmacology, Glaxo Group Research, Ware, Herts, SG12 0DJ, England.
LA English
DT Journal
FA AB; LA; CT
FS Literature

L8 ANSWER 80 OF 188 DRUGU COPYRIGHT 2004 THE THOMSON CORP on STN
AN 1986-25136 DRUGU P
TI Effects of 6-Nitroquipazine on (3H0)-5-HT Overflow in Hypothalamic Slices from Normal and PCPA Treated Rats.
AU Galzin A M; Langer S Z; Pasarelli F
CS Synthelabo
LO Paris, France
SO Br.J.Pharmacol. (87, Mar. Suppl., 17P, 1986) 4 Ref.
CODEN: BJPCBM ISSN: 0007-1188
AV Department of Biology, Laboratories d'Etudes et de Recherches Synthelabo (L.E.R.S.), 58 rue de la Glaciere, 75013 Paris, France.
LA English
DT Journal
FA AB; LA; CT
FS Literature

L8 ANSWER 81 OF 188 DRUGU COPYRIGHT 2004 THE THOMSON CORP on STN
AN 1986-09245 DRUGU P
TI Cortical Acetylcholine Release is Increased and GABA Outflow is Reduced during Morphine Withdrawal.
AU Antonelli T; Beani L; Bianchi C; Rando S; Somonato M; Tanganelli S
LO Ferrara, Italy

CODEN: BJPCBM ISSN: 0007-1188
AV Department of Pharmacology, University of Ferrara, Ferrara, Italy.
LA English
DT Journal
FA AB; LA; CT
FS Literature

L8 ANSWER 82 OF 188 DRUGU COPYRIGHT 2004 THE THOMSON CORP on STN
AN 1985-14315 DRUGU B P
TI RU 24969 A 5-HT1 Agonist, Stimulates Inositol Phospholipid Breakdown in Rat Brain Slices.
AU Godfrey P P; McClue S J; Minchin M C W; Young M
LO Oxford, United Kingdom
SO Br.J.Pharmacol. (84, Mar, Suppl., 112P, 1985) 7 Ref.
CODEN: BJPCBM ISSN: 0007-1188
AV MRC Clinical Pharmacology Unit, Radcliffe Infirmary, Oxford OX2 6HE, England.
LA English
DT Journal
FA AB; LA; CT
FS Literature

L8 ANSWER 83 OF 188 DRUGU COPYRIGHT 2004 THE THOMSON CORP on STN
AN 1985-14281 DRUGU P
TI Stereoselective Antagonism at the 5-HT Autoreceptor by the Optical Isomers of Methiothepin.
AU Hibert M; Middlemiss D N
CS Merrell-Dow
LO Strasbourg, France
SO Br.J.Pharmacol. (84, Mar, Suppl., 65P, 1985) 3 Ref.
CODEN: BJPCBM ISSN: 0007-1188
AV Merrell-Dow Research Institute, Strasbourg Centre, 16, rue d'Ankara, 67084 Strasbourg, France.
LA English
DT Journal
FA AB; LA; CT
FS Literature

L8 ANSWER 84 OF 188 DRUGU COPYRIGHT 2004 THE THOMSON CORP on STN
AN 1985-01584 DRUGU P
TI 5HT-Receptor Antagonist Properties of SCH-23390 in Vascular Smooth Muscle and Brain.
AU Hicks P E; Schoemaker H; Langer S Z
CS Synthelabo
LO Paris, France
SO Eur.J.Pharmacol. (105, No. 3-4, 339-42, 1984) 1 Fig. 1 Tab. 8 Ref.
CODEN: EJPHAZ ISSN: 0014-2999
AV Department of Biology, Laboratoires d'Etudes et de Recherches Synthelabo, 58, rue de la Glaciere, 75013 Paris, France.
LA English
DT Journal
FA AB; LA; CT
FS Literature

L8 ANSWER 85 OF 188 DRUGU COPYRIGHT 2004 THE THOMSON CORP on STN
AN 1984-17164 DRUGU P
TI The Antagonism by Ketamine of N-Methyl D-Aspartate in Slices of Rat Cerebral ***Cortex*** .
AU Harrison N L; Simmonds M A
LO London, United Kingdom
SO Br.J.Pharmacol. (81, Mar. Suppl., 44P, 1984) 5 Ref.
CODEN: BJPCBM ISSN: 0007-1188
AV MRC Neuropharmacology Research Group, Department of Pharmacology, The School of Pharmacy, 29/39 Brunswick Square, London WC1N 1AX, England.
LA English
DT Journal
FA AB; LA; CT
FS Literature

L8 ANSWER 86 OF 188 DRUGU COPYRIGHT 2004 THE THOMSON CORP on STN
AN 1984-12232 DRUGU P
TI Effect of Adenosine and Methylxanthines on Neurotransmitter Release from Cortical and Hippocampal Slices.
AU Pedata F; Corradetti R; Moroni F; Pepeu G
LO Florence, Italy

CODEN: APTOA6
AV Department of Pharmacology, Florence University, Florence, Italy.
LA English
DT Journal
FA AB; LA; CT; MPC
FS Literature

L8 ANSWER 87 OF 188 DRUGU COPYRIGHT 2004 THE THOMSON CORP on STN
AN 1984-04124 DRUGU P
TI Diazepam Antagonizes GABA- and Muscimol-Induced Changes of Acetylcholine Release in Slices of Guinea-Pig Cerebral ***Cortex*** .
AU Tanganelli S; Bianchi C; Beani L
LO Ferrara, it.,
SO Arch.Pharmacol. (324, No. 1, 34-37, 1983) 3 Tab. 21 Ref.
CODEN: NSAPCC ISSN: 0028-1298
AV Department of Pharmacology, University of Ferrara, Via Fossato di Mortara, 23, I -44100 Ferrara, Italy.
LA English
DT Journal
FA AB; LA; CT; MPC
FS Literature

L8 ANSWER 88 OF 188 DRUGU COPYRIGHT 2004 THE THOMSON CORP on STN
AN 1984-00168 DRUGU P
TI Lack of Effect of the Putative Central 5-HT Agonist, 8-Hydroxy 2-(DI -N-Propylamino) Tetralin (8-OH-DPAT) on the 5-HT Autoreceptor.
AU Middlemiss D N
CS Merrell
LO Strasbourg, France
SO Arch.Pharmacol. (324, Suppl., R19, 1983) 2 Ref.
CODEN: NSAPCC ISSN: 0028-1298
AV Centre de Recherche Merrell International, 16, rue d'Ankara 67084 Strasbourg-Cedex, France.
LA English
DT Journal
FA AB; LA; CT; MPC
FS Literature

L8 ANSWER 89 OF 188 DRUGU COPYRIGHT 2004 THE THOMSON CORP on STN
AN 1983-40128 DRUGU P
TI Evidence for Pharmacological Similarity Between Alpha2 Adrenoceptors in the Vas Deferens and Central Nervous System of the Rat.
AU Doxey J C; Gadie B; Lane A C; Tulloch I F
CS Reckitt
LO Hull, United Kingdom
SO Br.J.Pharmacol. (80, No. 1, 155-61, 1983) 4 Fig. 1 Tab. 30 Ref.
CODEN: BJPCBM ISSN: 0007-1188
AV No Reprint Address
LA English
DT Journal
FA AB; LA; CT; MPC
FS Literature

L8 ANSWER 90 OF 188 DRUGU COPYRIGHT 2004 THE THOMSON CORP on STN
AN 1983-19399 DRUGU P
TI A Comparison Between the Effects of GABA Uptake Inhibitors on the Action of GABA, Muscimol and Isoguvacine.
AU Scholfield C N
LO Belfast, United Kingdom
SO Br.J.Pharmacol. (78, No. 3, Suppl., 88P, 1983) 1 Tab. 4 Ref.
CODEN: BJPCBM ISSN: 0007-1188
AV Physiology Department, Queen's University, 97, Lisburn Road, Belfast, BT9 7BL, U.K.
LA English
DT Journal
FA AB; LA; CT
FS Literature

L8 ANSWER 91 OF 188 DRUGU COPYRIGHT 2004 THE THOMSON CORP on STN
AN 1983-10753 DRUGU P
TI Influx and Binding of Radioisotope-Labeled Baclofen in the Rat ***Cerebellum*** .
AU Kato K; Goto M; Fukuda H
LO Tokyo, Japan
SO Jpn.J.Pharmacol. (32, Suppl., 65P, 1982)

AV Department of Toxicology and Pharmacology, Faculty of Pharmaceutical Sciences, The University of Tokyo, Bunkyo -ku, Tokyo 113, Japan.
LA English
DT Journal
FA AB; LA; CT; MPC
FS Literature

L8 ANSWER 92 OF 188 EMBASE COPYRIGHT 2004 ELSEVIER INC. ALL RIGHTS RESERVED. on STN
AN 88217427 EMBASE
DN 1988217427
TI 2-Hydroxy-saclofen: An improved antagonist at central and peripheral GABA(B) receptors.
AU Kerr D.I.B.; Ong J.; Johnston G.A.R.; Abbenante J.; Prager R.H.
CS Department of Pharmacology, University of Sydney, Sydney, NSW 2006, Australia
SO Neuroscience Letters, (1988) 92/1 (92-96).
ISSN: 0304-3940 CODEN: NELED5
CY Ireland
DT Journal
FS 002 Physiology
030 Pharmacology
037 Drug Literature Index
LA English
SL English

L8 ANSWER 93 OF 188 EMBASE COPYRIGHT 2004 ELSEVIER INC. ALL RIGHTS RESERVED. on STN
AN 82201489 EMBASE
DN 1982201489
TI Prostaglandin-related renin release from rabbit renal cortical slices.
AU Spokas E.G.; Wong P.Y.K.; McGiff J.C.
CS Dept. Pharmacol., New York Med. Coll., Basic Sci. Build., Valhalla, NY 10595, United States
SO Hypertension, (1982) 4/3 II (II-96-II-100).
CODEN: HPRTDN
CY United States
DT Journal
FS 037 Drug Literature Index
003 Endocrinology
018 Cardiovascular Diseases and Cardiovascular Surgery
028 Urology and Nephrology
002 Physiology
LA English

L8 ANSWER 94 OF 188 EMBASE COPYRIGHT 2004 ELSEVIER INC. ALL RIGHTS RESERVED. on STN
AN 78395755 EMBASE
DN 1978395755
TI Stimulation of acetylcholine output from brain slices caused by the ionophores BrX-537A and A 23187.
AU Casamenti F.; Mantovani P.; Pepeu G.
CS Dept. Pharmacol., Univ. 50134 Florence, Italy
SO British Journal of Pharmacology, (1978) 63/2 (259-265).
CODEN: BJPCBM
CY United Kingdom
DT Journal
FS 037 Drug Literature Index
030 Pharmacology
008 Neurology and Neurosurgery
LA English

L8 ANSWER 95 OF 188 LIFESCI COPYRIGHT 2004 CSA on STN
AN 82:37542 LIFESCI
TI The stimulus-induced release of 5-hydroxytryptamine and tryptophan from superfused rat brain synaptosomes.
AU Collard, K.J.; Evans, T.N.W.; Suter, H.A.; Wilkinson, L.S.
CS Dep. Physiol., Univ. Coll., Cardiff, Wales, UK
SO J. NEURAL TRANSM., (***1982***) vol. 53, no. 2-3, pp. 223-230.
DT Journal
FS M; N3
LA English
SL English

L8 ANSWER 96 OF 188 MEDLINE on STN

DN PubMed ID: 1313954
TI Phosphorus nuclear magnetic resonance studies on the calcium-dependent energy metabolism of rat cerebrum under conditions of increased potassium in vitro.
AU Takei M; Kawano Y; Yamada K
CS Department of Physiology, Medical College of Oita, Japan.
SO Neuroscience research, ***(1992 Jan)*** 12 (5) 596-605.
Journal code: 8500749. ISSN: 0168-0102.
CY Ireland
DT Journal; Article; (JOURNAL ARTICLE)
LA English
FS Priority Journals
EM 199205
ED Entered STN: 19920529
Last Updated on STN: 19950206
Entered Medline: 19920513

L8 ANSWER 97 OF 188 MEDLINE on STN
AN 89338605 MEDLINE
DN PubMed ID: 2547638
TI Benzofuran analogues of baclofen: a new class of central and peripheral GABAB-receptor antagonists.
AU Kerr D I; Ong J; Johnston G A; Berthelot P; Debaert M; Vaccher C
CS Department of Pharmacology, University of Sydney, New South Wales, Australia.
SO European journal of pharmacology, ***(1989 May 19)*** 164 (2) 361-4.
Journal code: 1254354. ISSN: 0014-2999.
CY Netherlands
DT Journal; Article; (JOURNAL ARTICLE)
LA English
FS Priority Journals
EM 198909
ED Entered STN: 19900309
Last Updated on STN: 19970203
Entered Medline: 19890920

L8 ANSWER 98 OF 188 SCISEARCH COPYRIGHT (c) 2004 The Thomson Corporation. on STN
AN 1998:188649 SCISEARCH
GA The Genuine Article (R) Number: YZ387
TI 5-HT autoreceptors in the regulation of 5-HT release from guinea pig raphe nucleus and hypothalamus
AU Moret C (Reprint); Briley M
CS PIERRE FABRE RES CTR, 17 AVE JEAN MOULIN, F-81100 CASTRES, FRANCE (Reprint)
CYA FRANCE
SO NEUROPHARMACOLOGY, (***NOV-DEC 1997***) Vol. 36, No. 11-12, pp. 1713-1723.
Publisher: PERGAMON-ELSEVIER SCIENCE LTD, THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD, ENGLAND OX5 1GB.
ISSN: 0028-3908.
DT Article; Journal
FS LIFE
LA English
REC Reference Count: 41
ABSTRACT IS AVAILABLE IN THE ALL AND IALL FORMATS

L8 ANSWER 99 OF 188 SCISEARCH COPYRIGHT (c) 2004 The Thomson Corporation. on STN
AN 95:523931 SCISEARCH
GA The Genuine Article (R) Number: RL400
TI SPECIFIC ACCUMULATION OF INOSITOL 1,4,5-TRISPHOSPHATE IN RABBIT BASILAR ARTERY IN RESPONSE TO NORADRENALINE BUT NOT 5-HYDROXYTRYPTAMINE
AU MURPHY T V; GARLAND C J (Reprint)
CS UNIV BRISTOL, SCH MED SCI, DEPT PHARMACOL, UNIV WALK, BRISTOL BS8 1TD, AVON, ENGLAND (Reprint); UNIV BRISTOL, SCH MED SCI, DEPT PHARMACOL, BRISTOL BS8 1TD, AVON, ENGLAND
CYA ENGLAND
SO EUROPEAN JOURNAL OF PHARMACOLOGY-MOLECULAR PHARMACOLOGY SECTION, (***18*** JUL 1995***) Vol. 290, No. 2, pp. 141-144.
ISSN: 0922-4106.
DT Article; Journal
FS LIFE
LA ENGLISH
REC Reference Count: 17

L8 ANSWER 100 OF 188 SCISEARCH COPYRIGHT (c) 2004 The Thomson Corporation. on STN
AN 94:102642 SCISEARCH
GA The Genuine Article (R) Number: MU956
TI IMPORTANCE OF INOSITOL (1,4,5)-TRISPHOSPHATE, INTRACELLULAR CA2+ RELEASE AND MYOFILAMENT CA2+ SENSITIZATION IN 5-HYDROXYTRYPTAMINE-EVOKED CONTRACTION OF RABBIT MESENTERIC-ARTERY
AU SEAGER J M; MURPHY T V; GARLAND C J (Reprint)
CS UNIV BRISTOL, DEPT PHARMACOL, UNIV WALK, BRISTOL BS8 1TD, ENGLAND (Reprint); UNIV SOUTHAMPTON, DEPT PHYSIOL & PHARMACOL, SOUTHAMPTON S09 3TU, ENGLAND
CYA ENGLAND
SO BRITISH JOURNAL OF PHARMACOLOGY, (***FEB 1994***) Vol. 111, No. 2, pp. 525-532.
ISSN: 0007-1188.
DT Article; Journal
FS LIFE
LA ENGLISH
REC Reference Count: 59
ABSTRACT IS AVAILABLE IN THE ALL AND IALL FORMATS

L8 ANSWER 101 OF 188 SCISEARCH COPYRIGHT (c) 2004 The Thomson Corporation. on STN
AN 91:276697 SCISEARCH
GA The Genuine Article (R) Number: FK269
TI OPPOSING EFFECTS OF DOPAMINE-D2 RECEPTOR STIMULATION ON THE SPONTANEOUS AND THE ELECTRICALLY EVOKED RELEASE OF [H-3] GABA ON RAT PREFRONTAL ***CORTEX*** SLICES
AU RETAUX S (Reprint); BESSON M J; PENITSORIA J
CS UNIV PARIS 06, INST NEUROSCI, NEUROCHIM ANAT LAB, 9 QUAI ST BERNARD, F-75230 PARIS 05, FRANCE (Reprint)
CYA FRANCE
SO NEUROSCIENCE, (***1991***) Vol. 42, No. 1, pp. 61-71.
DT Article; Journal
FS LIFE
LA ENGLISH
REC Reference Count: 59
ABSTRACT IS AVAILABLE IN THE ALL AND IALL FORMATS

L8 ANSWER 102 OF 188 USPATFULL on STN
AN 2002:326033 USPATFULL
TI N-[(substituted five-membered di- or triaza diunsaturated ring)carbonyl] guanidine derivatives for the treatment of ischemia
IN Hamanaka, Ernest S., Gales Ferry, CT, United States
Guzman-Perez, Angel, Stonington, CT, United States
Ruggeri, Roger B., Waterford, CT, United States
Webster, Ronald T., Ledyard, CT, United States
Mularski, Christian J., Chester, CT, United States
PA Pfizer, Inc., New York, NY, United States (U.S. corporation)
PI US 6492401 B1 20021210
WO 9943663 19990902 <--
AI US 1999-367731 19990818 (9)
WO 1999-IB206 19990205
PRAI US 1998-76362P 19980227 (60)
DT Utility
FS GRANTED
LN.CNT 8541
INCL INCLM: 514/359.000
INCLS: 514/406.000; 548/255.000; 548/362.500; 548/306.100; 546/165.000; 546/145.000; 546/175.000
NCL NCLM: 514/359.000
NCLS: 514/406.000; 546/145.000; 546/165.000; 546/175.000; 548/255.000; 548/306.100; 548/362.500
IC [7]
ICM: A61K031-41
ICS: A61K031-415; C07D249-04; C07D231-56; C07D403-02
EXF 548/255; 548/374.1; 548/262.2; 548/362.5; 548/306.1; 514/359; 514/406; 546/165; 546/145; 546/175
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 103 OF 188 USPATFULL on STN
AN 2001:25917 USPATFULL
TI 2-(1,2,4-triazole-1-yl)-1,3,4-thiadiazole derivatives having an effect on the C.N.S. and the heart

Barkoczy, Jozsef, Budapest, Hungary
Berecz, Gabor, Budapest, Hungary
Simig, Gyula, Budapest, Hungary
Egyed, Andras, Budapest, Hungary
Ivanicsne Megyeri, Katalin, Budapest, Hungary
Drabant, Sandor, Budapest, Hungary
Kertesz, Szabolcs, Budapest, Hungary
Miklosne Kovacs, Aniko, Budapest, Hungary
Nagyne Gyonos, Ildiko, Budapest, Hungary
Szecseyne Hegedus, Maria, Budapest, Hungary
Szenasi, Gabor, Budapest, Hungary
Wellmann, Janos, Budapest, Hungary
Pallagi, Katalin, Budapest, Hungary
Schmidt, Eva, Budapest, Hungary
Tihanyi, Karoly, Budapest, Hungary
Trinka, Peter, Budapest, Hungary
Csorgo , Margit, Budapest, Hungary
PA EGIS Gyogyszergyar Rt., Budapest, Hungary (non-U.S. corporation)
PI US 6191152 B1 20010220
WO 9830561 19980716 <--
AI US 1999-341362 19990920 (9)
WO 1998-HU5 19980113
19990920 PCT 371 date
19990920 PCT 102(e) date
PRAI HU 1997-103 19970114
HU 1997-104 19970114
HU 1997-105 19970114
HU 1997-106 19970114
DT Utility
FS Granted
LN.CNT 3857
INCL INCLM: 514/363.000
INCLS: 544/134.000; 544/367.000; 546/277.000; 548/137.000
NCL NCLM: 514/363.000
NCLS: 514/217.100; 514/252.050; 514/254.030; 544/134.000; 544/367.000; 546/209.000; 546/268.700; 548/137.000
IC [7]
ICM: C07D417-04
ICS: A61K031-433
EXF 548/137; 548/138; 548/367; 546/227; 514/363
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 104 OF 188 USPATFULL on STN
AN 2000:134882 USPATFULL
TI Piperazinylalkylthiopyrimidine derivatives, pharmaceutical compositions containing the same and a process for the preparation of the novel compounds
IN Jakoczi, Ivan, Monor, Hungary
Bozsing, Daniel, Budapest, Hungary
Ratz nee Simonek, Ildiko, Budapest, Hungary
Gacsalyi, Istvan, Budapest, Hungary
Szenasi, Gabor, Budapest, Hungary
Schmidt, Eva, Budapest, Hungary
Miklos nee Kovacs, Aniko, Budapest, Hungary
Bilkei-Gorzo , Andras, Budapest, Hungary
Blasko , Gabor, Budapest, Hungary
Gyertyan, Istvan, Budapest, Hungary
Nemeth, Gabor, Budapest, Hungary
Simig, Gyula, Budapest, Hungary
Tihanyi, Karoly, Budapest, Hungary
Egyed, Andras, Budapest, Hungary
PA Egis Gyoyszergyar RT, Budapest, Hungary (non-U.S. corporation)
PI US 6130215 20001010
WO 9716429 19970509 <--
AI US 1998-66465 19980623 (9)
WO 1996-HU61 19961025
19980623 PCT 371 date
19980623 PCT 102(e) date
PRAI HU 1995-3099 19951031
DT Utility
FS Granted
LN.CNT 1891
INCL INCLM: 514/252.000
INCLS: 544/295.000; 540/575.000; 514/212.000
NCL NCLM: 514/252.140

IC [7]
ICM: A01N043-58
EXF 544/295; 514/252
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 105 OF 188 USPATFULL on STN
AN 2000:98425 USPATFULL
TI Dexanabinol derivatives and their use as neuroprotective pharmaceutical compositions
IN Mechoulam, Raphael, Jerusalem, Israel
Pop, Emil, Gainesville, FL, United States
Sokolovsky, Mordechai, Tel Aviv, Israel
Kloog, Yoel, Hertzlyia, Israel
Biegon, Anat, Tel Aviv, Israel
PA Ramot University Authority for Applied Research and Industrial Development Ltd., Tel Aviv, Israel (non-U.S. corporation)
Yissum Research Develpoment Company of the Hebrew University in Jersusalem, Jerusalem, Israel (non-U.S. corporation)
PI US 6096740 20000801
WO 9520958 19950810 <--
AI US 1998-11814 19980928 (9)
WO 1995-US1470 19950206
19980928 PCT 371 date
19980928 PCT 102(e) date
RLI Continuation-in-part of Ser. No. US 1994-192886, filed on 7 Feb 1994, now patented, Pat. No. US 5521215 which is a continuation-in-part of Ser. No. US 1992-865088, filed on 8 Apr 1992, now patented, Pat. No. US 5284867 which is a continuation-in-part of Ser. No. US 1990-609588, filed on 6 Nov 1990, now abandoned
DT Utility
FS Granted
LN.CNT 2533
INCL INCLM: 514/236.800
INCLS: 514/255.000; 514/314.000; 514/325.000; 514/382.000; 514/455.000; 544/109.000; 544/375.000; 546/135.000; 546/282.700; 548/252.000; 549/291.000
NCL NCLM: 514/236.800
NCLS: 514/100.000; 514/254.110; 514/314.000; 514/325.000; 514/382.000; 514/455.000; 544/109.000; 544/375.000; 546/135.000; 546/282.700; 548/252.000; 549/291.000
IC [7]
ICM: A61K031-352
ICS: A61K031-496; C07D295-037; C07D311-80; C07D453-04
EXF 514/236.8; 514/255; 514/314; 514/325; 514/382; 514/455; 544/109; 544/375; 546/135; 546/282.7; 548/252; 549/391
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 106 OF 188 USPATFULL on STN
AN 1999:75753 USPATFULL
TI MU opioid receptor ligands: agonists and antagonists
IN Dooley, Colette T., San Diego, CA, United States
Houghten, Richard A., Del Mar, CA, United States
PA Torrey Pines Institute for Molecular Studies, San Diego, CA, United States (U.S. corporation)
PI US 5919897 19990706 <--
AI US 1995-488659 19950607 (8)
DT Utility
FS Granted
LN.CNT 3436
INCL INCLM: 530/330.000
INCLS: 530/331.000; 530/345.000; 514/018.000; 514/019.000; 260/998.200
NCL NCLM: 530/330.000
NCLS: 260/998.200; 514/018.000; 514/019.000; 530/331.000; 530/345.000
IC [6]
ICM: C07K005-00
EXF 530/330; 530/331; 530/345; 514/18; 514/19; 260/998.2
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 107 OF 188 USPATFULL on STN
AN 1999:37117 USPATFULL
TI Methods of treating or ameliorating the symptoms of venomous bites and stings
IN Cohen, Marlene Lois, Carmel, IN, United States
Johnson, Kirk Willis, Camby, IN, United States
PA Eli Lilly and Company, Indianapolis, IN, United States (U.S.

PI US 5886003 19990323 <--
AI US 1997-813131 19970307 (8)
PRAI US 1996-14039P 19960325 (60)
US 1996-14119P 19960325 (60)
DT Utility
FS Granted
LN.CNT 1286
INCL INCLM: 514/280.000
INCLS: 514/285.000; 514/292.000
NCL NCLM: 514/280.000
NCLS: 514/285.000; 514/292.000
IC [6]
ICM: A61K031-44
EXF 514/280; 514/292; 514/285
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 108 OF 188 USPATFULL on STN
AN 1999:19349 USPATFULL
TI Aminoalkyl-indoles
IN Audia, James E., Indianapolis, IN, United States
Baker, Stephen Richard, Yateley, England
Carrera, Jesus Ezquerra, Madrid, Spain
Peteira, Carlos Lamas, Madrid, Spain
Tercero, Concepcion Pedregal, Madrid, Spain
PA Eli Lilly and Company, Indianapolis, IN, United States (U.S. corporation)
PI US 5869691 19990209 <--
AI US 1997-838377 19970408 (8)
RLI Division of Ser. No. US 1995-444449, filed on 19 May 1995, now patented, Pat. No. US 5643916
DT Utility
FS Granted
LN.CNT 1581
INCL INCLM: 548/494.000
INCLS: 548/504.000; 548/507.000; 548/426.000; 548/427.000
NCL NCLM: 548/494.000
NCLS: 548/426.000; 548/427.000; 548/504.000; 548/507.000
IC [6]
ICM: C07D209-18
ICS: C07D209-20; C07D209-10
EXF 546/79; 548/494; 548/504; 548/507
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 109 OF 188 USPATFULL on STN
AN 1999:19161 USPATFULL
TI Method of treating or ameliorating the symptoms of common cold or allergic rhinitis
IN Johnson, Kirk Willis, Camby, IN, United States
Nelson, David Lloyd Garver, Carmel, IN, United States
Phebus, Lee Alan, Fountaintown, IN, United States
PA Eli Lilly and Company, Indianapolis, IN, United States (U.S. corporation)
PI US 5869497 19990209 <--
AI US 1997-813472 19970307 (8)
DT Utility
FS Granted
LN.CNT 1240
INCL INCLM: 514/278.000
INCLS: 514/300.000
NCL NCLM: 514/278.000
NCLS: 514/300.000
IC [6]
ICM: A61K031-44
EXF 514/300; 514/278
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 110 OF 188 USPATFULL on STN
AN 1999:7412 USPATFULL
TI Indole-ethanamines
IN Audia, James E., Indianapolis, IN, United States
Droste, James J., Indianapolis, IN, United States
Murdoch, Gwyn L., Greenwood, IN, United States
Nelson, David L., Carmel, IN, United States
PA Eli Lilly and Company, Indianapolis, IN, United States (U.S. corporation)

AI US 1997-845053 19970418 (8)
RLI Division of Ser. No. US 1995-481714, filed on 7 Jun 1995, now patented, Pat. No. US 5760051 which is a continuation-in-part of Ser. No. US 1994-206839, filed on 11 Mar 1994, now patented, Pat. No. US 5500431 which is a continuation-in-part of Ser. No. US 1993-48544, filed on 14 Apr 1993, now abandoned
DT Utility
FS Granted
LN.CNT 3152
INCL INCLM: 514/411.000
INCLS: 548/427.000
NCL NCLM: 514/411.000
NCLS: 548/427.000
IC [6]
ICM: A61K031-40
ICS: C07D209-60
EXF 514/411; 548/427
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 111 OF 188 USPATFULL on STN
AN 1999:7397 USPATFULL
TI Tetrahydro-beta-carbolines
IN Audia, James E., Indianapolis, IN, United States
Baker, Stephen Richard, Camberley, England
Carrera, Jesus Ezquerra, Madrid, Spain
Peteira, Carlos Lamas, Madrid, Spain
Tercero, Concepcion Pedregal, Madrid, Spain
PA Eli Lilly and Company, Indianapolis, IN, United States (U.S. corporation)
PI US 5861410 19990119 <--
AI US 1997-833751 19970409 (8)
RLI Division of Ser. No. US 1995-444449, filed on 19 May 1995, now patented, Pat. No. US 5643916
DT Utility
FS Granted
LN.CNT 1628
INCL INCLM: 514/285.000
INCLS: 514/292.000; 546/070.000; 546/086.000; 546/087.000
NCL NCLM: 514/285.000
NCLS: 514/292.000; 546/070.000; 546/086.000; 546/087.000
IC [6]
ICM: A61K031-44
ICS: C07D471-04; C07D487-04
EXF 546/86; 546/87; 546/70; 514/292; 514/285
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 112 OF 188 USPATFULL on STN
AN 1999:7396 USPATFULL
TI Tetrahydro-beta-carbolines
IN Audia, James E., Indianapolis, IN, United States
Baker, Stephen Richard, Surrey, England
Carrera, Jesus Ezquerra, Madrid, Spain
Peteira, Carlos Lamas, Madrid, Spain
Tercero, Concepcion Pedregal, Madrid, Spain
PA Eli Lilly and Company, Indianapolis, IN, United States (U.S. corporation)
PI US 5861409 19990119 <--
AI US 1997-835774 19970408 (8)
RLI Division of Ser. No. US 1995-444449, filed on 19 May 1995, now patented, Pat. No. US 5643916
DT Utility
FS Granted
LN.CNT 1604
INCL INCLM: 514/280.000
INCLS: 546/018.000; 546/049.000
NCL NCLM: 514/280.000
NCLS: 546/018.000; 546/049.000
IC [6]
ICM: A61K031-44
ICS: C07D471-04
EXF 546/49; 514/280
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 113 OF 188 USPATFULL on STN
AN 1999:7395 USPATFULL

IN Audia, James E., Indianapolis, IN, United States
Baker, Stephen Richard, Surrey, England
Carrera, Jesus Ezquerra, Madrid, Spain
Peteira, Carlos Lamas, Madrid, Spain
Tercero, Concepcion Pedregal, Madrid, Spain
PA Eli Lilly and Company, Indianapolis, IN, United States (U.S. corporation)
PI US 5861408 19990119 <--
AI US 1997-835452 19970408 (8)
RLI Division of Ser. No. US 1995-444449, filed on 19 May 1995, now patented, Pat. No. US 5643916
DT Utility
FS Granted
LN.CNT 1544
INCL INCLM: 514/278.000
INCLS: 546/049.000; 546/070.000
NCL NCLM: 514/278.000
NCLS: 546/049.000; 546/070.000
IC [6]
ICM: A61K031-44
ICS: C07D471-04; C07D471-10
EXF 546/86; 546/87; 546/49; 546/70; 546/18; 514/278
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 114 OF 188 USPATFULL on STN
AN 1999:1660 USPATFULL
TI Method of using (2-imidazolin-2-ylamino) quinoxalines in treating ocular neural injury
IN Wheeler, Larry A., Irvine, CA, United States
Woldemussie, Elizabeth, Laguna Niguel, CA, United States
Lai, Ronald K., Santa Ana, CA, United States
PA Allergan, Waco, TX, United States (U.S. corporation)
PI US 5856329 19990105 <--
AI US 1995-496262 19950628 (8)
DT Utility
FS Granted
LN.CNT 628
INCL INCLM: 514/255.000
INCLS: 514/912.000
NCL NCLM: 514/249.000
NCLS: 514/912.000
IC [6]
ICM: A61K031-495
EXF 514/255; 514/912
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 115 OF 188 USPATFULL on STN
AN 1998:162647 USPATFULL
TI Angiotensin IV peptides and receptor
IN Harding, Joseph W., Pullman, WA, United States
Wright, John W., Pullman, WA, United States
PA Washington State University Research Foundation, Pullman, WA, United States (U.S. corporation)
PI US 5854388 19981229 <--
WO 9400492 19940106 <--
AI US 1994-360784 19941222 (8)
WO 1993-US6038 19930624
19941222 PCT 371 date
19941222 PCT 102(e) date
DT Utility
FS Granted
LN.CNT 4073
INCL INCLM: 530/329.000
INCLS: 530/387.200; 530/387.900; 530/388.240; 436/548.000; 260/112.500; 424/177.000
NCL NCLM: 530/329.000
NCLS: 436/548.000; 514/017.000; 514/018.000; 530/330.000; 530/331.000; 530/387.200; 530/387.900; 530/388.240
IC [6]
ICM: A61K038-04
ICS: A61K039-06; C07K016-00; C07K005-00
EXF 530/329; 530/387.9; 530/388.24; 530/389.2; 436/548; 260/112.5; 424/177
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 116 OF 188 USPATFULL on STN

TI Aza spiro compounds acting on the cholinergic system with muscarinic agonist activity
IN Fisher, Abraham, Holon, Israel
Karton, Yishal, Ness-Ziona, Israel
Marciano, Daniele, Ramat-Hasharon, Israel
Barak, Dov, Rehovot, Israel
Meshulam, Haim, Bat Yam, Israel
PA Israel Institute for Biological Research, Nessziona, Israel (non-U.S. corporation)
PI US 5852029 19981222 <--
AI US 1996-627222 19960118 (8)
RLI Continuation-in-part of Ser. No. US 1993-94855, filed on 20 Jul 1993, now patented, Pat. No. US 5534520 which is a continuation-in-part of Ser. No. US 1991-685397, filed on 9 Apr 1991, now abandoned which is a continuation-in-part of Ser. No. US 1990-507708, filed on 10 Apr 1990, now abandoned
DT Utility
FS Granted
LN.CNT 4189
INCL INCLM: 514/278.000
INCLS: 546/016.000; 546/019.000; 546/020.000
NCL NCLM: 514/278.000
NCLS: 546/016.000; 546/019.000; 546/020.000
IC [6]
ICM: C07D491-10
ICS: C07D491-20; A61K031-445; A61K031-46
EXF 546/19; 546/16; 546/20; 514/278
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 117 OF 188 USPATFULL on STN
AN 1998:154423 USPATFULL
TI Amino acid derivatives with anticholecystokinin activity
IN McDonald, Iain Mair, Paddock Wood, United Kingdom
PA James Black Foundation Limited, London, England (non-U.S. corporation)
PI US 5847125 19981208 <--
WO 9314066 19930722 ##STR1## <--
AI US 1994-256145 19940707 (8)
WO 1993-GB28 19930108
19940707 PCT 371 date
19940707 PCT 102(e) date
PRAI GB 1992-420 19920109
DT Utility
FS Granted
LN.CNT 1298
INCL INCLM: 540/582.000
INCLS: 546/016.000; 546/019.000; 560/016.000; 560/024.000; 560/038.000; 562/427.000
NCL NCLM: 540/582.000
NCLS: 546/016.000; 546/019.000; 560/016.000; 560/024.000; 560/038.000; 562/427.000
IC [6]
ICM: C07D223-32
ICS: C07D491-113; C07D317-10
EXF 540/582; 546/16; 546/19; 560/16; 562/427
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 118 OF 188 USPATFULL on STN
AN 1998:134997 USPATFULL
TI Method and agents for inducement of endogenous nitric oxide synthase for control and management of labor during pregnancy
IN Harrison, Michael R., San Francisco, CA, United States
Heymann, Michael A., San Francisco, CA, United States
Riemer, Robert Kirk, Half Moon Bay, CA, United States
Natuzzi, Eileen Stack, San Francisco, CA, United States
PA The Regents of the University of California, Oakland, CA, United States (U.S. corporation)
PI US 5830848 19981103 <--
AI US 1995-450126 19950525 (8)
RLI Continuation-in-part of Ser. No. US 1994-198512, filed on 18 Feb 1994, now patented, Pat. No. US 5508045 which is a continuation-in-part of Ser. No. US 1992-959006, filed on 9 Oct 1992, now abandoned
DT Utility
FS Granted
LN.CNT 2712
INCL INCLM: 514/002.000

NCL NCLM: 514/002.000
NCLS: 424/085.100; 424/085.200; 424/085.500; 530/399.000
IC [6]
ICM: A61K038-19
ICS: A61K038-22; A61K045-65; C07K014-435
EXF 514/2; 424/85.1; 424/85.2; 424/85.5; 530/399
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 119 OF 188 USPATFULL on STN
AN 1998:122443 USPATFULL
TI 16-methyl-11,16-dihydroxy-9-oxoprost-2,13-dien-1-oic acid and derivatives
IN Mammarella, Carlos Alberto Genaro, Buenos Aires, Argentina
Buschi, Carlos Alberto, Buenos Aires, Argentina
Giarcovich, Silvia Susana, Buenos Aires, Argentina
PA New Pharma International Corp., Montevideo, Uruguay (non-U.S. corporation)
PI US 5817694 19981006 <--
AI US 1993-72188 19930604 (8)
PRAI CL 1992-57092 19920608
DT Utility
FS Granted
LN.CNT 1480
INCL INCLM: 514/530.000
INCLS: 514/573.000; 560/121.000
NCL NCLM: 514/530.000
NCLS: 514/573.000; 560/121.000
IC [6]
ICM: A01N037-08
EXF 560/121; 514/530; 514/573
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 120 OF 188 USPATFULL on STN
AN 1998:61666 USPATFULL
TI Tetrahydro-beta-carbolines
IN Audia, James E., Indianapolis, IN, United States
Droste, James J., Indianapolis, IN, United States
Evrard, Deborah A., Indianapolis, IN, United States
Fludzinski, Pawel, Indianapolis, IN, United States
Murdoch, Gwyn L., Greenwood, IN, United States
Nelson, David L., Carmel, IN, United States
PA Eli Lilly and Company, Indianapolis, IN, United States (U.S. corporation)
PI US 5760051 19980602 <--
AI US 1995-481714 19950607 (8)
RLI Continuation-in-part of Ser. No. US 1994-206839, filed on 11 Mar 1994, now patented, Pat. No. US 5500431 which is a continuation-in-part of Ser. No. US 1993-48544, filed on 14 Apr 1993, now abandoned
DT Utility
FS Granted
LN.CNT 3163
INCL INCLM: 514/292.000
INCLS: 546/085.000; 546/086.000; 546/087.000
NCL NCLM: 514/292.000
NCLS: 546/085.000; 546/086.000; 546/087.000
IC [6]
ICM: A61K031-44
ICS: C07D471-04
EXF 514/292; 546/85; 546/86; 546/87
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 121 OF 188 USPATFULL on STN
AN 1998:54916 USPATFULL
TI Quinolinecarboxylic acid derivatives
IN Ohuchi, Yutaka, Tokyo, Japan
Suzuki, Masaji, Tokyo, Japan
Asanuma, Hajime, Tokyo, Japan
Yokomori, Sadakazu, Tokyo, Japan
Hatayama, Katsuo, Tokyo, Japan
PA Taisho Pharmaceutical Co., Ltd., Tokyo, Japan (non-U.S. corporation)
PI US 5753673 19980519 <--
WO 9531455 19951123 <--
AI US 1996-578532 19960118 (8)
WO 1995-JP954 19950518
19960118 PCT 371 date

PRAI JP 1994-103177 19940518
DT Utility
FS Granted
LN.CNT 2096
INCL INCLM: 514/304.000
INCLS: 514/235.200; 544/128.000; 546/126.000
NCL NCLM: 514/304.000
NCLS: 514/235.200; 544/128.000; 546/126.000
IC [6]
ICM: A61K031-46
ICS: C07D451-06; C07D451-04
EXF 546/126; 544/128; 514/235.2; 514/304
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 122 OF 188 USPATFULL on STN
AN 1998:36752 USPATFULL
TI Naphthylpiperazinyl compounds useful for treating 5HT.sub.2B receptor mediated conditions
IN Audia, James E., Indianapolis, IN, United States
Cohen, Marlene L., Carmel, IN, United States
Gidda, Jaswant S., Carmel, IN, United States
Nelson, David L. G., Carmel, IN, United States
PA Eli Lilly and Company, Indianapolis, IN, United States (U.S. corporation)
PI US 5736544 19980407 <--
AI US 1996-621408 19960325 (8)
RLI Division of Ser. No. US 1995-380566, filed on 6 Feb 1995 which is a continuation-in-part of Ser. No. US 1994-212622, filed on 11 Mar 1994, now abandoned
DT Utility
FS Granted
LN.CNT 5339
INCL INCLM: 514/247.000
NCL NCLM: 514/247.000
IC [6]
ICM: A01N043-58
EXF 544/395; 514/247; 514/657
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 123 OF 188 USPATFULL on STN
AN 1998:1802 USPATFULL
TI Method for treating 5-HT.sub.2B receptor related conditions
IN Audia, James E., Indianapolis, IN, United States
Cohen, Marlene, Carmel, IN, United States
Gidda, Jaswant S., Carmel, IN, United States
Nelson, David L., Carmel, IN, United States
PA Eli Lilly and Company, Indianapolis, IN, United States (U.S. corporation)
PI US 5705519 19980106 <--
AI US 1995-440013 19950512 (8)
RLI Division of Ser. No. US 1995-380566, filed on 6 Feb 1995 which is a continuation-in-part of Ser. No. US 1994-212622, filed on 11 Mar 1994, now abandoned
DT Utility
FS Granted
LN.CNT 5448
INCL INCLM: 514/415.000
NCL NCLM: 514/415.000
IC [6]
ICM: A01N043-38
EXF 514/415; 548/469; 548/509
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 124 OF 188 USPATFULL on STN
AN 97:107093 USPATFULL
TI Method for treating 5HT.sub.2B receptor related conditions
IN Audia, James E., Indianapolis, IN, United States
Cohen, Marlene L., Carmel, IN, United States
Gidda, Jaswant S., Carmel, IN, United States
Nelson, David L. G., Carmel, IN, United States
PA Eli Lilly and Company, Indianapolis, IN, United States (U.S. corporation)
PI US 5688807 19971118 <--
AI US 1995-380566 19950206 (8)
RLI Continuation-in-part of Ser. No. US 1994-212622, filed on 11 Mar 1994,

DT Utility
FS Granted
LN.CNT 5501
INCL INCLM: 514/285.000
INCLS: 514/292.000; 546/086.000; 546/087.000
NCL NCLM: 514/285.000
NCLS: 514/292.000; 546/086.000; 546/087.000
IC [6]
ICM: A61K031-435
EXF 546/78; 546/85; 546/86; 546/87; 514/285; 514/292
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 125 OF 188 USPATFULL on STN
AN 97:78447 USPATFULL
TI Tetrahydro-beta carbolines
IN Audia, James E., Indianapolis, IN, United States
Baker, Stephen Richard, Camberley, England
Carrera, Jesus Ezquerra, Madrid, Spain
Peteira, Carlos Lamas, Madrid, Spain
Tercero, Concepcion Pedregal, Madrid, Spain
PA Eli Lilly and Company, Indianapolis, IN, United States (U.S. corporation)
PI US 5663178 19970902 <--
AI US 1995-380565 19950206 (8)
DT Utility
FS Granted
LN.CNT 1553
INCL INCLM: 514/284.000
INCLS: 546/070.000
NCL NCLM: 514/284.000
NCLS: 546/070.000
IC [6]
ICM: C07D471-04
ICS: A61K031-44
EXF 546/70; 514/284
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 126 OF 188 USPATFULL on STN
AN 97:56713 USPATFULL
TI .omega.-amino-.alpha.-phenylalkanonitrile derivatives
IN Gillet, Claude L., Blanmont, Belgium
Bovy, Philippe R., St. Louis, MO, United States
Gorissen, Hugo, Grez Doiceau, Belgium
Snyers, Michel P., Limal, Belgium
PA G. D. Searle & Co., Skokie, IL, United States (U.S. corporation)
PI US 5643947 19970701 <--
AI US 1995-448911 19950524 (8)
RLI Continuation of Ser. No. US 1993-40824, filed on 31 Mar 1993, now abandoned which is a continuation of Ser. No. US 1992-811450, filed on 19 Dec 1992, now abandoned which is a continuation of Ser. No. US 1991-638006, filed on 5 Jan 1991, now abandoned which is a continuation of Ser. No. US 1989-454341, filed on 21 Dec 1989, now abandoned
DT Utility
FS Granted
LN.CNT 709
INCL INCLM: 514/523.000
INCLS: 558/390.000
NCL NCLM: 514/523.000
NCLS: 558/390.000
IC [6]
ICM: C07K255-24
ICS: A61K031-275
EXF 538/408; 558/390; 514/523
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 127 OF 188 USPATFULL on STN
AN 97:56682 USPATFULL
TI Tetrahydro-beta-carbolines
IN Audia, James E., Indianapolis, IN, United States
Baker, Stephen Richard, Camberley, England
Carrera, Jesus Ezquerra, Madrid, Spain
Peteira, Carlos Lamas, Madrid, Spain
Tercero, Concepcion Pedregal, Madrid, Spain
PA Eli Lilly and Company, Indianapolis, IN, United States (U.S. corporation)

AI US 1995-444449 19950519 (8)
RLI Division of Ser. No. US 1995-380565, filed on 6 Feb 1995, now abandoned
DT Utility
FS Granted
LN.CNT 1562
INCL INCLM: 514/285.000
INCLS: 514/292.000; 546/070.000; 546/086.000; 546/087.000
NCL NCLM: 514/285.000
NCLS: 514/292.000; 546/070.000; 546/086.000; 546/087.000
IC [6]
ICM: A61K031-44
ICS: C07D471-04; C07D487-04
EXF 546/70; 546/86; 546/87; 514/285; 514/292
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 128 OF 188 USPATFULL on STN
AN 97:54311 USPATFULL
TI .mu.opioid receptor ligands: agonists and antagonists
IN Dooley, Colette T., San Diego, CA, United States
Houghten, Richard A., Del Mar, CA, United States
PA Torrey Pines Institute For Molecular Studies, San Diego, CA, United States (U.S. corporation)
PI US 5641861 19970624 <--
AI US 1995-487006 19950607 (8)
DT Utility
FS Granted
LN.CNT 1822
INCL INCLM: 530/329.000
NCL NCLM: 530/329.000
IC [6]
ICM: A61K038-08
ICS: A61K038-04
EXF 530/329
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 129 OF 188 USPATFULL on STN
AN 97:47433 USPATFULL
TI Intermediates to tetrahydro-beta-carbolines
IN Audia, James E., Indianapolis, IN, United States
Droste, James J., Indianapolis, IN, United States
Evrard, Deborah A., Indianapolis, IN, United States
Fludzinski, Pawel, Indianapolis, IN, United States
Murdoch, Gwyn L., Greenwood, IN, United States
Nelson, David L., Carmel, IN, United States
PA Eli Lilly and Company, Indianapolis, IN, United States (U.S. corporation)
PI US 5635528 19970603 <--
AI US 1995-481716 19950607 (8)
RLI Continuation-in-part of Ser. No. US 1994-206839, filed on 11 Mar 1994, now patented, Pat. No. US 5500431, issued on 19 Mar 1996 which is a continuation-in-part of Ser. No. US 1993-48544, filed on 14 Apr 1993, now abandoned
DT Utility
FS Granted
LN.CNT 3182
INCL INCLM: 514/415.000
INCLS: 514/419.000; 548/504.000; 548/507.000
NCL NCLM: 514/415.000
NCLS: 514/419.000; 548/504.000; 548/507.000
IC [6]
ICM: A61K031-405
ICS: C07D209-16
EXF 514/415; 514/419; 548/494; 548/504; 548/507
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 130 OF 188 USPATFULL on STN
AN 97:42890 USPATFULL
TI 8-substituted tetrahydro-beta-carbolines
IN Audia, James E., Indianapolis, IN, United States
Droste, James J., Indianapolis, IN, United States
Nissen, Jeffrey S., Indianapolis, IN, United States
PA Eli Lilly and Company, Indianapolis, IN, United States (U.S. corporation)
PI US 5631265 19970520 <--
AI US 1995-380564 19950206 (8)

now abandoned which is a continuation of Ser. No. US 1994-212404, filed on 11 Mar 1994, now abandoned
DT Utility
FS Granted
LN.CNT 1457
INCL INCLM: 514/292.000
INCLS: 546/085.000; 546/086.000; 546/087.000
NCL NCLM: 514/292.000
NCLS: 546/085.000; 546/086.000; 546/087.000
IC [6]
ICM: A61K031-395
ICS: C07D471-04
EXF 514/292; 546/85; 546/86; 546/87
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 131 OF 188 USPATFULL on STN
AN 97:40795 USPATFULL
TI Tetrahydro-beta-carbolines
IN Audia, James E., Indianapolis, IN, United States
Baker, Stephen R., Camberley, England
Carrera, Jesus E., Madrid, Spain
Peteira, Carlos L., Madrid, Spain
Tercero, Concepcion P., Madrid, Spain
PA Eli Lilly and Company, Indianapolis, IN, United States (U.S. corporation)
PI US 5629317 19970513 <--
AI US 1995-444450 19950519 (8)
RLI Division of Ser. No. US 1995-380565, filed on 6 Feb 1995, now abandoned
DT Utility
FS Granted
LN.CNT 1594
INCL INCLM: 514/278.000
INCLS: 514/279.000; 514/280.000; 514/292.000; 546/018.000; 546/041.000; 546/049.000; 546/053.000; 546/085.000; 546/086.000; 546/087.000; 546/070.000
NCL NCLM: 514/278.000
NCLS: 514/279.000; 514/280.000; 514/292.000; 546/018.000; 546/041.000; 546/049.000; 546/053.000; 546/070.000; 546/085.000; 546/086.000; 546/087.000
IC [6]
ICM: A61K031-44
ICS: C07D471-10; C07D487-04; C07D487-10
EXF 546/18; 546/70; 546/41; 546/49; 546/53; 546/85; 546/87; 514/278; 514/285; 514/279; 514/280; 514/292
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 132 OF 188 USPATFULL on STN
AN 97:20639 USPATFULL
TI Kappa receptor selective opioid peptides
IN Dooley, Colette T., San Diego, CA, United States
Houghten, Richard A., Del Mar, CA, United States
PA Torrey Pines Institute for Molecular Studies, San Diego, CA, United States (U.S. corporation)
PI US 5610271 19970311 <--
AI US 1995-472219 19950607 (8)
DT Utility
FS Granted
LN.CNT 839
INCL INCLM: 530/328.000
INCLS: 530/330.000
NCL NCLM: 530/328.000
NCLS: 530/330.000
IC [6]
ICM: A61K038-07
ICS: A61K038-08; C07K005-10; C07K007-06
EXF 514/809; 514/15; 514/18; 530/302; 530/328; 530/330
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 133 OF 188 USPATFULL on STN
AN 97:20543 USPATFULL
TI Use of .alpha..sub.1A -selective adrenoceptor agonists for the treatment of urinary incontinence
IN Craig, Douglas A., Fair Lawn, NJ, United States
Forray, Carlos C., Paramus, NJ, United States
Gluchowski, Charles, Wayne, NJ, United States

PA Synaptic Pharmaceutical Corporation, Paramus, NJ, United States (U.S. corporation)
PI US 5610174 19970311 <--
AI US 1995-459410 19950602 (8)
DT Utility
FS Granted
LN.CNT 1626
INCL INCLM: 514/401.000
INCLS: 514/402.000; 514/400.000; 514/396.000; 514/605.000; 514/394.000; 514/414.000; 514/415.000; 514/418.000; 514/452.000; 514/466.000
NCL NCLM: 514/401.000
NCLS: 514/394.000; 514/396.000; 514/400.000; 514/402.000; 514/414.000; 514/415.000; 514/418.000; 514/452.000; 514/466.000; 514/605.000
IC [6]
ICM: A61K031-415
ICS: A61K031-18; A61K031-40; A61K031-405
EXF 514/400; 514/396; 514/402; 514/605; 514/394; 514/414; 514/415; 514/418; 514/452; 514/466; 514/401
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 134 OF 188 USPATFULL on STN
AN 97:16051 USPATFULL
TI Bicyclic heterocyclic derivatives having .alpha..sub.1 adrenergic and 5HT.sub.1A activities
IN Leonardi, Amedeo, Milan, Italy
Motta, Gianni, Barlassina, Italy
Riva, Carlo, Varese, Italy
Testa, Rodolfo, Milan, Italy
PA Recordati S.A., Chemical and Pharmaceutical Company, Chiasso, Switzerland (non-U.S. corporation)
PI US 5605896 19970225 <--
AI US 1994-299188 19940831 (8)
RLI Continuation-in-part of Ser. No. US 1993-67861, filed on 26 May 1993, now patented, Pat. No. US 5474994 which is a continuation-in-part of Ser. No. US 1992-888775, filed on 26 May 1992, now patented, Pat. No. US 5403842
PRAI IT 1992-MI408 19920225
DT Utility
FS Granted
LN.CNT 8029
INCL INCLM: 514/218.000
INCLS: 546/153.000; 546/169.000; 546/170.000; 546/171.000; 546/176.000; 546/174.000; 546/175.000; 546/196.000; 546/202.000; 546/204.000; 548/304.400; 548/491.000; 549/023.000; 549/049.000; 549/362.000; 549/398.000; 549/401.000; 549/403.000; 549/405.000; 514/234.500; 514/232.200; 514/233.500; 514/253.000; 514/314.000; 514/414.000; 514/443.000; 514/452.000; 514/394.000; 514/456.000; 514/469.000; 540/575.000; 544/143.000; 544/144.000; 544/146.000; 544/148.000; 544/151.000; 544/153.000; 544/363.000; 544/373.000; 544/376.000; 544/377.000
NCL NCLM: 514/218.000
NCLS: 514/232.200; 514/233.500; 514/234.500; 514/252.130; 514/253.070; 514/253.080; 514/254.110; 514/314.000; 514/394.000; 514/414.000; 514/443.000; 514/452.000; 514/456.000; 514/469.000; 540/575.000; 544/143.000; 544/144.000; 544/146.000; 544/148.000; 544/151.000; 544/153.000; 544/363.000; 544/373.000; 544/376.000; 544/377.000; 546/121.000; 546/153.000; 546/169.000; 546/170.000; 546/174.000; 546/175.000; 546/176.000; 546/196.000; 546/202.000; 546/204.000; 548/304.400; 548/491.000; 549/023.000; 549/049.000; 549/362.000; 549/398.000; 549/401.000; 549/403.000; 549/405.000
IC [6]
ICM: C07D243-08
ICS: C07D413-00; C07D215-16; C07D235-04; A61K031-395; A61K031-47; A61K031-38; A61K031-335
EXF 540/575; 544/143; 544/144; 544/146; 544/148; 544/151; 544/153; 544/363; 544/373; 544/376; 544/377; 546/153; 546/169; 546/170; 546/121; 546/176; 546/174; 546/175; 546/196; 546/202; 546/204; 548/304.4; 548/991; 549/23; 549/49; 549/362; 549/398; 549/401; 549/403; 549/405; 514/218; 514/234.5; 514/232.2; 514/233.5; 514/253; 514/314; 514/414; 514/443; 514/452; 514/394; 514/456; 514/469
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 135 OF 188 USPATFULL on STN
AN 96:65572 USPATFULL
TI Tetrahydro-pyrido-indole

Droste, James J., Indianapolis, IN, United States
Evrard, Deborah A., Cambridge, MA, United States
PA Eli Lilly and Company, Indianapolis, IN, United States (U.S. corporation)
PI US 5538981 19960723 <--
AI US 1995-438595 19950510 (8)
RLI Division of Ser. No. US 1994-206830, filed on 11 Mar 1994, now abandoned which is a continuation-in-part of Ser. No. US 1993-48392, filed on 14 Apr 1993, now patented, Pat. No. US 5300645
DT Utility
FS Granted
LN.CNT 2043
INCL INCLM: 514/292.000
INCLS: 546/085.000; 546/086.000; 546/087.000
NCL NCLM: 514/292.000
NCLS: 546/085.000; 546/086.000; 546/087.000
IC [6]
ICM: A61K031-44
ICS: C07D471-04
EXF 546/85; 546/86; 546/87; 514/292
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 136 OF 188 USPATFULL on STN
AN 96:65571 USPATFULL
TI Tetrahydro-pyrido-indole
IN Audia, James E., Indianapolis, IN, United States
Droste, James J., Indianapolis, IN, United States
Evrard, Deborah A., Cambridge, MA, United States
PA Eli Lilly and Company, Indianapolis, IN, United States (U.S. corporation)
PI US 5538980 19960723 <--
AI US 1995-437912 19950510 (8)
RLI Division of Ser. No. US 1994-206830, filed on 11 Mar 1994, now abandoned which is a continuation-in-part of Ser. No. US 1993-48392, filed on 14 Apr 1993, now patented, Pat. No. US 5300645
DT Utility
FS Granted
LN.CNT 2020
INCL INCLM: 514/285.000
INCLS: 546/070.000
NCL NCLM: 514/285.000
NCLS: 546/070.000
IC [6]
ICM: A61K031-44
ICS: C07D471-04
EXF 514/285; 546/70
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 137 OF 188 USPATFULL on STN
AN 96:60705 USPATFULL
TI Spiro compounds containing five-membered rings
IN Fisher, Abraham, 4717 David Elazar Street, Holon, Israel
Karton, Yishai, 8 Ben-Gurion Street, Ness-Ziona, Israel
Marciano, Daniele, 22 Usichkin Street, Ramat-Hasharon, Israel
Barak, Dov, 20 Usichkin Street, Removot, Israel
Meshulam, Haim, 13 Harishohim Street, Bat-Yam, Israel
PI US 5534520 19960709 <--
AI US 1993-94855 19930720 (8)
RLI Continuation-in-part of Ser. No. US 1991-685397, filed on 9 Apr 1991, now abandoned which is a continuation-in-part of Ser. No. US 1990-507708, filed on 10 Apr 1990, now abandoned
DT Utility
FS Granted
LN.CNT 2865
INCL INCLM: 514/278.000
INCLS: 546/016.000; 546/019.000; 546/020.000
NCL NCLM: 514/278.000
NCLS: 546/016.000; 546/019.000; 546/020.000
IC [6]
ICM: A61K031-445
ICS: C07D221-20; C07D491-10; C07D491-20
EXF 546/16; 546/19; 546/20; 514/278
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 138 OF 188 USPATFULL on STN

TI NMDA-blocking pharmaceuticals
IN Mechoulam, Raphael, Jerusalem, Israel
Sokolovsky, Mordechai, Tel Aviv, Israel
Kloog, Yoel, Hertzlyia, Israel
Biegon, Anat, Tel Aviv, Israel
PA Ramot University Authority for Applied Research and Industrial Development Ltd., Tel Aviv, Israel (non-U.S. corporation)
Yissum Research Development Company of the Hebrew University in Jerusalem, Jerusalem, Israel (non-U.S. corporation)
Pharmos Corp., New York, NY, United States (U.S. corporation)
PI US 5521215 19960528 <--
AI US 1994-192886 19940207 (8)
RLI Continuation-in-part of Ser. No. US 1992-865088, filed on 8 Apr 1992, now patented, Pat. No. US 5284867 which is a continuation of Ser. No. US 1990-609588, filed on 6 Nov 1990, now abandoned
PRAI IL 1989-92238 19891107
DT Utility
FS Granted
LN.CNT 1572
INCL INCLM: 514/454.000
NCL NCLM: 514/454.000
IC [6]
ICM: A61K031-35
EXF 549/454; 549/390; 514/454
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 139 OF 188 USPATFULL on STN
AN 96:31833 USPATFULL
TI Tetrahydro-beta-carbolines
IN Audia, James E., Indianapolis, IN, United States
Droste, James J., Indianapolis, IN, United States
Evrard, Deborah A., Cambridge, MA, United States
Fludzinski, Pawel, Berkshire, United Kingdom
Murdoch, Gwyn L., Greenwood, IN, United States
Nelson, David L., Carmel, IN, United States
PA Eli Lilly and Company, Indianapolis, IN, United States (U.S. corporation)
PI US 5508284 19960416 <--
AI US 1995-448005 19950523 (8)
RLI Division of Ser. No. US 1994-206839, filed on 11 Mar 1994 which is a continuation-in-part of Ser. No. US 1993-48544, filed on 14 Apr 1993, now abandoned
DT Utility
FS Granted
LN.CNT 3037
INCL INCLM: 514/285.000
INCLS: 546/070.000
NCL NCLM: 514/285.000
NCLS: 546/070.000
IC [6]
ICM: A61K031-44
ICS: C07D471-04
EXF 514/285; 546/70
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 140 OF 188 USPATFULL on STN
AN 96:23114 USPATFULL
TI Tetrahydro-.beta.-carbolines
IN Audia, James E., Indianapolis, IN, United States
Droste, James J., Indianapolis, IN, United States
Evrard, Deborah A., Cambridge, MA, United States
Fludzinski, Pawel, Berkshire, United Kingdom
Murdoch, Gwyn L., Greenwood, IN, United States
Nelson, David L., Carmel, IN, United States
PA Eli Lilly and Company, Indianapolis, IN, United States (U.S. corporation)
PI US 5500431 19960319 <--
AI US 1994-206839 19940311 (8)
RLI Continuation-in-part of Ser. No. US 1993-48544, filed on 14 Apr 1993, now abandoned
DT Utility
FS Granted
LN.CNT 3023
INCL INCLM: 514/280.000
INCLS: 546/049.000

NCLS: 546/049.000
IC [6]
ICM: A61K031-44
ICS: C07D471-04
EXF 514/280; 546/49; 546/56
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 141 OF 188 USPATFULL on STN
AN 96:17000 USPATFULL
TI Method of ameliorating cerebral circulation
IN Nishikibe, Masaru, Urayasu, Japan
Kamei, Kazuo, Fuchu, Japan
Nagura, Jun, Ichikawa, Japan
Fukuroda, Takahiro, Tokyo, Japan
PA Banyu Pharmaceutical Co., Ltd., Tokyo, Japan (non-U.S. corporation)
PI US 5494923 19960227 <--
AI US 1995-409669 19950324 (8)
RLI Division of Ser. No. US 1994-282657, filed on 29 Jul 1994, now patented, Pat. No. US 5444077 which is a continuation of Ser. No. US 1991-645309, filed on 24 Jan 1991, now abandoned which is a continuation of Ser. No. US 1988-254106, filed on 6 Oct 1988, now abandoned
PRAI JP 1987-251988 19871006
JP 1988-43526 19880226
DT Utility
FS Granted
LN.CNT 950
INCL INCLM: 514/356.000
NCL NCLM: 514/356.000
IC [6]
ICM: A81K031-44
EXF 514/356; 546/321

L8 ANSWER 142 OF 188 USPATFULL on STN
AN 96:9427 USPATFULL
TI Tetrahydro-pyrido-indole
IN Audia, James E., Indianapolis, IN, United States
Droste, James J., Indianapolis, IN, United States
Evrard, Deborah A., Cambridge, MA, United States
PA Eli Lilly and Company, Indianapolis, IN, United States (U.S. corporation)
PI US 5488053 19960130 <--
AI US 1994-206830 19940311 (8)
RLI Continuation-in-part of Ser. No. US 1993-48392, filed on 14 Apr 1993, now patented, Pat. No. US 5300645
DT Utility
FS Granted
LN.CNT 1999
INCL INCLM: 514/280.000
INCLS: 546/049.000
NCL NCLM: 514/280.000
NCLS: 546/049.000
IC [6]
ICM: A61K031-44
ICS: C07D471-04
EXF 546/49; 546/56; 514/280
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 143 OF 188 USPATFULL on STN
AN 95:110442 USPATFULL
TI Bicyclic heterocyclic derivatives having .alpha..sub.1 -adrenergic and 5HT.sub.1A
IN Leonardi, Amedeo, Milan, Italy
Motta, Gianni, Barlassina, Italy
Riva, Carlo, Varese, Italy
Testa, Rodolfo, Milan, Italy
PA Recordati S.A., Chemical and Pharmaceutical Company, Chiasso, Switzerland (non-U.S. corporation)
PI US 5474994 19951212 <--
AI US 1993-67861 19930526 (8)
RLI Continuation-in-part of Ser. No. US 1992-888775, filed on 26 May 1992, now patented, Pat. No. US 5403842
PRAI EP 1993-301264 19930222
DT Utility
FS Granted
LN.CNT 6301

INCLS: 514/253.000; 514/320.000; 514/324.000; 514/433.000; 514/456.000; 540/575.000; 544/295.000; 544/376.000; 546/196.000; 546/202.000; 546/204.000; 546/181.000; 546/169.000; 546/170.000; 546/176.000; 549/401.000; 549/403.000; 549/405.000; 549/023.000
NCL NCLM: 514/218.000
NCLS: 514/254.110; 514/320.000; 514/324.000; 514/433.000; 514/456.000; 540/575.000; 544/295.000; 544/376.000; 546/169.000; 546/170.000; 546/176.000; 546/181.000; 546/196.000; 546/202.000; 546/204.000; 549/023.000; 549/401.000; 549/403.000; 549/405.000
IC [6]
ICM: C07D307-30
ICS: C07D409-02; A61K031-50; A61K031-445
EXF 540/575; 544/295; 544/376; 546/196; 546/202; 546/204; 546/181; 546/169; 546/170; 546/176; 549/401; 549/403; 549/405; 549/23; 514/253; 514/218; 514/320; 514/324; 514/433; 514/456
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 144 OF 188 USPATFULL on STN
AN 95:90525 USPATFULL
TI Thieno[1,5]benzoidiazepine use
IN Greenwood, Beverley, Oklahoma City, OK, United States
Nelson, David L. G., Carmel, IN, United States
PA Eli Lilly and Company, Indianapolis, IN, United States (U.S. corporation)
PI US 5457101 19951010 <--
AI US 1994-253658 19940603 (8)
DT Utility
FS Granted
LN.CNT 363
INCL INCLM: 514/220.000
NCL NCLM: 514/220.000
IC [6]
ICM: A61K031-55
EXF 514/220
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 145 OF 188 USPATFULL on STN
AN 95:75986 USPATFULL
TI Ameliorant of cerebral circulation and optical isomer of NB-818, processes for its use
IN Nishikibe, Masaru, Urayasu, Japan
Kamei, Kazuo, Fuchu, Japan
Nagura, Jun, Ichikawa, Japan
Fukuroda, Takahiro, Tokyo, Japan
PA Banyu Pharmaceutical Co., Ltd., Tokyo, Japan (non-U.S. corporation)
PI US 5444077 19950822 <--
AI US 1994-282657 19940729 (8)
RLI Continuation of Ser. No. US 1991-645309, filed on 24 Jan 1991, now abandoned which is a continuation of Ser. No. US 1988-254106, filed on 6 Oct 1988, now abandoned
PRAI JP 1987-251988 19871006
JP 1988-43526 19880226
DT Utility
FS Granted
LN.CNT 980
INCL INCLM: 514/356.000
INCLS: 546/321.000
NCL NCLM: 514/356.000
NCLS: 546/321.000
IC [6]
ICM: A61K031-44
ICS: C07D211-90
EXF 514/356; 546/321
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 146 OF 188 USPATFULL on STN
AN 95:50179 USPATFULL
TI Composition for treating depression with (N-heteroaryl)alkylamines
IN White, John F., Wokingham, England
Minchin, Michael C. W., Oxford, England
Ennis, Christine, Maidenhead, England
PA John Wyeth & Brother, Limited, Maidenhead, England (non-U.S. corporation)
PI US 5422355 19950606 <--
AI US 1993-82077 19930624 (8)

now patented, Pat. No. US 5260331 which is a continuation of Ser. No. US 1991-816336, filed on 31 Dec 1991, now abandoned which is a division of Ser. No. US 1990-530758, filed on 30 May 1990, now patented, Pat. No. US 5086073, issued on 4 Feb 1992
PRAI GB 1989-12784 19890602
GB 1989-27087 19891130
DT Utility
FS Granted
LN.CNT 954
INCL INCLM: 514/311.000
INCLS: 514/357.000; 514/365.000
NCL NCLM: 514/311.000
NCLS: 514/357.000; 514/365.000
IC [6]
ICM: A61K031-47
ICS: A61K031-44; A61K031-425
EXF 514/415; 514/461; 514/469; 514/436; 514/311; 514/365; 514/357
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 147 OF 188 USPATFULL on STN
AN 95:29644 USPATFULL
TI Benzopyran and benzothiopyran derivatives
IN Leonardi, Amedeo, Milan, Italy
Motta, Gianni, Barlassina, Italy
Riva, Carlo, Varese, Italy
Testa, Rodolfo, Milan, Italy
PA Recordati S.A., Chemical and Pharmaceutical Company, Chiasso, Switzerland (non-U.S. corporation)
PI US 5403842 19950404 <--
AI US 1992-888775 19920526 (7)
PRAI IT 1992-408 19920225
DT Utility
FS Granted
LN.CNT 3226
INCL INCLM: 514/252.000
INCLS: 524/253.000; 544/295.000; 544/359.000; 546/196.000; 546/202.000; 549/023.000; 549/400.000; 549/403.000
NCL NCLM: 514/252.130
NCLS: 514/043.000; 514/252.200; 514/254.110; 544/295.000; 544/359.000; 546/196.000; 546/202.000; 549/023.000; 549/400.000; 549/403.000
IC [6]
ICM: A61K031-495
ICS: A61K031-50; C07D403-00
EXF 544/295; 544/359; 514/253; 514/252
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 148 OF 188 USPATFULL on STN
AN 95:25093 USPATFULL
TI Derivatives of aspartic acid and glutamic acid having anticholecystokinin activity
IN Broughton, Howard B., London, United Kingdom
Kalindjian, Sarkis B., Banstead, United Kingdom
Low, Caroline M. R., Croydon, United Kingdom
McDonald, Iain M., Paddock Wood, United Kingdom
Hull, Robert A. D., Tonbridge, United Kingdom
Shankley, Nigel P., Nr Edenbridge, United Kingdom
PA James Black Foundation Limited, Dulwich, United Kingdom (non-U.S. corporation)
PI US 5399748 19950321 <--
WO 9200958 19920123 <--
AI US 1993-961722 19930112 (7)
WO 1991-GB1111 19910708
19930112 PCT 371 date
19930112 PCT 102(e) date
PRAI GB 1990-15360 19900712
GB 1990-27283 19901217
DT Utility
FS Granted
LN.CNT 673
INCL INCLM: 562/427.000
INCLS: 514/381.000; 514/510.000; 514/533.000; 514/539.000; 514/562.000; 546/176.000; 548/252.000; 549/253.000; 560/010.000; 560/013.000; 562/428.000; 562/430.000
NCL NCLM: 562/427.000
NCLS: 546/176.000; 548/252.000; 549/253.000; 560/010.000; 560/013.000;

IC [6]
ICM: C07C311-37
EXF 574/381; 574/510; 574/533; 574/539; 574/562; 560/10; 560/13; 562/427; 562/428; 562/430; 546/176; 548/252; 549/253
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 149 OF 188 USPATFULL on STN
AN 94:95436 USPATFULL
TI Sulfonanilide derivatives and medicine
IN Morino, Akira, Kyoto, Japan
Morita, Iwao, Kyoto, Japan
Tada, Shin-ichi, Shiga, Japan
PA Nippon Shinyaku Co. Ltd., Japan (non-U.S. corporation)
PI US 5360822 19941101 <--
AI US 1993-171195 19931221 (8)
RLI Continuation of Ser. No. US 1992-917097, filed on 4 Aug 1992, now abandoned
PRAI JP 1990-227675 19900207
JP 1990-2136360 19900525
JP 1990-2278041 19901016
DT Utility
FS Granted
LN.CNT 976
INCL INCLM: 514/605.000
INCLS: 564/099.000
NCL NCLM: 514/605.000
NCLS: 564/099.000
IC [5]
ICM: C07C311-08
ICS: A61K031-18
EXF 514/605; 564/99
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 150 OF 188 USPATFULL on STN
AN 94:55545 USPATFULL
TI Benzodiazepine analogs
IN Bock, Mark G., Hatfield, PA, United States
Evans, Ben E., Lansdale, PA, United States
Freidinger, Roger M., Lansdale, PA, United States
PA Merck & Co., Inc., Rahway, NJ, United States (U.S. corporation)
PI US 5324726 19940628 <--
AI US 1992-968624 19921029 (7)
RLI Continuation-in-part of Ser. No. US 1992-824764, filed on 17 Jan 1992, now abandoned which is a continuation of Ser. No. US 1990-621500, filed on 7 Dec 1990, now abandoned which is a continuation-in-part of Ser. No. US 1989-452012, filed on 18 Dec 1989, now abandoned
DT Utility
FS Granted
LN.CNT 1217
INCL INCLM: 514/221.000
INCLS: 540/504.000; 540/505.000; 540/509.000; 540/510.000; 540/512.000; 540/513.000; 540/514.000; 540/572.000; 540/573.000
NCL NCLM: 514/221.000
NCLS: 540/504.000; 540/505.000; 540/509.000; 540/510.000; 540/512.000; 540/513.000; 540/514.000; 540/572.000; 540/573.000
IC [5]
ICM: A61K031-55
ICS: C07D243-24; C07D243-22; C07D243-16
EXF 514/221; 540/504; 540/505; 540/509; 540/510; 540/512; 540/513; 540/514; 540/572; 540/573
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 151 OF 188 USPATFULL on STN
AN 93:93821 USPATFULL
TI Composition for treating depression with (S- or O-heteroaryl)alkyl amines
IN White, John F., Wokingham, England
Minchin, Michael C. W., Oxford, England
Ennis, Christine, Maidenhead, England
PA John Wyeth & Brother Limited, Maidenhead, England (non-U.S. corporation)
PI US 5260331 19931109 <--
AI US 1992-970352 19921102 (7)
RLI Continuation of Ser. No. US 1991-816336, filed on 31 Dec 1991, now abandoned which is a division of Ser. No. US 1990-530758, filed on 30 May 1990, now patented, Pat. No. US 5086073

GB 1989-27087 19891130
DT Utility
FS Granted
LN.CNT 848
INCL INCLM: 514/438.000
INCLS: 514/415.000; 514/461.000; 514/469.000
NCL NCLM: 514/438.000
NCLS: 514/415.000; 514/461.000; 514/469.000
IC [5]
ICM: A61K031-34
ICS: A61K031-38; A61K031-405
EXF 514/415; 514/461; 514/469; 514/438
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 152 OF 188 USPATFULL on STN
AN 93:67611 USPATFULL
TI Use of glycosaminoglycans in the treatment of diabetic nephropathy and diabetic neuropathy
IN Egidio, Marchi, Bologna, Italy
Gianfranco, Tamagnone, Casalecchir di Reno, Italy
PA ALFA Wassermann S.p.A., Alanno, Italy (non-U.S. corporation)
PI US 5236910 19930817 <--
AI US 1992-871048 19920420 (7)
PRAI IT 1991-163 19910517
DT Utility
FS Granted
LN.CNT 539
INCL INCLM: 514/056.000
INCLS: 514/053.000; 514/054.000; 514/866.000
NCL NCLM: 514/056.000
NCLS: 514/053.000; 514/054.000; 514/866.000
IC [5]
ICM: A61K031-725
EXF 514/53; 514/54; 514/56; 514/866
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 153 OF 188 USPATFULL on STN
AN 93:52587 USPATFULL
TI .beta.-carbolines as cholecystokinin and gastrin antagonists
IN Evans, Ben E., Lansdale, PA, United States
PA Merck & Co., Inc., Rahway, NJ, United States (U.S. corporation)
PI US 5223509 19930629 <--
AI US 1992-841231 19920221 (7)
RLI Continuation of Ser. No. US 1990-593547, filed on 2 Oct 1990, now abandoned which is a continuation of Ser. No. US 1989-363357, filed on 2 Jun 1989, now abandoned which is a continuation of Ser. No. US 1988-244583, filed on 13 Sep 1988, now abandoned which is a continuation of Ser. No. US 1987-86134, filed on 17 Aug 1987, now abandoned
DT Utility
FS Granted
LN.CNT 814
INCL INCLM: 514/292.000
INCLS: 514/210.000; 514/211.000; 514/255.000; 514/542.000; 514/599.000; 546/085.000; 546/086.000; 546/087.000
NCL NCLM: 514/292.000
NCLS: 514/079.000; 514/081.000; 514/255.050; 514/542.000; 514/599.000; 546/085.000; 546/086.000; 546/087.000
IC [5]
ICM: A61K031-435
ICS: C07D471-04
EXF 514/210; 514/211; 514/255; 514/292; 514/542; 514/599; 546/85; 546/86; 546/87
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 154 OF 188 USPATFULL on STN
AN 93:48726 USPATFULL
TI Psychostimulant agent
IN Knoll, Jozsef, Budapest, Hungary
Simay, Antal, Budapest, Hungary
Szinnyei, Eva, Budapest, Hungary
Somfai, Eva, Budapest, Hungary
Torok, Zoltan, Budapest, Hungary
Mozsolits, Karoly, Sopron, Hungary
Bergmann, Janos, Visergad, Hungary
PA Chinoin Gyogyszer - es Vegyeszeti Termekek Gyara Rt., Buadpest, Hungary

PI US 5220068 19930615 <--
AI US 1991-649239 19910129 (7)
RLI Continuation of Ser. No. US 1988-269665, filed on 15 Jul 1988, now abandoned
PRAI HU 1986-4101 19860925
DT Utility
FS Granted
LN.CNT 677
INCL INCLM: 564/381.000
INCLS: 564/375.000; 564/376.000; 564/382.000
NCL NCLM: 564/381.000
NCLS: 564/374.000; 564/375.000; 564/376.000; 564/382.000
IC [5]
ICM: C07C211-27
ICS: A61K031-135
EXF 564/381; 564/382; 564/374; 514/654
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 155 OF 188 USPATFULL on STN
AN 93:37722 USPATFULL
TI Method of treatment and heterocyclic compounds used therein
IN Minchin, Michael C. W., Oxford, England
White, Alan C., Englefield Green, England
White, John F., Woosehill, England
PA John Wyeth & Brother, Limited, Maidenhead, England (non-U.S. corporation)
PI US 5210088 19930511 <--
AI US 1992-888665 19920527 (7)
RLI Continuation of Ser. No. US 1991-780372, filed on 21 Oct 1991, now patented, Pat. No. US 5118690 which is a continuation of Ser. No. US 1990-584216, filed on 18 Sep 1990, now abandoned
PRAI GB 1989-21304 19890920
DT Utility
FS Granted
LN.CNT 951
INCL INCLM: 514/307.000
NCL NCLM: 514/307.000
IC [5]
ICM: A61V031-47
EXF 514/307; 514/314; 546/167
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 156 OF 188 USPATFULL on STN
AN 93:37716 USPATFULL
TI 2-benzazepines with 5- and 6-membered heterocyclic rings to treat pain and anxiety disorders
IN Bock, Mark G., Hatfield, PA, United States
Evans, Ben E., Lansdale, PA, United States
Freidinger, Roger M., Lansdale, PA, United States
PA Merck & Co., Inc., Rahway, NJ, United States (U.S. corporation)
PI US 5210082 19930511 <--
AI US 1991-701275 19910516 (7)
DT Utility
FS Granted
LN.CNT 849
INCL INCLM: 514/213.000
INCLS: 514/217.000
NCL NCLM: 514/215.000
NCLS: 514/217.000
IC [5]
ICM: A61K031-55
EXF 514/217; 514/213
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 157 OF 188 USPATFULL on STN
AN 93:33491 USPATFULL
TI Cholecystokinin antagonists
IN Bock, Mark G., Hatfield, PA, United States
Freidinger, Roger M., Lansdale, PA, United States
PA Merck & Co., Inc., Rahway, NJ, United States (U.S. corporation)
PI US 5206238 19930427 <--
AI US 1992-870157 19920415 (7)
RLI Continuation of Ser. No. US 1990-612646, filed on 13 Nov 1990, now abandoned
DT Utility

LN.CNT 1004
INCL INCLM: 514/221.000
NCL NCLM: 514/221.000
IC [5]
ICM: A01K031-55
EXF 514/221
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 158 OF 188 USPATFULL on STN
AN 93:33490 USPATFULL
TI Benzodiazepine analogs
IN Freidinger, Roger M., Lansdale, PA, United States
Bock, Mark G., Hatfield, PA, United States
Evans, Ben E., Lansdale, PA, United States
PA Merck & Co., Inc., Rahway, NJ, United States (U.S. corporation)
PI US 5206237 19930427 <--
AI US 1991-699849 19910514 (7)
DT Utility
FS Granted
LN.CNT 1706
INCL INCLM: 514/219.000
INCLS: 514/221.000
NCL NCLM: 514/219.000
NCLS: 514/221.000
IC [5]
ICM: A61U031-55
EXF 514/219; 514/222; 514/221
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 159 OF 188 USPATFULL on STN
AN 93:33487 USPATFULL
TI Benzolactam analogs as antagonists of CCK
IN Bock, Mark G., Hatfield, PA, United States
Freidinger, Roger M., Lansdale, PA, United States
Evans, Ben E., Lansdale, PA, United States
PA Merck & Co., Inc., Rahway, NJ, United States (U.S. corporation)
PI US 5206234 19930427 <--
AI US 1991-718075 19910620 (7)
RLI Continuation-in-part of Ser. No. US 1990-602031, filed on 22 Oct 1990, now abandoned
DT Utility
FS Granted
LN.CNT 1114
INCL INCLM: 514/213.000
INCLS: 540/523.000; 546/157.000; 548/465.000; 548/438.000; 514/312.000; 514/414.000; 514/415.000
NCL NCLM: 514/212.070
NCLS: 514/183.000; 514/312.000; 514/414.000; 514/415.000; 540/523.000; 546/157.000; 548/438.000; 548/465.000
IC [5]
ICM: A61K031-55
ICS: C07D223-16
EXF 540/523; 546/157; 548/465; 548/438; 514/213; 514/312; 514/414; 514/415
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 160 OF 188 USPATFULL on STN
AN 93:10514 USPATFULL
TI Triazolobenzodiazepines
IN Freidinger, Roger M., Lansdale, PA, United States
Bock, Mark G., Hatfield, PA, United States
Evans, Ben E., Lansdale, PA, United States
PA Merck & Co., Inc., Rahway, NJ, United States (U.S. corporation)
PI US 5185331 19930209 <--
AI US 1991-699850 19910514 (7)
DT Utility
FS Granted
LN.CNT 2540
INCL INCLM: 514/220.000
NCL NCLM: 514/220.000
IC [5]
ICM: A61K031-55
EXF 514/220
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 161 OF 188 USPATFULL on STN

TI 1,4-benzodiazepines with 6-membered heterocyclic rings to treat panic and anxiety disorder
IN Freidinger, Roger M., Lansdale, PA, United States
Evans, Ben E., Lansdale, PA, United States
Bock, Mark G., Hatfield, PA, United States
PA Merck & Co., Inc., Rahway, NJ, United States (U.S. corporation)
PI US 5177071 19930105 <--
AI US 1991-716589 19910617 (7)
DT Utility
FS Granted
LN.CNT 783
INCL INCLM: 514/220.000
NCL NCLM: 514/220.000
IC [5]
ICM: A61U031-55
EXF 514/220
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 162 OF 188 USPATFULL on STN
AN 92:92760 USPATFULL
TI 2-Benzazepines with 5- and 6-membered heterocyclic rings, compositions and medical methods of use thereof
IN Freidinger, Roger M., Hatfield, PA, United States
Evans, Ben E., Lansdale, PA, United States
Bock, Mark G., Hatfield, PA, United States
PA Merck & Co., Inc., Rahway, NJ, United States (U.S. corporation)
PI US 5166151 19921124 <--
AI US 1991-668353 19910311 (7)
RLI Continuation of Ser. No. US 1989-353224, filed on 15 May 1989, now abandoned which is a continuation of Ser. No. US 1988-175641, filed on 25 Mar 1988, now abandoned
DT Utility
FS Granted
LN.CNT 930
INCL INCLM: 514/215.000
INCLS: 514/217.000; 540/578.000
NCL NCLM: 514/215.000
NCLS: 514/217.000; 540/578.000
IC [5]
ICM: C07D471-04
ICS: A61K031-44; A61K031-55
EXF 548/578; 544/216; 544/217
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 163 OF 188 USPATFULL on STN
AN 92:65956 USPATFULL
TI Composition and method for treatment of senile dementia
IN Pang, Peter K. T., 52225 Range Road, 205 Carriage Lane, Sherwood Park, Alberta, Canada T8A 2A6
Wang, Lawrence C. H., 406 Rooney Crescent, Edmonton, Alberta, Canada T6R 1C8
Benishin, Christina G., 218-53431 Range Rd., 221, Ardressan, Alberta, Canada T0B 0E0
Liu, Hsing J., 3543-105B St., Edmonton, Alberta, Canada T6J 2K9
PI US 5137878 19920811 <--
WO 9008315 19900726 <--
AI US 1991-768423 19910913 (7)
WO 1990-US121 19900112
19910913 PCT 371 date
19910913 PCT 102(e) date
RLI Continuation-in-part of Ser. No. US 1989-297021, filed on 13 Jan 1989, now patented, Pat. No. US 4966893
DT Utility
FS Granted
LN.CNT 456
INCL INCLM: 514/054.000
INCLS: 514/879.000; 424/195.100; 536/005.000; 536/127.000; 536/128.000
NCL NCLM: 514/054.000
NCLS: 424/728.000; 514/879.000; 536/005.000; 536/127.000; 536/128.000
IC [5]
ICM: A61K031-751
ICS: A01N031-00; G01N031-00
EXF 514/54; 514/879; 424/195.1; 536/5; 536/127; 536/128
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AN 92:44833 USPATFULL
TI Pharmaceutical tetrahydroisoquinolines
IN Minchin, Michael C. W., Oxford, England
White, Alan C., Englefield Green, England
White, John F., Wokingham, England
PA John Wyeth & Brother Limited, Maiden head, England (non-U.S. corporation)
PI US 5118690 19920602 <--
AI US 1991-780372 19911021 (7)
RLI Continuation of Ser. No. US 1990-584216, filed on 18 Sep 1990, now abandoned
PRAI GB 1989-21304 19890920
DT Utility
FS Granted
LN.CNT 1052
INCL INCLM: 514/314.000
INCLS: 546/167.000
NCL NCLM: 514/314.000
NCLS: 546/167.000
IC [5]
ICM: A61K031-47
ICS: C07D041-00
EXF 514/307; 514/314; 546/167
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 165 OF 188 USPATFULL on STN
AN 92:31856 USPATFULL
TI Linear free-sulfhydryl-containing oligopeptide derivatives as antihypertensive agents
IN Bovy, Philippe R., St. Louis, MO, United States
Manning, Robert E., St. Louis, MO, United States
O'Neal, Joan M., St. Louis, MO, United States
PA G. D. Searle & Co., Chicago, IL, United States (U.S. corporation)
PI US 5106834 19920421 <--
AI US 1988-290667 19881227 (7)
DT Utility
FS Granted
LN.CNT 1361
INCL INCLM: 514/015.000
INCLS: 514/013.000; 514/014.000; 530/328.000; 530/327.000; 530/326.000
NCL NCLM: 514/015.000
NCLS: 514/013.000; 514/014.000; 530/326.000; 530/327.000; 530/328.000
IC [5]
ICM: A61K037-02
ICS: C07K007-06
EXF 530/328; 530/327; 530/326; 514/15; 514/14; 514/13
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 166 OF 188 USPATFULL on STN
AN 92:13094 USPATFULL
TI Amino acid analogs as CCK-antagonists
IN Freidinger, Roger M., Hatfield, PA, United States
PA Merck & Co., Inc., Rahway, NJ, United States (U.S. corporation)
PI US 5089638 19920218 <--
AI US 1989-400608 19890830 (7)
RLI Division of Ser. No. US 1986-874928, filed on 16 Jun 1986, now patented, Pat. No. US 4880938
DT Utility
FS Granted
LN.CNT 739
INCL INCLM: 549/468.000
INCLS: 548/492.000; 548/571.000; 548/483.000; 549/462.000; 549/436.000; 549/057.000; 546/192.000; 546/225.000; 546/168.000; 544/106.000; 564/169.000; 564/183.000
NCL NCLM: 549/468.000
NCLS: 544/106.000; 546/168.000; 546/192.000; 546/225.000; 548/483.000; 548/492.000; 548/571.000; 549/057.000; 549/436.000; 549/462.000; 564/169.000; 564/183.000
IC [5]
ICM: C07D307-82
EXF 549/468
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 167 OF 188 USPATFULL on STN
AN 92:9121 USPATFULL

IN White, John F., Wokingham, England
Warren, Michael C., Oxford, England
Ennis, Christine, Maidenhead, England
PA John Wyeth & Brother Limited, Maidenhead, England (non-U.S. corporation)
PI US 5086073 19920204 <--
AI US 1990-530758 19900530 (7)
PRAI GB 1989-12784 19890602
GB 1989-27087 19891130
DT Utility
FS Granted
LN.CNT 897
INCL INCLM: 514/602.000
INCLS: 514/604.000; 514/647.000; 514/649.000; 514/650.000; 514/655.000; 514/657.000; 514/660.000; 514/315.000; 514/359.000
NCL NCLM: 514/602.000
NCLS: 514/315.000; 514/359.000; 514/604.000; 514/647.000; 514/649.000; 514/650.000; 514/655.000; 514/657.000; 514/660.000
IC [5]
ICM: A61K031-13
ICS: A61K031-18; A61K031-135; A61K031-445
EXF 514/655; 514/649; 514/602; 514/604; 514/647; 514/650; 514/657; 514/660; 514/315; 514/359
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 168 OF 188 USPATFULL on STN
AN 91:104215 USPATFULL
TI Method of treatment of learning deficiency
IN Knoll, Jozsef, Budapest, Hungary
Simay, Antal, Budapest, Hungary
Szinnyei, Eva, Budapest, Hungary
Somfai, Eva, Budapest, Hungary
Torok, Zoltan, Budapest, Hungary
Mozsolits, Karoly, Sopron, Hungary
Bergmann, Janos, Visegrad, Hungary
PA Chinoin Gyogyszer- es Vergyeszeti Termekek Gyara Rt., Budapest, Hungary (non-U.S. corporation)
PI US 5075338 19911224 <--
AI US 1989-420058 19891011 (7)
RLI Division of Ser. No. US 1988-269665, filed on 9 Nov 1988
PRAI HU 1986-4101 19860925
DT Utility
FS Granted
LN.CNT 685
INCL INCLM: 514/654.000
NCL NCLM: 514/654.000
IC [5]
ICM: A61K031-135
EXF 514/654
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 169 OF 188 USPATFULL on STN
AN 91:92552 USPATFULL
TI 4(2-indolyl)2-amino-pentanedioic acids and cholecyostokinin use thereof
IN Gasc, Jean-Claude, Bondy, France
Humbert, Daniel, Fontenay sous Bois, France
Vekens, Mario, Courbevoie, France
PA Roussel Uclaf, Paris, France (non-U.S. corporation)
PI US 5064853 19911112 <--
AI US 1990-478479 19900212 (7)
PRAI FR 1989-2093 19890217
DT Utility
FS Granted
LN.CNT 528
INCL INCLM: 514/419.000
INCLS: 548/492.000; 548/494.000
NCL NCLM: 514/419.000
NCLS: 548/492.000; 548/494.000
IC [5]
ICM: A61K031-405
ICS: C07D209-12
EXF 548/494; 514/419
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 170 OF 188 USPATFULL on STN
AN 91:26615 USPATFULL

IN Evans, Ben E., Lansdale, PA, United States
Bock, Mark G., Hatfield, PA, United States
Freidinger, Roger M., Hatfield, PA, United States
PA Merck & Co., Inc., Rahway, NJ, United States (U.S. corporation)
PI US 5004741 19910402 <--
AI US 1988-269212 19881109 (7)
RLI Division of Ser. No. US 1987-26420, filed on 16 Mar 1987, now patented, Pat. No. US 4820834 which is a continuation-in-part of Ser. No. US 1985-741972, filed on 10 Jun 1985, now abandoned which is a continuation-in-part of Ser. No. US 1985-705272, filed on 25 Feb 1985, now abandoned which is a continuation-in-part of Ser. No. US 1984-624854, filed on 26 Jun 1984, now abandoned
DT Utility
FS Granted
LN.CNT 8800
INCL INCLM: 514/221.000
INCLS: 514/925.000; 514/926.000; 514/927.000
NCL NCLM: 514/221.000
NCLS: 514/925.000; 514/926.000; 514/927.000
IC [5]
ICM: A61K031-55
EXF 514/221; 514/925; 514/926; 514/927
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 171 OF 188 USPATFULL on STN
AN 91:8790 USPATFULL
TI 2,4-dioxo-5-phenyl-2,3,4,5-tetrahydro-1H-1,5-benzodiazepines
IN Gasc, Jean-Claude, Bondy, France
Humbert, Daniel, Fontenay sous Bois, France
PA Uclaf, Roussel, Paris, France (non-U.S. individual)
PI US 4988692 19910129 <--
AI US 1989-457237 19891227 (7)
PRAI FR 1985-8817395 19851229
DT Utility
FS Granted
LN.CNT 418
INCL INCLM: 514/221.000
INCLS: 540/518.000
NCL NCLM: 514/221.000
NCLS: 540/518.000
IC [5]
ICM: C07D243-12
ICS: A61K031-55
EXF 540/518; 514/221
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 172 OF 188 USPATFULL on STN
AN 90:83617 USPATFULL
TI Method for treatment of senile dementia
IN Pang, Peter K. T., 52225 Range Road 232, 205 Carriage Lane, Sherwood Park, Alberta, Canada T8A 2A6
Wang, Lawrence C. H., 5012-144 St., Edmonton, Alberta, Canada T6G 2E9
Benishin, Christina G., 218-53431 Range Rd 221, Androssan, Alberta, Canada T0B 0E0
Liu, Hsing J., 3543-105 B St., Edmonton Alta., Canada T6J 2K9
PI US 4966893 19901030 <--
AI US 1989-297012 19890113 (7)
DT Utility
FS Granted
LN.CNT 287
INCL INCLM: 514/054.000
INCLS: 536/005.000; 514/879.000; 424/195.100
NCL NCLM: 514/054.000
NCLS: 424/728.000; 514/879.000; 536/005.000
IC [5]
ICM: A61K035-78
ICS: C07H015-20
EXF 023/230R; 536/5; 536/127; 536/128; 514/54; 514/879; 424/195.1
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 173 OF 188 USPATFULL on STN
AN 90:38516 USPATFULL
TI 2-(2-aminobenzyl or 2-nitrobenzyl)-1,2,3,4-tetrahydroisoquinoline derivatives
IN Kanmacher, Isabelle, 12, rue Hardouin Mansart, Mittelhausbergen, F-67200

Stambach, Jean-Francois, 10, rue d'Andlau, F-67000 Strasbourg, France
Jung, Louis, 205, route d'Oberhausbergen, F-67200 Strasbourg, France
Schott, Christa, 7, square du Chateau, F-67300 Schiltigheim, France
Stoclet, Jean-Claude, 13, boulevard Jean-Sebastian Bach, F-67000 Strasbourg, France
Heitz, Christiane, 3, rue des Bouvreuils, F-67100 Strasbourg, France
PI US 4925943 19900515 <--
WO 8705295 19870911 <--
AI US 1988-124793 19880105 (7)
WO 1987-FR54 19870304
19880105 PCT 371 date
19880105 PCT 102(e) date
PRAI FR 1986-3201 19860305
DT Utility
FS Granted
LN.CNT 766
INCL INCLM: 546/149.000
INCLS: 544/245.000; 544/246.000; 546/090.000; 546/146.000; 546/148.000
NCL NCLM: 546/149.000
NCLS: 544/245.000; 544/246.000; 546/090.000; 546/146.000; 546/148.000
IC [5]
ICM: C07D217-04
EXF 546/149; 546/148; 546/146; 546/90; 514/307
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 174 OF 188 USPATFULL on STN
AN 90:21505 USPATFULL
TI Method for binding opioid receptors
IN Meyers, Vera K., University of Wisconsin-Parkside, Greenquent Hall, Box No. 2000, Kenosha, WI, United States 53141
Koman, Ahmet, Vaktarg 4C, 75422 Uppsala, Sweden
PI US 4910152 19900320 <--
AI US 1986-869737 19860602 (6)
RLI Continuation-in-part of Ser. No. US 1985-697212, filed on 31 Jan 1985, now patented, Pat. No. US 4678779
DT Utility
FS Granted
LN.CNT 1188
INCL INCLM: 436/501.000
INCLS: 436/504.000; 436/545.000; 436/546.000; 436/800.000; 436/804.000; 436/805.000; 436/816.000; 424/001.100; 435/034.000; 435/035.000; 514/282.000
NCL NCLM: 436/501.000
NCLS: 435/034.000; 435/035.000; 436/504.000; 436/545.000; 436/546.000; 436/800.000; 436/804.000; 436/805.000; 436/816.000; 514/282.000
IC [4]
ICM: G01N033-566
ICS: G01N033-534; A61K043-00; C12Q001-04
EXF 424/1.1; 435/34; 435/35; 436/501; 436/504; 436/545; 436/546; 436/800; 436/804; 436/805; 436/816; 514/282
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 175 OF 188 USPATFULL on STN
AN 89:92644 USPATFULL
TI Amino acid analogs
IN Freidinger, Roger M., Hatfield, PA, United States
PA Merck & Co., Inc., Rahway, NJ, United States (U.S. corporation)
PI US 4880938 19891114 <--
AI US 1986-874928 19860616 (6)
DT Utility
FS Granted
LN.CNT 759
INCL INCLM: 548/492.000
INCLS: 564/183.000; 564/169.000; 549/436.000; 549/057.000; 548/483.000; 548/571.000; 546/225.000; 546/168.000; 544/106.000
NCL NCLM: 548/492.000
NCLS: 544/106.000; 546/168.000; 546/225.000; 548/483.000; 548/571.000; 549/057.000; 549/436.000; 564/169.000; 564/183.000
IC [4]
ICM: C07D209-18
EXF 548/492; 548/483; 514/419
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 176 OF 188 USPATFULL on STN
AN 89:60883 USPATFULL

IN Vizi, Szilveszter, Budapest, Hungary
Szantai, Csaba, Budapest, Hungary
Szabo, Lajos, Budapest, Hungary
Toth, Istvan, Budapest, Hungary
Kovacs, Gabor, Budapest, Hungary
Marton, Jeno, Budapest, Hungary
Harsing, Laszlo, Budapest, Hungary
Somogyi, Gyorgy, Budapest, Hungary
Gaal, Jozsef, Budapest, Hungary
PA Chinoin Gyogyszer es Vegyeszeti Termekek Gyara Rt., Budapest, Hungary (non-U.S. corporation)
PI US 4851416 19890725 <--
AI US 1986-867323 19860523 (6)
PRAI HU 1985-1982 19850524
DT Utility
FS Granted
LN.CNT 778
INCL INCLM: 514/280.000
INCLS: 514/284.000; 546/048.000; 546/071.000
NCL NCLM: 514/280.000
NCLS: 514/284.000; 546/048.000; 546/071.000
IC [4]
ICM: A61K031-47
ICS: C07D455-03
EXF 546/48; 546/71; 514/280; 514/284
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 177 OF 188 USPATFULL on STN
AN 89:56397 USPATFULL
TI 1,4-Benzodiazepines with 5- and 6-membered heterocyclic rings and their use as cholecystokinins and gastrin antagonists
IN Freidinger, Roger M., Hatfield, PA, United States
Evans, Ben E., Lansdale, PA, United States
Bock, Mark G., Hatfield, PA, United States
PA Merck & Co., Inc., Rahway, NJ, United States (U.S. corporation)
PI US 4847248 19890711 <--
AI US 1988-141435 19880106 (7)
RLI Division of Ser. No. US 1986-946392, filed on 23 Dec 1986, now patented, Pat. No. US 4735941
DT Utility
FS Granted
LN.CNT 859
INCL INCLM: 514/214.000
INCLS: 540/558.000; 540/561.000; 540/562.000
NCL NCLM: 514/220.000
NCLS: 540/558.000; 540/561.000; 540/562.000
IC [4]
ICM: A61K031-395
ICS: C07D487-04
EXF 540/561; 540/562; 514/214
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 178 OF 188 USPATFULL on STN
AN 89:28036 USPATFULL
TI Benzodiazepine analogs
IN Evans, Ben E., Lansdale, PA, United States
Freidinger, Roger M., Hatfield, PA, United States
Bock, Mark G., Hatfield, PA, United States
PA Merck & Co., Inc., Rahway, NJ, United States (U.S. corporation)
PI US 4820834 19890411 <--
AI US 1987-26420 19870316 (7)
RLI Continuation-in-part of Ser. No. US 1985-741972, filed on 10 Jun 1985, now abandoned which is a continuation-in-part of Ser. No. US 1985-705272, filed on 25 Feb 1985, now abandoned which is a continuation-in-part of Ser. No. US 1984-624854, filed on 26 Jun 1984, now abandoned
DT Utility
FS Granted
LN.CNT 8808
INCL INCLM: 540/504.000
INCLS: 540/505.000; 540/506.000; 540/507.000; 540/508.000; 540/509.000; 540/510.000; 540/512.000; 540/513.000; 540/514.000; 540/564.000; 540/570.000; 540/571.000; 540/572.000; 540/573.000
NCL NCLM: 540/504.000
NCLS: 540/505.000; 540/506.000; 540/507.000; 540/508.000; 540/509.000;

540/570.000; 540/571.000; 540/572.000; 540/573.000
IC [4]
ICM: C07D243-24
ICS: C07D243-22; C07D243-20; A61K031-55
EXF 540/504; 540/505; 540/506; 540/507; 540/508; 540/509; 540/510; 540/512; 540/513; 540/514; 540/569; 540/570; 540/571; 540/572; 540/573
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 179 OF 188 USPATFULL on STN
AN 88:42346 USPATFULL
TI Benzodiazepine analogs and use as antogonists of gastrin and cholecystokinin
IN Bock, Mark G., Hatfield, PA, United States
Evans, Ben E., Lansdale, PA, United States
Freidinger, Roger M., Hatfield, PA, United States
PA Merck & Co., Inc., Rahway, NJ, United States (U.S. corporation)
PI US 4755508 19880705 <--
AI US 1987-20261 19870227 (7)
RLI Continuation-in-part of Ser. No. US 1985-741973, filed on 10 Jul 1985, now abandoned which is a continuation-in-part of Ser. No. US 1984-624852, filed on 26 Jun 1984, now abandoned
DT Utility
FS Granted
LN.CNT 1686
INCL INCLM: 514/221.000
INCLS: 540/542.000; 540/570.000; 540/571.000; 540/572.000
NCL NCLM: 514/221.000
NCLS: 540/542.000; 540/570.000; 540/571.000; 540/572.000
IC [4]
ICM: A61K031-55
ICS: C07D243-20; C07D243-16
EXF 514/221; 540/542; 540/570; 540/571; 540/572
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 180 OF 188 USPATFULL on STN
AN 88:40653 USPATFULL
TI 2-acyl-3-aminomethyl-1,2,3,4-tetrahydroquinolines
IN Vecchietti, Vittorio, Milan, Italy
Signorini, Massimo, Milan, Italy
PA Dr. Lo. Zambeletti S.p.A., Italy (non-U.S. corporation)
PI US 4753952 19880628 <--
AI US 1986-944931 19861222 (6)
PRAI GB 1985-31615 19851223
DT Utility
FS Granted
LN.CNT 566
INCL INCLM: 514/307.000
INCLS: 514/212.000; 540/597.000; 546/145.000; 546/146.000; 546/147.000
NCL NCLM: 514/307.000
NCLS: 514/210.210; 514/217.070; 540/597.000; 546/145.000; 546/146.000; 546/147.000
IC [4]
ICM: A61K031-47
ICS: C07D401-06; C07D217-16
EXF 546/145; 546/146; 546/147; 514/307; 514/212; 540/597
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 181 OF 188 USPATFULL on STN
AN 88:21134 USPATFULL
TI 1,4-benzodiazepines with 5- and 6-membered heterocyclic rings, useful as gastrointestinal and CNS agents
IN Freidinger, Roger M., Hatfield, PA, United States
Bock, Mark G., Hatfield, PA, United States
Evans, Ben E., Lansdale, PA, United States
PA Merck & Co., Inc., Rahway, NJ, United States (U.S. corporation)
PI US 4735941 19880405 <--
AI US 1986-946392 19861223 (6)
DT Utility
FS Granted
LN.CNT 915
INCL INCLM: 514/220.000
INCLS: 540/559.000
NCL NCLM: 514/220.000
NCLS: 540/559.000
IC [4]

ICS: C07D487-04
EXF 540/559; 544/184; 514/220
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 182 OF 188 USPATFULL on STN
AN 87:55212 USPATFULL
TI Benzofused lactams as cholecystokinin antagonists
IN Chang, Raymond S. L., Edison, NJ, United States
Parsons, William H., Rahway, NJ, United States
PA Merck & Co., Inc., Rahway, NJ, United States (U.S. corporation)
PI US 4684645 19870804 <--
AI US 1985-799049 19851118 (6)
RLI Continuation of Ser. No. US 1984-624848, filed on 26 Jun 1984, now abandoned
DT Utility
FS Granted
LN.CNT 1153
INCL INCLM: 514/213.000
INCLS: 514/312.000; 546/157.000; 540/461.000; 540/523.000
NCL NCLM: 514/183.000
NCLS: 514/212.070; 514/300.000; 514/307.000; 514/312.000; 540/461.000; 540/523.000; 546/157.000; 930/010.000; 930/024.000
IC [4]
ICM: A61K031-55
ICS: A61K031-47; A61K031-395
EXF 260/239.3B; 546/157; 514/213; 514/312
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 183 OF 188 USPATFULL on STN
AN 87:32233 USPATFULL
TI Triazolobenzodiazepines and pharmaceutical use
IN Bock, Mark G., Hatfield, PA, United States
Evans, Ben E., Lansdale, PA, United States
Freidinger, Roger M., Hatfield, PA, United States
PA Merck & Co., Inc., Rahway, NJ, United States (U.S. corporation)
PI US 4663321 19870505 <--
AI US 1985-741971 19850610 (6)
RLI Continuation-in-part of Ser. No. US 1984-624850, filed on 26 Jun 1984, now abandoned
DT Utility
FS Granted
LN.CNT 2439
INCL INCLM: 514/220.000
INCLS: 540/563.000; 540/564.000; 540/565.000; 540/566.000; 540/542.000
NCL NCLM: 514/220.000
NCLS: 540/542.000; 540/563.000; 540/564.000; 540/565.000; 540/566.000
IC [4]
ICM: A61K031-55
ICS: C07D487-04
EXF 260/245.5; 260/244.4; 260/243.3; 514/220; 540/563; 540/564; 540/565; 540/566; 540/542
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 184 OF 188 USPATFULL on STN
AN 85:37213 USPATFULL
TI Anti-psychotic phenylindene derivatives and acid addition salts thereof
IN Perregaard, Jens K., Olstykke, Denmark
PA Kefalas A/S, Copenhagen, Denmark (non-U.S. corporation)
PI US 4525360 19850625 <--
AI US 1983-539308 19831005 (6)
PRAI GB 1982-28729 19821007
DT Utility
FS Granted
LN.CNT 896
INCL INCLM: 514/277.000
INCLS: 514/340.000; 546/205.000; 546/206.000; 546/277.000; 546/278.000; 546/330.000; 546/339.000; 546/344.000; 546/348.000; 546/350.000; 514/341.000; 514/342.000; 514/357.000
NCL NCLM: 514/277.000
NCLS: 514/340.000; 514/341.000; 514/342.000; 514/357.000; 544/267.000; 546/205.000; 546/206.000; 546/269.700; 546/271.400; 546/274.400; 546/284.400; 546/330.000; 546/339.000; 546/344.000; 546/348.000; 546/350.000
IC [3]
ICM: A61K031-44

EXF 546/205; 546/206; 546/277; 546/278; 546/330; 546/339; 546/344; 546/348; 546/350; 424/263; 424/267
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 185 OF 188 USPATFULL on STN
AN 83:44050 USPATFULL
TI Xanthine derivatives useful as antidepressives
IN Ward, Terence J., Slough, England
Wood, Martyn D., Reading, England
Wyllie, Michael G., Maidenhead, England
PA John Wyeth and Brother Limited, Maidenhead, England (non-U.S. corporation)
PI US 4406903 19830927 <--
AI US 1982-338929 19820112 (6)
PRAI GB 1981-1820 19810121
DT Utility
FS Granted
LN.CNT 703
INCL INCLM: 424/253.000
INCLS: 544/268.000
NCL NCLM: 514/263.200
NCLS: 544/268.000
IC [3]
ICM: A61K031-52
ICS: C07D473-06; C07D473-08
EXF 544/268; 424/253

L8 ANSWER 186 OF 188 USPATFULL on STN
AN 77:43577 USPATFULL
TI Endogenous morphine-like compound
IN Spector, Sidney, Livingston, NJ, United States
PA Hoffmann-La Roche Inc., Nutley, NJ, United States (U.S. corporation)
PI US 4042682 19770816 <--
AI US 1976-674467 19760407 (5)
DT Utility
FS Granted
LN.CNT 334
INCL INCLM: 424/095.000
INCLS: 260/285.000; 424/260.000
NCL NCLM: 424/570.000
NCLS: 436/018.000; 436/094.000; 546/044.000
IC [2]
ICM: A61K035-30
ICS: A61K031-485; C07D489-00
EXF 424/95; 424/260; 260/285
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 187 OF 188 USPATFULL on STN
AN 77:6183 USPATFULL
TI Compositions and methods for fertility control
IN Gallegos, Alfredo J., Calzada General Anaya 209, Mexico City, Mexico
Cortes-Gallegos, Vincente, Farallon 275, Mexico City, Mexico
PI US 4006227 19770201 <--
AI US 1974-520646 19741104 (5)
RLI Continuation-in-part of Ser. No. US 1973-416212, filed on 15 Nov 1973, now abandoned
DT Utility
FS Granted
LN.CNT 788
INCL INCLM: 424/195.000
NCL NCLM: 424/764.000
IC [2]
ICM: A61K035-78
EXF 424/195
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 188 OF 188 USPATFULL on STN
AN 75:49552 USPATFULL
TI Angiotensin.sub.II position 8 analogs
IN Regoli, Domenico C., Magog, Canada
Park, Won Kil, Sherbrooke, Canada
PA University of Sherbrooke, Quebec, Canada (non-U.S. corporation)
PI US 3907762 19750923 <--
AI US 1971-212257 19711227 (5)
DT Utility

LN.CNT 584
INCL INCLM: 260/112.500
INCLS: 424/177.000
NCL NCLM: 530/316.000
NCLS: 930/020.000; 930/040.000; 930/DIG.590
IC [2]
ICM: C07C103-52
ICS: A61K037-26
EXF 260/112.5
CAS INDEXING IS AVAILABLE FOR THIS PATENT.
STN INTERNATIONAL LOGOFF AT 17:37:50 ON 02 DEC 2004